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The translocation t(8;21) stands out as a paradigm of genomic aberrations in which 
it’s fusion product (RUNX1/ETO) initiates and maintains the leukaemogenic 
transformation of haematopoietic stem cells. Like all leukaemias, t(8;21)-positive 
AML is characterised by extensive hyperproliferation and aberrant self-renewal. 
Here, in this thesis we show that silencing RUNX1/ETO by siRNA dysregulates the 
leukaemic molecular programme, restrains leukaemia expansion and ablates 
clonogenicity, suggesting therapeutic potentials. 
Aiming to develop a specific targeted therapy, we relied on the RNAi machinery to 
specifically knockdown RUNX1/ETO by a chemically modified siRNA encapsulated 
into a lipid nanoparticle. 
To enhance the efficacy of siRUNX1/ETO, we have introduced a combination of 2’-
sugar and phosphodiester backbone modifications and proved the robustness of the 
gene knockdown in vitro. Then, we have utilised a state-of-the-art microfluidic 
system to encapsulate the siRNA into a novel lipid nanoparticle that is approved for 
clinical use. The lipid nanoparticles provided a long-lasting RUNX1/ETO knockdown 
in vitro in cell lines, and in t(8;21) patient primary cells and PDXs in a co-culture 
system. The gene knockdown was also associated with irreversible changes in 
RUNX1/ETO transcriptional network and induced a cytostatic phenotype 
characterised by G1 cell cycle arrest and senescence. 
To gain insight into the pharmacokinetics and biodistribution of the nanoparticles, we 
have developed a protocol to label the lipid nanoparticles with a NIR dye that is 
compatible with in vivo imaging. Systemic administration of a single dose of the 
labelled nanoparticles caused a global body distribution in immunocompromised 
hosts, including leukaemic tissues and CNS. Our in-house optimised labelling 
protocol transforms the nanoparticles into a platform for tissue-specific delivery by 
substituting the dye with targeting motifs. 
Using comprehensive experimental settings in vivo, we have successfully achieved 
RUNX1/ETO knockdown in t(8;21) murine xenotransplantation model and proved the 
on-target effect of the nanoparticles. Further ex vivo testing revealed that 
II 
 
RUNX1/ETO repression triggers cellular senescence and initiates a myeloid 
differentiation programme, which were affirmed by RNA-seq analysis obtained from 
RUNX1/ETO knockdown mice. 
Our study, for the first time, shows that RUNX1/ETO depletion in vivo in a clinically 
relevant setting significantly prolongs the survival of leukaemic mice. Our novel 
approach for gene knockdown revealed that depleting RUNX1/ETO severely impairs 
clonogenicity and self-renewal, as well as prevents leukaemia propagation in 
secondary recipients. 
To exploit the therapeutic benefits of combinational chemotherapies with 
RUNX1/ETO knockdown, we carried in vitro drug toxicity assays and in vivo 
treatment. The combination of RUNX1/ETO depletion with DNA damage agents 
treatment resulted in a lost sensitivity to those chemotherapies. On the contrary, 
RUNX1/ETO knockdown enhanced the pharmacological inhibition of BCL2 with a 
small molecule inhibitor in vitro but not in vivo. 
Overall, this thesis developed a potent siRNA-based drug for RUNX1/ETO 
knockdown, which brings gene therapy from the lab closer to bedside. The thesis 
supports the notion that RUNX1/ETO guards the reservoir of leukaemic initiating 
cells, and shows how targeting the fusion transcript with siRNA significantly reduces 
the number of the long-term repopulating leukaemic stem cells providing an effective 
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1.1 Acute Myeloid Leukaemia 
1.1.1 Haematopoiesis and haematopoietic stem cell   
Pluripotent haematopoietic stem cells (HSCs) generate the adult haematopoietic 
system providing long-term production and maintenance of all blood cell types. In 
adults, HSCs comprise less than 0.1% of the bone marrow (BM) cells. The origin of 
the pluripotent HSCs is traced back to the Aorta-Gonad-Mesonephros (AGM) region 
during early embryogenesis (Fig 1-1A-B) (Thomson and Meyskens 1982, Bizzari and 
Mackillop 1985, Mendelson and Frenette 2014). 
Embryonic development of human HSCs (Fig 1-1C) begins at day 19 of gestation 
when the endothelial lining of the dorsal aorta upregulates the HSCs marker CD34. 
By the end of the third week of gestation, lymphoid and myeloid multilineage stem 
cells CD34+/CD45+ can be found in the intraembryonic coelom (Fig 1-1B) (Hirschi 
2012, Cao, Spielmann et al. 2019) . The first wave of haematopoiesis (pre-
circulation) starts in the yolk sac (YS) at day 27 of gestation. The haematopoietic 
trajectory in the YS has a mesoderm origin where a group of mesenchymal stem 
cells (MSCs) differentiate into primitive erythroblasts, and occasionally to primitive 
megakaryocytes and macrophages. At this stage, the haemogenic endothelium (HE) 
in the AGM region generates clusters of HSCs, which adhere to the ventral wall of 
the dorsal aorta. The second wave of haematopoiesis (circulation) in the YS 
produces definitive myeloid, megakaryocytes, erythroid and multipotent progenitors, 
which seed the foetal liver. The endothelial-to-haematopoietic migration (detachment 
of the HSCs from the HE) and colonising the foetal liver marks the transition to 
hepatic haematopoiesis by the end of the fourth week of gestation. Foetal liver 
remains the primary niche for HSCs maintenance and differentiation until birth. In 
parallel with hepatic haematopoiesis, bone marrow formation and osteogenesis mark 
the end of embryogenesis by the end of the second month of gestation when CD34-
/CD45+/CD68+ macrophages invade the bone marrow and facilitate chondrolysis. 
Finally, the definitive BM niche hosts and maintains the haematopoietic progenitors 
and HSCs throughout life (Bloom and Bartelmez 1940, Bertrand, Giroux et al. 2005, 
Hirschi 2012, Beaudin, Boyer et al. 2016, Ivanovs, Rybtsov et al. 2017, Cao, 





Fig 1-1: Human haematopoiesis during embryogenesis and development. (A) 
The localisation of the yolk sac, AGM region, liver, placenta and other embryonic 
tissues in a 33 days old human embryo. (B) Ventral wall of the dorsal aorta of a 38 
days old human embryo showing the intra-aortic haematopoietic clusters expressing 
CD45, RUNX1 and VE-cadherin. (C) Chronology of human haematopoiesis. The first 
primitive haematopoietic cells, monocytes and macrophages are produced in the 
yolk sac. Blood circulation starts at day 21 after the onset of cardiac contractions, 
and at day 27 the ventral wall of the dorsal aorta hosts the CD34+/CD45+ cells, 
which are also disseminated into the liver. HSCs emerge in the AGM region at day 
30 until day 42, then in the yolk sac at day 35, the liver around day 40 and finally 
HSCs enter the expansion phase in the bone marrow at day 60. Fading of the 
coloured rectangles represents the extinction of the process. Scale bar: 1 mm in A. 




HSCs undergo two progressive series, either self-renewal and maintaining the 
pluripotency or differentiation into more mature progenitor cells (Fig 1-2A, B). 
Haematopoietic development is a highly orchestrated process where the multipotent 
immature progenitors are committed to differentiate into lymphoid, myeloid, erythroid 
or megakaryocytic precursors in the bone marrow (Sabbath, Ball et al. 1985, Blair, 
Hogge et al. 1998). The multipotent myeloid and lymphoid precursors are highly 
proliferative and express specific receptors for growth, survival, and colony-
stimulation factors. During their differentiation, precursors follow successive stages 
until they lose the ability to divide further and become mature blood cells (Bertrand, 
Giroux et al. 2005, Amabile, Welner et al. 2013).  
Recent studies have showon significant HSCs heterogeneity resulting in a 
continuous segregation of lineage-specific features (Fig 1-2C). The new model of 
haematopoiesis challenges the classical model of lineage commitment and proposes 
a lineage-biased HSCs paradigm for blood cells formation and emergence of 
haematological malignancies (Haas, Trumpp et al. 2018). Moreover, there is 
evidence of progenitor reversibility and lineage switch between the lymphoid and 
myeloid progenitors, mostly in rare AML relapse cases (Ryotokuji, Yamaguchi et al. 
2016). The drivers for such a switch are still under investigation, and the new 
lineage-biased model of HSCs might deliver new insights into the regulation of 







Fig 1-2: Normal human haematopoiesis models. (A) HSC classical model of lineage commitment. HSC undergoes a series of 
intermediate differentiation stages where HSC first generates the common myeloid and common lymphoid progenitors, which later 
give rise to all blood cell types. Direct shortcut from HSC to megakaryocytes was recently proposed. (B)  HSC early split model 
where the lineage separation occurs in early stages. (C) Latest HSC lineage-bias commitment model where the HSC does not 
follow distinct intermediate stages of differentiation but is proposed to acquire transcriptional lineage priming features leading to a 




1.1.2 Leukaemogenesis  
 As normal haematopoiesis undergoes a highly orchestrated hierarchy of HSCs 
differentiation programmes, changes can lead to a transient or prolonged 
dysregulation of haematopoiesis. Leukaemia is defined as a condition of disordered 
haematopoiesis due to the acquisition of mutations in the haematopoietic 
progenitors, which favours their self-renewing, proliferative and survival properties 
and weakens their differentiation potential (Bonnet and Dick 1997, Hope, Jin et al. 
2004). 
Since antiquity, haematological disorders such as malaria and anaemia were noted 
to be associated with the spleen and liver. The first recorded description of the blood 
clotting dysfunction or ‘’haemophilia’’ goes back to 300-500 AD and comes from the 
Babylonian Talmud. Nine years after the development of the microscope by Hooke, 
the first description of red blood cells was made Anton van Leeuwenhoek during the 
Dutch Golden Age in 1674. White blood cells were later described as the “globuli 
albicantes” by Josef Lieutaud in 1749 (Buess 1959), while in the same year Jean-
Baptiste de Sénac also describes the colourless and nucleated cells of the blood 
(Senac 1926). Leukaemia was finally described by Cullen in 1811 when he noticed 
an increased amount of white blood cells in a 35 years old patient (Cullen 1811). 
Before the end of the 19th century, several cases of patients with an excessive 
amount of white blood cells had been reported, and some authors were even able to 
predict that the disease were caused by increased circulation of immature blood cells 
(Piller 2001). Nevertheless, the term “leukaemia” was only coined by Rudolf Virchow, 
a German pathologist, in 1855, based on the Greek word for “white blood” to 
describe the leukaemic cells (Virchow 1855). 
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1.1.3 Acute myeloid leukaemia landscape   
Acute myeloid leukaemia (AML) occurs when myeloid progenitors accumulate in the 
bone marrow disrupting blood production and commonly causing anaemia, 
immunodeficiency with recurrent infections and haemostasis deficiency with 
increased haemorrhagic risk. AML is a heterogeneous clonal disease which mainly 
affects elderly with a median age at diagnosis around 65 years (Lapidot, Sirard et al. 
1994, Bonnet and Dick 1997, Hope, Jin et al. 2004). Interestingly, some myeloid 
conditions can evolve into acute leukaemia including disorders such as 
granulocytopenia, thrombocytopenia and transient abnormal myelopoiesis.  
Acute myeloid leukaemia is classically diagnosed based on cytomorphological 
features of myeloblasts observed in samples of peripheral blood and bone marrow 
stained with Wright-Giemsa. Leukaemic cells display a distinctive nucleoli in a large 
irregular-round nuclei surrounded by a small cytoplasm (Strobel and Brandt 1986, 
Woronzoff-Dashkoff 2002). The French-American-British (FAB) classification (Table 
1-1) categories AML into eight subtypes (M0-M7) based on the cell differentiation 
status and type. 
 
Acute myeloid leukaemia 
M0 Undifferentiated acute myeloblastic leukaemia 
M1 Acute myeloblastic leukaemia with minimal maturation 
M2 Acute myeloblastic leukaemia with maturation 
M3 Acute promyelocytic leukaemia  
M4 Acute myelomonocytic leukaemia  
M5 Acute monocytic leukaemia  
M6 Acute erythroid leukaemia (Di or Guglielmo syndrome) 
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Table 1-1: FAB classification of AML. Adapted from (Bennett, Catovsky et al. 
1976). 
 
Leukaemia is defined by the presence of 30% or more of blasts but genetic testing is 
required to distinguish AML from other conditions of ineffective haematopoiesis such 
as myelodysplastic syndrome (MDS) or AML-related MDS (Piller 2001). In this 
regard, the World Health Organisation (WHO) revised the old FAB classification and 
introduced cytogenetic subgroups to the standard morphology classification (Table 
1-2). 
 
M7 Acute megakaryoblastic leukaemia (AMKL) 
AML with recurrent genetic abnormalities  
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
Acute promyelocytic leukaemia (APL) with t(15;17)(q22;q12); PML-RARA 
AML with t(6;9)(p23;q34); DEK-NUP214 
AML with t(9;11)(p22;q23); MLLT3-MLL 
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 
Provisional entity: AML with mutated CEBPA 
Provisional entity: AML with mutated NPM1 
AML with myelodysplasia-related change 
Therapy-related myeloid neoplasms 
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 Table 1-2: WHO classifications of AML and neoplasms. Adapted from (Falini, 
Tiacci et al. 2010) 
  
AML, not otherwise specified: 
Undifferentiated AML (M0) 
AML with minimal differentiation (M1) 
AML without maturation (M2) 
Acute  promyelocytic leukaemia (APL) (M3) 
Acute  myelomonocytic leukaemia (AMoL) (M4) 
Acute erythroid leukaemia (AEL) (M5) 
Erythroleukaemia, erythroid/myeloid (M6) 
Pure erythroid leukaemia (M6b) 
Acute megakaryoblastic leukaemia (AMKL) (M7) 
Acute basophilic leukaemia (ABL) 
Myeloid proliferations related to Down syndrome: 
Transient abnormal myelopoiesis (TAM) 
Myeloid leukaemia associated with Down syndrome (DS-AML) 
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) 




1.1.4 AML chromosomal alterations  
Chromosomal rearrangements are key indicators of haematopoietic malignancies, 
and 60% of AML patients carry abnormal karyotypes. Core binding factors (CBFs) 
are direct targets for gene rearrangements, and mutations in CBFs lead to acute 
leukaemia. The translocation between chromosome 8 and 21, or t(8;21)(q22;q22), 
was the first to be described in AML, and it affects the target genes RUNX1 and 
CBFB. For over 40 years, t(8;21) has been considered a milestone in understanding 
AML genetics (Burel, Harakawa et al. 2001, Singh, Mandoli et al. 2017). Since then, 
AML has been associated with a growing number of other frequent genetic 
abnormalities, including chromosomal translocations and other aberrations (Table 1-
3). Currently, the most common chromosomal abnormalities in AML are 
t(8;21)(q22;q22) detected in 15% of cases, followed by the inv(16)(p13;q22) and 
t(15;17), which are present in 12%  and 8% of AML cases respectively. In paediatric 
AML, about 19% of the cases are Mixed-Lineage Leukaemia (MLLr) caused by 
rearrangements affecting the MLL1 gene in 11q23, which lead to the expression of 
MLL fusion proteins. AML Mixed-lineage leukaemia is typically associated with 
poorer prognosis and a higher risk of relapse. Genetics of AML is complex disease 
but can be widely classified into three risk groups for prognostic purposes as having 
a favourable, intermediate and adverse impact on prognosis (Burnett, Hills et al. 
2010, Dohner, Estey et al. 2010, Falini, Tiacci et al. 2010). Table 1-3 shows the 
Medical Research Council (MRC) classification of AML according to patients’ 
outcome (Burnett, Hills et al. 2010). 
 
 
Favourable Risk  t(8;21)(q22;q22) 
t(15;17)(q22;q22) 
inv(16)(p13.1q22); t(16;16)(p13.1q22) 
Intermediate Risk  Normal karyotype or other cytogenetic abnormalities not 
classified as favourable or adverse.  
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Adverse Risk  inv(3)(q21;q26.2); t(3;3)(q21;q26.1) 







t(11q23), excluding t(9;11)(p21~22;q23) and 
t(11;19)(q23;p13) 
Complex karyotype of more than 4 independent 
chromosomal abnormalities.    
 
Table 1-3: MRC classification of AML. Adapted from (Burnett, Hills et al. 2010, 








Fig 1-3: MRC cytogenetic classification of AML. Distribution of cytogenetic 
abnormalities in AML from 59% of 5876 patient cases in the MRC trials 2010. 
Adapted from (Burnett, Hills et al. 2010, Dohner, Estey et al. 2010).  
 
 
1.1.5 AML mutational landscape  
Alongside the chromosomal aberrations, which can be detected by cytogenetic 
techniques, genome screening of somatic mutations that can predispose or influence 
the development and progression of AML can also be very informative to estimate 
prognosis (Burnett, Hills et al. 2010, Falini, Tiacci et al. 2010). Curiously, the genome 
of an AML case was the first human cancer to be fully sequenced. In the advent of 
next-generation sequencing (NGS) and high-throughput protocols, the number of 
mutations known to be associated with AML has been increasing (Taussig, Vargaftig 
et al. 2010, Thol, Kolking et al. 2012). Recent studies have identified several novel 




The clonal composition and expansion are crucial for the clinical outcome of AML. 
Point mutations account for two-thirds of mutation capable of driving AML, and most 
of them are associated with an intermediate risk outcome. To increase complexity, 
one-third of AML patients carry co-mutations, and some of these are exclusive of 
specific hotspots within certain genes. For instance, patients with NPM1 mutation 
have a high occurrence of NRASG12/13 but not NRASQ61 ,and those patients have 
intermediate risk (Shen, Zhu et al. 2011, Vaskova, Dubayova et al. 2015). 
Furthermore, some paediatric acute leukaemias can be associated with other 
genetic disorders and atypical driver mutations. For example, neonates and young 
children with trisomy 21 (Down syndrome, DS) carrying mutations on GATA1 have a 
500-fold increased risk of developing megakaryoblastic leukaemia (AMKL or DS-
AML) (Reinhardt, Reinhardt et al. 2012). Up to 10% of neonates with DS suffer from 
transient abnormal myelopoiesis (TAM) but only 30% of them progresses to AMKL 
within the first four years of life. In the absence of trisomy 21 genetic background, 
GATA1 mutations alone do not lead to leukaemia, and other cooperating mutations 
are always required to transform TAM to AMKL (Klusmann, Godinho et al. 2010, 
Scheer, Kratz et al. 2016, Uffmann, Rasche et al. 2017, Gialesaki, Mahnken et al. 
2018). 
AML undergoes ordered evolutionary trajectories, where mutations might occur or 
drive different stages during disease development (Hope, Jin et al. 2004). Mutations 
that affect epigenetic modifier genes such as IDH1/2, TET2 and ASXL1 are often 
present in elderly patients and increase the risk of developing leukaemia. Such 
mutations are acquired or present in the earliest stages of haematopoietic disruption 
and can be usually detected in the founder clones of AML, but are not sufficient for 
leukaemia transformation (Shen, Zhu et al. 2011). On the other hand, mutations in 
tyrosine kinases usually occur at later stages and often multiple mutations in these 
genes can be detected in different clones of the same patient. Secondary mutations 
such as in NPM1 followed by IDH1 and DNMT3A are associated with progression to 




   
Fig 1-4: Common mutation in AML and their frequencies. Distribution of 
cytogenetic abnormalities in AML from 59% of 5876 patient cases in the MRC trials 
2010. Adapted from (Vaskova, Dubayova et al. 2015)  
 
 
1.1.6 AML molecular pathogenesis  
As described, AML has complex and heterogeneous cytogenetics and results from a 
sequential acquisition of mutations and/or genomic alterations. The old FAB 
classification categorised AML mutations into two main classes. Class I mutations 
enhance the proliferation and survival via the activation of several signal transduction 
pathways such as FLT3, NRAS, and KIT. Class II mutations block the differentiation 
of myeloid progenitors by interfering with transcription factors such as RUNX1, 
CEPBA, and GATA1/2 (Garg, Nagata et al. 2015, Ryotokuji, Yamaguchi et al. 2016). 
However, this classification is continuously under revision, and some newly 
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discovered mutations either fit both or none of the classic classes. Consequently, 
new models of classifying AML according to mutations and genomic abnormalities 
have become ever more complex (Fig 1-5) (Shen, Zhu et al. 2011, Ryotokuji, 
Yamaguchi et al. 2016). Furthermore, some mutations strongly segregate with 
specific chromosomal abnormalities such as mutation of KIT in inv(16) and t(8;21) in 





Fig1-5: AML mutated genes.  Summary of AML mutated genes and their prognostic 
factors. Adapted from (Itzykson, Gardin et al. 2011, Shen, Zhu et al. 2011, Vaskova, 




1.2 t(8;21) positive AML 
1.2.1 RUNX1, a master regulator of haematopoiesis  
RUNX1 (also known as AML1, CBFα2 or PEBP2aB) belongs to the Runt-related 
transcription factors (RUNXs), which are required in Drosophila embryogenesis for 
sex determination, segmentation, and neurogenesis. The RUNX1 gene is located on 
chromosome 21 (21q22.12), spans 260 kb and contains 12 exons. RUNX1 has 
complex transcription and translation variants due to its distinctive 5’-UTRs and 
differential 3’-polyA sites. There are several alternative splice variants of RUNX1 
coding a range of protein products spanning from 20 to 52 kDa (Lorsbach, Moore et 
al. 2004, Lam and Zhang 2012). 
RUNX1 is tightly regulated during haematopoiesis and HSCs homeostasis by two 
tissue-specific enhancers (regulatory elements 1 and 2) and two promotors, distal 
promotor P1 and proximal promoter P2, both sequentially activated and linked to 
different 5’-UTRs (Fig 1-6). The transcript of P1 promotor controls RUNX1c 
expression that is required for the initiation but not the maintenance of definitive 
haematopoiesis. The P2 promotor strictly controls the dosage of RUNX1b and 
RUNX1a expression levels that are required to initiate and complete the endothelial-
to-hematopoietic transition and subsequent generation of haematopoietic cells from 
the haemogenic endothelium (HE). RUNX1 knockout mice die in early 
embryogenesis with deficient foetal haematopoiesis emphasising the pivotal role of 
RUNX1 as a master regulator of haematopoiesis. Even though RUNX1 expression is 
not essential for adult HSCs production and survival, disruption of RUNX1 levels 
perturbs the differentiation of several blood lineages. In adults, RUNX1 is expressed 
in all tissues except the heart and brain (Barseguian, Lutterbach et al. 2002, Lam 
and Zhang 2012, Ichikawa, Yoshimi et al. 2013, Martinez, Hinojosa et al. 2016, Lie, 





Fig 1-6: Schematic illustration of RUNX1 isoforms, locus and protein. (A) 
RUNX1 gene spliced variants and promotors localisation on RUNX1 locus on 
chromosome 21.  Both RUNX1a and RUNX1b are transcribed from the same P2 
promotor and contains 5 and 6 exons, respectively. RUNX1c is transcribed from the 
P1 promotor and has 8 exons. (B) The runt homology domain (RHD) is conserved 
between all the three isoform products of RUNX1. Adapted from (Sroczynska, 
Lancrin et al. 2009, Lam and Zhang 2012). 
 
RUNX1 has two main regulatory domains: the runt homology domain (RHD) 
encoded by exons 2-4, which is a DNA-binding domain and the transactivation 
domain (TAD) encoded by exon 6, which mediates protein-protein binding. RUNX1 
binds to the DNA via the RHD domain (128 amino acids) as a monomer (Fig 1-7A). 
The TAD domain interacts with E-twenty-six (ETS) family transcription factors RID, 
GATA1, MLL, CDK6, PU.1 and others. Furthermore, the core binding factor CBFβ 
does not bind DNA directly, but its interaction with RHD domain and forming the CBF 
heterodimer increases the DNA binding affinity by 10-fold. The dimerisation between 
CBFβ and the RHD domain protects RUNX1 from proteasomal degradation and 
supports the activation or repression of downstream targets (Lam and Zhang 2012, 
Obenauer, van Strien et al. 2015). 
RUNX1 does not only interact with other CBFs proteins but it also transcriptionally 
regulates co-regulators. RUNX1 requires cooperating factors to be able to bind the 
promoter and activates its target genes in tissue- and lineage-specific manner. For 
instance, RUNX1 binds ELF4 (ETS family member) to activate IL3 promotor and 
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interacts with LEF1 (Lymphoid Enhancer Binding Factor 1) to bind the enhancer of 
TCRβ. RUNX1 synergises with LEF1 and CREB (CAMP Responsive Element 
Binding Protein 1) to activate TCRα expression. RUNX1 also binds transcription 
factors directly or indirectly to regulate several master regulators of haematopoiesis 
such as GATA1, PU.1, C/EBPα (CCAAT Enhancer Binding Protein Alpha), and P300 
(E1A-associated cellular p300 transcriptional co-activator protein) (Graf 2002, 
Lorsbach, Moore et al. 2004). 
RUNX1 is regulated by post-translational modifications (Fig 1-7B). In CD34+ 
progenitors, RUNX1 is found to be phosphorylated by ERK (extracellular signal-
regulated kinases) on S266, T273, and S276. Phosphorylation at S397 via CDK1 or 
CDK6 alters its DNA binding affinity and mediates its degradation. Importantly, 
phosphorylation impairs interaction with histone deacetylases (HDACs) and 
contributes to RUNX1 capacity to activate transcription by reducing its interaction 
with transcriptional repressors. P300 can acetylate the N-terminus of RUNX1 on K24 
and K43, which controls interaction with MLL. Moreover, RUNX1 methylation 
promotes transcription repression. For example, RUNX1 methylation on R223 by 
PRMT4 (Type-I arginine methyltransferase) downregulates miR-223 which is 
involved in myeloid differentiation. Other post-translational modifications of RUNX1 
include ubiquitination that alters protein stability and activity (Jin, Jeon et al. 2004, 
Jongen-Lavrencic, Sun et al. 2008, Scholl, Gilliland et al. 2008). 
Mutated RUNX1 is frequently found in leukaemic chromosomal translocations and 
abnormal haematopoiesis (Fig 1-7C). Mutations in the RHD domain are often 
detected in familial platelet disorder with associated myeloid malignancy (FPD/AML) 
as a primary event that can progress to leukaemia. The most common chromosomal 
translocations affecting RUNX1 are t(8;21), t(12;21) and t(3;21). RUNX1 fusions that 
retain the RHD domain can bind DNA and dysregulate RUNX1 transcriptome (Zaidi, 







Fig 1-7: Schematic illustration of RUNX1 protein. (A) RUNX1 protein structure 
showing the main interacting proteins, the DNA-binding Runt domain is shown in 
green. (B) RUNX1 protein post-translational modifications and the resulting 
interactions (C). Somatic point mutations found in the RUNX1 transcript variant 2 in 
AML patients. The nonsense and frameshift changes are shown in red, the missense 
variants are shown in green. Adapted from (Blumenthal, Greenblatt et al. 2017, 




1.2.2 ETO, a co-repressor partner  
The eight twenty-one (ETO) genes belong to one evolutionarily conserved gene 
family and represent a homologue of the Drosophila nervy gene. In human, ETO 
locus is located in chromosome 8 and spans over 87 kb and 13 exons. The gene 
family gives rise to three main genes; MTG8 (also known as RUNX1T1, CBFA2T1, 
CDR or ETO), MTG16 (CBFA2T3, MTGR2 or ETO2), and MTGR (EHT or ETOR1). 
The molecular function of the ETO family is largely unexplored and the majority of 
ETO properties have been derived from studies of its fusion RUNX1/ETO. 
Nevertheless, ETO is widely viewed as a transcriptional corepressor upon 
dimerisation with histone deacetylases (Barseguian, Lutterbach et al. 2002).   
ETO produces two distinct protein isoforms consisting of 577 and 604 amino acids. 
ETO proteins do not bind DNA but can acquire this capacity when ETO fuses with 
genes encoding transcription factors where the DNA binding regions are present on 
the fusion gene such as RUNX1/ETO in t(8;21). ETO has four characteristic domains 
named NHR1-4 (Nervy Homology Regions) as shown in Fig 1-8. NHR1 is a 
homologue of the TATA-box binding protein of Drosophila and is responsible for 
protein-protein interactions. This domain is essential for ETO interactions with E-
proteins and nuclear localisation. NHR2 has a hydrophobic region with an α-helix 
structure responsible for homo- and hetero-dimerisation with other NHR domains. 
There is a binding site of SIN3 in NHR2, making this domain an essential factor for 
transcriptional repression. Both NHR3 and NHR4 are involved in the activation of 
some corepressors such as SMRT. NHR4, also known as MYND, contains two zinc 
finger motifs, but it does not bind the DNA. However, NHR4 mediates protein-protein 
interactions such as recruiting the corepressors NCOR and SMRT to the promotor of 
RUNX1 in RUNX1/ETO fusion. ETO also interacts with HDAC1-3 indirectly via 
NCOR and SIN3A through various regions inside and outside the NHR1-4 domains. 
ETO protein is expressed in the heart, brain, pancreas and lung tissues. Despite 
being detected in the CD34+ progenitors, ETO is globally downregulated in the 
haematopoietic system (Jakubowiak, Pouponnot et al. 2000, Amann, Nip et al. 2001, 





Fig 1-8. ETO protein structure. ETO consists of four Nervy Homology Regions 
NHR1-4. (Rulina et al., 2010).   
 
 
1.2.3 t(8;21)(q22;q22) a novel chromosomal abnormality   
The specific molecular mechanisms underlying chromosomal translocation are still 
vague. However, it has been suggested that a long non-coding RNA (lncRNA) 
named RUNXOR might be involved in the translocation process. RUNXOR is a 216 
kb un-spliced sense RNA transcribed from a 5 kb upstream the distal promotor (P1), 
overlaps all RUNX1 exons and introns, and interacts with the 3’-UTR of RUNX1 
promotors and enhancers. It has been found that RUNXOR lncRNA interacts with 
the chromatin at the exact intragenic site involved in RUNX1 chromosomal 
translocations with ETO leading to the formation of intrachromosomal loop, which 
may imply that RUNXOR regulates the translocation process (Wang, Li et al. 2014, 
Bracht, Wang et al. 2017). 
As aforementioned, the translocation t(8;21) is highly prevalent in AML, and leads to 
the creation of the fusion gene RUNX1/ETO (also known as AML1/ETO, 
RUNX1/RUNX1T1 or AML1/MTG8) and expression of the resulting RUNX1/ETO 
protein. In fact, RUNX1/ETO contributes to 12% - 15% of AML cases and 40% of the 
M2 subtype of AML, which associates with granulocytic differentiation. This genetic 
rearrangement can also be found in 6% of M1 (AML without maturation) cases but is 
far less common in M4 (AML with myelomonocytic differentiation) and M5 (AML with 
monocytic differentiation) cases. Both t(8;21) and inv(16) chromosomal changes are 
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grouped under the CBFβ leukaemia, and they indicate a favourable prognosis 
(Peterson and Zhang 2004, Burnett, Hills et al. 2010).  
RUNX1/ETO results from the fusion of the intron 5 of RUNX1 on chromosome 21 to 
either intron 1 or 1b of ETO on chromosome 8 when the t(8;21) takes place (Fig 1-
9A). When expressed, the fusion gene produces a transcript containing the RUNX1 
N-terminus DNA-binding domain and the repressor domains that are located towards 
the C-terminus of ETO. The resulting transcripts share a conserved and unique 
breakpoint, and since t(8;21) is an initiating event, all leukaemic cells will contain the 
same transcript. Thus, the chimaeric oncoprotein RUNX1/ETO is leukaemia-specific 
and is responsible for driving and maintaining key hallmarks of AML. RUNX1/ETO 
competes with RUNX1 binding to the DNA and disrupts the CBF complex leading to 
enhanced self-renewal and impaired myeloid differentiation (Heidenreich, Krauter et 
al. 2003, Gu, Hu et al. 2014). Despite being an early event that interrupts normal 
haematopoiesis, RUNX1/ETO and its fusion protein are not sufficient to start 
leukaemia, and secondary mutations must be required to generate the leukaemic 
phenotype (Burnett, Hills et al. 2010, Harada, Inoue et al. 2013).  
 
1.2.4 RUNX1/ETO protein characterisations and variants 
RUNX1/ETO has 752 amino acids, including nearly all ETO sequence at the C-
terminus, while the N-terminus of RUNX1 contains the Runt homology domain and 
regulates the interaction with DNA and transcription factors (Fig 1-9B). There are 
multiple isoforms of RUNX1/ETO transcripts, but most of the activity is coming from 
the full-length RUNX1/ETO protein. It was shown that one amino acid deletion or 
mutation in the NHR4 domain disturbs RUNX1/ETO structure and changes its ability 
to cause leukaemia (Peterson and Zhang 2004, Wang, Huang et al. 2009, Zaidi, 
Dowdy et al. 2009, Lam and Zhang 2012).  
A splice variant coding a shorter RUNX1/ETO protein has been described where an 
additional exon (exon 9a) is added to the ETO domain in the C-terminus. The 
truncated RUNX1/ETO9a has 575 amino acids and lacks the NHR4 and NHR3 
domains, which are essential for interaction with transcription repressors (Yan, 
Kanbe et al. 2006). In addition to RUNX1/ETO9a, another truncated splice variants 
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RUNX1/ETO11a is detected in t(8,21) AML cell lines. The expression of 
RUNX1/ETO11a in patients is insignificant, and the presence of this variant 
correlates with the expression of a truncated ETO11a protein in the testis tissue only. 
The spliced 11a exon at the C-terminus of ETO encodes 27 amino acids and does 
not correlate to any known functional motif (Kozu, Fukuyama et al. 2005). 
Post-translational modifications of RUNX1/ETO are poorly described in comparison 
to RUNX1 counterparts. The RHD domain post-translational modifications are 
preserved in both RUNX1 and RUNX1/ETO. However, the fusion lacks the 
regulatory parts of RUNX1 at the C-terminus, and thus several phosphorylation sites 
are lost in the fusion protein. RUNX1/ETO interactions with E3-ligases such as 
STUB1, SIAH1, and E2-conjugase UBCH8 lead to its ubiquitin-mediated degradation 








Fig 1-9: Schematic illustration of the translocation (8;21)(q22;q22). (A) The 
translocation chr.8 and chr.21 occurs between one breakpoint in RUNX1 gene in 
intron 5 and two possible breakpoints in ETO gene; either 1a or 1b intron. There is 
no splice acceptor in exon 1b in the ETO gene, thus the translocation leads to one 
fusion site. The dark-coloured boxes refer to the translated regions. In the 
RUNX1/ETO mRNA, the underlined numbers refer to ETO exons and the non-
underlined numbers refer to RUNX1 exons (B) Schematic illustration of RUNX1/ETO 
functional domains and its partners. Interacting proteins are located at their 
binding/interaction site along RUNX1/ETO regions. Vertical arrows refer to the region 
mediating the interaction. Adapted from (Wang, Huang et al. 2009, Lam and Zhang 
2012).   
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1.2.5 The molecular mechanism of RUNX1/ETO leukaemogenesis  
The t(8;21) leads to expression of the oncogenic RUNX1/ETO fusion protein which 
initiates, drives and maintains leukaemia by interfering with RUNX1-dependant 
transcriptional networks. In t(8;21) AML, the reservoir of the leukaemic blast is 
guarded by RUNX1/ETO that transforms the CD34+ haematopoietic stem and 
progenitors cells into clonogenic, self-renewing and hyperproliferative leukaemic 
cells. The translocation also associates with cooperating mutations that further 
enhance the proliferation and promote survival. For instance, almost 50% of t(8;21) 
patients carry non-overlapping mutations in C-KIT. Activating mutations in the RAS 
gene including KRAS and NRAS, and mutations in the FMS-like tyrosine kinase 3 
(FLT3) such as FLT3-ITD and FLT3-TKD, are detected in around 30% of t(8;21) 
AML patients. These mutations accelerate disease progression and reduce drug 
sensitivity. In general, the co-expression of RUNX1/ETO and activating mutations in 
the tyrosine kinase pathways leads to an aggressive leukaemic phenotype with a 
high incidence of relapse and poor prognosis (Wichmann, Chen et al. 2007, Nick, 
Kim et al. 2012). 
RUNX1/ETO enhances leukaemic cell clonogenicity by directly regulating several 
stem cell markers and self-renewal genes. (Martinez, Drescher et al. 2004, 
Ptasinska, Assi et al. 2012). Chromatin immunoprecipitation assays (Chip-Seq) show 
direct binding sites of RUNX1/ETO on the promotor of telomerase (TERT) leading to 
its constitutive expression. Moreover, RNAi-mediated depletion of RUNX1/ETO 
decreases TERT expression, triggers senescence and reduces clonogenicity of 
t(8;21) AML cell lines. Furthermore, RUNX1/ETO maintains high expression of the 
stem cell marker CD34 via direct binding to its transcription start site (TSS). 
Collectively, RUNX1/ETO is essential for the maintenance of the malignant 
phenotype by sustaining high expression of TERT and CD34 (Loke, Assi et al. 
2017). 
RUNX1/ETO can act as an activator and/or repressor of its direct target genes (Fig 
1-10). The RHD domain (N-terminus) regulates its binding to the DNA and drives it 
transcriptional activating activity, while ETO recruits class-I histone deacetylases 
leading to a closed chromatin structure and transcriptional repression (Loke, Assi et 
al. 2017). For example, ETO interacts with the NCOR/SMART complex leading to 
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histone deacetylation and repression of the granulocyte-macrophage colony-
stimulating factor (GM-CSF) promoter (Matsuura, Yan et al. 2012). Moreover, 
RUNX1/ETO recruits DNA (cytosine-5)-methyltransferase 1 (DNMT1) leading to 
DNA methylation and subsequent repression of its downstream genes. Generally, 
t(8;21) leukaemia is associated with epigenetic changes where RUNX1/ETO 
differentially alters chromatin accessibility and blocks differentiation of myeloid 
lineages (Gu, Hu et al. 2014). 
RUNX1/ETO can upregulate some of the RUNX1 target genes and it is not fully 
understood how the fusion changes DNA binding regions and shifts RUNX1 original 
transcriptome in the fusion protein. It is suggested that RUNX1/ETO may dissociate 
the corepressor SIN3A from RUNX1 leading to enhanced binding and thus 
transcription activation. For example, RUNX1/ETO differentially activates the 
granulocyte colony-stimulating factor (G-CSF) via enhanced RUNX1 binding 
following the previously explained mechanism (Matsuura, Yan et al. 2012).  
Although the main transcriptional activity of RUNX1/ETO is a consequent of its 
competitive binding to the RUNX1 heterodimeric partner CBFβ, the fusion protein 
can indirectly regulate transcription and independently from RUNX1. For instance, 
RUNX1/ETO binds PU.1 and displaces JUN resulting in transcriptional repression of 
PU.1. Moreover, RUNX1/ETO ceases transcriptional repression of several genes by 
competitive binding to their activators and thus significantly reducing promotor 
activation. For example, IgA and NP3 expression are reduced in the presence of 
RUNX1/ETO which prevents their activators TGF-β and C/EBPα to bind the 
promoters, respectively (Zaidi, Dowdy et al. 2009, Gu, Hu et al. 2014, Loke, Assi et 
al. 2017). 
AML propagation is driven by inhibition of the myeloid differentiation programmes by 
the RUNX1/ETO transcriptome. For instance, RUNX1/ETO represses CEBPA via 
direct binding, and RNAi-mediated depletion of the fusion gene triggers global 
chromatin changes towards the activation of C/EBPα network of myeloid 
differentiation. RUNX1/ETO blocks erythropoiesis through the inhibitory domain 
NHR4 of ETO, which prevents P300 acetylation of GATA1 resulting in a block of the 
erythroid lineage. Moreover, RUNX1/ETO activates the transcriptional repressor 
PLZF resulting in reduced myeloid differentiation. Collectively, RUNX1/ETO alters 
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the transcriptional network of several myeloid lineages to sustain the immature 
phenotype of the leukaemic blast (Heidenreich, Krauter et al. 2003, Lam and Zhang 
2012, Gu, Hu et al. 2014).  
Moreover, RUNX1/ETO cooperates with the Activation protein 1 (AP-1) to promote 
and maintain the progression of the cell cycle via a CCND-CDK complex. 
RUNX1/ETO directly binds CCND2 in a -30 kb element and interacts with the TSS 
inducing high expression of the cell cycle gene CCND2. Depletion of RUNX1/ETO by 
RNAi reduces CCND2 expression, inhibits proliferation and causes cell cycle arrest. 
Moreover, repression of CCND2 via RNAi or pharmacological inhibition of the 
CDK4/6 complex leads to G1 cell cycle arrest and induces cellular senescence 
(Martinez-Soria 2018). Cyclin D2 is involved in the phosphorylation of the tumour 
suppressor protein RB1, and its complex with CDK4/6 regulate the G1 to S phase 
transition. CCND2 is commonly mutated and overexpressed in AML, including 
t(8;21) (Buschges, Weber et al. 1999, Helsten, Kato et al. 2016). 
AML is characterised by downregulation of the retinoic acid signalling pathway (RA) 
which is involved in myeloid differentiation (Fazi, Zardo et al. 2007). RUNX1/ETO 
has a dominant negative effect on RA pathway by recruiting HDACs to RA promotor 
(Ferrara, Fazi et al. 2001). The retinoic acid receptor beta2 (RARβ2) has a tumour 
suppressor activity, but RUNX1/ETO downregulation of RA results in increased 
methylation on RARβ2 promotor and hinders transcription (Tabe, Konopleva et al. 
2006). 
The depletion of RUNX1/ETO leads to downregulation of Angiopoietin-1(ANGPT1), 
which regulates vascular development and angiogenesis. ANGPT1 is a secreted 
glycoprotein that binds the endothelial tyrosine-protein kinase receptors TIE-1 and 
TIE-2. The angiopoietin protein family (ANGPT1-4) are growth factors contribute to 
blood vessels maturation and stability (Patan 1998, Teichert-Kuliszewska, 
Maisonpierre et al. 2001, Parikh 2017). RUNX1/ETO induces high expression level 
of ANGPT1, which regulates to the leukaemic stem cell proliferation and interaction 
with the microenvironment by adhesion, migration and cell-cell interaction (Takakura, 
Watanabe et al. 2000, Loke, Assi et al. 2017).  
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RUNX1/ETO deregulates genes involved in leukaemic cell survival, such as the 
lysosomal-associated protein transmembrane 5 gene (LAPTM5) (Trombly, Whitfield 
et al. 2015, Nuylan, Kawano et al. 2016). While LAPTM5 is globally overexpressed in 
the haematopoietic system, RUNX1/ETO hypermethylates LAPTM5 promotor 
leading to transcriptional repression. LAPTM5 regulates the pH of the lysosome and 
consequently controls the lysosomal degradation pathway (autophagy) (Inoue, 
Misawa et al. 2009, Chen, Wang et al. 2017). Overexpression of LAPTM5 in AML 
cell lines decreases autophagy activity and increases sensitivity to chemotherapies 








Fig 1-10: Schematic illustration of RUNX1/ETO transcriptional network. (A) 
Transcription repression, RUNX1/ETO displaces RUNX1 from its binding sites. 
RUNX1/ETO recruits transcription corepressor such as HDACs, NCOR, and SIN3A. 
RUNX1/ETO also coordinates with DNMT1 for chromatin methylation and 
transcription repression. (B) Transcription activation, RUNX1/ETO, and RUNX1, 
along with CBFβ partners, bind to RUNX1 binding elements. RUNX1/ETO and 
RUNX1 complex then recruits AP-1. RUNX1/ETO also recruits the transcription 
coactivators such as P300 and PRMT1 to activate direct target genes. Adapted from 




1.2.6 t(8;21) AML animal models  
Several animal models were developed to study the effect of RUNX1/ETO on 
haematopoiesis. In Drosophila, RUNX1/ETO leads the expansion of immature 
haematopoietic progenitors, and this model helped to explain the role of calpain B (a 
Ca2+-dependent protease) as a mediator of RUNX1/ETO (Peterson and Zhang 
2004). The expression of RUNX1/ETO in zebrafish mirrors the human phenotype in 
terms of disruption of haematopoiesis and accumulation of immature blasts. Given 
that zebrafish haematopoiesis is very similar to its mammalian counterpart, this 
model is often used to screen chemical modulators of RUNX1/ETO. Despite quickly 
and inexpensively providing large numbers due to their short lifespans and high 
reproductive rate, zebrafish and Drosophila models are not commonly used and 
most recent in vivo studies have been performed on murine models (Peterson and 
Zhang 2004). 
The generation of a murine model of AML, and more specifically t(8;21) leukaemia, 
has always been a challenge and an optimal mouse model for RUNX1/ETO is yet to 
be created. The first attempt aimed to generate a RUNX1/ETO transgenic mouse by 
inserting the RUNX1/ETO gene into the RUNX1 locus and producing a RUNX1/ETO 
heterozygous mouse. Of interest, homozygous mice from this model died during the 
embryonic stage (E12.5) mimicking the phenotype of RUNX1 or CBFβ deletion. In 
those models, mice foetus failed to establish definitive liver haematopoiesis. Indeed, 
CD45+ cells isolated from heterozygous embryos could differentiate into dysplastic 
myeloid colonies and macrophages, while those taken from RUNX1 and CBFβ 
mutant mice could not develop any haematopoietic progenitors. In conclusion, early 
attempts to establish transgenic RUNX1/ETO mice revealed that RUNX1/ETO acts 
as a negative regulator of RUNX1 with other functions may stimulate 
leukaemogenesis (Yan, Kanbe et al. 2006, Hyde, Zhao et al. 2015). 
A second mouse model was generated by inserting controlled RUNX1/ETO 
promotors such as, tetracycline response element (Tet), Ca2+-binding proteins 
calgranulin B (Mrp8) which is expressed in the myeloid lineage, Cre recombinase-
mediated (Cre), and hematopoietic stem cell Sca-1 locus (Sca1) transgenic mice 
(Yuan, Zhou et al. 2001). 
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A xenograft mouse model was successfully generated by retroviral transduction of 
human CD34+ progenitors with the truncated fusion RUNX1/ETO9a and then 
transplanting them into immunodeficient mice. The 9a exon of ETO provides a stop 
codon at the end of exon 8 leading to the expression of a truncated version of the 
fusion protein. The expression of RUNX1/ETO9a in CD34+ cells leads to early onset 
of immature blast and AML in the xenograft model (Yan, Kanbe et al. 2006). 
Clinically, the co-expression of RUNX1/ETO9α with RUNX1/ETO is present in over 
50% of the M2 subtype of AML and often correlates with a lower count of aberrant 
myelocytes in the bone marrow with downregulated CD19 and upregulated CD56 
expressions. Although patients with t(8;21) have a favourable prognosis, the 
occurrence of RUNX1/ETO9α with an elevated level of C-KIT mutation indicates 
poor prognosis. The RUNX1/ETO9a xenograft model makes a clinically relevant 
model of AML in a murine background (Li, Chen et al. 2012, DeKelver, Lewin et al. 
2013). 
 
1.2.7 CBF AML treatment and clinical outcomes  
The standard AML treatment consists of two stages: induction and post-remission. 
Induction usually includes DNA damaging agents such as cytarabine (AraC) and 
anthracyclines, which cause cell death and reduce the bulk of leukaemic blasts. 
Post-remission treatments are usually selected according to the leukaemia karyotype 
and age of the patient. The most common combinational therapy is a high dose of 
AraC with mitoxantrone (Burnett, Hills et al. 2010, Grimwade, Hills et al. 2010).  
Generally, CBF leukaemias, including t(8;21) AML, share a good prognosis and a 
high response rate to chemotherapy, especially to AraC, with complete remission 
achieved in around 90% after standard treatment. Some patients benefit from a 
combination of high a dose of AraC and HDACs inhibitors (Grimwade, Hills et al. 
2010). Although the treatment protocol is standardised for CBF AML, the t(8;21) 
patients have the worst response in comparison to those with in(16) AML. The 
overall survival is 4.4 years with 14% relapse incidents compared to 7.1 years for 
t(8;21) and inv(16), respectively (Cairoli, Beghini et al. 2006, Burnett, Hills et al. 
2010, Vaskova, Dubayova et al. 2015).     
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In some cases, when chemotherapies fail to restore normal haematopoiesis, stem 
cell transplantation can be a third option, but bone marrow transplantation is not 
widely common in t(8;21) leukaemia. The MRC clinical data showed a subtle 
difference in the survival between standard chemotherapy and stem cells 
transplantation while other trials in Europe suggested that transplantation might lead 
to a worse prognosis. In summary, there is a need for better treatment for t(8;21) 
AML and new treatments should increase the survival rate, reduce relapse and 
lessen the burden of the side effects (Burnett, Hills et al. 2010, Vaskova, Dubayova 





1.3 Gene Silencing via RNAi  
1.3.1 Small RNAs biogenesis 
Genome scales up with developmental complexity, but the number of protein-coding 
genes does not correlate with this organismal complexity. For example, the single-
celled eukaryote T. vaginalis has 160 million base pair (bp) of genomic DNA coding 
over 60,000 protein-coding genes while human DNA (2.9 billion bp) compasses just 
around 20,000. The so-called ‘’ junk DNA’’ is believed to be differentially transcribed 
to generate non-coding RNAs that regulate the architecture of gene expression 
during development and differentiation (Cech and Steitz 2014, Deniz and Erman 
2017, Liu, Liu et al. 2017, Belair, Sim et al. 2018). 
The first evidence for small non-coding RNA (sRNA) gene-mediated silencing was 
found in plants and fungi, yet those silencing pathways are believed to be dominant 
in almost all eukaryotic cells including humans (Davis, Zuckerman et al. 2010). To 
date, research led to the identification of over twenty distinct sRNA classes. Some 
sRNA subtypes have been extensively studied while others remain poorly 
understood (Diederichs 2014).  
The discovery of double-stranded RNA (dsRNA) as a putative regulator of post-
transcriptional gene expression has elucidated several puzzling observations of gene 
regulation in plants and yeast. This phenomenon was termed as RNA interference 
(RNAi). RNA interference depends on dsRNA to inhibit protein synthesis by targeting 
specific messenger RNA (mRNA) for degradation or translational inhibition. RNAi-
mediated gene silencing became a ubiquitous research tool for understanding 
biology and gene regulation in eukaryotes (Davis, Zuckerman et al. 2010, Schuck, 
Gursinsky et al. 2013, Liu, Liu et al. 2017).   
It is estimated that over 60% of human mature mRNAs undergo several RNAi-
mediated pathways, mostly promoting mRNA decay. Several genes regulate RNA 
interference biogenesis and pathways such as AGO2, R2D2, DICER2, TRBP, 
GW182 and others. The best two understood classes of RNA interference are 
microRNA (miRNA) and short interference RNA (siRNA). Both miRNA and siRNA 
assemble into a protein complex named the RNA Induced Silencing Complex (RISC) 
(Diederichs 2014, Schirle, Sheu-Gruttadauria et al. 2014).   
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The canonical biogenesis of endogenous siRNAs and miRNAs involves several 
steps of endonucleolytic processing of nuclear dsRNA precursors by RNase III family 
enzymes (Fig 1-11). In the nucleus, dsRNAs are transcribed by RNA polymerase II 
from the vast majority of the DNA, and these precursors are called pri-miRNA, which 
encode one or several precursor miRNAs and/or siRNAs. The cytoplasmic fully 
complement dsRNAs precursors follow endonucleolytic cleavage by DICER 
producing a duplex of 21 - 25 nucleotide-long known as siRNA. On the other hand, 
the nuclear pri-miRNAs are processed by DROSHA (RNase III family enzyme) 
resulting in hairpin per-miRNA transcripts. The pre-miRNAs are then exported to the 
cytoplasm where DICER performs a second cleavage producing the miRNA-miRNA* 
duplex in which miRNA is the antisense (also known as mature or guide strand) and 
the miRNA* is the sense (star or passenger strand) (Carthew and Sontheimer 2009, 





Fig 1-11. Small regulatory RNAs biogenesis and mechanisms. (A) pri-miRNA is 
processed by DROSHA/DHCR8 complex to produce pre-miRNA which are exported 
to the cytoplasm. DICER processes pre-miRNA by removing the hairpin to generate 
miRNA-miRNA* duplex which is loaded into the RISC complex. After loading into 
RISC, the antisense strand is selected by AGO2, and the sense strand is released. 
The antisense strand directs the RISC complex to a complementary mRNA. (B) Long 
dsRNA are exported to the cytoplasm where DICER generates 21 - 25 nucleic acid 
short siRNA which is loaded into the RISC complex. The selection of the antisense 
strand and recognition of the mRNA are performed by the RISC complex in the same 
mechanism of miRNA. RNA interference by siRNA and miRNA lead to transcript 
repression by several mechanisms, including miRNA degradation and translation 




1.3.2 Short interference RNA (siRNA)  
Synthetic siRNA is a double-stranded oligonucleotide where the antisense strand is 
complementary to a specific mRNA. However, the sense strand is not supposed to 
perform any RNAi-mediated gene regulation. In the cytoplasm, siRNA incorporates 
into the RISC complex and targets specifically the complementary mRNA resulting in 
either mRNA cleavage or inhibition of ribosomal translation. RISC assembly requires 
both siRNA and miRNA to be at least 14 nucleotides long and carry a 5’-
monophosphate and a 3’-dinucleotide overhang (Pham and Sontheimer 2005, 
Tomari and Zamore 2005, Maiti, Nauwelaerts et al. 2011).  
 
1.3.3 Structural insights into AGO functions 
The Argonaute proteins family (AGOs) is found in almost every living organism. 
While there is only one AGO protein in the fission yeast (Schizosaccharomyces 
pombe), there are up to 27 AGO family members in C. elegans. In humans, there are 
eight subfamilies of AGO proteins involved in several silencing pathways, which are 
divided into four clades (AGO1-4) and four PIWI clades (PIWI1-4). The catalytic 
activity of RISC is believed to be solely controlled by AGO2, although AGO1-3-4 can 
bind dsRNA (Pham and Sontheimer 2005, Vasselon, Bouttier et al. 2013, Yi 2018).  
AGO2 hosts the siRNA in which it plays two roles in RISC functions. First, the 
recognition of the siRNA termini and second facilitating the slicing activity. Within 
RISC, the full complementary base pairing between the siRNA and mRNA requires 
conformational changes in AGO2 structure. One AGO2 protein can catalyse many 
silencing cycles where the siRNA guide strand remains bound to the protein, and the 
cleaved mRNA fragments are released (Kawamata and Tomari 2011, Nakanishi 





1.3.4 AGO2 functional domains 
AGO2 consists of four domains, PIWI in the C-terminus, PAZ, middle domain (MID), 
and an N-terminus domain. AGO2 has a bilobate architecture where the first lobe is 
made of the MID and PIWI domains, whereas the N-terminus and PAZ domains 
make the second lobe (Fig 1-12). The PAZ domain recognises and binds the 3’-ends 
of the siRNA. The PIWI domain acts as RNase H endoribonuclease and performs 
the mRNA cleavage. The MID domain adopts the ribose binding domain of the 
lactose repressor (DNA-binding protein) and binds to the 5’-phosphate of the guide 




Fig 1-12. Structure of human Argonaute protein AGO2. (A) Schematic illustration 
of AGO2 protein domains. AGO2 contains four functional domains connected by two 
linker domains. N-terminus and PAZ domains are connected by L1 domain, MID and 
PIWI domains are connected by L2 domain. (B) Crystal structure of AGO2 domains 
hosting a guide RNA in red. The 3’-terminus of the RNA is hosted in the PAZ domain 




1.3.5 Recognition of siRNA termini 
The PAZ domain is responsible for initiating RISC assembly as well as determining 
which strand of the siRNA is the antisense. PAZ differentially interacts with the 
thermodynamically stable end that is characterised by strong Watson−Crick base 
pairings. PAZ domain hosts the first two 3’-end overhang nucleotides of the 
antisense in a sequence-nonspecific recognition and makes less interaction with the 
5’-end (Gu, Jin et al. 2012, Kwak and Tomari 2012). 
The two terminal bases at 3’-end of the antisense stay exposed to the solvent where 
their phosphodiester backbone interacts with the PAZ side chain. Additionally, a 
hydrophobic pocket in PAZ domain partly hosts the terminal 3’-end nucleobase of 
the antisense (Pham and Sontheimer 2005). 
The 5’-end of the siRNA antisense strand is hosted in a deep pocket between the 
PIWI and MID domains. The 5’-end phosphate group is crucial for RISC assembly as 
it twists and does not base pair with the mRNA. The 5’-end is also recognised by two 
invariant lysines in the MID domain. However, the 5’-end does not play any role in 
recognition of the antisense (Frank and Nagar 2017, Schlundt, Tants et al. 2017, 
Sasaki, Tadakuma et al. 2018). 
 
1.2.6 RISC slicer activity  
In eukaryotic cells, AGO2 functions similarly to RNase H as an RNA-guided 
endonuclease. The seed region (5 nucleotides between the 2nd and 7th base of the 
antisense at the 5’-end) makes the first interaction with the target mRNA, but a full 
complementarity between the antisense and mRNA and is required for efficient 
RISC-mediated cleavage. The endonucleolytic attach occurs at the mRNA scissile 
phosphate group located opposite to the phosphodiester bridge between the 10th 
and 11th nucleotides of the antisense 5’-end (Martinez and Tuschl 2004, Schwarz, 
Tomari et al. 2004, Sontheimer 2005).   
Similarly, to RNase H, the catalytic cleavage performed by the PIWI domain requires 
a divalent metal cation such as Mg2+. Given that RISC mechanism is endonuclease 
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analogue, the 5’-end products carry a 3’-OH group, and the 3’-end products carry a 
5’-phosphate group (Fig 1-13). RNase H enzymes are characterised by a catalytic 
tetrad motif (Asp-Glu-Asp-Asp), but the catalytically active PIWI domain in AGO2 
carriers an (Asp-Asp-His) motif which coordinates two Mg+2 between the antisense 
and mRNA (Martinez and Tuschl 2004, Schwarz, Tomari et al. 2004, Sontheimer 




Fig 1-13. mRNA cleavage mechanism and products mediated by RISC. The 
mRNA nucleotides pair to the 10th and 11th antisense nucleotides (counting from 
the 5’-end). AGO2 provides the catalytic motifs where one or more Mg2+ cations 
directly coordinate the oxygen atoms of the water molecules. The cleavage 
products are 3′-hydroxyl and 5′-phosphate. Adapted from (Martinez and Tuschl 




The RNA duplex formed from the base pairing between the antisense and mRNA is 
about 2 rounds of α-helix given that every 10 nucleotides make one RNA turn. For 
this reason, in order for RISC to perform its endonucleolytic activity, AGO2 first 
undergoes structural rearrangement to accommodate the full-length RNA duplex by 
shifting the two lobs apart to allow mRNA full hybridisation with the antisense. The 
new conformation of AGO2 leads to the release of the antisense 3’-end from the 
PAZ domain. (Lingel, Simon et al. 2003, Schlundt, Tants et al. 2017, Yi 2018).  
Mismatches are not highly tolerated in siRNA in comparison with miRNA. The full 
complementarity between the target mRNA and antisense is crucial for efficient 
endonucleolytic cleavage. For this reason, introducing a mismatch in the seed region 
may reduce target recognition, and the presence of several mismatches in the 
antisense impairs the efficacy of the cleavage (Tomari and Zamore 2005). The 
introduction of mismatches is a universal tool for the design of reference and control 
oligonucleotides (Haley and Zamore 2004).      
 
 
1.4 siRNA chemical modification 
To utilise the RNAi pathway as a therapeutic agent, siRNA should overcome several 
pharmacokinetic (PK) and pharmacodynamic (PD) challenges. Oligonucleotides, and 
siRNA specifically, are susceptible to enzymatic degradation and have a poor 
pharmacokinetic profile in the systemic circulation. The siRNA pharmacodynamics 
challenges are target specificity, off-target binding and immunostimulation. For these 
reasons, chemical modifications have been investigated to control the nucleases 
stability, bioavailability, binding affinity and specificity (Kobayashi and Tomari 2016, 
Shen and Corey 2018). In general, chemical modifications are classified into three 
main categories;  
1- Phosphodiester linkage modifications.  
2- Sugar modifications.   




The potency of siRNA is driven by its target specificity. Introducing chemical 
modifications to siRNA changes both siRNA-mRNA and siRNA-protein interactions, 
which may improve the silencing efficiency. Given that the human genome encodes 
homologous regions, it is difficult to silence these transcripts efficiently by siRNA. 
That is because a full complementarity of mRNA to siRNA in the seed region is the 
major determent of siRNA specificity. It is not always feasible to eliminate the off-
target binding of siRNA by sequence adjustments making it challenging to 
discriminate between the on-target and off-target silencing. However, chemical 
modifications that weaken the (siRNA/RISC)-mRNA interactions might reduce the 
off-target silencing (Lee, Seok et al. 2015, Jiang, Zhu et al. 2017) . 
Since riboendonucleases such as RNase A, as well as, exonucleases exist in almost 
every intra and extracellular environment or body fluid, it is crucial to increase siRNA 
enzymatic stability. Several RNases catalyse the hydrolysis of oligonucleotides into 
shorter fragments. For example, RNase H2, which requires divalent cations such as 
Mg+2, targets oligonucleotides at the 3’-phosphodiester and gives 3’-OH and 5’-
phosphate products. Moreover, exonucleases attack the 3’-end, and hydrolysis 
progress toward the 5’-end (Martinez and Tuschl 2004, Schwarz, Tomari et al. 2004, 
Sontheimer 2005).    
The first chemical modification of oligonucleotides is phosphorothioate linkage (PS) 
at the 3’-end of the siRNA. This modification enhances the siRNA serum stability. 
Among the earliest potent modifications is the substitution of 2’-OH of the ribose in 
pyrimidine bases with either fluoro (2’-F) or O-methyl (2’-O-Me) moieties. Those 
modifications improve siRNA PK and PD in vivo. Combinations of PS with 2’-F 
and/or 2’-O-Me result in much more stable siRNA in comparison with each 
modification alone (Watts, Martin-Pintado et al. 2010, Wei, Jones et al. 2011, Lee, 
Seok et al. 2015). 
Food and Drug Administration (FDA) approved in 2010 an antisense-based drug 
called ‘’Kynamro’’, carries PS and 2’-O-Me modifications. Kynamro have been 
proven a potent inhibitor of apolipoprotein B synthesis, and shown to be effective in 




The activity of 2’-sugar modifications depends on the charge and size of the 
introduced group. Replacement of 2’-OH with a more electronegative element such 
as F leads to sugar conformation and alters the geometry of the oligonucleotide α-
helix. This structural change reduces the efficiency of nucleases attack and improves 
siRNA stability. On the other hand, introducing a neutral group such as O-Me does 
not significantly interfere with the sugar puckering and thus does not improve siRNA 
stability against metal-dependent endonucleases. However, 2’-O-Me enhances 
siRNA stability by lessening the efficacy of water molecule nucleophilic attack on the 
phosphodiester backbone (Watts, Martin-Pintado et al. 2010, Wei, Jones et al. 
2011).  
The sugar ribose exists in two different forms, either C2’-endo (South) as in DNA or 
C3’-endo (North) in RNA (Fig 1-14). The favourable gauche confirmation for 2’-F is 
C3’-endo because the fluorine atom will be in the same orientation with the ring 4O’ 
in a stable α-helix confirmation. In unmodified RNA, 2’-OH makes hydrogen bonds 
with water molecules in the solvent around the phosphodiester group in the minor 
groves, but 2’- F hinders the formation of these hydrogen bonds. On the contrary, 
since 2’-F is antiperiplanar, the nucleobases are more polar, which lead to stronger 
Watson−Crick interactions. For this reason, 2’-F modification shifts the balance 
towards C3’-endo, which improves RNA duplex stability via enhancing W-C base 
pairing in α-helix. The North confirmation can also be generated by 2’-O-Me 
modification (Watts, Martin-Pintado et al. 2010, Deleavey and Damha 2012).  
2’-F modifications are well tolerated in both siRNA strands. In general, 2’-F 
modification enhances the stability of pyrimidine-rich sequences toward 
endonucleases, but it does not provide significant resistance in comparison with 2’-
O-Me modification (Eder, DeVine et al. 1991, Beigelman, Karpeisky et al. 1995).  
Importantly, 2’-modifications influence the melting temperature of the siRNA. In fact, 
the master role in siRNA design is to create thermodynamic asymmetry in the duplex 
that favours the retention of the antisense in the RISC complex. For instance, 2’-F 
modification at the siRNA 5’-end stabilises the siRNA by creating two types of 
hydrogen bonds (Fig 1-15). The first type is pseudo hydrogen bonds in purine bases 
between the 2’-F and H8 of the same base. The second type of hydrogen bonds is 
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formed between 2’-F and H8 of the 3′-complementary neighbouring base (Watts, 




Fig 1-14. Pseudorotational wheel of furanose interactions. The α-form of RNA 
sugar is C3’-endo (North), and the β-form of DNA sugar is C2’-endo (South). X= OH 




Fig 1-15. Pseudohydrogen interactions between 2’-F and H8 in purine.  
Introducing 2’-F to the sugar prefers the North confirmation where the 2’-F is 
antiperiplanar and can form interaction with the H8 of it is won purine base (right) or 




Since the 70s, phosphorothioate (PS) modification is a proven approach to increase 
siRNA stability against endonucleases. The modification is achieved by replacing 
one of the non-bridging oxygen atoms of the phosphate group with a sulphur atom. 
Phosphodiester linkage is negatively charged under physiological conditions (pKa = 
2). The synthesis of PS oligonucleotides via standard phosphoramidite synthesis 
methods yields diastereomeric products, which may contribute to variable activities. 
The Rp isomer is more susceptible to RNase H degradation while the Sp 
configuration exhibits stronger nuclease resistance. The stereo-random PS isomer is 
more stable in comparison with the Sp and Rp isomers. For this reason, controlling 
PS chirality is vital for predicting the therapeutic activity of the siRNA (Cook, Holman 
et al. 1969, Zon and Geiser 1991, Jaroszewski, Clausen et al. 1996, Iannitti, 
Morales-Medina et al. 2014). 
Nevertheless, elimination of the chiral phosphor centre by substituting both oxygen 
atoms of the phosphate group with two sulphur atoms (PS2) results in only non-
isomeric products (Bailey, Shen et al. 2017). Combination of 2’-O-Me and PS2 
modifications enhance the siRNA activity and improve stability. Of notice, when 2’-O-
Me and PS modification increases siRNA duplex stability, the combination of PS2 
with 2’-O-Me not elevate the melting point of the siRNA duplex but it increases 
siRNA loading into RISC (Incarnato, Anselmi et al. 2017). 
Phosphorothioate and 2’-sugar modifications are position dependent. In general, 
modifications at the 3’-end of the antisense strand are more effective than 5’-end 
modifications. In fact, body fluids contain more 3’-end exonucleases than 5’-end 
nucleases. Moreover, modifications at the 5’-end might impair the affinity of the seed 
region to the targeted mRNA. The most well-tolerated modifications on the antisense 
strand are those 2’-F as they are feasible almost along the whole stand. On the 
contrary, 2’-O-Me modifications on the antisense strand are strictly sequence-
dependent. The 2’-O-Me is more effective at the 3’-end and in the centre of the 
siRNA sense strand (Eder, DeVine et al. 1991, Heemskerk, de Winter et al. 2009, 
Iannitti, Morales-Medina et al. 2014). 
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1.5 Oligonucleotide delivery  
1.5.1 siRNA delivery challenges 
Oligonucleotide delivery to their target by systemic administration is a major 
challenge facing the development of siRNA therapeutics. Oligonucleotides are 
negatively charged under physiological conditions and cannot maintain their effective 
dose in the targeted site for a prolonged period. That is because oligonucleotides are 
not stable in the bloodstream and undergo rapid elimination by the kidney via tubular 
secretion. Beside renal secretion, siRNA is also retained and accumulated in the 
liver. Due to the siRNA large molecular weight (about 13 kDa) and its hydrophilic 
properties and negative charge, naked siRNA cannot pass the cellular membrane by 
passive diffusions. For these reasons, introducing chemical modifications and 
developing delivery vehicles are essential for the development of siRNA-based drugs 
(Juliano 2016, Kaczmarek, Kowalski et al. 2017, Khvorova and Watts 2017). 
siRNA has immunogenic properties when they are administered systemically. The 
immune stimulation by siRNA is either sequence dependant controlled by the 
stimulation of the pattern recognition receptors (PRRs) or sequence independent 
driven by the status of the 5’-phosphate terminus. The innate immune system 
recognises siRNA and induces the production of pro-inflammatory cytokines such as 
IL-1, IL-6, IL-12, and TNF-α (Whitehead, Dahlman et al. 2011, Lim and Staudt 2013, 
Meng and Lu 2017). 
Moreover, siRNA activates different members of the toll-like receptor family (TLR). 
For instance, siRNA activates TLR-3 pathway resulting in release of interferons IFN-
α and IFN-β, which lead to enhanced proliferation of the natural killer (NK) cells and 
memory T cells. Single-stranded RNA also can activate TLR-8, which is enriched in 
the myeloid lineage, leading to hyperproliferation of NK cells. Furthermore, siRNA 
activates, in a sequence-independent manner, the RNA helicase protein retinoic 
acid-inducible gene 1 (RIG-1) and triggers a strong interferon response. The dsRNA-
dependent protein kinase (PKR) can also be activated by siRNA resulting in 
translational inhibition and increased interferons secretion (Clemens and Elia 1997, 
Pang, Keeble et al. 2000, Hiratsuka, Watanabe et al. 2008, Dalpke and Helm 2012).    
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Chemical modification and the avoidance of specific motifs during siRNA design can 
reduce the immunostimulatory potential. The cytoplasmic receptors RIG-1 and PKR 
also bind bunt ended oligonucleotides and 5’-triphosphate. The TLR-7 and TLR-8 
receptors recognise AU- and GU-rich motifs, but 2’-O-Me modifications reduce the 
activation of these TLR pathways (Forsbach, Nemorin et al. 2008, Zhang, Ohto et al. 
2017). 
With the exception of the liver, systemic delivery to haematopoietic tissues and 
organs has proved to be challenging. Leukaemic cells are circulating in the body 
fluids, and malignant HSCPs are hidden in the protective bone marrow niche. 
Moreover, siRNA has slow penetration through the capillary endothelium 
emphasising the need for a delivery system. Nanoparticles can cope with some of 
the delivery challenges. For instance, encapsulating siRNA into a nanoparticle 
protects the siRNA from serum nucleases, provides improved biodistribution and 
enhances the pharmacodynamic and pharmacokinetic properties. Nanoparticles can 
be functionalised with surface ligands that improve the accumulation of siRNA in the 
relevant leukaemic compartments (Juliano 2016, Kaczmarek, Kowalski et al. 2017). 
The efficiency of the delivery vehicle depends on the size and charge of the 
nanoparticle. The diameter of a nanoparticle between 20 - 70 nm is desirable for 
targeting leukaemic cells because it allows cellular uptake by receptor-mediated 
endocytosis. The reticuloendothelial system usually recognises nanoparticles larger 
than 100 nm and shortens their half-life. Moreover, nanoparticles carrying high 
positive or negative charge coagulate rapidly with serum proteins and have short 
circulation time. Typically, the nanoparticle circulation time can be enhanced by the 
addition of polyethylene glycol (PEG) which stabilises the surfaces and provides a 
stealth effect. However, PEGylation reduces the efficacy of the siRNA endosomal 
escape and triggers an immune response. For these reasons, the development of 
nontoxic nanoparticle for siRNA delivery is an arduous task that requires multi-
disciplinary skills (Hoarau, Delmas et al. 2004, Akinc, Goldberg et al. 2009, Semple, 
Akinc et al. 2010, Chen, Tam et al. 2016).  
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1.5.2 Polymer nanoparticle   
Micellar delivery systems are intensively investigated drug nanocarriers. Micelles are 
formed from synthetic copolymers bearing at least two polymer blocks that provide 
amphiphilic properties. The physical phenomena behind the self-assembly of 
micelles is the hydrophilic and hydrophobic interactions between the polymer chains 
and the solvent. When the concentration of amphiphilic molecules reaches a specific 
concentration, known as the critical micelles concentration (CMC), these molecules 
assemble in symmetric structures. These self-assembled structures vary from 
spherical vesicles, cylinders, tubes and bilayer or lamellar. The formed micellar 
structure depends on the critical packing parameter of the amphiphilic molecule, 
which is determined by the ratio between the volume of the hydrophobic chain and 
the length of the hydrophilic chains (Jones and Leroux 1999, Zhang, Huang et al. 
2014, Braunova, Kostka et al. 2017, Keskin and Tezcaner 2017). Synthetic polymers 
allow for the addition of conjugates to the surface of the micelles. Functionalised 
micelles with ligands specific for leukaemic cells such as single-chain variable 
fragment (scFv) (Jhaveri and Torchilin 2014), aptamers or short peptides against 
specific surface markers enhance the association of the micelles with the leukaemic 
cells and increase the bioavailability of the siRNA (Bolu, Sanyal et al. 2018). 
Despite a large amount of research on synthetic polymers for drug delivery, very few 
are showing promising clinical perspectives mainly due to cytotoxicity. Water-soluble 
polymers, especially cationic polymers such as polyethyleneimine (PEI), efficiently 
encapsulate siRNA due to the electrostatic interaction between the protonated 
polymer chains and the negatively charged siRNA (Shi, Chou et al. 2013, Navarro, 
Pan et al. 2015). These particles are called polyplexes, and they have fast cellular 
uptake and easy endosomal release by the so-called proton sponge mechanism. 
Following endocytosis, polyamines absorb protons in the endosomes leading to an 
increase the endosomal membrane potential. Consequently, chloride molecules are 
diffused into the endosome to restore the equilibrium leading to rapid raise of 
osmotic pressure and further swelling of the endosome followed by rupture and 
release of the endosome contents onto the cytoplasm (Benjaminsen, Mattebjerg et 
al. 2013, Jhaveri and Torchilin 2014). 
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Under physiological conditions, polyplexes interact and aggregate with negatively 
charged serum proteins. For this reason, shielding polyplexes with PEG is required 
to improve circulation time. Moreover, cationic polymers usually have high 
cytotoxicity. Shortening the length of the polymer may reduce the toxicity but also 
destabilise the polyplexes. The chemical addition of PEG to copolymers generates 
triblock copolymers which are less toxic and have prolonged circulation time (Werfel, 
Jackson et al. 2017). 
 
1.5.3 Cell-penetrating peptides (CPP)    
Cell-penetrating peptides (CPPs) consist of 5 - 40 amino acids, typically positively 
charged or have amphipathic properties. Polycationic CPPs complex siRNA by 
electrostatic interactions. Moreover, some CPPs covalently couple siRNA via linkers 
capable of releasing siRNA upon cellular uptake. The most common CPPs are 
arginine-rich such as the HIV-TAT peptide which has high cell penetrating properties. 
Furthermore, some peptides have tissue-specific homing properties such as the LSD 
peptide (CLSDGKRKC) which target melanoma and osteocarcinoma cells, and 
293P-1 peptide (SNNNVRPIHIWP) is specific for hepatocytes. Cell-penetrating 
peptides can target leukaemic surface markers such as TLR-2 receptor and 
integrins. The mechanism by which CPPs entre the cell is not well defined and 
mostly contributed to surface binding followed by active endocytosis, membrane 
internalisation or membrane flip-flop mechanism (Ishihara, Goto et al. 2009, Li, Lv et 
al. 2014). 
 
1.5.4 Lipid-based delivery systems     
Lipid-based delivery systems are attractive nanocarriers for oligonucleotides due to 
their high encapsulation efficiency and reduced immunogenicity. The most two 
intensively studies lipid nanocarriers of siRNA are liposomes and lipid nanoparticles 
(LNPs) (Fontana, Liu et al. 2017, Shajari, Mansoori et al. 2017).  
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A liposome is closed phospholipid bilayers with aqueous core and spherical 
structure. Alec Bangham in 1965 described membrane-like vesicles as swollen 
phospholipid systems and called them bangosomes which are later named 
liposomes (Bangham, Standish et al. 1965). Liposomes are promising drug carriers 
with improved biodistribution and minimal toxicity. Unilamellar liposomes are typically 
generated under low pressure via simple techniques involving extrusion through 
polycarbonate filters. Liposomes with diameters less than a 100 nm can be produced 
by sonication and extrusion of lipid films. It is feasible today to produce liposomes, 
and LNPs with size ranges between 20 to 200 nm via microfluidics mixing 
techniques (Al-Jamal and Kostarelos 2011, Abu Lila and Ishida 2017, Yue and Dai 
2018).  
Liposomes have been widely used in drug delivery due to their chemical and 
structural properties. A typical liposome can encapsulate both hydrophobic 
molecules within its lipid shell, and hydrophilic molecules in the aqueous core. The 
size and surface charge of liposomes influence their stability and pharmacokinetic 
properties in vivo. Research in the late 80s led to the development of the first clinical 
liposome encapsulating doxorubicin. There are several clinically approved lipid-
based vehicles encapsulating different drugs, mostly cancer therapeutics (Table 1-
4). The size of these liposomes is less than 100 nm, which provides enhanced 
penetration retention (EPR) in the targeted site after intravenous administration. 
Besides the hydrodynamic diameter, several factors influence the EPR, such as 
surface charge and vascularity of the targeted site (Cullis and Hope 2017, Yue and 
Dai 2018) (Barata, Sood et al. 2016, Bobo, Robinson et al. 2016).    
 
Name  Drug  Disease  Year approved  
AmBisome amphotericin B Fungal infections 
Leishmaniasis 
1990 (Europe), 1997 (USA) 






Table 1-4: Lipid-based drugs in the clinic. Adapted from (Barata, Sood et al. 
2016, Bobo, Robinson et al. 2016) 
 
Formulations of lipid with the siRNA-loaded solid core, such as metal-based 
nanoparticles can improve siRNA delivery. It is also possible to shield polyplexes 
and micelles with a lipid mono or bilayer. This strategy stabilises the nanoparticle 
structure by eliminating the effect of the critical micelle concentration (Braunova, 
Kostka et al. 2017, Keskin and Tezcaner 2017).   
Lipids are versatile materials to design unique siRNA nanocarriers, such as LNPs. 
Lipid nanoparticles do not contain large aqueous core. Instead, they have packed 
core with several islands encapsulating hydrophilic materials. LNPs consist of 
ionisable cationic lipids, helper lipid, cholesterol and stabilising agent such as 
polyethylene glycol or dextran. The flexibility of lipid formulations allows for control 
over the LNPs size and charge. For example, the rigidity and permeability of the LNP 
membrane can be modulated by changing the cholesterol concentration. The 
Breast cancer 2003 (Europe, Canada) 
DaunoXome daunorubicin Kaposi’s sarcoma 1996 (Europe), 1996 (USA) 
Myocet doxorubicin Breast cancer 2000 (Europe) 
Abelcet amphotericin B Aspergillosis 1995 (USA) 
Amphotec amphotericin B Aspergillosis 1996 (USA) 
Visudyne verteporphin Macular 
degeneration 
2000 (USA), 2003 (Japan) 
Lipo-Dox doxorubicin Kaposi’s sarcoma, 
breast and ovarian 
cancer 
2001 (Taiwan) 





addition of helper lipid can alter the lipid membrane structure. Typically, helper lipids 
are added to LNPs formulations to improve stability and bioavailability. For example, 
addition of cationic lipid, such as dipalmitoylphosphatidylcholine (DOPC) leads to 
laminar bilayer structure. Another class of helper lipids are 
thehosphorylethanolamines which promote active endocytosis such as 1,2-
distearoyl-sn-glycerol-3-phosphoethanolamine (DSPE). Sphingomyelin and 
phosphocholine lipids are commonly used in formulations of stable liposomes and  
LNPs. Furthermore, LNPs stability is achieved by the addition of PEG that provides a 
shielding effect. Helper lipids should be added to LNPs formulations with caution 
because they slowdown siRNA endosomal release as well as trigger immunogenic 
responses (Bao, Jin et al. 2013, Chen, Tam et al. 2014, Leung, Tam et al. 2014, 
Cheng and Lee 2016, Hashiba, Sato et al. 2017). 
Immunoliposomes are generated from the coupling of ligands such as antibodies, 
antibody fragments (scFv), CPPs or small molecules. Targeting ligands are usually 
chemically bound to hydrophobic anchors. The anchors are either added to the lipid 
formulation or added to liposomes by postinsertion. Among the most commonly used 
anchors, PEGylated helper lipids terminating with functional groups, such as 
maleimide or azide, which allow thiol-maleimide Michael additions or azide-alkyne 
cycloaddition, respectively. Functionalised immunoliposomes and LNPs accumulate 
in the targeted site and have improved pharmacodynamics (Leung, Tam et al. 2014, 
Fisher, Mattern-Schain et al. 2017, Hashiba, Sato et al. 2017, Kuang, Ku et al. 
2017).   
Ionisable cationic amino-lipids (Fig 1-16) such as dilinoleylmethyl 4-
dimethylaminobutyrate (Dlin-MC3-DMA) and 2,2-dilinoleyl 4-dimethylaminoethyl-
[1,3]-dioxolane (Dlin-KC2-DMA) are used for potent LNPs formulations. These LNPs 
have demonstrated high in vivo efficacy with low doses in several animal models 
(Semple, Akinc et al. 2010, Maier, Jayaraman et al. 2013). Ionisable lipid-based 
LNPs have provided improved tolerable preclinical vehicles for siRNA delivery. The 
Food and Drug Administration (FDA) approved LNP/siRNA drug called ONPATTRO 
or Patisiran for patients with transthyretin-related hereditary amyloidosis (ATTR) 
(Rizk and Tuzmen 2017, Hoy 2018). Other similar LNPs encapsulating 
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oligonucleotides are in clinical trials for liver cancer, hypercholesterolemia and others 
(Table 1-5).   
 
 
Fig 1-16: Chemical structure of ionisable cationic lipids. Adapted from (Semple, 
Akinc et al. 2010) 
 
 
Table 1-5: LNP/siRNA drugs in clinical trials. Adapted from (Rizk and Tuzmen 
2017) 
 
Name  siRNA target   Disease  Phase  
Patisiran TTR Transthyretin induced 
amyloidosis 
Approved   
ARB 1467 PLK1 Hepatocellular 
carcinoma 
Phase 2 
 HBV Hepatitis B Phase 2 
 KSP  and VEGF Liver cancer Phase 1 
 PCSK9 Atherosclerosis Phase 1 
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Ionisable cationic lipid nanoparticles have high encapsulation efficiency of siRNA 
because the formulation is performed with the so-called ‘’ethanol loading procedure’’. 
The amino lipids have pKa < 7 and siRNA packaging is carried out at acidic pH, 
where the lipids are positively charged, and siRNA carry a negative charge. The 
technique (Fig 1-17) in brief includes vigorous mixing of ethanol-dissolved lipid 
mixture with the siRNA solution in sodium acetate buffer (pH = 4), which allows high 
loading efficiency of the negatively charged siRNA into the positively charged lipids. 
The second step involves rapid controlled mixing in a microfluidic system to 
formulate LNP/siRNA particles. Finally, pH then increases to physiological values. 
Molecular modelling and structural studies on LNP/siRNA have shown that 
microfluidic systems produce nanoparticles with hydrophobic core containing 
multiple inverted lipid micelles encapsulating the siRNA (Fig 1-18) (Leung, Hafez et 
al. 2012, Gilleron, Querbes et al. 2013, Leung, Tam et al. 2015, Cullis and Hope 




Fig 1-17: Ethanol loading technique of LNP/siRNA. Lipids are dissolved in 
ethanol and mixed with siRNA in aqueous solution at pH = 4. The electrostatic 
interactions between the positively charged lipid and negatively charged siRNA drive 
the inverted micelles formation. If the mixing is vigorous and rapid enough then the 
aggregation of these micelles is eliminated as PEGylated lipid shields these micelles 





Fig 1-18: LNPs structure. (A) Molecular modelling of a cross section of LNP/DNA 
produced in the microfluidic system. The composition of the LNP/DNA is Dlin-KC2-
DMA (yellow), cholesterol (pink), DSPC (grey), charged polar lipid moiety (cyan), 
PEG (violet), DNA (red). The ratios of mixing is lipid/DSPC/cholesterol/PEG-lipid 
(4:1:4:1; mol/mol) and DNA-to-lipid ratio is 0.05 wt/wt. (B). Cryo-TEM microscopy 
image of LNP/siRNA. The composition of the LNP/siRNA is Dlin-KC2-DMA/ DSPC/ 
Chol/ PEG-lipid (40/11.5/47.5/1; mol/mol) and siRNA/lipid ratio is 0.06 wt/wt, scale 
bar 100 nm. (C). Cryo-TEM microscopy image of LNP containing 5 nm diameter of 
negatively charged gold nanoparticles. The LNP/Au-NP composition is Dlin-KC2-
DMA /DOPE/ Chol/ PEG-lipid (40/11.5/47.5/1; % mol) and Au-NP to lipid ratio is 
2.2x1013 particles/µmol lipid, scale bar 100 nm. (Leung, Hafez et al. 2012, Leung, 








Fig 1-19: Schematic illustration of ONPATTRO composition and mode of 
action. ONPATTRO consists of chemically modified siRNA, targeting 3’-UTR of TTR 
mRNA, encapsulated into Dlin-MC3-DMA lipid nanoparticle. The drug is formulated 
under acidic pH using microfluidic system. The nanoparticles are injected 
intravenously at 0.3 mg/kg every three weeks (q3w). Where for the siRNA, r: RNA 
bases, D: DNA bases and m: 2’-O-Me modified bases. Adapted from (Setten, Rossi 




1.6 Aims of the project  
The main goal of the project was to establish a delivery system for siRNA, which has 
the potential for clinical use. The aims are as follow;  
1. Enhancing the siRNA potency by introducing chemical modifications.   
2. Establishing a lipid nanoparticle (LNP) system for siRNA delivery, and validating the 
gene knockdown in vitro in cell lines, and in co-culture in t(8;21) primary and PDX 
cells. 
3. Establishing a gene knockdown in vivo and exploiting the therapeutic potential of 











2.1 Materials  
2.1.1 Lab equipment  
Instrument Manufacturer 
Allegra X-12R centrifuge Beckman Coulter 
Allegra X-22R centrifuge Beckman Coulter 
5415 R microfuge Eppendorf 
GeneAmp PCR System 2700 Applied Biosystems 
FACS Calibur Beckton Dickinson 
FACS Canto II Beckton Dickinson 
ND-1000 spectrophotometer Nanodrop Technologies 
FLUOstar Omega Microplate Reader  BMG labtech 
Elektroporations-Impulsgenerator EPI 2500 Dr. L Fischer, Heidelberg 
Zetasizer Nano ZS Marvern Panalytical  
Viia7 PCR System  Applied Biosystems 
Table 2-1: Equipment.   
 
2.1.2 Softwares 
Software  Software developer  
GraphPad Prism 7  GraphPad Software lnc 
Image Lab   Bio-Rad Laboratories 
SDS 2.0 Applied Biosystems  
Primer express 2.0 Applied Biosystems  
FunRich 3.1.3 Mathivanan and colleagues 
FlowJo -V10  FlowJo 
RStudio R 
QuantStudio Real Time PCR Applied Biosystems 
Table 2-2: Software.    
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2.1.3 General Chemicals  
Chemicals were purchased at analytical grade from Sigma-Aldrich Ltd, Bio-Rad, 
VWR, Thermo Fisher Scientific, R&D Systems, EMC microcollections GmbH.   
Chemical  Supplier   
2-mercaptoethanol  Sigma 
Acetone  Thermo Fisher Scientific 
Ammonium persulphate Chem Cruz 
Acrylamide 40% (1:29) Sigma 
Acrylamide 30% (1:37.5) Sigma 
CHAPS  Sigma 
Dimethylsulphoxide Sigma 
Dithiothreitol BioRad 
Dried skimmed milk  Marvel  
Ethanol  Thermo Fisher Scientific 
Ethylenediaminetetraacetic acide Sigma  
HEPES Sigma  
Hydrochloride acid  Sigma  
Immobilon membrane  Millipore  
Luciferin  Roche  
Methanol  Thermo Fisher Scientific 
Paraformaldehyde  Sigma  
PEG400  Sigma 
Phosal 50 PG Fisher Scientific 
Phosphate buffered saline  Gibco  
Propidium Iodide  Sigma 
Protein Assay Reagent BioRad 
RNase A QIAGEN 
Sodium chloride  Sigma  
Sodium dodecyl sulfate  Sigma  
Sodium hydroxide  Sigma  
SulfoCyanaine7.5 alkyne Lumiprobe GmbH 
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Sybr Green  Lifetech  
Tetramethylethylenediamine Sigma  
Tris  Sigma  
Trypan blue Sigma 
Triton 100 Sigma 
Tween 20 Sigma  
XenoLight™ D-Luciferin Caliper Life Sciences 




2.1.4 Experimental kits 
Kit Supplier  
Qiashredder QIAGEN 
RNeasy Mini Kit QIAGEN 
RNeasy Micro kit QIAGEN 
RevertAid™ H Minus cDNA Synthesis Kit Thermofisher  




2.1.5 Cell culture media and supplements  
Item  Supplier  
Fetal calf serum Gibco 
RPMI1640 Sigma  
DMEM Sigma 
GM-CSF R&D Systems 
IL-3 R&D Systems 
IL-6 R&D Systems 
FLT-3L STEMCELL Technologies 
Trypsin  R&D Systems 
L-Glutamine R&D Systems 
SFEM STEMCELL Technologies  
FGF-1 STEMCELL Technologies 
100X Myeloid Expansion STEMCELL Technologies 
SR1 STEMCELL Technologies 
Table 2-5: Cell culture media and supplements.   
 
 
2.1.6 RT-PCR primers (Sigma-Aldrich Ltd) 
Gene    5’  →  3’ 
GAPDH Fw: 5’- TGG CAT GGC CTT CCG T -3’ 
Rev: 5’- TCT CCA GGC GGC ACGT T -3’ 
hGAPDH  
 
Fw: 5’- GAA GGT GAA GGT CGG AGT C -3’ 
Rev: 5’- GAA GAT GGT GAT GGG ATT TC -3’ 
TBP Fw: 5’- CCT AAA GAC CAT TGC ACT TCG T -3’ 
Rev: 5’- GTT CGT GGC TCT CTT ATC CTC A -3’ 
RNUX1/ETO Fw: 5’- AAT CAC AGT GGA TGG GCC C -3’ 
Rev: 5’- TGC GTC TTC ACA TCC ACA GG -3’ 
ANGPT1 Fw: 5’- TCT CTT CCC AGA AAC TTC AAC ATC T -3’ 
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Rev: 5’- TCA TGT TTT CCA CAA TGT AAT TCT CA-3’ 
TERT Fw: 5’- GGA GAA CAA GCT GTT TGC GG -3’ 
Rev: 5’- AGG TTT TCG CGT GGG TGA G -3’ 
CCND2 Fw: 5’- CTG TGT GCC ACC GAC TTT AAG TT -3’ 
Rev: 5’- TGC TCC CAC ACT TCC AGT TG -3’ 
LAPTM5 Fw: 5’- CTC CCC AGC CAG GAG GAT AT -3’  
Rev: 5’- CCA CCG AGT TCA TGC ACT TG -3’ 
CEBPA Fw: 5’- GAG GGA CCG GAG TTA TGA CA -3’ 
Rev: 5’- AGA GGC GCA CAT TCA CAT T -3’ 
CD34 
 
Fw: 5’- AAA GCA CCA ATC TGA CCT GAA AA -3’  
Re: 5’- CGA GGT GAC CAG TGC AAT CA -3’ 
RUNX1 Fw: 5’- TCC ACA AAC CCA CCG CAA GT -3’ 
Rev: 5’- CGC TCG GAA AAG GAC AAG C -3’ 
CCND2 Fw: 5’- CTG TGT GCC ACC GAC TTT AAG TT -3’ 
Rev: 5’- TGC TCC CAC ACT TCC AGT TG -3’ 
Table 2-6: PCR primers.   
 
 
2.1.7 siRNA oligonucleotides 
Name  5’  →  3’ Supplie
r  
siRE 5’- CCUCGAAAUCGUACUGAGAAG -3’ 






3’- dTPSdTGGAGCUUUAGCAUGACUCU -5’ 
Axolabs 
GmbH 
siMM 5’- CCUCGAAUUCGUUCUGAGATT -3’ 




















Table 2-7: siRNA sequences. F and OMe refer to 2’-modified ribose with fluoro and 
methoxy, respectively. d refers to 2’-deoxyribose and PS refers to phosphorothioate 




2.1.8 Immunoblot antibodies  
Epitope  Dilution  Company  
mouse α-GAPDH  
 
1:300,000 (5% milk in T-
BST) 
HyTest, Turku, Finland  
 
rabbit α-hGAPDH  
 
1:1000 (5% milk in T-BST) Abcam 
rabbit α-hTERT 1:1000 (5% milk in T-BST) Cell Signalling  
 
rabbit α-RUNX1/RHD 1:40 – 1:60 (5% milk in T-
BST) 
Merc Millipore 
rabbit α-RUNX1/RHD 1:250 (5% milk in T-BST) Santa Cruz Biotechnology 
rabbit α-CCND2 1:250 (5% milk in T-BST) Proteintech 
rabbit α-BCL2 1:1000 (5% BSA in T-BST) Cell Signalling  
rabbit α-BCLXL 1:1000 (5% BSA in T-BST) Cell Signalling  
rabbit α-MCL1 1:1000 (5% BSA in T-BST Cell Signalling  
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rabbit α-BIM 1:1000 (5% BSA in T-BST Cell Signalling  
Mouse α-Clathrin Heavy 
Chain 
1:1000 (5% milk in T-BST) BD Biosciences  
Mouse α-βActin (HRP 
conjugated) 
1:1000 1:250 (5% milk in 
T-BST) 
Abcam  
α-rabbit IgG-HRP  
 
1:2,500 – 1:10,000 1:250 
(5% milk in T-BST) 
Amersham  
 
α-mouse IgG-HRP  1:2,500 – 1:10,000 1:250 
(5% milk in T-BST) 
Amersham  
 
Table 2-8: Western blotting primary and secondary antibodies.  
 
 
2.1.9 FACS antibodies  
Epitope  Company  
Mouse CD45 PE-Cy7 BD Pharmingen 
human  CD45 APC BD Pharmingen 
human  CD45 FITC BD Pharmingen 
human  CD33 APC R&D Systems 
human  CD33 BV 420 BD Pharmingen 
human  CD34 PE BD Pharmingen 
human  CD34 APC-Cy7 BD Pharmingen 
human  CD14 APC BD Pharmingen 
human  CD11b BV 420 BD Pharmingen 






2.1.10 Cell culture media  
Cells Medium  Supplemented  
Kasumi-1 RPMI 1640 10% FCS 
SKNO-1 RPMI 1640 15% FCS, 5 ng/ml GM-
CSF 
MSCs DMEM  20% FCS 
1% L-Glutamine 
8 ng/ml FGF-1 
1% Penicillin/Streptomycin 
Patient t(8;21) primary , 
t(8;21) PDX 
SFEM  20% FCS 
1 mM L-Glutamine  
1X myeloid expansion  
10 ng/ml IL3  
20 ng/ml FLT3-L 
1% Penicillin/Streptomycin 
Table 2-10: Cell culture full media.  
 
 
2.1.11 Cell Lines  
Cell line  Origin   Cytogenetics   Identifier 
Kasumi-1  Relapsed 
childhood (7 








SKNO-1  Relapsed young 








Table 2-11: Cell clines origins and genetic features.  
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2.1.12 Primary and PDX samples  
Cells Origin   Cytogenetics   
LK19 6 year old – 
male  
45,X,-Y,t(8;21)(q22;q22)[10]; No FISH; FLT3 
and NPM1 wild type 
LK111 16 year old – 
male  
46,XY,t(8;21;8)(p21;q22;q22)[8]/47,idem,+4[4]; 
FISH: RUNX1-RUNX1T1 fusion 
positive[99/100]; cKIT c.2446G>T, 
p.Asp816Tyr (D816V) mutation detected. 
PDX1 (RL048)/ 
NSG mice 
72 year old - 
Relapse  
t(8;21)(q22;q22) 
Homozygous TET2 mutation 
c.4179delA:p.T1393fs 




Relapse  t(8;21)(q22;q22) 
Heterozygous ETV6 insertion: 
c.313_314insGG:p.R105fs 
Heterozygous GATA1 mutation: 
c.158C>A:p.A53D 
Heterozygous KIT deletion: 
c.1253_1255del:p.418_419del 
Heterozygous NOTCH mutation: 
c.4898G>A:p.R1633H 
Heterozygous NOTCH mutation: 
c.6980G>A:p.R2327Q 
Heterozygous WT1 insertion: 
exon6:c.420_421insGTGTGCGA:p.R141fs 
MSCs N.A (Pal, Blair et al. 2016) 




2.2 Methods   
2.2.1 Freezing and thawing cell lines  
Cells were centrifuged at 350 g for 5 min, then the cell pellet was resuspended in 
chilled freezing media (10% DMSO + 90% FCS) at concentration between 0.5 x 107 -
1.0 x 107 cells/ml. Then up to 1 ml of the cell suspension was transferred into 
cryovials and frozen at -80°C for 24 hours then moved to liquid nitrogen tank for 
prolonged storage. 
Frozen cells were thawed quickly and tenfold diluted in pre-warmed media then 
centrifuged at 350 g for 5 min. The supernatant containing DMSO was removed and 
cell pellet was resuspended in fresh media to a final cell density 0.5 x 106 -1.0 x 106 
cells/ml and transferred into an appropriate plate or flask. 
 
2.2.2 Cell counting using dye exclusion method  
Cells were counted using trypan blue which selectively stains the dead cells with 
dark blue colour. The negatively charged trypan blue molecules pass only through 
the membrane of damaged and dead cells while viable cells do not absorb the dye. 
Patient primary and PDX cells taken from spleen were counted using methylene blue 
to lyse the red blood cells. 
For suspension cell lines, equal volumes from cell suspension and trypan blue were 
mixed, giving a dilution factor of 2. For adherent cell lines, after tryptic digest of the 
adherent monolayer cells and stopping the enzymatic activating of trypsin, 
appropriate dilution factor using fresh media applied (1:10 or 1:20) and then 1 
volume of trypan blue added. Finally, 10 µl of the cell suspension/dye solution was 
loaded into one side of haemocytometer and the live/dead cells were counted under 
10X microscope magnification. 
The haemocytometer consists of two chambers, and each chamber has four 
squares. Each square is divided into 16 (4×4) smaller squares. Determination of the 





𝐶 = 𝑛 × 𝐹 × 𝐷 
Where D is the dilution factor and F is the chamber factor. 
 





𝑠𝑢𝑟𝑓𝑎𝑐𝑒 𝑥 𝑑𝑒𝑝𝑡ℎ 𝑜𝑓 𝑡ℎ𝑒 𝑐ℎ𝑎𝑚𝑝𝑒𝑟
=
1000 𝑚𝑙
1𝑚𝑚2 𝑥 0.1 𝑚𝑚
=  10,000 
 
In the proliferation assays, cells were counted twice using two different aliquots of 
the cells suspension, and then the average of the two counts was applied to 
calculate cells density. If the difference between the two counts was more than 10%, 
a third independent aliquot of cell suspension was counted.   
 
2.2.3 Routine cell line culture – suspension cells     
Leukaemic cell lines Kasumi-1 and SKNO-1 were cultured at 0.5 x 106 - 1.5 x 106 
cells/ml cell density. Cells were cultured in 25 cm2 or 75 cm2 flasks in a fully 
humidified incubator at 37oC and 5% CO2. Cells were counted every 2 - 3 days and 
splitted 1:2 or 1:3. Cells were routinely checked for mycoplasma contamination. The 
authentication certificates for Kasumi-1 and SKNO-1 cells are provided in the 
supplementary tables (s-Table-1 & sTable-2).  
 
 2.2.4 Mesenchymal stem cells culture 
Mesenchymal stem cells (MSCs) were cultured in 6-well plates in a fully humidified 
incubator at 37oC and 5% CO2. Cells were split when they reached 60% confluency. 
To split the cells, the medium was aspirated, and adherent cells were washed once 
with PBS, then an appropriate volume of 1X trypsin was added for 1 - 5 minutes. 
Following incubation with trypsin, a twofold volume of complete culture medium 
containing FCS was added to inhibit the enzymatic activity of trypsin. Finally, cells 
were counted and seeded at the desired density. MSCs were kept in culture for 5 - 7 
passages only or until they showed differentiation or slow proliferation.   
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2.2.5  t(8;21) primary and PDX co-culture  
AML t(8;21) patient primary and patient-derived xenograft (PDX) cells were cultured 
on 50% confluent MSCs feeder layer. Directly after harvesting PDX cells from the 
mice or thawing frozen vials, cells were washed twice with 5%FCS in PBS, then cell 
pellet was suspended in fully supplemented SFEM media and seeded on MSCs after 
removing the MSCs media. Depending on the viability of the cells, cells were seeded 
at densities ranging from 0.2 x 106 – 0.5 x 106 cells/ml.   
 
2.2.6 siRNA hybridisation 
siRNAs were provided lyophilised as separate single strands. In order to rehydrate 
the oligonucleotides, the required volume of hybridisation buffer was added to each 
tube to make 200 µM final concentration. The tube was then vortexed and 
centrifuged for 1 min at maximum speed and stored at -80oC.  
In order to make the double-stranded siRNA, equal molar quantities of each strand 
were added into RNase free Eppendorf tube, vortexed and centrifuged for 1 minute 
at maximum speed. The tube was then placed at 95oC in a pre-heated heat block for 
5 minutes. Finally, the heat block was switched off allowing the hybridisation mixture 
to gradually reach room temperature. Placing the single stands at 95oC excludes any 
secondary structures and ensures complete annealing of the complementary 
strands. 
The original siRNA single strands were kept at -80oC and working solutions at -20oC.  
The siRNA rehydration and hybridisation were performed in a sterile environment 
using RNase free equipment.  
 
Hybridisation buffer  
HEPES 25 mM 
NaCl 100 mM 
pH 7.5 
Table 2-13: Hybridisation buffer recipe.    
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2.2.7 LNP/siRNA formulation – Hannover (Germany)   
Dr. Nidhi Jyostana performed the packaging of siRNA into the Dlin-MC3-DMA lipid 
nanoparticle at Hannover Medical School in the laboratory of Prof. Michael Heuser’s 
lab (Germany). 
In brief, siRNA were hydrated in sodium acetate buffer (25 mM NaAc, pH = 4) and 
quantified using a NanoDrop A260 assay then equal molar amounts of siRNA were 
hybridised. Formulation of LNP/siRNA was performed in NanoAssemblr (Precision 
Nanosystems) where the lipid organic solution (Table 2-14) and the siRNA aqueous 
solution were pumped through a microfluidic mixer at a combined 12 ml/min flow 
rate. The final LNP/siRNA solution was then dialysed against PBS overnight at 4°C 
to remove ethanol and raise the LNPs pH to physiological condition values (pH = 
7.4). Finally, the nanoparticles were sterile filtered by passing through a 0.2 µm 







Table 2-14: LNP/siRNA formulation composition. All components were dissolved 
in Ethanol.    
 
The encapsulation efficiency of siRNA was determined by Quant-iT Ribogreen RNA 
assay (Life Technology). First, the LNP/siRNA solution was lysed by incubating with 
1% Triton X-100 for 10 - 15 minutes at 37°C. Second, the Quant-iT Ribogreen assay 
was perfumed according to the manufacturer protocol, and the absorbance intensity 
was measured at 480 nm.    
  
Composition  Molar ratio % 
Dlin-MC3-DMA  50 
DSPC 10 




2.2.8 LNP/siRNA physical parameters measurements  
The physical parameters of LNP/siRNA were measured using Malvern Zetasizer. 
Determination of the hydrodynamic diameter of the nanoparticles was performed 
after diluting the mixture 1:100 in PBS. The charge of the particles was quantified 
after applying 1:1000 dilution in deionised water.   
 
2.2.9 LNP/siRNA particles labelling 
In order to label the nanoparticles with ligands, DSPE-PEG-N3 was added to the 
lipid mixture at 0.3% molar ratio. After LNP/siRNA formation, free azide groups were 
supposed to be covering the surface of the particles (LNP/siRNA)N3. These azide 
groups were utilised in a click chemistry reaction.  
A Cyanine7.5 derived dye (SulfoCyanine7.5 alkyne) was chosen for fluorescence 
imaging in vivo.  The dye carries an alkyne group that can react with the free azide 
molecules in the presence of a catalyst such as copper. Decorating the LNPs with  
SulfoCyanine7.5 was achieved by click chemistry reaction. The table below (Table 4-
2) shows the composition of the reaction. In brief, copper was dissolved in 55% 
DMSO/water solution at 500 mM concentration, and Ascorbic acid stock solution was 
prepared at 500 mM. To start the reaction, 10 µl of the copper was added to 10 µl of 
ascorbic acid in 1.5 ml Eppendorf tube and heated for 20 minutes at 40°C in a heat 
block, then 890 µl of (LNP/siRNA)N3 and 100 µl of SulfoCyanine7.5 alkyne were 
added. Finally, the heat block temperature was adjusted to 25°C and the reaction 
was kept overnight. After completion of the reaction, the nanoparticle solution was 
purified by dialysed against PBS for 10 - 12 hours at 4°C. The ascorbic acid and 
SulfoCyanine7.5 solutions, as well as the click chemistry reaction, are 
photosensitive, so all procedures were carried in the dark and tubes were warped 






Composition/reagent  Final concentration  
(LNP/siRNA)N3 50 - 300 µM   
SulfoCyanine7.5 alkyne 100 µM 
DMSO 55% vol  
CuCl2 0.5 mM 
Ascorbic Acid  0.5 mM 
Table 2-15: Click reaction composition. 
 
2.2.10 Lipid quantification in the LNP/siRNA  
The total lipid concentration in the LNP/siRNA mixture was determined indirectly 
using a calorimetric measurement of the phospholipid (DSPC) which makes 10% of 
total LNPs mixture. The amount of DSPC was measured by recording the 
absorbance of the complex formed between ammonium ferrothiocyanate 
[(NH4)Fe(SCN)4] and the phosphorus in DSPC. 
In brief, 100 mM and 400 mM of ferric chloride hexahydrate FeCl3.6H2O and 
ammonium thiocyanate NH4SCN solutions were prepared in deionised water, 
respectively. Then 0.5 M ammonium ferrothiocyanate [(NH4)Fe(SCN)4] solution was 
generated by mixing the ferric chloride and ammonium thiocyanate at 1:1 volume 
ratio. A serial dilution (0 - 50 µM) of DSPC lipid was prepared in ethanol, and the 
LNPs mixture was diluted 1:10 with ethanol. In a glass test tube, 500 µl of the 
lipid/ethanol solution was combined with 500 µl of ammonium ferrothiocyanate and 
vortexed for few second then 2 ml of chloroform was added to the mixture. 
Ammonium ferrothiocyanate is not soluble in organic solvents, but its complex with 
phospholipids is soluble in chloroform. The deep red-coloured chloroform layer was 
then removed using a glass Pasteur pipette, and 100 µl was transferred into a 96-
well plate and absorbance was recorded at 488 nm in microplate reader.  
The recorded absorbances were plotted against the corresponding DSPC 
concentrations in µM. Absorbances of three independent dilutions of 250 µg/ml 
LNP/siMM-mod stock solutions were recorded and the final DSPC concentration was 
then calculated from the linear regression plot.  
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2.2.11 Electroporation  
One day before electroporation, cells were supplemented with 1:3 volume of fresh 
media. On the day of electroporation, cells were counted and desired cell number 
was taken. Cells were centrifuged at 300 g for 5 minutes then cell pellet was 
resuspended in fresh media at 1 x 107 – 1 x 108 cells/ml density. Next, 100 - 700 µl of 
cell suspension was moved into 4 mm gap-width cuvettes followed by addition of 
siRNA solution. After 10 - 15 minutes of performing electroporation, cells were 
transferred into plates or flasks, and the cells density was adjusted to 0.5 x 106 
cells/ml in the appropriate media then placed onto fully humidified incubator at 37oC 
and 5% CO2. 
Cell lines were electroporated using different voltages to obtain the optimal 
transfection rate. The electroporation parameters were 330 V (for Kasumi-1) or 350 
V (for SKNO-1) delivered with a single square wave pulse during 10 ms. Primary 
t(8;21) cells were electroporated three times with three pulses of 80 V during 5 ms 
each in 1 mm gap electroporation cuvette.  
In the serial electroporation experiments, cells were electroporated every three days 
following the same procedures as mentioned earlier.  
 
 
2.2.12 LNP/siRNA treatment of cell lines  
siRNA transfection of cell lines using lipid nanoparticles was performed at 1 x 106 
cells/ml density. The desired volume of LNP/siRNA was added to the cell suspension 
and mixed well. After 24 hours of treatment, cells were washed three times with PBS 
and resuspended in fresh media at 0.5 x 106 cells/ml density. Only one single 
treatment of LNP/siRNA was applied. In the proliferation assays, cells were counted 




2.2.13 LNP/siRNA treatment of t(8;21) primary and PDX cells  
t(8;21) primary and PDX cells were treated with LNP/siRNA in co-culture system in 
96- or 48-well plates. At first, leukaemic cells were added on top of MSCs feeders at 
1 x 106 cells/ml density. After 24 hours, the LNP/siRNA solution was added to a final 
concentration of 4 µg/ml. In order to maintain the viability of leukaemic cells and due 
to the limited number of primary and PDX cells, there was no further washing with 
PBS to remove the access amount of LNP/siRNA. After 24 h of treatment, leukaemic 
cells were moved onto a new 50% confluent MSCs and seeded at 0.2  x 106 cells/ml 
density. 
  
2.2.14 Cell proliferation analysis   
In the proliferation assay, cells were counted every 2 - 3 days and the desired cell 
number was taken after adjusting the cell density to 0.5 x 106 cells/ml. The following 
equation was used to calculate the corrected cell number: 




Where:         N(i2)cor = corrected cell number at time point i2  
                     N(i2) = determined cell number at time point i2 
                     N(i1) = determined cell number at time point i1  
                     N(cont) = cell number of the taken cells for the next time point  
 
The previous equation was utilised to calculate the doubling time. The Ln(Ni2)cor 
values were plotted against the corresponding time points to generate a linear 
regression plot. The doubling time was then calculated from the linear regression 
equation using the following formula:   




Where,          tD: doubling time in days.  
                      µ: slope of the linear regression line 
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2.2.15 Cellular senescence staining     
The induction of cellular senescence was assessed using X-Gal staining at pH = 6.0 
to detect the β-Galactosidase presence in the lysosome. Cellular senescence β-
galactosidase staining kit from Sell Signalling was used after slight modifications in 
the kit protocol. In brief, 0.1 x 106 - 0.5 x 106 cells were harvested and washed once 
with PBS in 1.5 ml Eppendorf tube. Cells were fixed with 1X fixation solution for 15 
minutes at room temperature then washed three times with PBS. The staining 
solution was prepared according to the manufacturers protocol and pH was precisely 
adjusted to 6.0 at 37°C. Finally, cell pellet was resuspended in 500 µl of staining 
solution and transferred onto a 24-well plate. The plate was tightly sealed with 
parafilm and placed at 37°C incubator (without CO2) overnight at 37° C. 
 
 
2.2.16 Cell cycle analysis      
Cell cycle analysis was performed in flow cytometry after staining DNA with either 
propidium iodide (PI) or Hoechst-33342.  
Cells have different DNA content at each phase of the cell cycle. SKNO-1 and 
Kasumi-1 cell lines are diploid. This means that cells in the G0/G1 phase have 2n 
DNA content and cells in the tetraploid phase G2/M have 4n DNA content. Cells that 
are in the S phase occupy the area between G0/G1 and G2/M. Quantification of 
each phase was performed after eliminating the doublets and plotting the histogram 
between the single cell events and the area occupied by each population. The 
apoptotic cells in subG1 phase occupy the areas before the G0/G1 peak. The 
following histogram in Fig 2-1A represents the corresponding DNA content for each 
cell cycle phase. The gating strategy for cell cycle profiling and quantification of the 
population in each phase was performed according to the representative scheme Fig 







Fig 2-1. Cell Cycle analysis.  (A) Schematic illustration of cell cycle profile. (B) The 
gating strategy in Kasumi-1 and SKNO-1 cell lines.  
 
PI  staining buffer Citrate buffer  Hoechst -33342 staining 
buffer  
Propidium iodide 20 µg/ml Sucrose  250 mM Hoechst 33258   2 µg/ml   
NP40    0.5% Sodium citrate 40 mM NaCl   150 mM 
EDTA   0.5 mM  KCl  30 mM 
PBS  
pH= 7.2  
 Na2HPO4   10 mM 
pH= 7.0 




PI cell cycle stain 
In brief, 0.2 x 106 - 0.5 x 106 cells were taken for cell cycle staining. At first, cells 
were washed once with PBS and resuspended in 200 µl of cold citrate buffer after 
addition of 1 ng/ml of RNase A. Second, cells were incubated for 5 minutes at 4°C 
then 800 µl of PI staining solution was added. Stained cells were incubated with the 
stain for 10 minutes in the dark and then taken for analysis by flow cytometry. 
 
Hoechst -33342 cell cycle stain 
Hoechst-33342 fluorescent stain was used to measure the cell cycle when the cells 
were expressing GFP, such as Kasumi-1 p.SLIEW and SKNO-1 p.SLIEW. That is 
because GFP fluorescence overlaps with PI excitation wavelength. Similarly, in the 
case of LNP/siRNA treatment, the Dil dye fluorescence overlaps with PI excitation. 
In brief, 0.2 x 106 - 0.5 x 106 cells were harvested and washed once with PBS then 
500 µl of Hoechst stain was added. Stained cells were kept in the dark until flow 




2.2.17 RNA extraction using RNeasy Kit    
Cells were harvested and washed once with PBS then RNA extraction was carried 
out according to the manufacturer protocol. In brief, 0.5 x 106 - 5 x 106 cells were 
lysed with 350 µl (600 µl for cell number > 5 x 106 cells) RLT lysis buffer. Cell lysate 
was transferred into a QIAshredder column and centrifuged for 1 minute at maximum 
speed. An equal volume of 70% ethanol was added then the total volume was 
transferred into RNeasy spin column and centrifuged for 30 seconds at 8000 g. The 
flow-through containing protein was transferred into 2 ml Eppendorf tube and 1 ml of 
chilled acetone was added. Protein samples were stored at -20°C for at least 24 
hours and protein extraction was processed as described under 2.2.22.  
The RNeasy column was then moved to a new tube and membrane washed once 
with 700 µl RW1 buffer (8000 g for 30 seconds). RNA was precipitated by two 
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washing steps of 500 µl of RPE buffer (8000 g for 30 seconds then 8000 g for 2 
minutes). The column was moved into a new tube and the membrane dried out by 
centrifugation for 1 minute at full speed. Finally, the column was moved into 
nuclease free collection Eppendorf tube and RNA was eluted (8000 g for 30 second) 




2.2.18 RNA extraction using RNeasy Micro Kit    
RNeasy micro kit was used to isolate RNA from samples containing less than 0.5 x 
106 cells. In brief, cells were washed once with PBS and cell pellet was lysed with 
350 µl of RLT Plus buffer, then the lysate was loaded onto a QIAshredder column. 
The homogenised lysate was generated in the same way as described previously in 
2.2.17. Then, 350 µl of 70% ethanol was added and the total volume transferred into 
RNeasy micro-column following by centrifugation at 8000 g for 30 seconds. Flow-
through containing protein was collected as described in 2.2.22.The RNeasy micro-
column was washed with 700 µl of RW1 buffer (8000 g for 30 seconds), then RNA 
was precipitated by 500 µl of RPE buffer (8000 g for 30 seconds) followed by 500 µl 
of 80% ethanol (8000 g for 2 minutes). The membrane was dried out by 
centrifugation for 5 minutes at full speed. Finally, RNA was eluted in 12 - 14 µl of 
nuclease free water. The quantity and purity of RNA were determined by Nanodrop.  
 
 
2.2.19 cDNA synthesis by reverse transcription    
Revert Aid H Minus 1st strand cDNA kit (Thermo Fisher K1632) was used for cDNA 
synthesis. In brief, up to 1000 ng of RNA was diluted in 11 µl of nuclease free water 
and 1 µl of random hexamers was added. The mixture was then incubated at 70°C 
for 5 minutes to disrupt the RNA secondary structures, followed by rapid cooling to 
4°C and 8 µl of the master mix (Table 2-16) was added. The final 20 µl PCR reaction 
was then heated to 25°C for 10 minutes, followed by 42°C for 60 minutes. Finally, 
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the enzymes were denatured by heating for 10 minutes at 70°C and the cDNA was 
cooled down to 4°C after completion for the cDNA synthesis.  
Composition/reagent  Volume (µl) 
5X reaction buffer  4 
dNTP mix (10 mM) 2 
Riboblock RNase inhibitor 1 
RevertAid H minus reverse transcriptase 1 
Table 2-17: cDNA synthesises master mix composition.  
 
2.2.20 mRNA real time quantification by RT-PCR  
Real time quantitative reverse transcription polymerase chain reaction qRT-PCR was 
performed in 384-well plates using Applied Biosciences ABI Prism- 7900HT 
Sequence Detection System or Viia7 system. Samples were measured in triplicates 
where in each well 2 µl of diluted cDNA was added to 8 µl of PCR master mix (Table 
2-17). The 384-well plate was then sealed with adhesive cover and spun to collect 
the PCR mixture in the bottom of the wells. The PCR thermal cycles consisted of 
heating for 2 minutes at 50°C followed by 10 minutes at 95°C to denature the cDNA, 
inactivate the Uracil-DNA Glycosylate (UDG) and activate the polymerase. The 
extension step was carried out for 15 seconds at 60°C. The amplification continued 
for 40 cycles consisted of 95°C for 15 seconds and at 60°C for 1 minute.  The final 
step was one cycle of 15 seconds at 95°C, 15 seconds at 60°C and finally 15 




SybrGreen (2X) * 5 
Primer mix (10 mM) 0.3 
RNase free water 2.7 
Table 2-18: Real Time RT PCR master mix composition. * SybrGreen (2X) is a 
mixture of SYBR Green 1 Dye, AmpliTaq Gold DNA Polymerase, dNTPs with dUTP, 
Passive Reference 1 (ROX), and buffer (unknown).  
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2.2.21 Gene expression analysis by qRT-PCR 
Analysis of qRT PCR data was performed in SDS2.3 software and QuantStudio 
Real-Time PCR software. Starting from the cycle threshold (Ct) of each replicate, the 
mean of the Ct was calculated. The ΔCt for each gene was calculated by subtracting 
the Ct of the gene from the Ct of the housekeeping gene. Then the ΔCt values were 
used to calculate the ΔΔCt Ct for each sample after subtracting the ΔCt of the 
experimental sample from the ΔCt of the control. Given that in each cycle the DNA 
content was doubled, then the fold change is 2-ΔΔCt.  
Ct sample – Ct housekeeping gene = -ΔCt sample  
-ΔCt sample – (-ΔCt control) = -ΔΔCt sample  
 2-(-ΔΔCtsample) = fold change of gene expression (relative mRNA expression) 
 
 
2.2.22 Protein isolation  
Protein collected during RNA extraction (see 2.2.17) was precipitated after storing 
the sample at -20°C for 24 hours in order to increase the precipitation yield. The 
protein/acetone mixture was centrifugation at maximum speed for 20 minutes at 4°C 
then the supernatant was removed. Finally, protein pellet was dissolved in 50 - 150 
µl of urea buffer and stored at -20°C.  
RIPA buffer was used to isolate the protein directly from cell pellet. In brief, cells 
were collected and washed twice with PBS then cell pellet was lysed with 50 -  200 
µl RIPA buffer (50 µl for 1 x 106 cells). Cells were lysed on ice for 30 minutes 
including vortexing for 30 seconds every 5 - 10 minutes. Cell lysate was then 
centrifuged at maximum speed for 15 minutes at 4°C to precipitate the debris. 
Finally, the supernatant containing the protein was moved into a new Eppendorf tube 






Lysis buffer  Recipe  
Urea buffer  9 M urea  
4% CHAPS 
1% DTT  
RIPA 50 mM Tris 
1 mM EDTA 
1 mM EGTA 
150 mM NaCl 
0.5% Sodium deoxycholate 
0.1% SDS 
1% Triton X-100 
5 mM NaF  
pH = 7.5 
Table 2-19: Protein lysis buffers.    
 
2.2.23 Protein quantification  
Bradford assay (Bio-Rad) or BCA assay (Pierce, Thermo Fisher) were used to 
quantify the protein concentration. Bradford assay was used to quantify protein 
dissolved in urea buffer. That is because urea buffer contained 9 M urea, which is 
beyond the BCA assay compatibility (maximum 3 M urea). The presence of SDS in 
RIPA buffer was also not compatible with the Bradford assay.  
BCA assay was performed according to the manufacturer protocol. In brief, BSA 
standard (0.1 - 2 mg/ml) was prepared and 10 µl of the standard solution was 
pipetted in triplicate into a 96-well plate. Protein samples were prepared with relevant 
dilutions (e.g. 1:10 dilution for 5 million cells) then 10 µl was pipetted in triplicates. 
Finally, 50 parts of reagent A were mixed with 1 part of reagent B and 190 µl from 
the working solution were transferred into a 96-well plate. After 2 hours incubation at 
37°C, absorbance was recorded at 562 nm in microplate reader.  
Bradford assay was performed following the manufacturer protocol. In brief, BSA 
standard (0.1 - 2 mg/ml) was prepared in urea buffer. Protein samples were diluted 
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in urea buffer with relevant dilution (1:10 for 2 million cells). Then 5 µl from the 
standard or the sample was pipetted in triplicate into a 96-well plate. Bradford dye 
was diluted from stock solution at 1:5 in water and 195 µl was added to each well. 
After 10 minutes incubation at room temperature, absorbance was measured at 570 
nm in microplate reader.    
Protein concentration was calculated after generating the BSA standard curve. Then 
the concentration of sample in mg/ml was calculated from the linear regression 
equation of the standard followed by applying the dilution factor.  
 
2.2.24 Gel electrophoresis  
High molecular weight proteins > 200 kDa were separated using Bis-Tris gel system. 
Low to medium molecular weight proteins were separated in SDS-PAGE system.   
In general, SDS-PAGE (SDS polyacrylamide gel electrophoresis) separates proteins 
according to their molecular weight as the presence of SDS in the sample buffer and 
the gel itself uniforms the negative charges of the proteins. Thus, the movement of 
the proteins under an electric field is proportional to the log10 of the protein 
molecular weight. When the protein sample was prepared in RIPA buffer, the 
disulphide bonds in the protein was reduced by addition of 2-mercaptoethanol in the 
sampling buffer (5%) and boiling at 95°C for 10 minutes before loading the samples 
onto the gel. On the other hand, if the protein sample was prepared in urea buffer, 
the boiling step was skipped.   
SDS-polyacrylamide gel consists of two layers; a top layer (stacking) which is 4% 
polyacrylamide, and a resolving (separating) layer that ranges between 7 - 20% 
polyacrylamide. The gel mixture was prepared by adding 25% v/v of 4X gel buffer to 
deionised water followed by addition of to 40% acrylamide-bis-acrylamide (1:29) or 
30% acrylamide-bis-acrylamide (1:37.5). The mixture was then homogenised by 
mixing followed by addition of 0.1% w/v ammonium persulphate (APS) and 0.01% 
w/v TEMED. Finally, the gel mixture was poured into 1mm or 1.5 mm casting 
chamber followed by few hundred microliters of 70% ethanol to degas the gel. Ones 
the separating gel was set (about 15 minutes), ethanol was removed and the 
stacking gel mixture was poured on the top of the separating gel. Finally, the desired 
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compatible comb was added.  After 15 minutes, the gel was ready to use or to 
storage at 4°C up to two weeks. 
Gels were placed in the electrophorese tanks and filled with electrophoresis buffer. 
Before loading the samples, wells were cleaned using a fine syringe needle. Protein 
samples and ladder were loaded onto the wells and electrophoresis started at 50 V 
until the sample buffer dye passed into the separating gel, then the voltage was 
increased to 100 - 150 V to resolve the proteins.  
In the standard SDS-PAGE, proteins were already denatured in the sampling buffer 
pH = 7 - 7.4 which contains detergents and 2-mercaptoethanol as a reducing agent, 
the basic pH (pH = 8.8) facilitates protein alkylation, de-amination and re-oxidisation 
of the reduced cysteines which were occurred during the electrophoresis. Thus, 
proteins reform disulphide bonds in the stacking gel (pH = 6.8) as they move away 
from the reducing agents (2-mercaptoethanol) in the sample buffer. However, in Bis-
Tris polyacrylamide gel, the re-oxidation of cysteine is prevented in the weak acidic 
gel pH = 6.8 as the cysteine will be completely protonated pKa = 8.18. Moreover, the 
presence of NaHSO3 as a reducing agent in the electrophoresis buffer maintains the 
reducing integrity in the whole gel. Bis-Tris and MOPS electrophoresis system was 
used to resolve only the high molecular weight proteins.  
The following table includes the two types of polyacrylamide gels and 
electrophoresis buffers used. 
 
 SDS-PAGE Bis-Tris 
% polyacrylamide  8 – 10  4 – 8  
pH 8.8 6.8 
Electrophoresis buffer Tris-Glycine  MOPS 
% SDS 0.1 0 
kDa of resolved protein  10 – 160  50 – 450  
U(V)/ t(hour) 100 V / 1 hour 25 V / 10 – 16 hours 




2.2.25 Immunoblotting   
Immunoblotting followed the gel electrophoresis to detect specific proteins using the 
relevant blotting system and antibodies. In brief, gel was removed from the glass 
plates and a methanol-activated PVDF membrane (0.4 µm) was placed next to the 
gel and the blotting sandwich was assembled. Blotting was performed at 4°C to 
prevent heating the buffer. Two different blotting systems were used depending on 
the gel type as shown in the following table.  
 SDS-PAGE Bis-Tris 
Blotting buffer   Tris-Glycine  CAPS 
% Methanol  10 15 
pH 6.8 11 
U(V)/ t(hour) 100 V / 1 hour 25 V/ 16 hours 
or 50 V/ 4 hours 
Table 2-21: Protein transfer conditions.    
 
Ponceau-S red staining was used to assess the loading and blotting efficiency. The 
stain also helps to denature the proteins in the membrane and increases binding 
affinity of the antibodies. Membrane was then blocked with 10% milk or 5% BSA for 
30 minutes followed by overnight incubation with the relevant primary antibody at 
4°C. Membrane was washed several times (10 minutes each) with T-BST to remove 
the unbound and weakly bound primary antibody then incubated with the secondary 
antibody for 1 hour at room temperature. Then membrane was washed serval times 
for 10 minutes each with T-BST followed by addition of ECL solutions and detecting 
the chemiluminescence. The chemiluminescence signal was either recorded by 
automated Bio-Rad system or captured on X-Ray film in a darkroom.   
Membrane stripping was performed for sequential detection of proteins. In brief, 
membrane was washed once with T-BST followed by three washes with mild 
stripping buffer for 10 minutes each. After 30 minutes of stripping, membrane was 
washed twice with PBS for 10 minutes followed by blocking with milk or BSA and 





Buffer  Component  
4X stacking buffer 0.5 M Tris 
0.4% SDS 
 pH = 6.8 
4X separating buffer 1.5 M Tris 
 0.4% SDS 
 pH = 8.8 





SDS-PAGE blotting buffer   1X Tris-Glycine 
10% methanol  
10X TBS 100 mM Tris.Cl 
1.5 M NaCl 
pH = 8 
Ponceau-S red staining  0.1% Ponceau-S red 
5% acetic acid  
6X SDS-PAGE loading buffer  50% 4X stacking buffer  
0.1% bromophenol blue   
36% SDS 
30% Glycerol  
15% 2-mercaptoethanol  
20X MOPS electrophoresis 
buffer 
250 mM MOPS 
250 mM Tris 
5 mM EDTA 
pH = 11 
Bis-Tris electrophoresis buffer 1X MOPS  
5 mM NaHSO3 
0.5% SDS 
10X CAPS 50 mM CAPS 
pH = 11  
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2X Bis-Tris gel sampling buffer  25% 4X stacking buffer  
25% 1.25 M Bis-Tris buffer  
0.1% bromophenol blue   
0.5% 1 M NaHSPO3 
35% Glycerol  
Mild stripping buffer  200 mM Glycine  
10% Tween-20 
1% SDS  
pH = 2.2 
Table 2-22: Gel electrophoresis conditions.    
 
2.2.26 Colony formation assay  
Colony formation assay (CFA) was performed using methylcellulose semi-solid 
media. The media was prepared by dissolving 0.56 g of methylcellulose in 5 ml PBS 
followed by autoclaving. Under sterile conditions, 85 ml of RPMI and 10 ml of FCS 
was added to the methylcellulose and stirred overnight at 4°C. The media was then 
filtered through a 0.2 µm syringe filter and stored at 4°C. In the case of SKNO-1 cell 
lines, GM-CSF was added to the methylcellulose media at 5 ng/ml concentration.  
In order to perform the routine CFA, cells were centrifuged at 300 x g for 5 minutes 
then resuspended in fresh media at 0.5 x 106 cells/ml in fresh media. 25 µl of cell 
suspension was then added to 2.5 ml of the methylcellulose media and pipetted 
gently without air bubbles. Into a 24-well plate, 0.5 ml of the suspension was added 
to three wells and incubated at 37°C and 5% CO2 for approximately one week, or 
until the formation of colonies. Colonies number was determined by counting under 
microscope using 4X magnification, and the selection criteria were that each colony 
> 25 cells. 
For the colony replating experiments, colonies were collected into a 50 ml falcon 
tube and washed twice with PBS. The harvested cells were then resuspended in 




2.2.27 Determination of cell viability  
To administer the drug dose, cells were collected and centrifuged at 300 x g for 5 
minutes then resuspended in fresh media at 0.1 x 106 cells/ml. The cell suspension 
was then transferred into a 96-well plate (90 µl per well). Stock solutions of the drugs 
were prepared in their appropriate solvent and stored in aliquots at -20°C. The 
working solutions were prepared at 10X concentrations prior to use by diluting the 
stock in the culture medium. For each condition, 10 µl of the working solution was 
added in triplicates. Finally, the cells were incubated at 37°C and 5% CO2 for 2 - 3 
days.  
Two different assays, luciferase and resazurin, were used to assess the drug 
response in cell lines. 
Luciferase assay performed using (Promega Luciferase Assay System) in Kasumi-1 
p.SLIEW and SKNO-1 p.SLIEW cells, which express the firefly luciferase gene. In 
order to perform the assay, the luciferin working solution was prepared according to 
the manufactural protocol by adding 10 ml of the luciferase assay buffer to one vial 
of lyophilised luciferin. To perform the assay, 20 µl of luciferin working solution was 
pipetted into 50 µl of cell suspension in a 96-well plate followed immediately by 
recording the bioluminescence in a microplate photometer. 
The fluorescence-based assay, resazurin, was used in Kasumi-1 and SKNO-1 cells. 
Under oxidation-reduction conditions, resazurin can be reduced to resorufin and shift 
its weak fluorescence into highly red- florescence. Resazurin stock solution was 
prepared by dissolving 1 g resazurin in 50 ml PBS to make a100X stock solution. 
The stock solutions were aliquoted and stored at -20°C. Before performing the 
assay, the 100X stocks were thawed and diluted 1:10 in PBS, followed by addition of 
10 µl of the 10X working solution to each well. Finally, the 96-well plate was covered 
with aluminium foil and incubated at 37°C and 5% CO2 for 4 hours. In a microplate 






2.3 Animal work    
2.3.1 Animal husbandry   
Three immunodeficient mice strains were used in the in vivo studies as shown in 
Table 2-23. Mice weighing and checking were carried out at least twice per week. 
Mice were checked every day when they showed high leukaemic burden and during 
the dosing period. Mice general health condition assessment included mentoring of 
movement, anaemia, coat quality, piloerection, and the colour of the eyes, paws, feet 
and ears.  
Mice were humanely culled by cervical dislocation when they reached the protocols 
endpoints as they were defined by the project license PPL60/4552 and Home Office 
regulations. The endpoints are:   
1. Body weight loss of 20% or more, (30% if mouse is under treatment).  
2. Body weight loss of 10% – 20% and maintained low for three days.  
3. Tumour size is 1 cm in any dimension, (1.5 cm if mouse is under treatment).  
4. Tumours are affecting the mice movement.   
5. Any sign of sickness that is severely affecting the health of the mouse.  
 
 
Abbreviation  Strain name Source  
NSG NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ Jackson 
Laboratory 
Rag2-/- ɣC-/- (RG) Rag2−/−Il2rg−/−129×Balb/c Jackson 
Laboratory 




Markus G. Manz 
Table 2-23: Mice strain and genetic background.  
   
89 
 
2.3.2 Intrahepatic transplantation  
Intrahepatic (IH) injection method was used to transplant Kasumi-1 p.SLIEW and 
t(8;21) PDX cells. The injection was performed using a fine flexible Hamilton needle 
under a sterile environment in a category II hood. Newborn mouse (2 - 4 days old) 
was held firmly by the end of the thumb and the index finger then the needle was 
inserted in the top of the chest under the skin. When the needle reached the end of 
the ribs, the needle was pushed toward the right side of the mouse chest in 45° 
wherein it simultaneously bent and reached the liver. Finally, 25 µl of cell suspension 
was released slowly and the needle was withdrawn smoothly. After injection, the 
mouse was placed back into the nest and monitored. 
 
2.3.3 Intrafemoral transplantation  
Primary and primograft t(8;21) AML patient cells were injected with intrafemoral (IF) 
route in NSG female mice. The injections were performed under a sterile 
environment in a category II hood. Mice were anaesthetised with 5% isoflurane then 
anaesthesia was marinated with 2 - 3% isoflurane. Before transplantation, mice were 
weighed and injected with 5 mg/kg Carprofen for analgesia. The injected leg was 
shaved and sterilised with skin disinfection spray. A hole was made in the injected 
femur by inserting 29G insulin needle in the kneecap and through the femur then the 
needle was removed and A new needle containing the sample was inserted and 20 
µl of cell suspension was injected. After injection, the mouse was placed back into 
the cage and monitored for anaesthesia recovery. 
    
2.3.4 Intraperitoneal dosing route  
Intraperitoneal (IP) injection route was used to inject luciferin, Carprofen, and 
LNP/siRNA. The injection was performed using 29G insulin needle.  
For injection of adult mice, the mouse was restrained firmly by tightly scruffing the 
skin back the body then the needle was inserted at 45° into the peritoneal area. The 
injection site of male mice is located in the upper peritoneal area in order to avoid the 
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testicles. The injection site of the females is located in the lower abdomen below the 
nipples.  
For injection of pups (5 - 16 days), the mouse was held on its back and placed above 
the middle finger where the index and the middle fingers gripped the tail. The needle 
was inserted at 45° in the lower abdominal avoiding the stomach. The injection site 
was switched every time in order to avoid bruising.  
 
2.3.5 Intravenous dosing route 
Intravenous (IV) injection route was used to inject the LNP/siRNA. In brief, the 
mouse was restrained under category II hood. In order to reveal the vain, the tail was 
either massaged or placed in warm water. Finally, the tail was stretched straight 
tightly and the needle inserted at around 180° and the drug released steadily. Once 
the injection was completed, pressure was applied on the injection site for 30 
seconds to prevent any bleeding, then the mouse was placed back in the cage and 
monitored.  
 
2.3.6 Oral gavage dosing route 
Oral gavage was used to dose mice with ABT-199 and its control vehicle (CV). The 
gavage was performed using a round-tipped gavage needle. The mouse was tightly 
scuffed and held in a vertical angle. Then the needle was inserted into the mouse 
mouth while pushing the head back, allowing the needle to go through the 
oesophagus into the stomach. When the needle stopped in the stomach, the volume 








ABT-199  20 mg/ml  
Phosal 50 PG  60% 
PEG400     30% 
Ethanol   10% 
Phosal 50 PG  60% 
PEG400     30% 
Ethanol   10% 
Table 2-24: ABT-199 and control vehicle recipe for oral gave.  
 
2.3.7 In vivo imaging 
Bioluminescence imaging was performed using an in vivo imaging system (IVIS). In 
brief, the mouse was injected with 5 mg/kg luciferin by IP route. After 5 minutes, the 
mouse was anaesthetised with 5% isoflurane in anaesthesia induction box. 
Anaesthesia was then maintained with 2 - 3% isoflurane. The mouse was then 
placed on a 37°C heat mat inside the IVIS machine where the head was placed into 
a face mask to maintain the anaesthesia. Ten minutes after the luciferin injection, 
imaging was performed then the mouse was placed back in the cage and monitored 
for recovery. 
 
2.3.8 Mice dissection and cells isolation  
Leukaemic cells were collected from several sites such as tumours, spleen, bone 
marrow. The spleens and tumours were weighed first then homogenised, and cells 
passed through a cell strainer using PBS under sterile conditions. Leukaemic cells 
engrafted in the bone marrow were extracted from the femur, tibia, desk, and spine. 
In brief, bones were cleaned from muscles crushed in mortar and pestle and passed 
through a cell strainer using PBS under sterile conditions.  
Harvested cells were washed once with PBS and counted using trypan blue and 
methylene blue to lyse the murine red blood cells. Viable cells were either cultured 









Chapter 3  
Establishment of in vitro RUNX1/ETO knockdown utilising modified 






Successful RUNX1/ETO knockdown using unmodified siRNA has long been 
established in our group. The siRUNX1/ETO (siRE) specifically targets the fusion 
site of RUNX1/ETO transcript, and a mismatch control siRNA (siMM) has also been 
generated by swapping two nucleotides in the antisense strand. The group has also 
optimised electroporation protocols to deliver 100 - 500 nM siRNA sequentially. 
Using t(8;21) AML cell lines, a single electroporation of 200 nM siRE can reduce 
RUNX1/ETO expression by twofold after 48 hours, followed by a maximal reduction 
in the protein level after 72 hours. The disruption of RUNX1/ETO transcriptional 
network has been observed within 24 hours post electroporation. We have defined a 
set of early responding RUNX1/ETO direct target genes including CD34 and 
CEBPA. Furthermore, we have shown that the clonogenic potential of leukaemic cell 
lines is also affected after a single transfection. However, transcriptional modulation 
of late responding RUNX1/ETO direct and indirect target genes such as TERT and 
CCND2 requires sequential transfections with siRE. Moreover, serial administration 
of siRE is needed to resolutely reduce proliferation, cause G1 cell cycle arrest and 
induce senescence (Martinez, Drescher et al. 2004, Soria, Tussiwand et al. 2009, 
Ptasinska, Assi et al. 2012). 
Therapeutic siRNAs are designed to exhibit maximal activity after parenteral 
administration (Cullis and Hope 2017). Chemical modifications of oligonucleotides 
are routinely used to improve the siRNA resistance to nucleases and produce 
favourable pharmacodynamics and pharmacokinetic profiles (Haley and Zamore 
2004, Ameres, Martinez et al. 2007, Huang, Cheng et al. 2016). Several functional 
studies have been conducted by our group relying on achieving RUNX1/ETO 
depletion by siRE. Considering that the PhD project aims to exploit RUNX1/ETO 
knockdown therapeutic potential, I have introduced several chemical modifications to 
the siRNA. The chemically modified siRUNX1/ETO (siRE-mod) harbours 
modifications on the 2’-OH of the ribose and 3’-phosphodiester backbone. 
Oligonucleotides administration by systemic route activates the innate immunity by 
the toll-like receptors (TLRs). Moreover, naked siRNA has very poor 
pharmacokinetics when administered intravenously. To diminish the siRNA 
immunogenicity and enhance the therapeutic index, many studies have developed 
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novel lipid nanoparticle formulations (Semple, Akinc et al. 2010, Maier, Jayaraman et 
al. 2013). Based on previous reports of successful siRNA-mediated gene silencing in 
vivo (Leung, Tam et al. 2014), we have chosen the Dlin-MC3-DMA lipid nanoparticle 
(LNP) to encapsulate the siRNA targeting RUNX1/ETO. We assessed the depletion 
of RUNX1/ETO by lipid nanoparticles encapsulating chemically modified 
siRUNX1/ETO (LNP/siRE-mod) in t(8;12) cell lines as well as in primary and patient 




The aims of the project include: 
1. To enhance the overall RUNX1/ETO knockdown by introducing chemical 
modifications, which stabilise the siRNA and reduce the off-target effect.    
2. To encapsulate the modified siRNA into LNP and determine the physical 
parameters of the LNP/siRNA system.  
3. To establish a robust depletion of RUNX1/ETO using LNP/siRNA in t(8;21) 
AML cell lines.  
4. To investigate the efficacy of LNP/siRNA in t(8;21) primary and t(8;21) PDX 






3.3 Experimental design 
3.3.1 Establishment of modified siRNA  
The effect of single chemical modification on the siRNA activity was already known 
from the literature. In order to obtain an enhanced RUNX1/ETO knockdown, a 
combination of several modified nucleotides was introduced in the same time. These 
modifications were already established and validated by pharmaceutical companies 
such as Alnylam and IONIS (Davis, Zuckerman et al. 2010, Adams, Gonzalez-
Duarte et al. 2018).  The chemical modification were as follow,  
a. The 2’-OH substituted with 2’-F at the first 4 nucleotides of the sense strand at 
the 5’-end.  
b. The 2’-OH substituted with 2’-H at the last 5 nucleotides of the sense strands 
at the 3-’end. The same substitution but placed at the 3’-end of the antisense 
stand by having two deoxyribose thymidine moieties.   
c. All the ribose of the pyrimidine nucleotides in the middle of the sense strand 
modified with 2’-OMe.  
d. The phosphodiester backbone between the first and the second nucleotide at 
the 3’-end of each strand replaced with phosphorothioate 3’-PS.  
 
Sequences of the unmodified siRUNX1/ETO (siRE), modified siRUNX1/ETO (siRE-
mod), mismatch siRNA (siMM) and modified mismatch siRNA (siMM-mod) are 
shown in Table 3-1. The chemical structures of modified ribose units and 
phosphodiester backbone are shown in Fig 3-1.  
 











Table 3-1: siRNA sequence and the chemical modifications. The 2’-modified 
ribose with fluoro and methoxy are indicated as F and OMe, respectively. The 2’-
deoxyribose was annotated as d. The PS refers to the phosphorothioate-modified 
backbone.   
   
 
 
Fig 3-1: siRNA chemical modifications. From left to right, the 2’-hydroxyl of the 
sugar ribose was replaced with either fluoro, hydrogen or methoxy group. The 3’-




3.3.2 siRNA modifications efficiency in vitro.  
The efficiency of modified siRNA in depleting RUNX1/ETO was assessed in t(8;21) 
AML cell lines Kasumi-1 and SKNO-1. siRNAs were transfected by electroporation 
using two settings, either single or sequential electroporation.  
Sequential electroporation of Kasumi-1 and SKNO-1 cell lines were performed every 
3 days as described in 2.2.11. During the experiments, cells were collected for 
functional analysis including cell count (see 2.2.14), cell cycle profiling (2.2.16), 
colony formation assay (2.2.26), senescence-associated β-Galactosidase staining 
97 
 
(2.2.15), and assessment of RNA and protein expression (2.2.17 to 2.2.25) as shown 
in (Fig 3-2).  
 
 
Fig 3-2: Schematic illustration of the serial electroporation experiments.   
 
 
In order to determine the prolonged siRNA activity, a single electroporation with 
escalating concentrations of the siRNA was performed. Cells were collected on days 
3 and 7, RNA extracted for qRT-PCR and cell lysate prepared and measured for 
Western blotting.  
 
 
3.3.5 Treatment with LNP/siRNA in AML cell lines  
The RUNX1/ETO knockdown efficiency of lipid nanoparticles LNP/siRNA in vitro was 
explored in Kasumi-1 and SKNO-1 cell lines. Treatment of cell lines using 
LNP/siRNA was performed at a cell density of 1 x 106 cells/ml as described in 2.2.12. 
At the end of each treatment period, cells were washed twice with PBS and 
resuspended in the relevant culture media at 0.5 x 106 cells/ml density. Cell count 
was performed every 2- 3 days throughout the experiments, and cell densities were 
maintained between 0.5 x 106  to 1 x 106 cells/ml. Cells were taken at several time 
points for functional analysis.  
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3.3.6 Primary and PDX treatment with LNP/siRNA  
AML t(8;21) patient primary and t(8;21) PDX cells were co-cultured on MSCs feeder 
layer as described in 2.2.13. One day prior to treatment, primary cells were cultured 
on MSCs at a density of 1 x 106 cells/ml (approximately 50% confluence). Co-
cultures were treated with 4 µg/ml of LNP/siRE-mod and LNP/siMM-mod for 24 
hours, then AML primary cells were moved onto new MSCs feeders and kept at 0.2 x 
106 – 0.5 x106 cells/ml density. Analysis of gene expression and protein level were 
performed after 3 and 6 days post treatment. 
PDX cells were thawed and cultured overnight on matrigel. On the next day, PDX 
cells were counted and seeded on MSCs feeder at 1 x 106 cells/ml density. After 24 
hours, 4 µg/ml LNP/siRNA was added to the co-cultures. Next day, PDX cells were 
moved onto new MSCs feeder and kept at 0.2 x 106 - 0.5 x 106 cells/ml density. Cells 




3.4.1 Efficacy of chemically modified siRNA in vitro 
3.4.1.1 RUNX1/ETO knockdown effect on proliferation  
The efficacy of siRNA modification was tested in Kasumi-1 and SKNO-1 cell lines by 
assessing the proliferation after RUNX1/ETO knockdown. Previous work performed 
by our group has led to routine conditions for sequential electroporation by applying 
either 200 or 500 nM siRE for an effective RUNX1/ETO knockdown. In my 
experiments, I have used a reduced concentration of 100 nM siRNA in order to 
compare the potency of siRE-mod and siRE. 
Serial electroporation with siRNAs targeting RUNX1/ETO led to reduced cell 
proliferation. The doubling time of Kasumi-1 and SKNO-1 increased by two-fold. 
Moreover, siRE-mod and siRE robustly inhibited proliferation in both cell lines when 
100 nM siRNA was electroporated four times (Fig 3-3A, C). Notably, two sequential 
electroporations of siRE-mod were sufficient to significantly reduce proliferation for a 
prolonged period compared to siRE treated cells (Fig 3-3B, D).  
 
3.4.1.2 RUNX1/ETO knockdown at mRNA level  
The potency of modified siRE-mod was also assessed by observing its ability to induce 
robust changes at the mRNA level. RUNX1/ETO expression was measured after 48 
hours of electroporation. In Kasumi-1 and SKNO-1 cell lines, RUNX1/ETO expression 
decreased by 60% in the siRE and siRE-mod treated cells in comparison to the control 
siMM treated cells (Fig 3-4A, B).  
The reduction of RUNX1/ETO mRNA was consistent in the siRE or siRE-mod 
transfected cells. However, CEBPA expression, a direct target gene of RUNX1/ETO, 
greatly increased in the siRE-mod transfected cells in comparison with the siRE. The 
enhanced upregulation in CEBPA transcript was observed in both cell lines (Fig 3-
4C, D). Upon RUNX1/ETO knockdown in Kasumi-1, CEBPA mRNA increased by 2- 
and 2.5-fold when cells transfected with siRE and siRE-mod, respectively. The siRE-
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mod did not provide significant upregulation of CEBPA in Kasumi-1. However, the 
difference in SKNO-1 cell line was statistically significant (p= 0.023). 
 
 
Fig 3-3: RNAi mediated RUNX1/ETO knockdown effect on proliferation. Cell lines 
were electroporated sequentially at 1 x 107 cells/ml density with 100 nM of siRE, siRE-
mod or siMM and untreated mock control. The electroporation was performed either 
four times on days 0, 3, 6 and 9 (A & C), or twice on days 0 and 3 (B and D). Error 
bars represent the Standard Error of the Mean (SEM) of four independent experiment 
at each time point.  For the last time point (day 12) *P<0.05, **P<0.01, ***P<0.001, 





Fig 3-4: RNAi mediated knockdown of RUNX1/ETO in Kasumi-1 and SKNO-1. 
Cell lines were electroporated at 1 x 107 cells/ml density with 100 nM of siRE, siRE-
mod, siMM or untreated mock control. After 48 hours of electroporation, 
RUNX1/ETO mRNA level (A and B) was measured against the siMM treated control 
and GAPDH served as a housekeeping gene. The expression level of CEBPA was 
measured after 48 hours of electroporation (C & D). Error bars represent SEM of 




The reduction of RUNX1/ETO mRNA was maintained during the course of four serial 
electroporations in both Kasumi-1 and SKNO-1 (Fig 3-5). Sequential electroporations 
with 100 nM were not sufficient to further reduce RUNX1/ETO mRNA level. It was 
evident, throughout the electroporation experiments, that there was a basal level of 





Fig 3-5: RNAi mediated knockdown of RUNX1/ETO in Kasumi-1 (A) and SKNO-1 (B). 
Cell lines were serially electroporated at1 x 107 cells/ml density on days 0, 3, 6, and 9 with 
100 nM of siRE, siRE-mod, siMM or untreated mock control. RNA expression was measured 
against siMM treated cells and GAPDH served as a housekeeping gene. Error bars 





3.4.1.3 RUNX1/ETO knockdown at protein level  
In order to confirm RUNX1/ETO knockdown on the protein level, samples were 
collected at several time points for Western blotting. To detect RUNX1/ETO and 
RUNX1 simultaneously an antibody recognises the N-terminus of RUNX1 protein 
was used. 
The knockdown of RUNX1/ETO was stronger in siRE-mod treated cells in 
comparison with siRE (Fig 3-6). The siRE-mod was able to reduce RUNX1/ETO 
level more effectively throughout the serial electroporation experiments consistent in 
both Kasumi-1 and SKNO-1 cell lines.   
In line with previous observations by our group, the robust depletion of RUNX1/ETO 
led to a reduction in RUNX1 level. The serial electroporation experiments showed 
that cells transfected with siRE-mod had an enhanced reduction in RUNX1 protein 
expression, especially in the SKNO-1 cell line (Fig 3-6). This finding indicated robust 






Fig 3-6: RUNX1/ETO protein level in Kasumi-1 (left) and SKNO-1 (right) on day 
6. Cell lines were serially electroporated on days 0 and 3 with 100 nM of siRE, siRE-
mod, siMM or untreated control. Cell lysates were collected on day 6. Membranes 
were blotted against α-RUNX1 antibody and α-GAPDH loading control. Marker size 
in kDa was presented on the left of the blots. 
 
 
The serial electroporation experiments did not provide evidence that siRE-mod was 
substantially more potent than siRE in reducing RUNX1/ETO mRNA expression. 
Moreover, both siRE and siRE-mod robustly reduced RUNX1/ETO protein level after 
two sequential electroporations as shown in Fig 3-6. In order to confirm whether 
siRE-mode outperforms siRE, the effect of one single transfection was investigated.   
Single electroporation showed that siRE-mod provided a stronger and prolonged 
reduction in RUNX1/ETO protein level in comparison with siRE transfected cells. 
When electroporating SKNO-1 cells once with a serial dilution of siRNAs, 
RUNX/ETO protein level remained low in the siRE-mod treated cells, while siRE 






Fig 3-7: RUNX1/ETO protein level in SKNO-1 on days 3 and 7. Cells were electroporated 
ones with 1, 10, 20, 50, 100, 200, 500 nM of either siRE or siRE-mod, and with 500 nM of 
siMM or untreated mock control. Cell lysates were collected on days 3 and 7 for Western 
blotting analysis. Membranes were blotted against α-RUNX1 antibody and α-GAPDH 




The serial electroporation experiments showed downregulation in RUNX1/ETO direct 
target genes. When Kasumi-1 cells were serially electroporated with 100 nM siRNA, 
RUNX1/ETO was virtually absent on day 9 (Fig 3-8). The knockdown led to a 
reduction in CCND2, a direct target gene of RUNX1/ETO, protein level. Moreover, 
Western blotting showed that RUNX1/ETO knockdown reduced RB1 
phosphorylation at T-821 and the total RB1 protein level. These findings led us to 
investigate the cell cycle profile after RUNX1/ETO repression because RB1 
phosphorylation status and CCND2 expression regulate the cell cycle (Bertoli, 





Fig 3-8: RUNX1/ETO knockdown in Kasumi-1 on day 9. Kasumi-1 cells were 
serially electroporated on days 0, 3 and 6 with 100 nM of siRE, siRE-mod, siMM or 
untreated mock control. Cell lysates were collected on day 9. Membranes were 
blotted against α-RUNX1, α-CCND2, α-RB1, α-p-RB1-T-821 and α-GAPDH loading 






3.4.1.4 RUNX1/ETO knockdown effects on the cell cycle  
The depletion of RUNX1/ETO in Kasumi-1 and SKNO-1 did not only reduce 
proliferation, but it also led to G1 cell cycle arrest. Single transfection with siRNA did 
not lead to an apparent cell cycle arrest, although subtle changes in the cell cycle 
profile were detectable 24 hours after transfection. However, serial electroporation 
resulted in prolonged G1 cell cycle arrest upon RUNX1/ETO knockdown.     
Observing the morphological changes in cells upon knockdown was consistent with 
the results of the cell cycle profiling. The knockdown of RUNX1/ETO reduced the cell 
diameter. These observations were confirmed in flow cytometry, which showed a 
significant reduction in the forward scatter of RUNX1/ETO knockdown cells (Fig 3-
9A, B). After two serial electroporations on days 0 and 3, the side scatters on day 6 
for the untreated cells and mismatch transfected Kasumi-1 cells were 270 and 268 
K, respectively, while siRE and siRE-mod transfected cells had 191 and 182 K side 
scatter. The knockdown of RUNX1/ETO in SKNO-1 cells reduced the side scatters of 
the cells in a similar manner as shown in Fig (3-9B). 
Moreover, RUNX1/ETO knockdown predominantly led to cell cycle arrest without any 
increase in cell death as shown through the absence of cell debris and apoptotic 
nuclei  in Fig 3-9A. After serial electroporations, the sub-G1 population was equal in 
both RUNX1/ETO knockdown cells and the controls as shown in Fig (3-9A). For this 












Fig 3-9: Forward and side scatter of RUNX1/ETO depleted cells. Cell lines were 
electroporated twice with 100 nM siRNA on days 0 and 3, followed by flow analysis 
on day 6. (A) Flow cytometry profile showing the forward and side scatters of 
Kasumi-1 cells on day 6 after transfection with siMM (control) and siRE-mod 
(RUNX1/ETO knockdown). (B) The geometric mean of the side scatter of Kasumi-1 
(left) and SKNO-1 (right) on day 6. Error bars represent SEM of three independent 






Propidium iodide (PI) staining showed that RUNX1/ETO knockdown by siRE and 
siRE-mod led to more than 50% reduction in the S phase of Kasumi-1 (Fig 3-10A) 
and 25% reduction in the S phase of SKNO-1 (Fig 3-10B). The siRE-mod did not 
induce any stronger cell cycle arrest compared to the siRE on day 6 when siRNAs 
were serially electroporated on days 0 and 3. Moreover, when siRE and siRE-mod 
were serially electroporated three or four times, the level of G1 cell cycle arrest was 
similar in both siRE and siRE-mod treated cells.  
Even though both siRE and siRE-mod caused comparable G1 cell cycle arrest on 
day 6 after two serial electroporations compared to the siMM (Fig 3-10A, B), the cell 
cycle arrest was maintained until day 12 in siRE-mod treated cells in Kasumi-1 cell 
line (Fig 3-10C). In Kasumi-1 cells, RUNX1/ETO knockdown on day 12 elevated the 
G1 phase to 72% and 78% in siRE and siRE-mod transfected samples (p= 0.016) 
compared to  65% in control treated cells. Additionally, siRE-mod transfected cells 
had also significantly (p= 0.032) fewer cells in the S phase on day 12 in comparison 
with siRE treated cells. Cell cycle profiling of Kasumi-1 showed 19% and 14% in the 
S phase of siRE and siRE-mod transfected cells, respectively. Nevertheless, two 
sequential electroporations led to liminal changes in the cell cycle profile of SKNO-1 
on day 12 (Fig 3-10D). 
SKNO-1 cell line culturing medium contains 7 ng/ml GM-CSF and 20% FCS. Under 
these conditions, it was not feasible to obtain a strong growth inhibition or clear 
changes in the cell cycle profile after RUNX1/ETO knockdown. For this reason, the 
GM-CSF concentration and FCS content were reduced to 5 ng/ml and 15%, 
respectively. The reduction in GM-CSF and FCS did not affect SKNO-1 proliferation 
or change RUNX1/ETO knockdown level. This optimised condition of SKNO-1 









Fig 3-10: Cell cycle profile after RUNX1/ETO depletion in Kasumi-1 and SKNO-
1. Cell lines were electroporated twice with 100 nM siRNA on days 0 and 3. Cell 
cycle profiling by PI staining was performed on days 6 (A & B) and 12 (C & D). Error 
bars represent SEM of three independent experiments. *P<0.05, **P<0.01, 





3.4.1.5 RUNX1/ETO knockdown effects on senescence  
The knockdown of RUNX1/ETO led to induction of cellular senescence. The number 
of senescent cells was determined after staining with senescence-associated β-
galactosidase activity assay. Upon staining, senescent cells appeared dark green 
under a bright-field microscope while the proliferative cells remained unstained. The 
inclusion criteria used to count senescent cells was that their shape was unchanged, 
and over 50% of the cell surface appeared as dark green. 
RUNX1/ETO knockdown with single transfection did not lead to senescence. Four 
sequential electroporations with siRE and siRE-mod resulted in 40% and 60% 
senescence, respectively, in Kasumi-1 cells (Fig 3-11A). Notably, when siRE-mod 
was serially electroporated twice, it induced the same level of senescence obtained 
with four transfections using siRE under the same conditions.  
Similarly, the modified siRE-mod induced significantly higher senescence levels in 





Fig 3-11: Induction of senescence after RUNX1/ETO knockdown in Kasumi-1 
(A) and SKNO-1 (B). Serial electroporations of Kasumi-1 and SKNO-1 with 100 nM 
of siRNA were performed on days 0, 3, 6 and 9. Staining with X-Gal was performed 
every three days. Cell count was carried under a bright-field microscope. Error bars 
represent SEM of three independent experiments, *P<0.05, **P<0.01, ***P<0.001, 
two-tailed Student’s t-test. 
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3.4.1.6 RUNX1/ETO knockdown effects on clonogenicity 
To investigate the effect of RUNX1/ETO knockdown on self-renewal, and to evaluate 
the level of RUNX1/ETO knockdown in a more stringent assay, colony formation 
assay (CFA) was performed. Our group optimised a protocol for colony formation in 
t(8,21) AML cell lines using methylcellulose semi-solid media. The plating of naïve 
untreated cells at 5 x 103 cells/ml resulted in up to 30% and 20% colonies in Kasumi-
1 and SKNO-1, respectively.  
Multiple CFA replating is commonly used to test the long-term self-renewal capacity. 
The effect of the cell density on colony formation was tested. When the CFA was 
performed using different cell numbers (0.5, 1, 2, 5, and 10 x 103 cell/well), the CFA 
recovery was constant (Fig 3-12). Regardless of the starting seeding density, 
Kasumi-1 cells yielded in about 30% colonies of the seeded cells, and 20-25% of 
SKNO-1 cells. The inclusion criteria used to count colonies was the presence of 
more than 25 cells in a single colony. 
 
Fig 3-12: Colony formation assay of Kasumi-1 (A) and SKNO-1 (B). Cells lines 
were seeded for colony formation at  0.5, 1, 2, 5, and 10 x 103 cells/well in 0.5 ml 
methylcellulose media. After approximately one week, (A) Kasumi-1 and (B) SKNO-1 
colonies were counted. Data represent the percentage of counted colonies divided 
by the seeded cell number. Four wells were counted per sample. Error bars 
represent the standard deviation of the percentage of counted colonies in four wells 





RUNX1/ETO knockdown resulted in significant reduction of clonogenicity of Kasumi-
1 and SKNO-1 cell line (Fig 3-13). The siRE-mod outperformed siRE and led to over 
80% reduction in clonogenicity of Kasumi-1 compared to a 65% reduction in siRE by 
comparison with the siMM control (Fig 3-13A). Replating Kasumi-1 colonies did not 
significantly differ between siRE and siRE-mod transfected cells and siRE-mod 
provided a more substantial decrease in clonogenicity.  
In SKNO-1 cells, siRE-mod transfected cells formed significantly fewer colonies in 
comparison with siRE (Fig 3-13B). RUNX1/ETO knockdown by siRE resulted in a 
40% reduction in CFA, while siRE-mod yielded in 50% reduction in clonogenicity.  
Similar to Kasumi-1, replating of SKNO-1 colonies also proved that RUNX1/ETO 
knockdown achieved with siRE-mod was more potent in impairing clonogenicity (Fig 
3-13B). 
Remarkably, RUNX1/ETO knockdown by single electroporation impaired Kasumi-1 
and SKNO-1 self-renewal up to 5 replatings (Fig 3-14). The siRE-mod significantly 
outperformed siRE in impairing clonogenicity in the first and second platings in both 
cell lines. In SKNO-1 cell line, siRE-mod substantially reduced the colony formation 
potential until the last replating, while in Kasumi-1 both siRNAs had showed similar 
potency (Fig 3-14). 
Notably, the first and second generations of CFA took about 8-10 days to form large 
round backed colonies. However, the replated cells were able to form colonies 














Fig 3-13: Colony formation assay of Kasumi-1 (A) and SKNO-1 (B) after 
RUNX1/ETO knockdown. Cell lines were electroporated with 100 nM siRNA and 
2000 cells per well were seeded after 24 hours of the knockdown in methylcellulose 
semi-solid media. The solid-filled column represents the total colonies number after 9 
days, the pattern-filled column represents the re-plated (2000 cells per well) colonies 
number after 7 days. Error bars represent SEM of three independent experiments 










Fig 3-14:  Replating experiment for colony formation of Kasumi-1 (A) and 
SKNO-1 (B) after RUNX1/ETO knockdown. Cell lines were electroporated with 100 
nM siRNA and seeded after 24 hours of transfection in methylcellulose semi-solid 
media at 4 x 103 cells/ml density. After counting, colonies were collected and washed 
twice with PBS, then cells were resuspended in methylcellulose at 4x103cell/ml 
density. Colonies were counted when large (more than 25 cells) backed colonies 
were formed. For the first and second platings, error bars represent SEM of three 
independent experiments (four wells were counted per experiment), *P<0.05, 





3.4.2 LNP/siRNA efficacy in vitro  
3.4.2.1 LNP/siRNA characterisation 
In vitro experiments in Kasumi-1 and SKNO-1 cell lines showed that the siRE-mod 
outperformed the siRE. The next pursued step was to encapsulate the siRNA into a 
lipid nanoparticle. Throughout the PhD project, five different batches of LNP/siRNA 
were generated using independently synthesised siRNA batches. For this reason, 
where applicable, statistical analyses were performed on independent biological 
replicates using independent LNP/siRNA formulations.  
Quality control measurements for each LNP/siRNA batch were performed in 
Zetasizer to ensure its suitability for the in vitro and in vivo experiments. These 
measurements included the particles’ size, charge and polydispersity. The dynamic 
light scattering measurement reflected the hydrodynamic size of the LNP/siRNA 
particles, the polydispersity index (PDI) reflected the homogeneity of the LNP/siRNA 
solution, and the zeta potential indicated the surface charge of the particles. 
Throughout the in vitro and in vivo experiments, the size of LNP/siRE-mod, 
LNP/siMM, and LNP/siMM-mod were in the range between 65 to 85 nm, as shown in 
Table 3-2. The PDI numbers were below 0.25, indicating that the LNP/siRNA 
mixtures had a uniform distribution of the particles size. 
LNP/siRNA solution was stable for over one year stored at 4°C. There were no 
significant changes in the size, PDI or charge of LNP/siRE-mod, LNP/siMM or 
LNP/siMM-mod in either concentrated or 1:100 diluted solutions (Fig 3-15A, B & C). 
The lipid nanoparticles had a small negative charge between -4 to -7 mV after 
packaging, and the surface charge increased to become more neutral over time. The 
LNP/siRNA charge did not exceed the 1 mV after 76 weeks of storage at 4°C (Fig 3-
15D). There was not any significant difference between the particles encapsulating 







Fig 3-15: LNP/siRNA physical parameters as assessed by the Zetasiser. 
LNP/siRNA solution was diluted 1:100 in PBS for size and PDI measurements, and 
diluted1:1000 in deionised water for the zeta potential measurement. (A) Changes in 
the LNP/siRNA particle size after 24 weeks. (B) changes in the polydispersity of the 
LNP/siRNA mixture after 24 weeks. (C) Changes in the LNP/siRNA charge over 24 
weeks. (D) Changes in 1:1000 diluted LNP/siMM particles zeta potential over 18 
months. All measurements were performed after calibrating the measurement 












efficiency  (%) 
Batch.1 
Sep.2015 
LNP/siRE-mod 84.6 0.22 -5 54.5 
LNP/siMM 76.1 0.19 -4.19 43 
Batch.2 
Feb.2016 
LNP/siRE-mod 76.3 0.16 -6.3 87 
LNP/siMM 77.9 0.18 -4.9 83 
Batch.3 
May.2017 
LNP/siRE-mod 65.6 0.08 -6.6 93 
LNP/siMM 68.4 0.1 -8.15 94 





73.0 0.11 -4.2 96 
 
Table 3-2: LNP/siRNA formulations and physical parameters. Measurement of 
the particles size, PDI and zeta potential were performed in Zetasizer within one 
week of the particles formulations. The packaging efficiency was determined after 




3.4.2.2 Lipid quantification in the LNP/siRNA 
The therapeutic action of the LNP/siRNA particles is due to the siRNA molecules. 
Thus, in vitro and in vivo doses were calculated based on the siRNA content. 
Although the lipid molecules in the vehicle were not relevant for gene knockdown, it 
was crucial to determine the siRNA to lipid ratio in order to rule out the side effects 
and cytotoxicity of the vehicle component.  
The total lipid content was measured in a colourimetric assay that quantified the total 
amount of phospholipids in the particles. The lipid mixture contained 10% molar ratio 
of DSPC. The absorbance of the complex between ammonium ferrothiocyanate 
[(NH4)Fe(SCN)4] and the phosphorus in the DSPC showed that the LNP/siRNA 
mixture contained around 1.1 mM DSPC. The methods of quantifying DSPC was 
adapted (Stewart 1980) and as described in 2.2.10.   
For 250 µg/ml LNP/siMM-mod, the final total lipid concentration was estimated to be 
11 mM. The aforementioned calorimetric assay determined only the organic 
phosphorus in the mixture. The presence of lipid-like compounds in the lipid mixture 
might have influenced or interfered with the absorbance. Nevertheless, the method 




3.4.2.3 LNP/siRNA cytotoxicity  
The first step in establishing RUNX1/ETO knockdown in vitro was determining the 
optimal LNP/siRNA concentration and exposure time. The criteria for the effective 
LNP/siRNA dose were minimal cytotoxicity, robust repression of RUNX1/ETO and 
dysregulation of its target genes in both t(8;21) cell lines.  
During the PhD project, four LNP/siRNA batches were made. Dr Nidhi Jyotsana in 
Hannover Medical School (Germany) performed the LNP/siRNA formation and 
quantified the siRNA content by Quant-iT RiboGreen as briefly described in 2.2.7. 
The encapsulation efficiency of siRNA was above 80% apart from the first batch 
(Table 3-2). 
The encapsulation efficiencies varied between the LNP/siRNA batches. However, 
the difference in the cytotoxicity of different LNP/siRNA batches was minimal. In the 
Kasumi-1 cell line, both 5 µg/ml and 0.125 µg/ml LNP/siRNA doses had minimal 
cytotoxicity after 24 hours of continuous exposure (Fig 3-16A). Moreover, there was 
no substantial or statistically significant differences in the cytotoxicity between lipid 
nanoparticles encapsulating either siMM or siRE-mod (Fig 3-16B). 
The Lipid mixture contained DiI dye that prevented the use of available absorbance 
or fluorescence-based toxicity assays. Cytotoxicity assays such as WST-1, WST-8, 
and resazurin were not successful in providing meaningful readings using a plate 
reader due to the interference of Dil spectra. Consequently, cell viability was 










Fig 3-16: Cytotoxicity of LNP/siRNA in Kasumi-1. (A) Kasumi-1 cells were treated 
with 0.125, 0.5, 2 and 5 µg/ml of LNP/siMM for 24 hours. After 24 hours, cells were 
washed twice with PBS and resuspended in media and counted on days 2, 3 and 6. 
Columns represent the average of two independent experiments. (B) Kasumi-1 cells 
were treated with 2 µg/ml of either LNP/siMM or LNP/siRE-mod for 24 hours. After 
24 hours, cells were washed twice with PBS and resuspended in fresh media and 
counted after 48 hours. Cell viability was determined with trypan blue. Error bars 




3.4.2.4 LNP/siRNA dose and exposure time optimisation  
The first experiment in SKNO-1 cell line showed that 24 hours continues exposure to 
0.2 µg/ml LNP/siRNA resulted in a 40% reduction in RUNX1/ETO mRNA on day 2 
(Fig 3-17A). However, RUNX1/ETO direct target genes such as CCND2, ANGPT1 or 
LAPTM5 did not change greatly (Fig 3-17B, C, D). Treatment with 2 µg/ml 
LNP/siRNA for 24 hours led to a 60% knockdown of RUNX1/ETO. Moreover, 
RUNX1/ETO transcriptional network was significantly dysregulated with 2 µg/ml 
LNP/siRNA treatment in comparison with the 0.2 µg/ml dose. For example, 
RUNX1/ETO repression led to about 40% downregulation of CCND2 mRNAs. (Fig 3-
16B). RUNX1/ETO late responding target genes were substantially dysregulated 
after six days of treatment. For instance, ANGPT1 was reduced two-fold, and 
LAPTM5 was increased 2.5-fold upon RUNX1/ETO knockdown (Fig 3-17C, D).  
Similarly, Kasumi-1 cells treated with 2 µg/ml LNP/siRNA for 24 hours had 70% 
reduction in RUNX1/ETO transcript while 0.2 µg/ml dose resulted in a mild reduction 
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(Fig 3-18A). Furthermore, Kasumi-1 treated with 2 µg/ml LNP/siRNA for 24 hours 
showed robust regulation of RUNX1/ETO target genes. For instance, RUNX1/ETO 
repression led to a reduction in CCND2, ANGPT1 and TERT mRNAs, and an 






Fig 3-17: qPCR analysis in SKNO-1 after LNP/siRNA treatment. SKNO-1 cells 
were incubated at 1 x 106 cells/ml density with either 0.2 or 2 µg/ml of LNP/siMM or 
LNP/siRE-mod for 15 minutes, 1, 4 and 24 hours. Treated cells were washed twice 
with PBS and resuspended in SKNO-1 media at 0.5 x 106 cells/ml density. On day 3, 
cell lysates were taken for the analysis of RUNX1/ETO and CCND2 expressions as 
shown in A and B, respectively. On day 6, the mRNA levels of ANGPT1 and 
LAPTM5 were measured as shown in C and D, respectively. The analysis of the 
expression data of LNP/siRE-mod treated samples were normalised against 






Fig 3-18: LNP/siRNA treatment in Kasumi-1. Kasumi-1 cells were incubated at 1 x 
106 cells/ml density with either 0.2 or 2 µg/ml of LNP/siMM or LNP/siRE-mod for 15 
minutes, 1, 4 and 24 hours. Treated cells were washed twice with PBS and 
resuspended in Kasumi-1 media at 0.5x106 cells/ml density. (A) On day 3, cell 
lysates were taken for the analysis of RUNX1/ETO mRNA. (B) On day 8, the mRNA 
level of RUNX1/ETO, CCND2, ANGPT1, LAPTM5, and TERT of the 2 µg/ml of 
treated cells. The analysis of the gene expression level of LNP/siRE-mod treated 
cells was normalised against LNP/siMM treated cells and GAPDH served as a 
housekeeping gene. (C) Western blotting on day 10 for 2 µg/ml treated cells. 
Membranes were blotted against α-RHD, α-TERT, α-CCND2 and α-GAPDH loading 
control. Marker size in kDa are presented on the left side of the blots.  
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Treatment with low LNP/siRNA concentrations and for short periods was not 
sufficient to induce robust RUNX1/ETO knockdown or changes in the fusion protein 
target genes. For this reason, 24 hours treatment with 2 µg/ml LNP/siRNA was 
considered the optimal dose for the in vitro functional studies. A dose of 2 µg/ml of 
LNP/siRNA corresponds to 150 nM siRNA given that siRNA MW ≈ 13.3 kg/mol. The 
LNP/siRNA dose was comparable with the siRNA molarity used in the 
electroporation experiments (100 nM). Nevertheless, LNP/siRNA treatment was 
applied once rather than repetitive administrations.   
 
3.4.2.5 LNP/siRNA treatment effects on proliferation  
The phenotype of RUNX1/ETO knockdown cells by LNP/siRNA was investigated in 
Kasumi-1 and SKNO-1 cell lines. Cells at 1 x 106 cells/ml density were treated with 2 
µg/ml LNP/siRE-mod or LNP/siMM for 24 hours as described in 2.2.12. 
LNP/siRNA-mediated RUNX1/ETO knockdown significantly reduced Kasumi-1 
proliferation (Fig 3-19A). However, the reduction in Kasumi-1 proliferation was less 
pronounced compared to what the serial electroporation achieved. On the other 
hand, LNP/siRNA did not provide a significant impact on SKNO-1 proliferation, but a 






Fig 3-19: LNP/siRNA mediated RUNX1/ETO knockdown effect on Kasumi-1 and 
SKNO-1 proliferation. Kasumi-1 cell line (A) and SKNO-1 cell line (B) were treated 
at 1 x1 06 cells/ml density with 2 µg/ml of LNP/siRE-mod or LNP/siMM. After 24 
hours, cells were washed twice with PBS and cultured at 0.5 x 106 cells/ml density 
and counted every three days. Error bars represent SEM of three independent 




3.4.2.6 The dynamics of RUNX1/ETO knockdown by LNP/siRNA 
Quantitative RT-PCR showed that LNP/siRNA treatment resulted in a rapid 
RUNX1/ETO knockdown and a robust dysregulation of the fusion transcriptional 
network in t(8;21) AML cell lines.  
In Kasumi-1 cell lines, RUNX1/ETO expression was quickly reduced by 80% after 24 
hours while and 60% - 70% knockdown was maintained over a week (Fig 3-20, A). 
The mRNA level of RUNX1/ETO had gradually recovered after 9 days of LNP/siRNA 
treatment. The robust knockdown of RUNX1/ETO resulted in a substantial 
modulation of its direct target genes. For instance, CCND2 expression level was 
decreased by 40% after 24 hours, while the maximal reduction was observed on day 
6 (Fig 3-19, B). Other RUNX1/ETO activated genes such as CD34 and ANGPT1 
were also downregulated in the mRNA level, 70% and 90% reductions were 
observed in CD34 and ANGPT1 on days 6 and 3, respectively (Fig 3-20, E & F).  
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Moreover, RUNX1/ETO-repressed genes such as CEBPA and LAPTM5 were 
strongly upregulated after the knockdown. CEBPA transcript level was increased 4-
fold and 5-fold after 24 hours and 48 hours of treatment, respectively (Fig 3-20D). 
After 9 days of treatment, LAPTM5 expression exceeded the 5-fold increase in the 
LNP/siRE-mod treated Kasumi-1 in comparison with the control treatment LNP/siMM 
(Fig 3-20G).  
Similarly to Kasumi-1, LNP/siRNA treatment achieved robust knockdown of 
RUNX1/ETO in SKNO-1 cells. RUNX1/ETO transcript level was reduced by 60% 
until day 9, and 40% knockdown was detected on day 12 (Fig 3-21A). CCND2 was 
downregulated after the knockdown, and 40% reduction was observed on day 6 (Fig 
3-20B). Genes that are repressed by RUNX1/ETO were also upregulated after the 
knockdown. There was a 2.5-fold increase in CEBPA after 24 hours of the treatment 
(Fig 3-21D), and over 8-fold increase in LAPTM5 on day 6 (Fig 3-21E).  
Telomerase, a direct target gene of RUNX1/ETO, belongs to the late responding 
genes. It has been observed that RUNX1/ETO knockdown led to an increase in 
TERT expression for the first two days of treatment in Kasumi-1 and SKNO-1 cells. 
However, one week upon the knockdown, TERT expression was reduced by 50% in 
Kasumi-1 (Fig 3-19D) and 20% in SKNO-1 (Fig 3-21C). 
Western blotting confirmed RUNX1/ETO knockdown at protein level. A single dose 
of 2 µg/ml LNP/siRNA provided a potent knockdown up to two weeks in Kasumi-1 
and SKNO-1 cell lines (Fig 3-22). In Kasumi-1, RUNX1/ETO protein level was 
decreased more than 90% after 24 hours of treatment. The reduction in RUNX1/ETO 
remained potent for the first week and 32% knockdown was observed on day 15 (Fig 
3-22,A). Similarly, in SKNO-1 cells, the LNP/siRNA treatment led to strong 
knockdown ar protein level (Fig 3-22,A). The knockdown of RUNX1/ETO resulted in 
approximately 40% reduction at protein level in CCND2 on day 3 (Fig 3-22,B).  
Two different loading controls were used in Kasumi-1 Western blot due to technical 








Fig 3-20: mRNA level of RUNX1/ETO and its direct target genes in Kasumi-1 
after LNP/siRNA treatment. Kasumi-1 cells were treated at 1 x 106 cells/ml density 
with 2 µg/ml of LNP/siRE-mod or LNP/siMM. After 24 hours, cells were washed twice 
with PBS and resuspended in media at 0.5 x 106 cells/ml. Cell lysates were taken at 
days 1, 2, 3, 6, 9, 12 and 15. The expression of LNP/siRE-mod treated samples was 







Fig 3-21: mRNA level of RUNX1/ETO and its direct target genes in SKNO-1 after 
LNP/siRNA treatment. SKNO-1 cells were treated at 1 x 106 cells/ml density with 2 
µg/ml of LNP/siRE-mod or LNP/siMM. After 24 hours, cells were washed twice with 
PBS and resuspended in media at 0.5sx 106 cells/ml. Cell lysate was taken at days 
1, 2, 3, 6, 9, 12 and 15. The expression of LNP/siRE-mod treated samples was 









Fig 3-22: RUNX1/ETO knockdown upon LNP/siRNA treatment. Kasumi-1 and 
SKNO-1  cells were treated at 1 x 106 cells/ml density with 2µg/ml of LNP/siRNA. 
After 24 hours, cells were washed twice with PBS and resuspended in media at 0.5 x 
106 cells/ml density. Cell lysates were taken at days 1, 2, 3, 6, 9, 12 and 15 for 
western botting. Membranes were blotted against α-RUNX1, α-CCND2 antibodies and 
α-GAPDH and α-ACTB served as loading controls. Marker size in kDa is presented 
on the left side of the blot. 
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3.4.2.7 LNP/siRNA effects on the cell cycle 
Given that LNP/siRNA contained Dil dye, it was not possible to use PI for cell cycle 
staining. Hoechst 33342 live cell staining was used to quantify the DNA content and 
generate the cell cycle profile as described in 2.2.16.  
LNP/siRNA-mediated RUNX1/ETO knockdown resulted in G1 cell cycle arrest in line 
with the electroporation experiments. On day 8, LNP/siRNA treatment in Kasumi-1 
led to a 14% increase in the G0/G1 phase, together with a 50% reduction in the S 
phase (Fig 3-23A). The same effect was observed in the SKNO-1 cell cycle. 
RUNX1/ETO knockdown by LNP/siRNA resulted in an increase in the G0/G1 phase 




Fig 3-23:  Cell cycle profile on day 8 after LNP/siRNA treatment in Kasumi-1 (A) 
and SKNO-1 (B). Cells were treated at 1 x 106 cells/ml density with 2µg/ml of 
LNP/siRNA. After 24 hours, cells were washed twice with PBS and resuspended in 
media at 0.5 x 106 cells/ml density. On day 8, cells were washed once with PBS, 








3.4.2.8 LNP/siRNA effects on senescence 
The senescence-associated beta-galactosidase assay showed that RUNX1/ETO 
knockdown by LNP/siRNA led to cellular senescence. Twelve days upon LNP/siRNA 
treatment, 40% of LNP/siRE-mod treated Kasumi-1 cells were positive for X-Gal 
staining while less than 8% were positive in the LNP/siMM treated control and the 
untreated control cells (Fig 3-24A, C). The knockdown of RUNX1/ETO with 
LNP/siRNA in SKNO-1 also led to 20% senescence in comparison with 6% in the 






Fig 3-24:  Induction of senescence after LNP/siRNA treatment in Kasumi-1 (A& 
C) and SKNO-1 (B& D). Cells were treated at 1 x 106 cells/ml density with 2 µg/ml of 
LNP/siRNA. After 24 hours, cells were washed twice with PBS and resuspended in 
media at 0.5 x 106 cells/ml density. On day 12, cells were washed with PBS, fixed at 
room temperature and stained overnight at 37oC with X-Gal as described in 2.2.15.    
Positively stained cells were counted under a bright-field microscope. Scale bar= 20 




3.4.2.9 LNP/siRNA effects on clonogenicity 
RUNX1/ETO knockdown by LNP/siRNA remarkably reduced the clonogenic potential 
of AML t(8;21) cell lines (Fig 3-25). Treatment with LNP/siRE-mod resulted in over 
fivefold reduction in clonogenicity in Kasumi-1 and SKNO-1 cells. Furthermore, 
replating of the colonies showed that the clonogenicity was greatly impaired in the 
RUNX1/ETO knockdown cells. The LNP/siMM did not provide any significant effect 
on clonogenicity of Kasumi-1 or SKNO-1, although a slight reduction in colonies 
number was observed in the first plating. However, upon re-plating, LNP/siMM 
treated cells formed as many colonies as the untreated cells, which may indicate a 




Fig 3-25: Colony Formation Assay of Kasumi-1 (A) and SKNO-1(B) treated with 
LNP/siRNA. Cells were treated at 1 x 106 cells/ml density with 2 µg/ml LNP/siRNA. 
After 24 hours, cells were washed twice with PBS and suspended in methylcellulose 
media at 4000 cells/ml density. After 7 days, colonies were counted and cells 
washed in PBS and replated at 4000 cell/ml density. The solid-filled columns 
represent the total colonies number after 7 days, and the pattern-filled column 
represents the replated colonies number after 8 days. Error bars represent SEM of 
three independent experiments (four wells were counted per experiment), *P<0.05, 





RUNX1/ETO knockdown at the mRNA level was stable even after seeding the cells 
in colony formation. In SKNO-1 harvested colonies, there was a significant reduction 
(~30%) in RUNX1/ETO (Fig 3-26A). Moreover, SKNO-1 colonies also presented a 
significant increase (~50%) in LAPTM5 expression (Fig 3-26, B) and over 40% 
reduction in RUNX1 (Fig 3-26C). Kasumi-1 colonies also showed a reduced 
RUNX1/ETO expression by 22% (Fig 3-26A). There was reduction in ANGPT1 
(~50%) and RUNX1 (~20%), respectively (Fig 3-27C, D) and increase in LAPTM5 





Fig 3-26: qPCR analysis in SKNO-1 harvested colonies after the first round of 
plating. SKNO-1 cells were incubated at 1 x 106 cells/ml with 2 µg/ml LNP/siRNA. 
After 24 hours, cells were washed twice with PBS and resuspended in SKNO-1 
colony formation media at 4000 cells/ml density and seeded. After 7 days, colonies 
were washed twice with PBS and cell lysates were taken for RNA extraction. 
Quantitative RT-PCR of RUNX1/ETO, LAPTM5, and RUNX1 expressions are shown 
in A, B and C respectively. The gene expression of LNP/siRE-mod treated cells was 
normalised against LNP/siMM treated cells and GAPDH served as a housekeeping 
gene. Error bars represent SEM of three independent experiments, *P<0.05, 







Fig 3-27: qPCR analysis in Kasumi-1 harvested colonies after the first round of 
plating. Kasumi-1 cells were incubated at 1 x 106 cells/ml with 2 µg/ml LNP/siRNA. 
After 24 hours, cells were washed twice with PBS and resuspended in Kasumi-1 
colony formation media at 4000 cells/ml density and seeded. After 7 days, colonies 
were washed twice with PBS and cell lysates were taken for RNA extraction. 
Quantitative RT-PCR of RUNX1/ETO, LAPTM5, ANGPT1, and RUNX1 expressions 
are shown in A, B, C and D respectively. The gene expression of LNP/siRE-mod 
treated cells was normalised against LNP/siMM treated cells and GAPDH served as 







3.4.3 LNP/siRNA efficacy in t(8;21) primary cells 
LNP/siRNA-mediated RUNX1/ETO knockdown in t(8;21) primary cells was 
investigated in two primary patient cells. Before applying any LNP/siRNA treatment, 
cells were seeded on MSCs feeders for 24 hours then treated with 4 µg/ml 
LNP/siRNA as described in 2.2.13.  
In the LK19 primary sample, treatment with LNP/siRE-mod resulted in a 62% 
reduction in RUNX1/ETO mRNA after three days of treatment and CEBPA was 
upregulated onefold (Fig 3-28). The knockdown of RUNX1/ETO in LK19 also led to a 
40% reduction in CCND2 level and 60% reduction in ANGPT1 (Fig 3-28).  
LK111 primary sample showed 56% knockdown of RUNX1/ETO after 4 days of 
LNP/siRNA treatment. The knockdown resulted in twofold upregulation in CEBPA 
expression. 
 
Fig 3-28: qPCR analysis of AML t(8;21) primary patient cells. Primary cells were 
seeded on top of MSCs feeder layer. On the next day, 2 µg/ml of LNP/siRNA was 
applied. AML cells were separated from the feeders and harvested on day 3 for 
LK19 and day 4 for LK111. The gene expression of LNP/siRE-mod treated cells was 





3.4.4 LNP/siRNA efficacy in t(8;21) PDXs 
Two AML t(8;21) PDX models (PDX1 and PDX2) were tested RUNX1/ETO 
knockdown ex vivo. PDXs cells were seeded on MSCs feeders for 24 hours then 
treated with 4 µg/ml LNP/siRNA. Leukaemic cells were harvested at days 3 and 6 for 
analysis. 
RUNX1/ETO knockdown level after 3 days of treatment in PDX1 and PDX2 was 40% 
(Fig 3-29A). However, the knockdown on the protein level was greater in PDX2. 
PDX1 had 25% reduction in RUNX1/ETO protein level and PDX2 has 80% reduction 
(Fig 3-29B). RUNX1/ETO direct target genes were also affected after the 
knockdown, for example, CCND2 protein was reduced to 43% in PDX1 and 
completely depleted in PDX2 (Fig 3-29B). 
RUNX1/ETO knockdown in PDX1 caused changes in RUNX1/ETO target genes. 
The mRNA level of RUNX1/ETO recovered partially 6 days after treatment where 
only 25% of knockdown was detected by qRT-PCR (Fig 3-29C). However, the fusion 
downstream targets were greatly changed at day 6 in comparison with day 3. The 
knockdown led to over 90% reduction in ANGPT1 transcript level 6 days after 
treatment. Moreover, RUNX1/ETO-repressed genes were upregulated with 
LNP/siRNA treatment, for instance, CEBPA and LAPTM5 increased 150 % and 








Fig 3-29: RUNX1/ETO knockdown in t(8;21) PDXs. AML t(8;21) PDXs cells were 
seeded on MSCs feeders. On the next day, 2 µg/ml LNP/siRNA were added, and 
AML cells were harvested on days 3 and 6. (A) RUNX1/ETO mRNA expression on 
day 3 was normalised to the LNP/siMM-mod control and GAPDH served as a 
housekeeping gene. (B) Western blotting showing the protein level on day 3 for 
RUNX1/ETO and CCND2, membrane was incubated with α-RUNX1 antibody, α-
CCND2, and α-GAPDH loading control. (C) The mRNA level of RUNX1/ETO and its 
target genes in PDX1 on days 3 and 6. The expression level was normalised to the 




3.5 Results summary and analysis  
RNAi-mediated gene knockdown using transient siRNA transfection is efficient in 
AML cell lines in vitro, however, gene knockdown in primary or PDX cells as well as 
in vivo is typically more challenging. Implementation of siRNA in the clinic faces 
several challenges such as; low intracellular and extracellular stability, poor 
pharmacokinetics, TLR immuno-stimulation, and the off-target silencing 
(Zimmermann, Lee et al. 2006, Shimizu, Kida et al. 2008, Hernandez, Stockdale et 
al. 2012, Huang, Cheng et al. 2016). This PhD project was designed to overcome 
the siRNA associated pharmacological challenges, and explore the therapeutic 
benefits of interfering with the fusion gene RUNX1/ETO. 
The PhD project was designed to follow sequentially three main steps. The first part 
of the project was introducing chemical modifications to maximise the siRNA 
knockdown efficiency. The second step was to encapsulate the siRNA into a non-
toxic delivery vehicle that allows in vivo systemic administration. The vehicle should 
also protect the siRNA from degradation, improve the circulation time, provide a 
window for targeted tissue accumulation and uptake, and stimulate the endosomal 
escape. The final step was to study the effect of the knockdown on a 
xenotransplantation model of AML. 
Combination of several well-established chemical modifications on both strands of 
RUNX1/ETO siRNA led to a robust depletion of the RUNX1/ETO fusion in the mRNA 
and protein levels. The modified siRNA also demonstrated a stronger effect on 
modulating RUNX1/ETO transcriptional network in comparison with the unmodified 
siRNA. Modulation of RUNX1/ETO expression by modified siRNA yielded stronger 
effects on inhibiting proliferation, induction of G0/G1 cell cycle arrest, initiating 
cellular senescence, and reducing clonogenicity. Colony formation replating 
experiments showed that depletion of RUNX1/ETO has a long-lasting effect, which 
proves the importance of RUNX1/ETO on self-renewal. 
Following the validation of the siRNA modifications, the modified siRNA and the 
mismatch control were encapsulated into a Dlin-MC3-DMA lipid nanoparticle. That 
work was carried out at Dr. Heuser lab in Hannover (Germany) using a microfluidic 
packaging system (NanoAssemblr, Precision NanoSystems) (Leung, Hafez et al. 
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2012, Jyotsana, Sharma et al. 2018). The encapsulation efficiency of the siRNA was 
high and the LNP/siRNAs parameters were reproducible. Long storage did not affect 
the nanoparticles’ parameters or compromise the siRNA efficacy. The size and 
charge of LNP/siRNAs were optimal for in vitro gene knockdown and allowed rapid 
and robust modulations of RUNX1/ETO expression and its target genes with minimal 
toxicity. 
A co-culture system has already been established in our lab for primary and 
primograft ALL cells expansion ex vivo (Pal, Blair et al. 2016). Due to the limited 
number of cells in the t(8;21) primaries and PDXs experiments, there was no proper 
characterisation of cell proliferation. Nevertheless, the MSCs feeders were able to 
support the expansion of PDXs and did not impair the gene knockdown.  
The lipid nanoparticle demonstrated the ability to a achieve strong gene knockdown 
in two t(8;12) patient primary cells in the co-culture system. LNP/siRNA was also 
potent in reducing RUNX1/ETO expression and modulating its transcriptional 
network in t(8;12) PDXs in the mRNA and protein levels. 
Confirming a robust knockdown of RUNX1/ETO with the modified siRNA and 
LNP/siRNA in vitro and in ex vivo in co-culture, made the targeting of RUNX1/ETO in 
vivo feasible. LNP/siRNA was taken forward for the in vivo studies in a 




















Previous studies in our group proved the role of the oncoprotein RUNX1/ETO in 
initiating and maintaining the propagation of leukaemia in t(8;21) AML cell lines in 
vitro. The transcription factor RUNX1/ETO interferes with RUNX1 transcriptome 
leading to activation of self-renewal genes and repression of myeloid differentiation 
programmes (Ptasinska, Assi et al. 2012, Loke, Assi et al. 2017). It was also found 
that RNAi-depletion of RUNX1/ETO in vitro upregulates CEBPA expression, 
alleviating the myeloid differentiation block (Martinez, Drescher et al. 2004). 
Furthermore, in vitro studies demonstrated that transient depletion of RUNX1/ETO 
by siRNA (siRE), administered by electroporation, in Kasumi-1 cells significantly 
increased the median survival of transplanted mice, and enhanced the median 
survival by 50% from 64 to 90 days (Soria, Tussiwand et al. 2009). 
The knockdown experiments utilising chemically modified siRNA encapsulated into 
nanoparticles proved robust RUNX1/ETO repression in vitro. The next step of this 
project was to assess the potency of LNP/siRNA in vivo and investigate the 
therapeutic benefits of the knockdown using the modified version of siRNA. In vivo 
experiments were carried out in a xenotransplantation model for Kasumi-1 cells in 
the immunodeficient Rag2-/- ɣC-/-mice. In order to assess leukaemic burden and 
engraftment in vivo, transplanted Kasumi-1 cells were stably transduced with the 
p.SLIEW vector allowing for a continuous expression of firefly luciferase (Luc) and 
green fluorescent protein (eGFP) genes. Kasumi-1 p.SLIEW cells were previously 
generated and validated (Bomken, Buechler et al. 2013). In the mouse 
transplantation model, Kasumi-1 cells usually do not engraft in the bone marrow, and 
occasionally the spleen is 3 to 10-fold enlarged. The usual engraftment of Kasumi-1 
cells, however, results in forming extra-medullary tumours in the abdominal. 
Harvested cells from these tumours mainly express the human markers CD45, 
CD33, and CD34. For these reasons, the in vivo model is suitable to investigate the 






4.2 Aim  
The second aim of the PhD was silencing RUNX1/ETO expression in vivo in 
xenotransplantation model of t(8; 21) AML to:   
1. Study the pharmacodynamics of LNP/siRNA in Rag2-/- ɣC-/- mice upon 
systemic administration. 
2. Prove the on-target RUNX1/ETO knockdown in leukaemic cells. 
3. Determine the survival benefits after RUNX1/ETO depletion. 







4.3 Experimental design   
4.3.1 t(8,21) AML murine models  
Three different t(8;21) leukaemia murine models were used during the project. The 
xenotransplantation model for Kasumi-1 cell line was performed in Rag2-/- ɣC-/- mice. 
The RL048 and CC209 t(8;21) PDXs were generated in NSG and MISTRG mice, 
respectively. 
Rag2-/- ɣC-/- immunodeficient mice are suitable to host human haematopoietic cells 
because they do not exhibit B and T cells due to the loss of Rag2 gene. The IL-2 
receptor gamma chain knockout (ɣC-/-) also ensures the profound T cell defect by 
eliminating the cytokines receptors IL-2, IL-4, IL-7, IL-9 and IL-15 and consequently 
rendering NK cells activation (Sugamura, Asao et al. 1996). Moreover, Rag2-/- ɣC-/- 
mice have normal haematopoietic parameters such as red blood cells, white blood 
cells, haemoglobin and platelets (Ohbo, Suda et al. 1996, Mazurier, Fontanellas et 
al. 1999). We performed intrahepatic transplantation of Kuasmi-1 cells in newborn 
Rag2-/- ɣC-/- mice because the liver in young mice resembles a suitable niche for 
leukaemia engraftment (Cheung, Fung et al. 2010). 
NSG mice are immunodeficient with mutation in the DNA repair complex protein 
(Prkdc) gene, which impairs B and T cells development and leads to a severe 
combined immunodeficiency genotype (SCID). The mice also have a complete 
knockout of the IL-2 receptor gamma chain. The immunodeficient NSG mice support 
the engraftment of CD34+ haematopoietic stem cells as well as leukaemic cells 
taken directly from the patients (Ito, Hiramatsu et al. 2002, Andre, Erbacher et al. 
2010). 
The humanised MISTRG mice carry the Rag2-/- ɣC-/- immunodeficiency, and they 
express the human version of several cytokines necessary for development of the 
innate immune system. MISTRG mice express M-CSF, IL-3, GM-CSF, and THPO. 
Moreover, these mice also have the human SIRPα-encoding BAC transgene, in 
which the binding of SIRPα to CD47 enables the murine phagocytes to accept the 
engrafted human cells. MISTRG mice are highly permissive for human 
haematopoiesis and were reported to support the engraftment of AML patient-
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derived xenografts (Rongvaux, Willinger et al. 2014, Saito, Ellegast et al. 2016, 
Wunderlich and Mulloy 2016). 
 
4.3.2 Pharmacokinetics of LNP/siRNA in Rag2-/-ɣC-/- mice 
In order to monitor the biodistribution of the lipid nanoparticles in vivo, we have 
labelled the nanoparticles with a near-infrared (NIR) fluorescent dye called 
SulfoCyanine7.5 as described in 2.2.9. The labelled nanoparticles, hereinafter, 
LNP/siRNA-SulfoCyanine7.5 were formulated twice and tested in two independent 
pharmacokinetics (PK) studies. 
The first PK experiment (Fig 4-1) consisted of four Rag2-/- ɣC-/- mice transplanted 
with Kasumi-1 p.SLIEW. The targeted group contained three mice and one mouse 
served as a control. Upon confirmation of engraftment by IVIS, mice were 
intravenously (IV) injected with 0.5 mg/ml (~ 50 µl) LNP/siRNA-SulfoCynanine7.5. 
The control mouse received 50 µl of the control vehicle (10% SulfoCyanine7.5/PBS) 
by tail injection. In vivo imaging by IVIS was performed 2, 4, 6, 24, 48, and 120 hours 
post injection. At day 5, mice were culled and IVIS imaging was performed on 
harvested tumours and organs. 
For the second PK experiment (Fig 4-2) four mice were used. All mice were 
transplanted with Kasumi-1 p.SLIEW cells followed by IVIS to assess to assess the 
engraftment. Mice were then injected by intraperitoneal (IP) route with unlabelled 
LNP/siRNA (not carrying the SulfoCyanine7.5 dye). Each mouse received 1 mg/ml of 
LNP/siRNA per day for three consecutive days. On day 4, three mice were given one 
IV injection of 0.5 mg/ml (~ 50 µl) LNP/siRNA-SulfoCyanine7.5. The control mouse 
was injected with 50 µl 10% SulfoCyanine7.5/PBS. IVIS was performed 1, 4, 24, and 
72 hours post injection. On DAY 3, mice were culled, tumours and organs were 





Fig 4-1: Experimental set up: Lipid nanoparticles pharmacokinetics in vivo, 
first PK study. Newborn Rag2-/- ɣC-/- mice were transplanted with Kasumi-1 
p.SLIEW cells and engraftment was assessed by IVIS. Three mice were injected 
with 0.5 mg/ml of LNP/siRNA-SulfoCyanine7.5. The control mouse was injected with 
50 µl of 10% SulfoCyanine7.5/PBS. Fluorescent and bioluminescence imaging were 
performed after 2, 4, 6, 24, 48, and 120 hours. Five days after LNP/siRNA-
SulfoCyanine7.5 injection, mice were culled and harvested tumours and organs were 
imaged by IVIS. 
 
 
Fig 4-2: Experimental set up: Lipid nanoparticles pharmacokinetics in vivo, 
second PK study. Newborn Rag2-/- ɣC-/- mice were transplanted with Kasumi-1 
p.SLIEW cells and engraftment was assessed by IVIS. Mice were treated with 3 
consecutive doses of 1 mg/ml of LNP/siRNA every 24 hours. On the fourth day, mice 
were injected with 0.5 mg/ml of LNP/siRNA-SulfoCyanine7.5 or 50 µl of 10% 
SulfoCyanine7.5/PBS. Fluorescent and bioluminescence imaging were performed 
after 1, 4, 24, and 72 hours. After 3 days of injection, mice were culled and harvested 
tumours and organs were imaged by IVIS.  
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4.3.3 In vivo knockdown experiments    
Gene knockdown in vivo was performed in a xenotransplantation model of Kasumi-1 
cells in Rag2-/- ɣC-/- mice. In brief, Kasumi-1 p.SLIEW cells stably expressing 
luciferase (Luc) and eGFP were injected intrahepatically in newborn mice as 
described in 2.3.1. After waning, IVIS imaging was performed to confirm the 
engraftment of leukaemic cells by biochemiluminescence assay as described in 
2.3.6. 
During the project, four independent LNP/siRNA formulations were used in four in 
vivo experiments. Each in vivo experiment consisted of two arms,  
I. Control arm, nanoparticles encapsulating mismatch siRNA. 
II. RUNX1/ETO targeted treatment arm, nanoparticles encapsulating the 
modified siRUNX1/ETO. 
In the first three experiments, after confirming the engraftment by IVIS, mice were 
treated with LNP/siRNA by IV route. In the fourth experiment, mice were treated by 
IP route three days after transplantation. The doses and treatment schedules are 
shown in figures Fig 4-3, Fig 4-4, Fig 4-5, and Fig 4-6.   
Leukaemic burden was assessed by IVIS and mice were culled when they reached 
any of the protocol endpoints stated in 2.3.1. The endpoints for mice under treatment 
were: 
1. Body weight loss of 30% or more. 
2. Body weight loss of 10 – 20% and maintained low for three consecutive days. 
3. Tumour size is 1.5 cm or more in any dimension. 
4. The tumour is affecting the movement or feeding. 
5. Any sign of sickness that is severely affecting the health of the mouse. 
The numbers of mice required during the animal studies were determined using two 
different approaches. The resource equation approach was followed in the first three 
in vivo experiments. That is because there was no prior information about the 
predicted level of RUNX1/ETO knockdown or the effectiveness of nanoparticles 
treatment. The power calculation was used to determine the size of the cohort 
needed for the survival experiments. 
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Based on the resource equation method, the acceptable degree of freedom (DF) for 
the error when using ANOVA analysis is 10 to 20. The in vivo experiments consisted 
of two treatment groups and the predicted readout were quantitative variables, such 
as IVIS signals or gene expression. Given that these experiments aimed to compare 
the effect of the treatment between the two groups, the collected data can be 
analysed by one-way ANOVA or independent student t-test (Festing and Altman 
2002, Charan and Kantharia 2013). Thus, animal numbers were calculated as follow:  
𝑛 =  
𝐷𝐹
𝑘
+ 1     
Where; n = number of animals per group, DF = 10 or 20 to calculate the minimum or 
maximum number of animals, and K = number of groups.     
The maximum 𝑛 =  
20
2
+ 1 = 11 
The minimum 𝑛 =  
10
2
+ 1 = 6  
The total number of animals needed for the knockdown experiments should be 
between 12 to 22 mice, with at least 6 mice per group. 
 
The survival experiment consisted of four treatment arms. The power calculation was 
performed using the following formulas, 








1 − 𝛽 = 2𝛷(𝑧 − 𝑧1−𝑎) − 1  
𝑧 = (𝛿 − |ln(𝜃)|)√𝑛 ∗ 𝑝𝐴 ∗ 𝑝𝐵 ∗ 𝑝𝐶 ∗ 𝑝𝐶 
Where; θ is the hazard ratio. We have considered θ = 0.24 based on former work in 
our group showed that in vitro knockdown of RUNX1/ETO reduced the hazard of 
death of transplanted mice by 76% (Soria, Tussiwand et al. 2008). 
pA,pB,pC and pD are the proportions of the group size allocated to the four groups. 
We have considered pA = pB = pC = pD = 0.25 
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pE is the overall probability of the event. The readout was survival, thus the 
probability is pE = 0.5 where at each time point the mouse is either live or dead. 
Φ is the standard normal distribution function. 
1 – β is the power and we have considered 1 – β = 0.8 
δ is the testing margin. In our experiment we have considered δ = -2.  
The power and testing margin values were considered from the literature and former 
work in our lab (Charan and Kantharia 2013, Martinez-Soria 2018).  
After applying the aforementioned equations and values in RStudio, the minimum 
number of animals per group was found to be 7. Thus, the survival experiment 
consisted of 28 mice. 
The xenotransplantation model was generated by injecting leukaemic cells in 
newborn mice. The first in vivo experiment consisted of 9 mice instead of 12 
because the allocated letters for the experiment did not provide the needed number 
of animals. The following table (Table 4-1) shows the number and gender of mice 
used throughout the four experiments. 
 
Experiment  Control group RUNX1/ETO targeted group Total number  
1st in vivo 3 females & 1 male  3 females & 2 males  9 
2nd in vivo 5 females & 1 male  4 females & 2 males  12 
3rd in vivo 2 females & 5 males  3 females & 5 males  15 
4th in vivo 8 females & 6 males  8 females & 6 males  28 
Table 4-1: Animal number and gender distribution throughout the in vivo 
experiments. 
 
At the end of each experiment, Kasumi-1 p.SLIEW cells from treated mice were 
harvested and frozen as viable cells as described in 2.3.7 and 2.2.1. During the ex 
vivo proliferation assay and colony formation, 1% penicillin/streptomycin (P/S) 
antibiotic was added to the media. The RNA and protein expression of RUNX1/ETO 
and its target genes were quantified in qRT-PCR and Western blotting. 
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4.3.4 Self-renewal assays      
In order to investigate the effect of RUNX1/ETO depletion in vivo on the self-renewal, 
harvested cells where either seeded for ex vivo colony formation assay or 
retransplanted into new recipients mice. 
Two independent secondary retransplantation experiments were conducted using 
harvested cells from the third in vivo experiment as shown in Table 4-2. In the 
secondary retransplantations, Kasumi-1 p.SLIEW cells were injected into newborn 
Rag2-/- ɣC-/- mice as described in 2.3.1 (Fig 4-5). 
Mice were dosed with LNP/siRNA as shown in (Fig 4-5). The first secondary 
retransplantation experiment was carried out three days after finishing the 
LNP/siRNA treatment. During this experiment, two mice were used from each 
treatment group, and harvested Kasumi-1 p.SLIEW cells from treated mice were 
transplanted into two litters (2 and 5 days old). The second retransplantation 
experiment was performed at a later time point using frozen cells from treated mice. 
Kasumi-1 p.SLIEW cells were thawed, two from each treatment arm, and 
transplanted into one litter (2 days old). 
 
 Primary treated mice (third in vivo 
experiment)  
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Fig 4-3: Experimental set up of the first in vivo experiment. Nine newborn Rag2-/- 
ɣC-/- mice were transplanted intrahepatically with Kasumi-1 p.SLIEW cells. After 6 
weeks, engraftment was assessed by IVIS and mice were randomised into two 
groups, RUNX1/ETO targeted group received LNP/siRE-mod treatment and control 
group received LNP/siMM treatment. Mice were IV dosed with 0.5 mg/kg of 
LNP/siRNA twice. Leukaemia burden was assessed by IVIS throughout the 
experiment and mice were culled when they reached any of the protocol endpoints 
described in 4.3.3. 
 
Fig 4-4: Experimental set up of the second in vivo experiment. Twelve newborn 
Rag2-/- ɣC-/- mice were transplanted, randomised and treated as described in Fig 4-3. 
Mice were dosed by three IV inactions of 0.5 mg/kg of LNP/siRNA, and leukaemia 






Fig 4-5: Experimental set up of the third in vivo experiment. Fifteen newborn 
Rag2-/- ɣC-/- mice were used for the experiment following the same setting as 
described in Fig 4-3. LNP/siRNA was administered by two routes as shown in the 
scheme. Mice received 2 x IP doses of 2 mg/kg followed by 3 x IV doses of 1 mg/kg 
of LNP/siRNA. Three days after finishing the treatment, two mice from each group 
were culled and harvested cells were retransplanted into new recipients as described 
in 4.3.4. Mice were imaged by IVIS to assess leukaemia burden and culled when 
they reached any of the protocol endpoints. 
 
 
Fig 4-6: Experimental set up of the fourth in vivo experiment. Twenty-eight 
newborn Rag2-/- ɣC-/- mice were intrahepatically transplanted with Kasumi-1 p.SLIEW 
cells followed by lipid nanoparticles treatment by IP route as indicated in the scheme 
above. The RUNX1/ETO targeted group (14 mice) was treated with LNP/siRE-mod 
and the control group (14 mice) was treated with LNP/siMM-mod. Mice were 
monitored and leukaemia expansion was assessed by IVIS imaging. Mice were 




4.4.1. Pharmacokinetics of LNP/siRNA in Rag2-/- ɣC-/-   
The lipid mixture contained a fluorescent dye, Dil, which is not suitable for in vivo 
imaging. That is because the fluorescence spectrum of Dil overlaps with the 
autofluorescence of mice tissue preventing accurate quantification of the emitted 
signal. For this reason, the lipid nanoparticles were labelled with SulfoCyanine7.5, a 
NIR dye, which is compatible with in vivo imaging. 
There is not any published protocol for click chemistry reaction on the surface of lipid 
nanoparticles. For this reason we have optimised a protocol for labelling the lipid 
nanoparticles as described in 2.2.9. First, the click reaction components were 
assigned to the lipid mixture and the dye. The NIR dye was obtained as a  
SulfoCyanine7.5 alkyne, and a new molecule (DSPE-PEG2000-N3) was introduced 
to the lipid mixture before performing the LNP/siRNA formulation. DSPE-PEG2000-
N3 contains a phospholipid part, the DSPE, and a polyethylene glycol bearing a 
terminus azide group (PEG2000-N3). The azide group can readily react with alkyne 
to form a stable triazole. 
Given the amphiphilic properties of DSPE-PEG2000-N3, during the siRNA 
packaging in the lipid nanoparticles, the DSPE is entrapped in the hydrophobic layer, 
and the PEG2000-N3 is oriented either towards the surface or the hydrophilic centre. 
The DSPE-PEG2000-N3 was added at 0.3% mol ratio to the lipid mixture, which 
means its theoretical concentration in the LNP/siRNA solution is 300 µM. The lipid 
nanoparticle has a solid core of tightly packed hydrophilic pocket encapsulating the 
siRNA. For this reason, some of the PEG2000-N3 might be present in those pockets 
rather than on the surface. Taken together, the concentration of free azide groups on 
the LNP/siRNA surface was speculated to be around 50 µM. 
Following the procedures described in 2.2.9, the click reaction was performed by 
dissolving CuCl2 to a 0.5 mM in a solution of 50% DMSO in H2O. A final mixture of 
ascorbic acid, LNP/siRNA and SulfoCyanine7.5 alkyne was mixed in a 1.5 
Eppendorf tube and heated for 20 minutes at 40°C then the CuCl2 solution was 
added to the mixture and left in the Eppendorf tube overnight at 25°C in the dark. 
Next day, the labelled LNP/siRNA was dialysed using 3,500 MWCO dialysis tubes 
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against PBS at 4°C. The dialysis was performed in the dark overnight, and the PBS 
was changed three times. After completion of the dialysis, the size and charge of 
LNP/siRNA-SulfoCyanaine7.5 were determined by Zetasizer. The colour of the 
labelled nanoparticles became green/blue which is the same colour of 
SulfoCyanaine7.5 dye. Elimination of the copper or ascorbic acid form the click 
reaction served as negative controls. Under these conditions, we did not observe 
any changes in the colour of the nanoparticles after dialysis, meaning the click 
reaction did not happen. Addition of the NIR dye to the LNP/siRNA did not 
significantly affect the diameter of particles, but the polydispersity (PDI) of the 
practices increased by twofold (Fig 4-7A, B). Moreover, the zeta potential became 





Fig 4-7: LNP/siRNA parameters before and after labelling with NIR dye. 
Measurements of the dynamic light scattering in Zetasizer of nanoparticles before 
and after performing the click reaction. (A) The diameter of the nanoparticles 
measured in nm scale in the Y-axis. (B) Changes in the polydispersity of the 
nanoparticle mixture after the click reaction. (C) Surface charge of the nanoparticles 
measured as a zeta potential in mV. All measurements were performed at 25°C after 
one-minute temperature calibration. 
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The Zetasizer measurements showed that the labelled nanoparticles (LNP/siRNA-
SulfoCyanine7.5) have suitable diameter and charge for in vivo treatment. The first 
PK study showed that a single intravenous injection of the nanoparticles provided a 
global body distribution. The nanoparticles accumulated in the liver after 2 hours of 
the intravenous injection. The mean of the fluorescence of treated mice liver 
remained higher than the untreated control until day 3 (Fig 4-8A).  
In the second PK study, pre-treatment with unlabelled LNP/siRNA was applied for 
continues three days to saturate the liver with the nanoparticles. Unexpectedly, upon 
intravenous injection of labelled nanoparticles, the liver fluorescence signal was 
twofold higher than the control. This means that the liver remained the first target of 












Fig 4-8: Liver uptake of the lipid nanoparticles. Analysis of fluorescence from 
Rag2-/- ɣC-/- mice treated with labelled nanoparticles. (A) Mice treated with labelled 
nanoparticles had threefold higher fluorescence signal than the control mouse. Data 
represent the mean of the NIR fluorescence of the liver of three mice in the targeted 
group and the fluorescence signal of the liver of the control mouse. Error bars 
represent the SEM of the fluorescence of three mice. (B) The liver remains the main 
target of the nanoparticles even after saturation with the nanoparticles. Mice were 
pre-treated with unlabelled nanoparticles to saturate the liver followed by IV injection 
of the labelled nanoparticles. Data represent the total fluorescence signal of the liver 
4 hours after the IV injections showing higher uptake of the labelled nanoparticle in 
the targeted mouse. The baseline measurement was performed 24 hours before the 




Furthermore, the labelled nanoparticles accumulated in the tumours after 
intravenous administration (Fig 4-9). Upon injection of luciferin, the bioluminescence 
signal overlapped with the fluorescence signal in the site of the tumours. In order to 
eliminate any emission from the luciferase activity into the NIR channel, the 







Fig 4-9: Accumulation of the LNP/siRNA in the tumour site. Mice were treated 
with the nanoparticles as described in scheme Fig 4-2. IVIS images show that the 
labelled nanoparticles reach the tumour site. (A) IVIS images demonstrate that the 
bioluminescence signal of the tumour colocalises with the fluorescence of the 
labelled nanoparticles. Scales are photons/second. (B) Harvested tumours confirmed 






Even though the liver was mostly the main target of the nanoparticles, IVIS imagining 
showed that the nanoparticles were detectable in several organs. LNP/siRNA- 
SulfoCyanine7.5 were trapped in the spleen, kidneys, lungs, and heart. The IVIS 
imaging was able to detect the fluorescence signal in the spine, bones and the brain 
(Fig 4-10). 
IVIS imagining cannot confirm that the fluorescence source is the bone marrow. The 
nanoparticles could be present in the periosteum membrane covering the bone 
surface. The excitation wavelength of SulfoCyanine7.5 dye is in the NIR channel. For 
this reason, it was not feasible to use flow cytometry or fluorescence microscopy to 





Fig 4-10: Pharmacokinetic of LNP/siRNA in Rag2-/- ɣC-/- mice. Mice were 
transplanted with Kasumi-1 p.SLIEW cells and treated with the nanoparticles as 
described in Fig 4-2. Fluorescence images show that the nanoparticles can be 
detected in several haematological compartments such as the liver, spleen, bones, 








4.4.2. LNP/siRNA mediated RUNX1/ETO knockdown in vivo 
The pharmacokinetic experiments confirmed that the nanoparticles have global body 
distribution in vivo, and they can potentially reach the tumour site, bones, and CNS 
upon systemic administration. The gene knockdown was investigated after 
LNP/siRNA IV treatment in the Kasumi-1 p.SLIEW transplantation model. 
LNP/siRNA was well tolerated in adult Rag2-/- ɣC-/- mice bearing leukaemic tumours. 
Mice received two or three doses of 0.5 mg/kg in the first and second in vivo 
experiments, respectively. The treatment did not decrease the body weight. 
Nevertheless, in the third in vivo experiment, mice showed a 10% - 15% drop in the 
body weight. That could be due to the treatment regimen as mice received two IV of 
2 mg/kg every 24 hours, followed by one IV of 1 mg/kg on the third day. The body 
weight recovered over the weekend after the addition of soaked diet. 
Harvested Kasumi-1 p.SLIEW cells showed a 28% reduction in RUNX1/ETO 
expression (Fig 4-11A) suggesting an on-target effect of LNP/siRNA treatment. 
Although the decrease in RUNX1/ETO mRNA was not statistically significant, 
several direct target genes were significantly changed. For example, LNP/siRE-mod 
treatment led to a significant 56% and 30% reduction in ANGPT1 and CD34 
transcripts, respectively. Moreover, LAPTM5 expression significantly increased after 
the treatment Fig (4-11A). 
When LNP/siRNA treatment was given in the same dose and injection route in the 
second experiment, RUNX1/ETO knockdown was 40% and statistically significant 
(p<0.05) (Fig 4-11B). The differences between the first and second in vivo 
experiments were that the mice were two weeks younger and received an additional 
dose of the nanoparticles in the second experiment. These may have contributed to 










Fig 4-11: LNP/siRNA treatment effect on Kasumi-1 p.SLIEW cells in vivo. Lipid 
nanoparticles have on-target effect on leukaemic cells in vivo as proved by RT-qPCR 
analysis. Mice were treated as described previously and shown in the schemes 
above. (A) The expression level of RUNX1/ETO, ANGPT1, CD34, and LAPTM5 in 
Kasumi-1 p.SLIEW cells harvested in the first in vivo experiment. (B) The knockdown 
of RUNX1/ETO mRNA in Kasumi-1 p.SLIEW in the second in vivo experiment. Gene 
expression in the LNP/siRE-mod treated arm was normalised to the control 
LNP/siMM treatment, and GAPDH served as a housekeeping gene. Error bars 
represent the SEM of Δct values in each treated group. *P<0.05, **P<0.01, 








RUNX1/ETO knockdown in vivo was more prominent at the protein level. Western 
blotting analysis of two harvested samples in the first in vivo experiment showed a 
reduction in RUNX1/ETO protein level upon LNP/siRE-mod treatment in comparison 
with the control (Fig 4-12A). It was not feasible to calculate the fold change for 
RUNX1/ETO protein expression because the control antibodies were not human-
specific. The control antibodies included GAPDH, Tubulin, and Actin. Nevertheless, 
considering RUNX1 a control, the reduction in RUNX1/ETO was apparent. 
Western blotting analysis of the second in vivo experiment showed that RUNX1/ETO 
protein was significantly reduced (up to 50%) using three doses of 0.5 mg/kg 
LNP/siRNA (Fig 4-12B, C). The fold change calculations were confidently carried out 
after obtaining human-specific GAPDH and Clathrin heavy chain 1 (CLTA) 
antibodies. The knockdown of RUNX1/ETO resulted in ~ 90% downregulation of 


















Fig 4-12: In vivo RUNX1/ETO knockdown at the protein level. End-point analysis 
of protein expression in harvested Kasumi-1 p.SLIEW cells cells. Mice were treated 
as indicated in Fig 4-11 schemes. (A) Immunoblot shows RUNX1/ETO protein level 
in one representative mouse from each treatment group for the first in vivo 
experiment. (B)  Western blotting showing RUNX1/ETO, CCND2, TERT, GAPHD, 
and CLTA proteins in harvested cells in the second in vivo experiment. (C) 
Densitometric quantification of RUNX1/ETO, CCND2, and TERT bands normalised 
to CLTA loading control. Error bars represent the SEM of the relative protein 
expression in each group, two-tailed Student’s t-test. The blue star represents two 
different lysates collected from the same mouse, and each lane was given a weight 





4.4.3. RUNX1/ETO depletion reduces leukaemia burden and ex vivo expansion  
Protein and RNA analysis confirmed that LNP/siRNA systemic treatment provided 
on-target effect on Kasumi-1 p.SLIEW cells in vivo. However, the knockdown of 
RUNX1/ETO did not reduce the luciferase signal (Fig 4-13A, B, C). The first in vivo 
experiment started when all transplanted mice had high quantitative 
bioluminescence signal (1x109 p/s) in order to monitor any changes upon treatments. 
During the week of LNP/siRNA treatment, the bioluminescence signal of LNP/siRE-
mod treated arm remained stable while the bioluminescence of the control group 
increased. However, three days after treatment, the IVIS signal of LNP/siRE-mod 
treated arm increased to the level control treated group. (Fig 4-13A). 
The leukaemic burden was high in the first in vivo experiment due to rapid increase 
in the bioluminescence signal. Thus, LNP/siRNA treatment started two weeks earlier 
in the second in vivo experiment but this did not make a difference (Fig 4-13B). In 
the third in vivo experiment, mice received a total of 8 mg/kg of siRNA through 
IP and IV injections during ten days, yet the bioluminescence increased when the 
treatment stopped (Fig 4-13C).    
The engraftment of Kasumi-1 p.SLIEW cells in Rag2-/-ɣC-/- led to the formation of 
granulocytic sarcomas-like tumours with yellow, pale colour. RUNX1/ETO 
knockdown in the first three in vivo experiments did not rescue the mice from the 
leukaemic burden as shown by IVIS. However, harvested tumours from the 
RUNX1/ETO targeted arm had consistently a distinct phenotype in comparison with 
the control treated arm. RUNX1/ETO knockdown in the first and second in vivo 
experiments led to the formation of flattened abdominal tumours with leaky vessels. 
On the other hand, mice in the control treatment arm developed yellow and pale 
tumours similar to the naïve transplantation model (Fig 4-13D). 
Furthermore, RUNX1/ETO knockdown in the third in vivo experiment with higher 
siRNA dose of 8 mg/kg LNP/siRNA, reduced the size of the tumours showing smaller 
tumours (< 0.25 g) in RUNX1/ETO targeted mice and consequently lower number of 
viable Kasumi-1 p.SLIEW cells were obtained (< 2x106 cells per mouse). The 
control-treated group showed substantially larger tumours (>1 g) and ~ 30x106 
Kasumi-1 p.SLIEW cells were harvested from each mouse. Moreover, the 
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RUNX1/ETO targeted group had tumours with leaky vessels (Fig 4-13D) replicating 




Fig 4-13: LNP/siRNA treatment effect on leukaemic tumours. Mice were 
transplanted with Kasumi-1 p.SLIEW cells and treated with LNP/siRNA as described 
previously and indicated in the schemes. IVIS imaging showed that LNP/siRNA 
treatment did not reduce leukaemia burden. Data represent the geometric mean 
(GM) of the bioluminescence signal of treated mice in the first (A), second (B) and 
third (C) in vivo experiments. Error bars represent SEM of the bioluminescence 
geometric mean. (D) Representative tumour images were taken after LNP/siRNA 




Despite on-target effect of systemic LNP/siRNA treatments on leukaemic cells and 
reduction in RUNX1/ETO expression in the first three in vivo experiments, the 




Fig 4-14: Kaplan-Meier survival graph of treated mice with LNP/siRNA. 
LNP/siRNA treatment did not increase the survival of leukaemic mice. Mice were 
transplanted as described previously and treated as indicated in the scheme above. 




Notably, ex vivo proliferation assay of harvested leukaemic cells from treated mice 
showed long-lasting anti-proliferative effect of RUNX1/ETO knockdown. In the first in 
vivo experiment, RUNX1/ETO knockdown impaired the proliferation of harvested 
Kasumi-1 p.SLIEW cells from LNP/siRE-mod-treated mouse. On the other hand, 
harvested cells from a control-treated mouse had a doubling time of 2.8 day, similar 
to the naïve Kasumi-1 cells doubling time (Fig 4-15A). 
Furthermore, harvested cells from the second in vivo experiment confirmed that 
RUNX1/ETO knockdown in vivo significantly inhibits proliferation ex vivo. Kasumi-1 
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p.SLIEW cells taken from five control mice (LNP/siMM treatment) proliferated rapidly 
with a doubling time of 2.8±0.2 days. On the other hand, cells harvested from the 
RUNX1/ETO knockdown mice expanded in different manner. For instance, one 
sample did not grow well, and cells died within the first week, two samples 
proliferated with 5 days doubling time, and three samples showed slow proliferation 
with doubling time between 7-12 days. The overall ex vivo proliferation rate of the 
LNP/siRE-mod-treated arm was significantly (p<10-3) lower than the LNP/siMM 
treated arm (Fig 4-15B). 
 
 
Fig 4-15: Ex vivo proliferation of harvested Kasumi-1 p.SLIEW cells after 
RUNX1/ETO knockdown in vivo. RUNX1/ETO knockdown inhibits the proliferation 
of harvested Kasumi-1 p.SLIEW ex vivo. Mice were treated with LNP/siRNA as 
indicated in the schemes showed above. (A) Ex vivo proliferation of harvested cells 
from one RUNX1/ETO targeted mouse and a control mouse from the first in vivo 
experiment. (B) Ex vivo proliferation of harvested cells of RUNX1/ETO targeted 
group and the control group from the second in vivo experiment. Proliferation lines 
represent the geometric mean of 5 and 6 samples. Error bars represent the SEM of 





4.4.4 In vivo knockdown of RUNX1/ETO triggers senescence 
Beta galactosidase staining of harvested cells from the third in vivo experiment 
showed that RUNX1/ETO knockdown triggers senescence. Four samples from each 
treatment arm were subject to X-gal staining assay as described in 2.2.15. 
LNP/siRE-mod treatment led to higher level (~ 50%) of senescent cells in 





Fig 4-16:  Induction of senescence after RUNX1/ETO knockdown in vivo. 
Newborn Rag2-/- ɣC-/- mice were transplanted with Kasumi-1 p.SLIEW cells, as 
described in 2.3.2.1. After one month, engraftment was assessed by IVIS. 
LNP/siRNA was administered as indicated in the scheme (4-5). Positive cells for the 
staining were counted under a bright-field microscope. Error bars represent the SEM 
of four mice from each treated group. *P<0.05, **P<0.01, ***P<0.001, two-tailed 





4.4.5 In vivo knockdown of RUNX1/ETO enhances the survival of leukaemic 
mice 
The first three in vivo experiments confirmed the on-target effect of LNP/siRNA, 
however RUNX1/ETO knockdown did not enhance the survival of treated mice. For 
this reason, a fourth experiment was planned with two aims. First, to investigate 
whether in vivo depletion of RUNX1/ETO would enhance before the establishment of 
large leukaemic mass. Second, to explore the potential use of a clinically relevant 
chemotherapy compound alongside the RUNX1/ETO knockdown and exploit the 
combinational therapeutic benefits. The second part of the experiment will be 
addressed in Chapter 5. 
Kasumi-1 p.SLIEW cells were transplanted in four litters, and pups were randomly 
marked by foot tattoo and divided into two treatment groups. Treatment started three 
days post-transplantation where each litter carried both treatment arms (LNP/siRE-
mod and LNP/siMM-mod). Since the toxicity of the lipid nanoparticles in young mice 
was unknown. Therefore, the first dose consisted of 1 mg/kg LNP/siRNA by IP route. 
Treated pups did not show any obvious signs of toxicity after 24 hours. Thus, the 
dose was increased to 2 mg/kg. Treatment with 2 mg/kg of LNP/siMM-mod and 
LNP/siRE-mod continued throughout three weeks every 2 - 3 days. 
Lipid nanoparticles treatment did not affect the main developmental milestones of the 
mice. At the end of the first week, the milk spot disappeared and light white fuzz 
appeared around the neck. Between days 8 and 10, the fuzz started to cover the 
whole body and skin became thicker. At day 10, the nipples were completely 
noticeable in the female mice, and it was feasible to distinguish the sex of the pups. 
The teeth fully erupted, and the eyes were open by day 12. By the end of the second 
week, the mice became very active, and the faeces became solid and darker, 
indicating that the mice had started feeding the solid diet. Daily handling of the pups 
and dosing 2-3 times per week might have affected the feedings by the mother, but 
there was no difference in the body weight of the treated mice and naïve untreated 
mice (Fig 4-17A, B). The body weight graph of the naïve mice was created from a 
separate litter consisting of four pups. LNP/siRNA treatment did not cause any 
significant changes in the body weight between the two treated arms or between the 




Fig 4-17: Body weight of treated Rag2-/-ɣC-/- mice during LNP/siRNA treatment. 
Newborn Rag2-/- ɣC-/- mice were transplanted and treated as described in Fig 4-6. 
Monitoring of the mice body weight shows that young mice tolerate the lipid 
nanoparticle treatment. (A) Body weight graphs of LNP/siMM-mod and LNP/siMM-
mod, and naïve untreated mice. (B) Body weight graph of the treated male and 





In vivo depletion of RUNX1/ETO significantly enhanced the survival of transplanted 







Fig 4-18: Survival of mice after RUNX1/ETO knockdown in vivo. LNP/siRNA 
increased the survival of leukaemic mice. Mice were transplanted and treated with 
the nanoparticles as described in scheme 4-6. Kaplan–Meier graph of the treated 
mice. Mice were culled when they reached any of the protocol endpoints mentioned 
in 4.3.3. 
 
After weaning the mice, IVIS imaging showed that the control group had significantly 
high bioluminescence signal (Log10 = 8.2). On the other hand, 11 out of 14 mice from 
the RUNX1/ETO targeted group had almost undetectable (<107 p/s) signal (Fig 4-
19A, C). Two weeks after weaning, the bioluminescence of the control group 
increased 1.5-fold. The bioluminescence of RUNX1/ETO targeted group remained 
under the quantitative level (<107 p/s) until week eight, where all control mice were 
culled (Fig 4-19B). 
Interestingly, the first IVIS imaging after weaning showed that leukaemic cells were 
engrafted in the abdominal or in the legs the control group. This engraftment 
behaviour is frequently observed in Kasumi-1 p.SLIEW in Rag2-/- ɣC-/- 
transplantation model. However, IVIS showed low bioluminescence emitted from the 








Fig 4-19: RUNX1/ETO depletion in vivo delays leukaemic cell engraftment. IVIS 
imaging of treated mice in the fourth in vivo experiment. (A) Analysis of 
bioluminescence at day 28 of the RUNX1/ETO targeted mice (LNP/siRE-mod) and 
control mice  (LNP/siMM-mod). (B) Serial bioluminescent monitoring over 7 weeks 
showing a rapid increase in the signal of the control group and a slow increase in the 
signal of the RUNX1/ETO targeted group. Data represent the GM of the IVIS signals 
for each group (C) Representative IVIS images of 8 mice from each group. Scales 
are photons/second.  
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4.4.6 RUNX1/ETO knockdown in vivo impairs leukaemic cells self-renewal    
Colony formation assay (CFA) of harvested Kasumi-1 p.SLIEW cells from treated 
mice showed a significant decrease in the colony formation ability of RUNX1/ETO 
knockdown cells (Fig 4-20). The reduction in clonogenicity was reproducible in all 
three in vivo experiments, regardless of the dosing regimen and the time of 
harvesting the cells (Fig 4-21).  
The ex vivo colony formation showed slower progress than the in vitro assay. It took 
up to two weeks for single cells to form large colonies in the control samples, but the 
size and number of colonies in the RUNX1/ETO targeted group were significantly 
smaller. This could be due to the effect of P/S present in the methylcellulose media. 
Harvested colonies from the RUNX1/ETO targeted group did not provide sufficient 
number of cells to perform replating assay. Some samples in the RUNX1/ETO 
targeted arm did not form any colonies even after four weeks.  
 
 
Fig 4-20: Ex vivo colony formation assay upon RUNX1/ETO knockdown in vivo. 
Harvested Kasumi-1 p.SLIEW from treated mice were seeded for colony formation in 
methylcellulose media. (A), (B) and (C) represent the normalised colonies number to 
the control group of the first, second and third in vivo experiments, respectively. 
Colony number was determined approximately after two weeks of incubation and 
four wells were counted per sample. Error bars represent SEM of the counted 








Fig 4-21: Detailed ex vivo colony formation assay. Colony formation was 
performed as described in Fig 4-20. (A), (B) and (C) show the total number of 
colonies in the first, second and third in vivo experiments, respectively. The grey and 
red bars represent the mean of counted colonies from the LNP/siMM, and LNP/siRE-
mod treated groups, respectively. Mice identification codes are shown on the right 
side of the graphs. The star on the graph (A) refers to two samples collected from 
the same mouse. 
  
 
In order to investigate the long-term effect of RUNX1/ETO depletion on self-renewal, 
harvested Kasumi-1 p.SLIEW cells from treated mice were retransplanted in 
secondary recipients. The retransplantation experiment of harvested cells from the 
third in vivo experiment showed that in vivo depletion of RUNX1/ETO severely 
impaired engraftment in the secondary recipient (p=0.0016) (Fig 4-22).  
Two sets of secondary transplantation experiments were conducted. The first 
attempt consisted of transplanting two Rag2-/-ɣC-/- litters, 3 and 5 days old. Each litter 
contained 4 pups. Three days after the last IV injection, four mice were culled for the 
secondary transplantation, and 0.25 x 106 cells of harvested viable Kasumi-1 
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p.SLIEW cells were intrahepatically transplanted on the same day into new newborn 
recipient mice. Injected samples were distributed evenly between the two litters 
where each litter contained both treatment groups. The 3 days old litter showed 
engraftment in the control group while the 5 days old litter did not engraft. The skin of 
the 5 days old mice was thick and it was difficult to perform the intrahepatic injection. 
There is a possibility that the cells were not injected into the liver. Thus, the 5 days 
old litter dropped from the analysis. 
Given that one litter in the first retransplantation experiment did engraft, a 2 days old 
litter was transplanted in a second attempt. In this experiment, 2 harvested Kasumi-1 
p.SLIEW samples from each group (RUNX1/ETO targeted group and control group) 
were thawed, and 0.25 x 106 cells were intrahepatically transplanted. Each sample 
was transplanted into two pups.  
Remarkably, the retransplantation experiment showed that all harvested cells from 
LNP/siMM treated mice engrafted with short latency (Fig 4-22A, B). However, 
transplantation of cells taken from LNP/siRE-mod treated mice resulted in 
significantly prolonged survival (Fig 4-22B). 
The first IVIS imaging after weaning the mice showed that all control mice 
(LNP/siMM primary treatment) had significantly high IVIS signal ~ 107 p/s, which 
increased over time until all mice reached the protocol endpoints. On the other hand, 
the IVIS signal of the RUNX1/ETO targeted group (LNP/siRE-mod treatment), 
however, had nonquantitative (<106) signal (Fig 4-22A). Moreover, transplantation of 
freshly harvested cells or previously frozen and thawed cells did not impact the IVIS 
signal or the overall survival of the control group. The median survival of the control 
group was 62 days, where the median survival of the RUNX1/ETO targeted group 
was beyond 210 days (p<0.0016). 
Interestingly, in the RUNX1/ETO targeted group, one mouse engrafted after 80 days. 
The mouse had a quantitative IVIS signal that increased gradually until the tumour 
size reached the protocol endpoint. The last mouse in this group at day 210 had a 
fivefold enlarged spleen and leukaemic cells invaded the right ovary while the left 
ovary and the uterus were normal (Fig 4-22C). Half of the mice in the RUNX1/ETO 









Fig 4-22: In vivo depletion of RUNX1/ETO impairs engraftment in secondary 
recipients. Harvested Kasumi-1 p.SLIEW cells from the primary treatment were 
intrahepatically injected in 2 or 3 days old Rag2-/-ɣC-/- mice. Treatment of the primary 
mice was performed as described in scheme Fig 4-5. (A) Serial bioluminescent 
monitoring over 12 weeks to assess leukaemia burden in the secondary 
retransplanted mice showing increase in the IVIS signal of the control group. Data 
represent the GM of the IVIS signal for each group. Error bars represent SEM of the 
IVIS signal of each group. (B) Kaplan–Meier graph of the retransplantation 





4.4.7 RUNX1/ETO knockdown initiates myeloid differentiation in vivo 
Harvested cells from the secondary transplantation experiment indicted an initiation 
of a myeloid differentiation programme (Fig 4-23). Despite there was not reduction in  
RUNX1/ETO expression level, the RUNX1/ETO targeted group showed significant 
upregulation of CEBPA and downregulation of CD34 at mRNA level (Fig 4-23A). 
Moreover, the RUNX1/ETO targeted group showed less surface expression of the 
stem cell marker CD34 (~ 6 to 8-fold reduction in the geometric mean), and a 




Fig 4-23: In vivo depletion of RUNX1/ETO triggers myeloid differentiation in the 
secondary recipient. Harvested Kasumi-1 p.SLIEW cells from the secondary 
retransplanted mice demonstrate initiation of the myeloid differentiation programme. 
(A) qRT-PCR analysis shows the expression level of CD34 and CEBPA in four mice 
in the control group, and two mice in the RUNX1/ETO targeted group. (B) Multicolour 
FACS analysis of harvested cells from control mice (left) and RUNX1/ETO targeted 
group (right) showing an increase in the CD11b and CD14 surface expression in the 
RUNX1/ETO knockdown mouse (top), and a decrease in the CD34 geometric mean 





4.4.8 RUNX1/ETO knockdown in vivo alters t(8;21) transcriptome   
Harvested cells from the third in vivo experiment were sent for RNA sequencing 
(RNA-seq). Two mice from each treatment arm were culled three days after 
completing the treatment followed by sorting Kasumi-1 p.SLIEW cells based on 
eGFP expression. One RUNX1/ETO targeted mouse did not give sufficient cell 
number for RNA extraction, thus cells from another mouse was collected. Following 
sorting and RNA extraction, four samples were sent for sequencing. 
Dr. Sirintra Nakjang performed the bioinformatic analysis of the RNA-seq data.  
Gene expression analysis showed that RUNX1/ETO knockdown mice (RE KD-1, RE 
KD-2 had different transcriptome from the control mice (MM ctr-1, MM ctr-2) (Fig 4-
24). Principle component analysis (PC1 and PC2) showed that control mice had 
similar gene expression while RUNX1/ETO knockdown mice differed in gene 
expression between each other and in comparison with the controls. 
 
Fig 4-24: Principal component analysis of RUNX1/ETO knockdown in vivo. 
Mice were transplanted with Kasumi-1 p.SLIEW cells ,and treated with the 
nanoparticles as shown in the ligand of Fig 4-5. Cells were collected from treated 
mice, sorted based on the eGFP expression followed by RNA extraction and RNA 
sequencing. MM ctr-1 and MM ctr-2 represent the control group, and RUNX1/ETO 




RNA-seq data were analysed using several computational analysis platforms 
including, Gene set enrichment analysis (GSEA), Gene Ontology (GO) and Kyoto 
Encyclopedia of Genes and Genomes (KEGG). Analyses were performed on the top 
differentially upregulated genes and differentially downregulated genes. Only genes 
which had more than twofold log2 change with p values <0.05 were included in the 
pathway analyses. 
KEGG pathway analysis showed that RUNX1/ETO knockdown in vivo induces 
several canonical pathways common in cancers including NF-κB, MAPK and others 
as shown in (Fig 4-25). The KEGG proved the on-target effect, and mapping the 
differentially expressed genes on KEGG pathways showed several known targets of 
RUNX1/ETO as shown in the supplementary figures (s-Fig 2 to 12). Moreover, GO 
and GSEA analyses on the differentially expressed protein-coding genes also 
revealed similar pathways to those shown in KEGG. The top 20 enriched pathways 
in KEGGG, GO, and GSEA can be attributed to 6 common functional categories as 
revealed by PANTHER classification system. These categories were, NF-κB induced 
pro-inflammatory response, TGF-β signalling, cytokine-receptor signalling, pathways 
in cancers, cell cycle regulation and metabolism as depicted in (Fig 4-26).  
RNA sequencing was performed only on 4 samples, 2 in each group. This small 
cohort is the main limitation of the experiment. It was not possible to send more 
samples for sequencing because sorting based on eGFP expression failed to give 
sufficient amounts of cells for downstream processing. Moreover, it was also not 
feasible to sequence more samples from other in vivo knockdown experiments due 





Fig 4-25: Pathway analysis of RUNX1/ETO knockdown in vivo. Pathways 
analysis was performed on the differentially regulated genes with P <0.05 using 










Fig 4-26: Classification of the functional pathways of RUNX1/ETO knockdown 
in vivo. Pathway analysis was performed using KEGG, GO and GSEA platforms. 
The resulted top 20 canonical pathways from pathway analyses were re-analysed 
using the PANTHER classification system. Statistical significance was determined by 
Fisher Exact test. 
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4.5 Results summary  
The main challenges facing siRNA therapeutics are the poor pharmacokinetics and 
pharmacodynamics of naked siRNA. Lipid-based delivery systems such as 
liposomes and nanoparticles are among the promising strategies to improve the 
siRNA bioavailability and pharmacokinetics (Leung, Tam et al. 2014, Park, Park et 
al. 2016, Viger-Gravel, Schantz et al. 2018). The second part of this project utilised a 
lipid nanoparticle system encapsulating the potent modified siRNA to study the effect 
of modulating RUNX1/ETO expression in vivo. 
Following siRNA chemical modification and optimisation of RUNX1/ETO knockdown 
using the lipid nanoparticles, the second aim of the study was to investigate the 
effect of RUNX1/ETO knockdown using lipid nanoparticles in vivo. The 
xenotransplantation model of t(8;21) AML was generated by intrahepatic injection of 
Kasumi-1 cells stably expressing luciferase into newborn Rag2-/-ɣC-/- mice. This 
xenotransplantation model is not optimal because transplanted mice develop solid 
tumours, and Kasumi-1 cells are rarely detected in the peripheral blood. The model 
also has low engraftment in the spleen and bone marrow. However, the engraftment 
behaviour is highly reproducible and consistent. Moreover, the tumours mainly 
consist of Kasumi-1 cells expressing CD34 and CD33 surface markers, and they can 
engraft serially in further transplantations (Soria, Tussiwand et al. 2009). This model 
was suitable for this project, particularly because Kasumi-1 cells do not lose the self-
renewal properties in vivo. 
The optimisation of in-house click reaction protocol, LNP/siRNA was successfully 
labelled with the SulfoCyanine7.5 dye. The methods of labelling did not significantly 
affect the nanoparticles parameters. The pharmacodynamics and biodistribution 
study indicated that the nanoparticles have global body distribution. Although the 
liver was enriched with the nanoparticles as shown by IVIS, the particles were 
detected in several organs, including the brain and the bone marrow.  
Although Kasumi-1 p.SLIEW cells form abdominal extra-medullary tumours, 
RUNX1/ETO knockdown was successfully achieved on the mRNA and protein 
levels. The systemic treatment proved that the LNP/siRNA reached the tumour site 
and provided on-target effect. 
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LNP/siRNA treatment did not affect the biological development of treated mice, and 
no toxicity was observed. This finding has high relevance for further in vivo studies 
as the toxicity has been confirmed not to be an obstacle. RUNX1/ETO knockdown in 
vivo significantly enhanced the median survival of the mice, implying that 
RUNX1/ETO is required for leukaemia expansion in vivo. 
The knockdown of RUNX1/ETO was associated with changes in RUNX1/ETO direct 
target genes including ANGPT1, CD34 and LAPTM5. The knockdown also 
significantly reduced CCND2 and TERT protein levels and triggered senescence. 
Moreover, RNA-seq showed that the most upregulated genes after RUXN1/ETO 
silencing correlated with the induction of pro-inflammatory response, deregulated 
angiogenesis and induction of C/EBP-associated myeloid differentiation. The 
downregulated genes identified by RNA-seq have also been linked to pathways 
relevant for self-renewal, clonogenicity and G-CSF induced proliferation.   
The transient depletion of RUNX1/ETO in vivo inhibited leukaemic cells proliferation 
ex vivo and severely impaired clonogenicity. The knockdown in vivo also remarkably 
impaired engraftment in secondary recipient mice. These findings emphasise the 
role of RUNX1/ETO in maintaining leukaemic self-renewal. 
Furthermore, RUNX1/ETO knockdown in vivo led to downregulation of the stem cell 
marker CD34 in the secondary recipient mice. The knockdown also elevated the 
expression level of the transcription factor CEBPA. Further characterisation of 
harvested cells revealed that RUNX1/ETO knockdown increased CD14 and CD11b 
expression. These findings imply that RUNX1/ETO knockdown in vivo led to 
monocytic differentiation. Giemsa stain would have proved the monocytic phenotype, 
but due to the time limit, it was not feasible to characterise the differentiation status 

























AML is a clonal disease with complex genomic aberrations that lead to drug 
resistance, primarily upon relapse. (Sabbath, Ball et al. 1985, Blair, Hogge et al. 
1998, Siddiqui, Hogge et al. 2016). AML treatments account for a broad spectrum of 
short- and long-term side effects including neurotoxicity, cardiotoxicity and infertility 
(Boyd, Aslostovar et al. 2018). It is, therefore, necessary to enhance 
chemosensitivity to achieve a higher cure rate with a less toxic burden. Currently, 
AML treatment focuses on eliminating leukaemic blast cells following two strategies, 
inducing DNA damage or enhancing mitochondrial apoptotic pathways. Despite the 
favourable prognoses of t(8;21) AML, approximately 30% of patients relapse with 
poor prognoses, which highlights the importance of finding new therapeutic 
strategies (Burnett, Hills et al. 2010). 
This project proved that RUNX1/ETO depletion by siRNA prevents leukaemia 
propagation and severely impairs self-renewal and expansion in secondary receipt 
mouse model. RUNX1/ETO knockdown in vivo did not lead to cell death. However, it 
caused a cytostatic phenotype indicated by G1 cell cycle arrest. Since RUNX1/ETO 
mandates the G1 to S phase progression in t(8;21) AML by regulating the CCND2-
CDK4/6 complex and its inhibitors p21 and p27 (Goel, DeCristo et al. 2018, 
Martinez-Soria 2018), we have hypothesised that the imbalance between the cyclins 
and the cyclin-dependent kinase inhibitors upon RUNX1/ETO suppression may 
prime leukaemic cells for apoptosis. 
Senescence and apoptosis are evolved to suppress tumorigenesis, and several 
senescence-causing effectors are oncogenic (Childs, Baker et al. 2014). 
RUNX1/ETO knockdown in vivo induced cellular senescence. However, in contrast 
to apoptotic cells, senescence is imperfect tumour-suppressive fate because 
senescent cells secrete many cytokines and factors that promote tissue and organ 
dysfunction (Maciel-Baron, Morales-Rosales et al. 2016, Ritschka, Storer et al. 
2017). Analysis of our RNA-seq data obtained from RUNX1/ETO knockdown in vivo 
showed a strong pro-inflammatory response marked by a signature of the 
senescence-associated secretory phenotype (SASP). Additionally, senescent cells 
are stably viable and some of the SASP inducers such as NF-κB may have tumour-
promoting effect (Salminen, Kauppinen et al. 2012, Nelson, Kucheryavenko et al. 
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2018). Since recent studies have shown that potent drug combinations could 
eliminate senescent cells (Chaikovsky and Sage 2018, Xu, Pirtskhalava et al. 2018), 
we aimed to explore whether RUNX1/ETO knockdown makes leukaemic cells more 
susceptible to apoptosis. 
For these reason, in this chapter we explored the therapeutic potential of several 
clinically relevant chemotherapies combined with RUNX1/ETO knockdown. It was 
hypothesised that if RUNX1/ETO repression sensitises leukaemic cells to 
chemotherapies, this might stratify dose reduction in current t(8;21) AML treatment to 









5.2 Aim  
The combination of RUNX1/ETO knockdown with different chemotherapy agents 
was investigated. The aims were as follow;    
1. To investigate the effectiveness of combinational treatment with RUNX1/ETO 
knockdown in vitro.  
2. To elucidate the relationship between RUNX1/ETO expression and possible 
synergy or additive effect.  
3. To test the combination of RUNX1/ETO depletion and the chemotherapy 







5.3 Experimental designs 
5.3.1 Drug treatment experiments  
Drug treatment with AraC, Rucaparib, and ABT-199 was performed on Kasumi-1 and 
SKNO-1 cell lines as well as on the stably transduced cell lines Kasumi-1 p.SLIEW 
and SKNO-1 p.SLIEW. Drug treatment was applied either with or without 
RUNX1/ETO knockdown (Fig 5-1). The knockdown of RUNX1/ETO was achieved by 
serial electroporation using 100 nM siRNA on day 0 and 3. On day 4, cells were 
counted and resuspended at 0.1 x 106 cells/ml density, and 90 µl of cell suspension 
was seeded into a 96-well plate. Drug treatment was performed by addition of 10 µl 
of 10X stock solution. Depending on the type of the drug solvent (e.g. DMSO), the 
concentration of the solvent was maintained at 0.1% for each well. The effect of the 
drug was determined either by reporter luciferase assay or fluorescent resazurin 
assay.  
RUNX1/ETO knockdown in vitro was achieved by electroporation due to the limited 
amount and high cost of lipid nanoparticles. 
 
 
Fig 5-1: Experimental set up of RUNX1/ETO knockdown and chemotherapies 
combinations. AML cell lines were serially electroporated on days 0 and 3 with 
siRNA. On day 4, cells were seeded into a 96-well pate and treated with the 
chemotherapy agent for 2 - 3 days. The bioluminescence luciferase assay and the 





5.3.2 The effect of G1 cell cycle arrest in response to BCL2 inhibition  
In order to test the effect of G1 cell cycle arrest on BCL2 inhibition, two experiments 
were performed in SKNO-1 cell line. We have chosen SKNO-1 to perform these 
experiments because we found that SKNO-1 cells require stronger RUNX1/ETO 
knockdown to cause G1 cell cycle arrest in comparison with Kasumi-1 cells, and they 
recover faster from the cycle arrest (Fig 3-10). Thus, conducting the experiments in 
this cell line will allow us to observe any changes in the sensitivity to the treatment.  
First, the cell cycle arrest in SKNO-1 cells was achieved by depleting RUNX1/ETO or 
CCND2. The repression was achieved by serial electroporation with 100 nM siRE-
mod, or a mixture of 200 nM (siCCND2_2 and siCCND2_4) as shown in Fig 5-2. 
Both siCCND2_2 and siCCND2_4 are validated siRNAs targeting CCND2 transcript 
(Martinez-Soria 2018). Drug treatment was applied 24 hours after two serial 
electroporations on day 0 and 3. The effect of BCL2 inhibition was assessed by 
resazurin assay on day 6. Cell cycle profiling was also performed on day 6 to 
quantify the level of cell cycle arrest. 
Second, RUNX1/ETO was depleted by single electroporation and cells were seeded 
in two sequential colony formation assays. At the end of the second replating, cells 
were collected, washed twice with PBS, seeded into a 96-well plate and treated with 
the BCL2 inhibitor ABT-199 (Fig 5-3). Cell cycle profiling was also performed within 
one hour after harvesting the colonies. The effect of BCL2 inhibition was assessed 
by resazurin assay after 2 days. 
 
5.3.4 Investigating BCL2 inhibition at protein level  
We have investigated the effect of ABT-199 treatment at the protein level in vitro in 
Kasumi-1 p.SLIEW cells because our in vivo knockdown experiments were 
performed on these cells. Furthermore, the RNA-seq data were obtained from 




Kasumi-1 p.SLIEW cells were electroporated with 100 nM of either siRE-mod or 
siMM on days 0 and 3. On day 4, ABT-199 treatment was applied and cells were 
collected for Western blotting on day 5. 
 
  
Fig 5-2: BCL2 inhibition sensitivity to the cell cycle arrest effect on. SKNO-1 
cells were serially electroporated on days 0 and 3 with siRNA and seeded for drug 
testing on day 4. After two days of continues treatment with ABT-199, drug activity 
was assessed by resazurin assay. PI cell cycle profiling was performed on day 4 





Fig 5-3: Prolonged RUNX1/ETO depletion effect on BCL2 inhibition. SKNO-1 
cells were electroporated with siRNA and seeded seeded in colony formation after 
24 hours. After 8 days, colonies were collected, washed twice with PBS and replated 
in a secondary colony formation assay. On day 17, colonies were collected followed 
by plating in a 96-well plate for drug testing. Cells were treated with ABT-199 for two 
days and drug activity assessed by resazurin assay. Cells were also stained with PI 
for cell cycle analysis on day 17. 
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5.3.5 ABT-199 treatment in vivo  
The fourth in vivo experiment (Fig 4-6) consisted of 28 mice divided into two primary 
treatment groups, 14 mice in each group, RUNX1/ETO treated group (LNP/siRE-
mod) and a control group (LNP/siMM-mod). After weaning, the leukaemic burden 
was assessed by IVIS imaging, then mice were randomised into four groups 
according to the IVIS signal. Mice were dosed with 100 mg/kg of ABT-199 or a 
control vehicle (CV) as shown in Fig 5-4.   
The treatment groups were as follows; 
LNP/siMM-mod + CV (7 mice; 3 females and 4 males) 
LNP/siMM-mod + ABT-199 (7 mice; 5 females and 2 males) 
LNP/siRE-mod + CV (7 mice; 4 females and 3 males) 
LNP/siRE-mod + ABT-199 (7 mice; 3 females and 4 males) 
Leukaemia propagation was monitored by IVIS every week. Mice were culled when 







Fig 5-4: Experimental set up of ABT-199 treatment in vivo upon. Mice were 
transplanted and treated with lipid nanoparticles as described in Fig 4-6 and shown 
in the scheme above. Upon weaning, leukaemia engraftment was assessed by IVIS 
imaging on days 28 and 33. On day 38, the RUNX1/ETO targeted group and the 
control group were divided into two subgroups (7 mice each) as indicated in 5.3.5. 
Mice received 10 oral gavage doses of 100 mg/kg of ABT-199 or CV over two 
weeks. Mice monitored by IVIS during and after the treatment and culled when they 






5.4.1 Sensitivity to AraC in response to RUNX1/ETO knockdown  
Sensitivity towards AraC was investigated only in Kasumi-1 p.SLIEW cells with and 
without RUNX1/ETO knockdown. The viability of Kasumi-1 p.SLIEW was measured 
after 3 days of continuous treatment with AraC. The control cells (siMM 
electroporated cells) were responsive to AraC with 540 nM (IC50). The depletion of 
RUNX1/ETO by siRE-mod reduced the sensitivity to AraC, and the IC50 became 
aournd1600 nM (Fig 5-5). 
Since RUNX1/ETO knockdown did not sensitise Kasumi-1 cells to AraC treatment, 
no further experiments were perused. 
 
 
Fig 5-5: Cytotoxicity of AraC in Kasumi-1 p.SLIEW cells after RUNX1/ETO 
knockdown. The viability of Kasumi-1 p.SLIEW cells after AraC treatment with and 
without RUNX1/ETO knockdown. Data is presented as the percentage of viable cells 
after projecting the chemiluminescence intensity to the corresponding cell number. 
Error bars represent the SEM of three independent experiments.   
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5.4.2 RUNX1/ETO knockdown and sensitivity to Rucaparib 
The response to the PARP inhibitor, Rucaparib, was also investigated following a 
similar approach to AraC experiments. The knockdown of RUNX1/ETO was 
achieved by two sequential electroporations and Rucaparib treatment was applied 
for 3 days. Kasumi-1 p.SLIEW cells were sensitive to Rucaparib at 3 µM (IC50). Upon 
RUNX1/ETO knockdown, Kasumi-1 p.SLIEW responsiveness to Rucaparib was 
reduced and the IC50 was not achieved (IC50 >34 µM) (Fig 5-6). For this reason, no 




Fig 5-6: Cytotoxicity of Rucaparib in Kasumi-1 p.SLIEW cells after RUNX1/ETO 
knockdown. The viability of Kasumi-1 p.SLIEW cells after Rucaparib treatment with 
and without RUNX1/ETO knockdown. Data is presented as described in the legend 





5.4.3 RUNX1/ETO knockdown in t(8;21) AML cells lines and their sensitivity to 
ABT-199  
BCL2 inhibition by ABT-199 was assessed using two independent assays, a 
fluorescent-based assay (resazurin) in Kasumi-1 and SKNO-1 cells lines, and a 
luciferase assay in both Kasumi-1 p.SLIEW and SKNO-1 p.SLIEW cells. Both AML 
cell lines, without electroporation, were sensitive in the nM range to BCL2 inhibition 
by ABT-199. The resazurin and luciferase assays both provided similar IC50 values. 
In Kasumi-1, the IC50 was 35 nM and 32 nM (Fig 5-7A) as measured by resazurin 
and luciferase, respectively. Similarly, SKNO-1 was sensitive to ABT-199 at IC50 of 
24 nM and 25 nM as measured by resazurin and luciferase, respectively (Fig 5-7B). 
These experiments showed that t(8;21) AML cell lines are sensitive to ABT-199 
treatment, and both luciferase and resazurin assays provide comparable results.   
 
 
Fig 5-7: Cytotoxicity of ABT-199 in AML t(8;21) cell lines. The viability of Kasumi-
1 (A) and SKNO-1 (B) cells to ABT-199 treatment. The luciferase assay data (blue 
line) is presented as described previously in the legend to Fig 5-5. The resazurin 
viability data (red line) is presented as the percentage of viable cells after projecting 
the fluorescence intensity to the corresponding cell number. Data presents the mean 
of three wells per treatment. Error bars represent the standard deviation of the mean 
of three wells per treatment.  
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The knockdown of RUNX1/ETO by siRNA enhanced the effect of ABT-199 treatment 
in vitro. The depletion of RUNX1/ETO in Kasumi-1 p.SLIEW cells reduced the IC50 
from 28 nM to 10 nM as measured by the luciferase reporter assay (Fig 5-8A). This 
effect was confirmed with the resazurin assay, as shown in (Fig 5-8C). Similarly, 
treatment with ABT-199 was more effective when SKNO-1 p.SLIEW cells were under 
RUNX1/ETO knockdown by siRNA. Luciferase assays showed a fivefold reduction in 
the IC50 (from 28 nM to 5 nM) upon RUNX1/ETO knockdown (Fig 5-8B). The 
resazurin assay confirmed that the IC50 was reduced from 18 nM to 7 nM in SKNO-1 
pSLIEW cells (Fig 5-8D). 
Notably, the effect of ABT-199 did not differ significantly between naïve cells without 
electroporation and cells under mismatch siRNA (siMM) transfection (Fig 5-7 & Fig 
5-8). The IC50 of the naïve cell line and the mismatch electroporated Kasumi-1 was 
35 and 37 nM, respectively (Fig 5-7A & Fig 5-8C). In SKNO-1 p.SLIEW cells, the IC50 
was 25 and 28 nM for naïve and siMM electroporated cells, respectively, as 
measured by luciferase assay (Fig 5-7B & Fig 5-8B). 
 
 
Fig 5-8: Cytotoxicity of ABT-199 in AML t(8;21) cell lines after RUNX1/ETO 
knockdown. The viability of Kasumi-1 (A, C) and SKNO-1 (B, D) cells to ABT-199 
treatment with (red line) and without (blue line) RUNX1/ETO knockdown. The 
luciferase assay data (A, B) is presented as described previously in the legend to Fig 
5-5. The resazurin viability data (C, D) is presented as described previously in the 
legend to Fig 5-7. Data presents the mean of three independent experiments. Error 
bars represent the SEM of three independent experiments. 
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5.4.4 The effect of the G1 cell cycle arrest on BCL2 inhibition  
RUNX1/ETO repression resulted in an enhanced response to ABT-199 treatment but 
not to DNA damage agents AraC and Rucaparib. Given that RUNX1/ETO 
knockdown leads to a cytostatic phenotype governed by G1 cell cycle arrest, we 
investigated the relationship between the cell cycle status and sensitivity to ABT-199 
treatment. We introduced the cell cycle arrest directly by deleting the cell cycle gene 
CCND2 by siRNA, or indirectly by RUNX1/ETO knockdown. 
The knockdown of either RUNX1/ETO by siRE-mod, or CCND2 by (siCCND2_2 & 
siCCND2_4) induced the same level of the G1 cell cycle arrest in SKNO-1 cells. The 
G1 phase increased to 60.5% and 63% after RUNX1/ETO and CCND2 knockdown, 
respectively, compared to 48% in the mismatch control (Fig 5-9A). The resazurin 
assay showed that CCND2 knockdown did not enhance the sensitivity to ABT-199. 
On the other hand, RUNX1/ETO knockdown enhanced the sensitivity to ABT-199 
treatment by fivefold (Fig 5-9B and Fig 5-8B, D). It cannot be concluded from one 
experiment that the G1 cell cycle arrest status does not influence the sensitivity to 
BCL2 inhibition. However, the results obtained from SKNO-1 cells reaffirm that 
RUNX1/ETO knockdown sensitises the cells to ABT-199. 
In order to elucidate the effect of RUNX1/ETO expression on BCL2 inhibition, 
RUNX/ETO was repressed by siRNA, and cells were plated in two serial replating of 
colony formation assay followed by treatment with ABT-199. Cell cycle profiling of 
harvested colonies showed that the knockdown cells do not have cell cycle arrest 
after two replatings (Fig 5-10A). Surprisingly, the RUNX1/ETO knockdown cells 
showed a twofold enhanced sensitivity to ABT-199 treatment. Harvested cells from 
the replated control colonies (siMM transfection) had an IC50 of 29 nM, while the 
RUNX1/ETO targeted cells (siRE-mod transfection) showed an IC50 of 16 nM (Fig 5-
10B). The prolonged effect of RUNX1/ETO repression on BCL2 inhibition has further 
confirmed our observation that the enhanced response to ABT-199 is independent of 
the G1 cell cycle arrest. For this reason, the effect of cell cycle arrest was not 
investigated any further. Additional experiments would have deciphered the relation 
between RUNX1/ETO expression and BCL2 inhibition, which was not pursued due 






Fig 5-9: Cytotoxicity of ABT-199 in SKNO-1 cells after the induction of G1 cell 
cycle arrest. The effect of G1 cell cycle arrest on SKNO-1 response to ABT-199 
treatment. The cell cycle arrest was induced by depleting RUNX1/ETO or CCND2 by 
siRNA. (A) Cell cycle profiling by PI staining. (B) The viability of SKNO-1 cells after 
ABT-199 treatment, and the depletion of RUNX1/ETO (red line), CCND2 (orange 
line) and without gene knockdown (blue line). The resazurin viability data  is 
presented as described previously in the legend to Fig 5-7. Data presents the mean 
of three wells per treatment. Error bars represent the standard deviation of the mean 






Fig 5-10: Long-term effect of RUNX1/ETO knockdown on sensitivity to ABT-
199. SKNO-1 cells susceptibility to ABT-199 cytotoxicity after perennial RUNX1/ETO 
knockdown. The RUNX1/ETO knockdown-associated G1 cell cycle arrest 
disappears after two rounds of colony formation replatings but the sensitivity to ABT-
199 remains. (A) PI cell cycle profiling of cells harvested from the RUNX1/ETO 
knockdown colonies and the mismatch control showing similar distributions of the 
cell cycle phases. (B) The viability of harvested SKNO-1 cells from the colony 
formation assays followed by ABT-199 treatment. The RUNX1/ETO-knockdown 
colonies are presented in the red line and the negative control in the blue line. The 
resazurin viability data was presented as described previously in the legend to Fig 5-
7. Data represents the mean of two independent experiments. Error bars represents 










5.4.5 BCL2 inhibition and RUNX1/ETO knockdown and effect on apoptosis  
Given that BLC2 is localised on the mitochondria surface and regulates cell survival 
by inhibiting pro-apoptotic proteins, we assessed the expression of various proteins 
involved in the mitochondrial apoptosis pathways in response to ABT-199 treatment 
and RUNX1/ETO knockdown. 
Western blotting showed that the depletion of RUNX1/ETO did not change BCL2 
level in Kasumi-1 p.SLIEW cells, but a slight increase in BCLXL and MCL1 was 
observed (Fig 5-11). The knockdown was also associated with an increase in BIM 
protein expression. Treatment with ABT-199 resulted in a general reduction in 
RUNX1/ETO as well as RUNX1 level with and without RUNX1/ETO knockdown. 
Interestingly, the combination of RUNX1/ETO and ABT-199 treatment led to a 
marked MCL1 reduction in comparison with the control siMM transfected cells. 
Furthermore, the depletion of RUNX1/ETO and ABT-199 treatment did not affect the 
expression of BCL2 and BCLXL as well as BIM. 
Due to experimental procedures, including stripping and reprobing of the membrane 
serval times, it was not possible to quantify the level of the housekeeping proteins. 
Nevertheless, Ponceau S red staining shows relatively equal loading and transfer.  
Interestingly, Ponceau S red staining showed a prominent band around 70 kDa, 
which disappeared after ABT-199 treatment. This band is unlikely to be serum 
albumin (~ 66.5 kDa) because the cell pellets were washed twice with PBS to 
remove any traces of FCS before lysing the cells with RIPA buffer. Ponceau S red is 
unselective stain for proteins and polypeptides (Stochaj, Berkelman et al. 2006). 
Thus, it is very difficult to assign this band to a specific protein. We have extensively 













Fig 5-11: RUNX1/ETO knockdown and BCL2 inhibition effects on apoptosis 
proteins. Western blotting was performed to examine the expression of several 
proteins associated with the mitochondrial apoptosis pathways in Kasumi-1 p.SLIEW 
cells. The modulation of the apoptosis pathway was introduced by RUNX1/ETO 
knockdown followed by ABT-199 treatment. Membrane was blotted against α-
RUNX1, α-MCL1, α-BCL2, α-BCLXL, and α-BIM antibodies. Ponceau S red stain 
was used to show the loading quality. Marker size in kDa is presented on the left 
side of the membrane.  
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5.4.6 ABT-199 treatment in vivo  
In vitro experiments suggested that t(8;21) AML cell lines are sensitive to BCL2 
inhibition by ABT-199. The combination of ABT-199 treatment and RUNX1/ETO 
knockdown was more effective than ABT-199 treatment alone. For this reason, the 
combination treatment was investigated in vivo. 
Following the LNP/siRNA treatment in the fourth in vivo experiment, each treatment 
group was further divided into two secondary treatment arms. The randomisation 
was performed based on the mean of two consecutive IVIS imaging after weaning. 
The ABT-199 treatment was applied after 10 days from completion of the LNP/siRNA 
treatment. 
After 10 doses of 100 mg/kg of ABT-199 or CV by oral gavage, the ABT-199 
treatment showed increase in the IVIS of all treated groups. Unexpectedly, Kasumi-1 
p.SLIEW cells were not sensitive to ABT-199 in vivo (Fig 5-12A). ABT-199 did not 
reduce the leukaemic burden of the LNP/siMM-mod control group, as the IVIS signal 
was similar to the LNP/siMM-mod + CV treatment group. Moreover, the combination 
of ABT-199 treatment and RUNX1/ETO knockdown led to a rapid increase in the 
IVIS signal in comparison with a combination of CV treatment and RUNX1/ETO 
knockdown. 
ABT-199 treatment resulted in only 10 days (p=0.057) increase in the median 
survival of the knockdown-control arm (LNP/siMM-mod) in comparison with the 
control group (LNP/siMM-mod+ CV treatment).  
The combination of BCL2 inhibition and RUNX1/ETO knockdown was therapeutically 
disadvantageous, as the median survival of the RUNX1/ETO targeted group was 
reduced (p=0.1) from 80 to 67 days in the LNP/siRE-mod + CV group and LNP/siRE-
mod + ABT-199 group, respectively.  Moreover, the median survival of the ABT-199 
treated arms LNP/siMM-mod, and LNP/siRE-mod were 55 and 67 days, respectively, 











Fig 5-12: The effect of ABT-199 treatment in vivo. (A) Leukaemia burden was 
assessed by the bioluminescence of engrafted mice. Data is presented as the mean 
of total bioluminescence from 7 mice in each of the fours treatment arms.  Error bars 
represent the SEM of the geometric mean of the total bioluminescence in each 




5.5 Results summary  
The heterogeneity of AML cytogenetic demands for more research on targeted and 
personalised treatment. Although t(8;21) AML is a favourable cytogenetic 
abnormality, a considerable cohort of patients has a poor prognosis if presented with 
additional mutations such as FLT3-ITD and C-KIT (Itzykson, Gardin et al. 2011, 
Ryotokuji, Yamaguchi et al. 2016). Patients with t(8;21) leukaemia are treated with 
combination therapies of high dose AraC and anthracyclines in the consolidation 
phase. Approximately 75% of treated patients have complete remission and some 
present disease-free survival. However, the current treatment options are highly 
toxic, which justifies the need for new therapeutic approaches (Schlenk, Dohner et 
al. 2008, Dohner, Estey et al. 2010, Vu and Kharas 2018). Given that RUNX1/ETO is 
a leukaemic specific fusion gene, and repression of the oncoprotein leads to a 
cytostatic phenotype, combination chemotherapies with RUNX1/ETO targeting may 
have a therapeutic advantage. 
The DNA damage agents AraC and Rucaparib showed an antagonistic effect when 
combined with RUNX1/ETO knockdown. The depletion of RUNX1/ETO led to G1 cell 
cycle arrest, and subsequently a reduction in the S phase. Given that, AraC and 
Rucaparib are both active in the S phase of the cell cycle, the reduced sensitivity to 
the DNA damage after RUNX1/ETO knockdown is expected. The obtained IC50 of 
AraC treatment in Kasumi-1 could potentially be achievable in clinical setting (Wang, 
Harrison et al. 2016), but the depletion of RUNX1/ETO reduced the sensitivity 
dramatically. Moreover, Kasumi-1 cells poorly responded to high doses of 
Rucaparib, suggesting that PARP inhibition by Rucaparib alone may not provide any 
therapeutic window for t(8;21) positive leukaemias. Nevertheless, a combination of 
AraC and Rucaparib together, or with other inhibitors might be beneficial, but this is 
beyond this project’s research questions. 
MCL1 expression is crucial for healthy haematopoietic stem cell expansion, but 
leukaemic stem cells rely on BCL2 expression for survival (Vairo, Innes et al. 1996, 
Opferman, Iwasaki et al. 2005). Recent clinical data shows that AML patients benefit 
from BCL2 inhibition by ABT-199 (Pan, Hogdal et al. 2014, Teh, Nguyen et al. 2018). 
Previous in vivo work performed in our group has also shown that inhibition of BCL2 
significantly prolonged the survival of immunocompromised mice bearing t(4;11) 
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AML leukaemia (unpublished data). For these reasons, the sensitivity of Kasumi-1 
and SKNO-1 cell lines to ABT-199 was investigated. The luciferase reporter assay, 
as well as the cytotoxicity fluorescence-based assay, equally showed that t(8;21) 
AML cell lines are sensitive to BCL2 inhibition by ABT-199 in the low nanomolar 
range. Interestingly, the depletion of RUNX1/ETO by siRNA enhanced the effect of 
ABT-199 treatment in vitro. Throughout the ABT-199 treatment experiments, the 
knockdown of RUNX1/ETO was achieved by a 100 nM siRNA. Therefore, we cannot 
conclude whether the enhanced sensitivity to BCL2 inhibition is synergistic or 
additive when combined with RUNX1/ETO knockdown. 
The enhanced cell death in the combination of RUNX1/ETO depletion and BCL2 
inhibition was independent of the G1 cell cycle arrest since the knockdown of the cell 
cycle gene CCND2 did not enhance the sensitivity to ABT-199. Furthermore, the 
pharmacological inhibition of the CDK4/6 complex by palbociclib does not change 
the sensitivity to ABT-199 treatment in t(8;21) and t(4;11) AML cell lines 
(unpublished data). Interestingly, BCL2 inhibition was susceptible to prolonged 
RUNX1/ETO depletion. The effect of RUNX1/ETO knockdown on BCL2 inhibition 
was detectable after two rounds of colony formation replatings. This finding may 
suggest a relationship between RUNX1/ETO expression and the mitochondrial 
apoptosis network. 
Despite the improved toxicity of ABT-199 treatment after RUNX1/ETO knockdown in 
vitro, this combination therapy was disadvantageous in vivo. ABT-199 dosing 
scheme was obtained from collaborators, and relevant to recent published literature 
(Scherr, Kirchhoff et al. 2019). However, ABT-199 monotherapy did not significantly 
increase the survival of the mice. Kasumi-1 cells were sensitive to ABT-199 in vitro 
but not in vivo. Several factors might have contributed to the low potency of ABT-199 
in vivo, including the pharmacodynamics, microenvironment, and the 
xenotransplantation model. Thus, it cannot be confirmed that BCL2 inhibition 
occurred in the cells in vivo. Unexpectedly, the combination of RUNX1/ETO 
knockdown by siRNA and ABT-199 treatment resulted in a faster expansion of 


















6.1 Introduction  
The chromosomal translocation t(8;21) is linked to over 12% of de novo AML cases. 
The translocation product RUNX1/ETO is an oncogenic transcription factor 
(Ptasinska, Assi et al. 2014). Although patients with t(8;21)-positive leukaemia have 
favourable prognoses, current treatment accounts for a broad spectrum of side 
effects (Burnett, Hills et al. 2010, Grimwade, Hills et al. 2010). The RUNX1/ETO 
transcript is leukaemia-specific and thus serves as an ideal model for specific 
targeting with siRNA (Heidenreich, Krauter et al. 2003). Former RNAi-based 
functional studies identified some of the mechanisms underlying the 
leukaemogenesis of RUNX1/ETO. Although these in vitro studies successfully 
proved that RUNX1/ETO initiates and maintains leukaemia propagation via complex 
transcriptional networks (Martinez, Drescher et al. 2004, Ptasinska, Assi et al. 2012), 
it was not possible to confirm these finding in vivo due to the lack of potent siRNA 
delivery systems. The first aim of this project was to silence RUXN1/ETO in vivo by a 
clinically compatible siRNA delivery system. 
The hallmark of t(8;21) leukaemia is associated with transformed haematopoietic 
stem cells (HSCs) characterised by hyperproliferation, enhanced self-renewal, high 
genomic stability and epigenetic changes in the myeloid lineage-specific transcription 
factors (Peterson and Zhang 2004, Loke, Assi et al. 2017). Chemoresistance in 
relapsed patients is widely postulated to be driven by malignant leukaemic stem 
cells, known as the leukaemic initiating cells (LICs). These LICs are intrinsically 
capable of escaping the toxic microenvironment caused by chemotherapy, altering 
their metabolic programme and resting in dormancy (Viale and Pelicci 2009, 
Cordeiro Gomes, Hara et al. 2016). Since RUNX1/ETO transforms the HSCs into a 
leukaemic reservoir, its knockdown might ultimately reduce leukaemia expansion 
and impair relapse (Soria, Tussiwand et al. 2009, Gessner, Thomas et al. 2010). The 
second aim of this study was to exploit the therapeutic potential of silencing 





6.2 Specific silencing of RUNX1/ETO by chemically modified siRNA  
6.2.1 The specificity of siRNA to RUNX1/ETO transcript    
The translocation between chromosomes 8 and 21 produces a single chimaeric 
transcript, with one unique breakpoint (Rulina, Spirin et al. 2010). The fusion site of 
RUNX1/ETO was targeted by siRNA (siRUNX1/ETO) composed of 21 nucleotides. 
The antisense of siRUNX1/ETO spans over the fusion breakpoint, and it has only 
seven nucleotides complementary to RUNX1. Given that a full complementarity 
between siRNA and mRNA is required for RISC activity (Haley and Zamore 2004, 
Ameres, Martinez et al. 2007), siRUNX1/ETO should eventually have no effect on 
the wild type RUNX1 which is highly expressed in haematopoietic cells (Zhang, 
Fujioka et al. 1994, Zhang, Hetherington et al. 1996, Lorsbach, Moore et al. 2004). 
Moreover, upon swapping two nucleotides in the antisense of siRUNX1/ETO, we 
observed that there was no effect on RUNX1/ETO or RUNX1, suggesting the 
mutated siRNA an appropriate mismatch control (Fig 3-4 & 3-5). The knockdown of 
RUNX1/ETO by single or serial electroporation resulted in specific depletion of the 
fusion without changing RUNX1 level, which proved the specific silencing of 
siRUNX1/ETO (Fig 3-6 & 3-7).  
 
6.2.2 Rational design of siRNA chemical modifications 
The use of chemically modified siRNA was inevitable since therapeutic interventions 
require maximal on-target activity with the lowest possible dose. The activity of 
siRNA comprises of three main processes, first access of the siRNA to its action site 
in the cells, second specific binding to the target mRNA within the RISC complex, 
and finally post-binding events including RISC recycling and mRNA degradation 
(Lee, Seok et al. 2015, Kaczmarek, Kowalski et al. 2017, Khvorova and Watts 2017). 
From this perspective, we have rationally placed several chemical modifications on 
siRUNX1/ETO and evaluated the activity of the siRNA in a series of comprehensive 
in vitro experiments. The modifications on the antisense strand were placed outside 
the seed region and towards the 3’-nt overhang in order to avoid interfering with the 
complementarity to the RUNX1/ETO transcript. The modifications of the sense 
strand were placed in several locations in order to increase the stability and reduce 
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the off-target binding. We have shown that the chemically modified siRUNX1/ETO 
had enhanced potency indicated by prolonged knockdown and robust changes in 
RUNX1/ETO downstream targets (Fig 3-4, 3-8,), thereby providing potential for 
reducing the siRNA dose and improved therapeutic index.  
 
I. Phosphorothioate modification (PS) enhances  nuclease resistance 
RNA and oligodeoxyribonucleotides are susceptible to degradation by 3’ to 5’ 
intracellular exonucleases and endonucleases (Dagle, Weeks et al. 1991). 
Phosphorothioate modification, which is achieved by substituting one of the 
nonbridging oxygen atoms with sulphur in the phosphate backbone, is the most 
common modification in the toolbox of oligonucleotides chemistry. PS modifications 
protect the single-stranded antisense and the double-stranded siRNA from serum 3’ 
to 5‘ exonucleases and intracellular nucleases (Eder, DeVine et al. 1991). 
Modified siRNA with PS linkage binds plasma proteins and has a higher affinity for 
cell surface proteins in comparison with unmodified siRNA. Modulation of this 
property is a tricky task. It is desirable to have high interaction with some serum 
proteins to improve the siRNA pharmaceutical profile, but not high enough to trigger 
unspecific internalisation. PS unspecific interactions with proteins may be 
therapeutically disadvantageous on its own due to the interaction with undesirable 
toxic proteins (Schlundt, Tants et al. 2017). 
While this study aimed to develop a therapeutic siRNA delivery system, the influence 
of PS modifications on siRUNX1/ETO serum stability, and nonspecific cellular uptake 
were not obstacles. For these reasons, only two PS linkers were introduced to each 
of the 3’-dT-dT overhangs in siRUNX1/ETO. The reduced PS content provided 
excellent nuclease stability as well as mitigated the drawback of nonspecific 
interactions with intracellular proteins. 
 
II. 3’-end modification influences the siRNA specificity 
The thermostability of siRNA duplex determines the on-target knockdown efficiency 
of the antisense strand and influences the off-target silencing of the sense stand 
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(Cerutti, Mian et al. 2000). Within RISC, PAZ domain selects the antisense 
exclusively based on the differential thermostability between the two ends. The PAZ 
domain retains the strand with the lowest melting temperature at the 3’-end and 
more stable 5’-end (Lingel, Simon et al. 2003, Haley and Zamore 2004). PS 
modifications on the 3’-end equitably reduce the melting temperature of the siRNA 
duplex in each end (Jaroszewski, Clausen et al. 1996). Moreover, modified 3’-
overhang was shown to increase the binding affinity to the PAZ domain (Sipa, 
Sochacka et al. 2007). On that account, we speculated that the modified overhangs 
(3’-dTPSdT) of siRUNX1/ETO should not impair the target specificity. Indeed, the 
knockdown experiment have proven the on-target activity and demonstrated 
enhanced gene knockdown (Fig 3-6, Fig 3-7). 
The influence of the 3’-end is minimal in the ‘’two-state’’ model of RISC catalytic 
activity. This model proposes that AGO2 first binds the mRNA by direct contact with 
the seed sequence, whereas the PAZ domain retains the 3’-end of the antisense. 
Then in the second step, PAZ releases the 3’-end while the mRNA-antisense duplex 
remains stable until the PIWI domain starts the endonucleolytic cleavage (Tomari 
and Zamore 2005). Recent structural studies support the this mechanism and 
suggest a favourable minimal kinetic model for AGO2 turnover by a series of 
consecutive 3’-end retention and release from the PAZ domain during each cleavage 
cycle (Somoza, Terrazas et al. 2010, Maiti, Nauwelaerts et al. 2011, Xu, Wang et al. 
2015). 
Arguably, weak interactions between the antisense and the PAZ domain enhance 
the siRNA catalytic activity and specificity, as previously reported in mechanistic and 
computational studies (Wang, Juranek et al. 2009, Tian, Simanshu et al. 2014). On 
the contrary, studies on 3’-end modified nucleosides analogues have shown that 
strong antisense-PAZ domain interactions substantially reduce the off-target activity 
without affecting the on-target potency (Valenzuela, Onizuka et al. 2016). 
Taken together, given that the PAZ domain is not involved in the contact between 
the seed region and the targeted mRNA (Wang, Juranek et al. 2009, Valenzuela, 
Onizuka et al. 2016), the dTPSdT motifs at the 3’-end antisense of siRUNX1/ETO 
perhaps has improved the binding affinity of the antisense to the RISC complex 
without compromising the specificity. Of note, this conclusion does not propose that 
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the affinity of the antisense to the PAZ domain is a good predictor of the siRNA 
specificity.  
 
III. 2’-sugar modifications  
The 2’-sugar modifications significantly alter siRNA duplex stability. The addition of a 
steric bulk by introducing 2’-F results in a North confirmation of the sugar (Pieken, 
Olsen et al. 1991, Beigelman, Karpeisky et al. 1995). This modification also 
enhances the thermal stability and reduces the melting temperature of the siRNA 
duplex (Watts, Martin-Pintado et al. 2010). Although the 2’-F modifications do not 
enhance the resistance towards exonucleases, it may confer some protection 
against endonucleases. For this reason, we have utilised the entropic advantage of 
the 2’-F modifications at 5’-end on the sense strand to improve the thermal stability 
of siRUNX1/ETO and entice the PAZ domain for recognition of the antisense (Lee, 
Seok et al. 2015).  
The naturally occurring 2’-O-Me modification changes the sugar puckering toward 
North and improves the siRNA duplex stability. Importantly, the 2’-O-Me enhances 
the resistance towards endonuclease for both single-stranded and double-stranded 
RNAs (Hernandez, Stockdale et al. 2012, Shen and Corey 2018). Towards this 
direction, we have modified all the pyrimidine nucleotides on the sense strand of 
siRUNX1/ETO with 2’-O-Me residues. 
The focus of this project was to enhance RUNX1/ETO knockdown by a modified 
siRNA. We did not pursue endonuclease stability assays but utilised gene 
knockdown as an indication of the modification potency. That is because the 2’-sugar 
modifications on siRUNX1/ETO require specific endonucleases that are not 
expressed in the cellular cytoplasm. Furthermore, the manufacturing cost of the 







6.2.3 Modified siRNA has a potent activity   
The repression of RUNX1/ETO have already been described in previous studies, 
including former work in our group, in which unmodified siRUNX1/ETO was used to 
achieve transient gene knockdown. However, serial transfections with up to 500 nM 
siRNA were required to achieve prolonged repression of RUNX1/ETO, thereby 
limiting the applicability of the siRNA in the therapeutic applications (Heidenreich, 
Krauter et al. 2003, Martinez, Drescher et al. 2004). In contrast, our modified 
siRUNX1/ETO has provided stronger efficacy and long-lasting effect at fivefold lower 
concentration and less frequent transfections (Fig 3-3 & 3-7). Having developed and 
functionally validated modified siRUNX1/ETO, gene knockdown in vivo has become 
more approachable. 
The enhanced potency of the chemically modified siRUNX1/ETO was not surprising. 
The PS and 2’-sugar modifications at the 5’-end of the sense strand meant to reduce 
the off-target effect as discussed above. Importantly, these modifications stabilised 
the 5’-end against nucleases. Recent in vivo studies have reported that siRNAs 
isolated from several organs after systemic administration were degraded at the 5’-
end (Jiang, Zhu et al. 2017). This may explain the potent activity at lower doses, as 
less siRNA molecules per cell are needed to achieve robust knockdown, and 
generating our modified siRUNX1/ETO has supposed to improve the clinical 
performance and herein associated dose toxicity. 
 
6.2.4 RUNX1/ETO repression beyond mRNA cleavage       
We have noticed that the reduction in RUNX1/ETO mRNA did not reflect the 
knockdown at the protein level on several occasions (Fig 3-20A, 3-21A & 3-22). A 
possible explanation would be RNAi non-silencing pathways were performed by the 
RISC complex (Filipowicz 2005, Matzke and Birchler 2005). Furthermore, the RNA-
seq data of RUNX1/ETO depletion in vivo and RNA-seq data generated under 
shRNA gene knockdown in vitro (unpublished data and not the focus of this project), 
have revealed that RUNX1/ETO regulates some genes involved in the RNAi 
machinery. Furthermore, the repression of RUNX1/ETO also has an impact on the 
expression of genes involved in the regulation of protein synthesis, such as the 
eukaryotic initiation factor (eIF2). Therefore, we hypothesise that mRNA cleavage by 
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siRUNX1/ETO is partly contributing to RUNX1/ETO downregulation, and other non-
silencing mechanisms might be involved in the gene knockdown. Further functional 
studies are recommended to identify possible regulatory pathways involved in 
stabilisation of RUNX1/ETO transcript and protein translation. 
Furthermore, previous studies showed that acetylation of RUNX1/ETO hinders the 
ubiquitin-mediated degradation and stabilises RUNX1/ETO and RUNX1 proteins. 
(Jin, Jeon et al. 2004, Bali, Pranpat et al. 2005, Wang, Huang et al. 2009). Disturbing 
the physical interaction between RUNX1/ETO and the heat shock protein 
90 (HSP90) has been reported to destabilise RUNX1/ETO. HDACs inhibitors 
treatment in Kasumi-1 cells have shown hyperacetylation of RUNX1/ETO-interacting 
proteins, such as HSP90, destabilisation of RUNX1/ETO and once the degradation 
triggered, a positive feedback for further RUNX1/ETO protein degradation is 
generated (Bali, Pranpat et al. 2005, Yang, Thompson et al. 2007). Therefore, the 
knockdown of RUNX1/ETO by siRUNX1/ETO to a certain threshold might shift the 




6.3 Lipid nanoparticle is a robust siRNA delivery system 
With the exception of the liver, systemic delivery remains the main challenge to 
implement siRNA therapeutics. The low stability and poor pharmacokinetics of 
intravenously administered siRNA have limited its therapeutic use (Huang, Cheng et 
al. 2016). Having generated a potent chemically modified siRUNX1/ETO, and taking 
in consideration the recent advances in ionisable lipid nanoparticles (LNPs) (Adams, 
Gonzalez-Duarte et al. 2018), we have utilised the Dlin-MC3-DMA lipid to 




6.3.1 LNPs have a prolonged stability 
Regardless of targeted gene or tissue, the siRNA delivery system should be 
amenable to upscaling and should exhibit a reasonable shelf life and preservation of 
the cargo activity. Despite the fact that different formulations of LNP/siRNA were 
used during this project, the nanopractices had consistently low polydispersity index 
(Table 3-2). We have noticed that one LNP/siRNA formulation was stable over one 
year without significant changes in the particles size and charge (Fig 3-15). The 
chosen lipid nanoparticle seemed to be suitable for RUNX1/ETO knockdown with the 
potential for clinical use.  
 
6.3.2 The chemistry and physics of Dlin-MC3-DMA nanoparticles     
The lipid pKa determines the potency of the lipid nanoparticles. Dlin-MC3-DMA lipid 
has a dimethylamine (DMA) head group with pKa = 6.2 to 6.5, which has been 
validated as a suitable cationic head group for gene silencing in vivo including non-
human primates animal models (Jayaraman, Ansell et al. 2012). In a broader 
perspective, the lipid head group influences the nanoparticle structure, siRNA 
packaging efficiency, cytotoxicity, and mechanism of endosomal release.  
 
I. LNP/siRNA formulation efficacy  
Within the context of Dlin-MC3-DMA nanoparticles, the DMA head group grants to 
the formed particles a nitrogen to phosphate ratio (N/P) of 3 to 6 depending on the 
formulation parameters. These N/P values are optimal for siRNA encapsulation and 
gene silencing in vivo (Semple, Akinc et al. 2010, Belliveau, Huft et al. 2012). During 
the LNP/siRNA formulation, loading of the negatively charged siRNA was performed 
under pH = 4. The acidic conditions ensure that all the lipid amino groups are fully 
protonated. This allows efficient electrostatic interactions and complexation between 
the siRNA and the lipid. During this project, we have produced four independent 
LNP/siRNA formulations with relatively consistent encapsulation efficiencies in three 
batches (~ 90%). This confirms that the lipid nanoparticle is a reliable and cost-
effective siRNA delivery system. 
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Neutral lipid-based delivery systems may have up to 20% of the siRNA attached to 
the outer surface and not adequately protected inside the vehicles (Stuart and Allen 
2000, Bartsch, Weeke-Klimp et al. 2004). This might results in an overestimation of 
the encapsulation efficiency. In contrast, the Dlin-MC3-DMA nanoparticles are 
formulated under a rapid mixing in a microfluidic system that forces the siRNA to be 
entrapped into the hydrophilic pockets inside the nanoparticle (Semple, Akinc et al. 
2010, Belliveau, Huft et al. 2012). For this reason, it can be surmised that the 
LNP/siRNA formulations had a small amount of surface-bound siRNA, which have 
improved the accuracy of the encapsulation quantification.  
 
II. PEG influence on the LNP/siRNA size and charge  
Structure and size of lipid nanoparticles are good indicators of their potency. 
Additionally, composition of the lipid mixture and the formulation procedures 
determine the diameter of the lipid nanoparticles. Dlin-MC3-DMA lipid has a 
relatively small hydrophilic heads group (DMA) which enables the lipid molecules to 
form inverted and non-bilayer structures (Gilleron, Querbes et al. 2013). The 
polyethylene glycol (PEG) ratio also influences the particles size, charge, and 
potency. Several studies have suggested that 10 - 30% PEG is required to provide 
stable steric shielding effect (Mu, Hu et al. 2013, Guan, Guo et al. 2017). However, 
high PEG ratios have prohibitive toxicity, insufficient siRNA-endosomal release, and 
immuno-stimulation (Mui, Tam et al. 2013, Chen, Tam et al. 2016). The lipid 
nanoparticles mixture consisted of only 1.5% PEG but still sufficient to significantly 
stabilise the nanoparticles without compromising the gene knockdown (Fig 3-14, 
3.4.5). For these reasons, we propose that the lipid nanoparticles acquired the 
desired properties for siRNA gene knockdown in vitro and in vivo. 
 
6.3.3 LNP/siRNA uptake mechanisms  
Size and charge of lipid nanoparticle accounts for its cellular uptake mechanism. A 
50 nm nanoparticle triggers active cellular endocytosis upon close to the cell surface 
(Hoarau, Delmas et al. 2004, Mund, van der Beek et al. 2018). The surface shielding 
also influences the uptake rate of the nanoparticles. It was shown that a high surface 
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density of PEG is associated with increased steric repulsion and slower uptake, and 
PEGylated neutral nanoparticles have been suggested to have the poorest uptake. 
Furthermore, surface charge significantly affects the particle uptake in a way that 
positively charged nanoparticles induce active phagocytic endocytosis when 
compared with negatively charged ones (Papisov 1998, Vonarbourg, Passirani et al. 
2006). 
Whilst the used lipid nanoparticles had a relatively small negative charge (Table 3-2), 
counter ions near the surface heavily influence the zeta potential measurement of 
particles in solution and possibly affect the estimation of the surface charge 
(Delgado, Gonzalez-Caballero et al. 2007). Furthermore, the nanoparticles may not 
retain their naïve charge under the physiological conditions in vitro. Our in vitro cell 
culture media contained up to 20% FCS, and serum proteins can incorporate into the 
surface of the nanoparticles and change their charge (Tadin-Strapps, Peterson et al. 
2011). We showed that the induction of RUNX1/ETO knockdown was rapid and 
potent during short periods, which may suggest that the lipid nanoparticles have fast 
cellular uptake (Fig 3-20A & 3-21A).  
Liposomes with phospholipid bilayers greater than 200 nm were shown to fuse into 
the cellular membrane and slowly release their cargo (Ziello, Huang et al. 2010). The 
Dlin-MC3-DMA lipid nanoparticles we have used are less than 100 nm in diameter. 
Moreover, these lipid nanoparticles have a solid condense core rather than a bilayer 
structures as it was shown in previous studies (Leung, Hafez et al. 2012, Leung, 
Tam et al. 2015). Therefore, we can assume that the fusion of the lipid nanoparticles 
into the cell membrane is less probable.  
Clathrin-mediated endocytosis (CME) is considered the main uptake pathway of 
particles less than 100 nm in diameter with relatively small positive or negative 
charge (-10 to +10 mV), such as positively charged PEI polyplexes (Rejman, 
Bragonzi et al. 2005, Rejman, Conese et al. 2006, Shi, Chou et al. 2013). Owing to 
the nanoparticles diameter (< 100 nm) and the negative charge (-8 to 0.25 mV), it 
can be sensibly assumed that the uptake mechanism is clathrin-mediated 
endocytosis (Ziello, Huang et al. 2010, Oh and Park 2014, Jyotsana, Sharma et al. 
2018, Mund, van der Beek et al. 2018). Slow siRNA release from liposomes and 
nanoparticles is associated with caveolin-mediated endocytosis (He, Bennett et al. 
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2014). We, however, have shown that LNP/siRNA treatment in vitro resulted in a 
rapid RUXN1/ETO silencing within less than 24 hours, even with as little as 15 min of 
exposure time (Fig 3-17A & 3-18A). This may suggest that caveolin-mediated 
endocytosis did not contribute largely to the uptake of the nanoparticles. Due to time 
constraints, it was not feasible to investigate the uptake mechanisms. Further 
experiments should be performed to validate this hypothesis by specific inhibition of 
the dynamin and clathrin, which are the regulatory proteins for caveolin and clathrin 
endocytosis, respectively.  
In conclusion, endocytosis has been studied for over five decades, yet a full 
understanding of its multiple types of machinery remains elusive (Schlossman, 
Schmid et al. 1984, Kaksonen and Roux 2018). Selective blocking of specific uptake 
route might elucidate the possible cellular uptake pathways (Mettlen, Loerke et al. 
2010, Fekri, Delos Santos et al. 2016). Nevertheless, such studies are performed in 
in vitro. This leaves the question of how these processes occur in a complex 
multicellular system in vivo considering factors such as the body fluids dynamics, cell 
membrane elasticity and immune system response. 
 
 
6.3.4 LNP/siRNA has low cytotoxicity   
Cytotoxicity of the delivery vehicle limits its therapeutic use. Our in vitro assessment 
of the toxicity (Fig 3-16) and in vivo work in adult and newborn mice (Fig 4-17) have 
demonstrated that the lipid nanoparticles has insignificant toxicity. This finding may 
not be surprising as Dlin-MC3-DMA cationic head group ‘’DMA’’ has the lowest 
toxicity amongst all the tertiary amino groups (Walker, Jones et al. 2010, Jayaraman, 
Ansell et al. 2012, Kanasty, Dorkin et al. 2013). Furthermore, the low ratio of PEG 
(1.5%) in the lipid mixture may have largely reduced the toxicity. The high siRNA 
encapsulation efficiency meant that the therapeutic dose could be achieved with 
fewer nanoparticles, which also minimise the cytotoxicity of the lipid mixture. Taken 
together, the Dlin-MC3-DMA nanoparticles provide a safe vehicle for siRNA delivery 
in vitro and in vivo. 
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It has been shown that the Dlin-MC3-DMA lipid nanoparticles are well tolerated in 
immunocompromised hosts. Previous research has demonstrated that lipid 
nanoparticles treatment does not alter the number of white blood cells, platelets, and 
haemoglobin. It was also shown that lipid nanoparticles treatment does not cause 
any significant changes in liver enzymes such as aspartate aminotransferase (ALT) 
and alanine aminotransferase (ALT), and has minimal effect on the kidney and 
pancreas functions. However, nanoparticles treatment was shown to significantly 
increase serum albumin in NSG mice due to the presence of the cationic amino 
group (DMA) in the lipids (Jyotsana, Sharma et al. 2019).  
Furthermore, it has been recently shown that Dlin-MC3-DMA nanoparticles treatment 
in immunodeficient hosts may stimulate the innate immune system, but it does not 
increase immunogenicity. It was reported that extended systemic administration of 
the nanoparticles in non-human primates elevates IL-6 serum level and induces a 
potent innate immune response (Hassett, Benenato et al. 2019, Sune-Pou, Limeres 
et al. 2019). For the clinical implementation of the lipid nanoparticles, it is essential to 
ensure that prolonged exposure to the lipid does not evoke an immunological 
response. We did not investigate the immune stimulation of the nanoparticles 
treatment due to the time constraints. Therefore, we suggest investigating whether 
the nanoparticles treatment can act as immunostimulants in immunodeficient and 
immunocompetence mice. It is necessary to look at the different immune-modulatory 
mechanisms following the nanoparticles treatment by monitoring the changes in 
serum interleukins, cytokines and interferons such as IL-1, IL-6, IL-12, lL-16, TNF-α, 
INF-α, INF-β and INF-γ. We also recommend exploring the effect of the 
nanoparticles on activating non-immunological cells in vitro, such as endothelial cells 
and fibroblasts, which are known to secrete several cytokines and immunogens. 
Current state-of-the-art multiplex ELISA and high throughput capillary immunoassays 
can be used to determine simultaneously the serum level of serval interleukins and 






6.3.5 LNP/siRNA efficiently releases the siRNA into the cytoplasm   
The job of the siRNA delivery vehicle does not end with the internalisation onto the 
cellular membrane. Efficient delivery systems should promote destabilisation of the 
endosome and the release of siRNA simultaneously from the vehicle and the 
endosome. Potent lipid formulations are expected to maintain stable lamellar phase 
to protect the siRNA, but also have a fast transition between the lamellar and the 
hexagonal phases, known as the transition temperature, within the endosome 
(Koltover, Salditt et al. 1998). Amphiphilic properties of lipid molecules determine the 
transition temperature where small hydrophilic centres and long hydrophobic tails 
exponentially reduce the transition temperature. The nanoparticles are expected to 
facilitate quick endosomal release of siRNA into the cytoplasm. That is because the 
Dlin-MC3-DMA lipid has a low transition temperature from lamellar to hexagonal 
phase due to its small polar head group and large unsaturated hydrophobic tail. The 
other factor that contributes to the transition temperature is cholesterol content. 
Liposomes consisting of 17% cholesterol can release over 90% of their encapsulated 
cargo within 5 minutes upon endocytosis (Zhigaltsev, Maurer et al. 2002, Viger-
Gravel, Schantz et al. 2018). The LNP/siRNA has 38.5% cholesterol, which is 
expected to lower the transition temperature further and fasten the siRNA release.   
Furthermore, intra-endosomal positive surface charge is required for endosomal 
release via the proton sponge effect (Hafez, Maurer et al. 2001, Semple, Akinc et al. 
2010). The pKa of Dlin-MC3-DMA is 6.2 to 6.5 meaning that the lipid molecules will 
be protonated inside the lysosome resulting in an increased proton sponge effect 
over time leading to the rapture of the endosome and siRNA release (Creusat, 
Rinaldi et al. 2010, Benjaminsen, Mattebjerg et al. 2013). Nevertheless, the 
understanding of endosomal release is not fully complete and many mechanistic 
gaps of the nanoparticles interactions with different stages of the endosome during 
maturations are still unknown. 
Overall, we have shown a rapid deletion of RUNX1/ETO transcript upon treatment 
with the lipid nanoparticles (Fig 3-20, 3-21 & 3-22), which can be explained by 




6.4 The consequences of RUNX1/ETO knockdown in vitro  
6.4.1 RUNX1/ETO depletion inhibits proliferation 
Fusion genes, namely those that act as transcription factors, can control malignant 
cell proliferation. The transit depletion of RUNX1/ETO by siRNA significantly 
inhibited t(8;21) cell lines proliferation. The notion of a fusion protein controlling the 
proliferation of haematopoietic stem cell is not new. For instance, RNAi-mediated 
knockdown of BCR/ABL by antisense or siRNA inhibit the proliferation of chronic 
myeloid leukaemia (CML) cells (Skorski, Szczylik et al. 1991, O'Brien, Kirkland et al. 
1994, Scherr, Battmer et al. 2003). 
We have shown that RUNX1/ETO enhances leukaemic cell proliferation (Fig 3-3 & 3-
19). There is contradictory research arguing that RUNX1/ETO expression represses 
proliferation, and other oncogenic factors are responsible for the hyperproliferative 
phenotype of leukaemic cells (Amann, Nip et al. 2001, Burel, Harakawa et al. 2001). 
Nonetheless, RUNX1/ETO inhibited proliferation after forced ectopic expression of 
RUNX1/ETO in cell lines do not carry the t(8;21) translocation. Furthermore, t(8;21) 
AML phenotype requires a sequence of genomic alterations, beginning with the 
translocation, expression of the fusion protein RUNX1/ETO which dysregulates 
RUNX1 transcriptional activity and establishes its oncogenic transcriptional network 
(Loke, Assi et al. 2017). For these reasons, as shown by our experiments on AML 
cell lines in which t(8;21) is the main oncogenic event, RUNX1/ETO attributes to the 
proliferation of leukaemic cells.  
Experiments performed in t(8;21) AML cell lines and primary patient cells showed 
that RUNX1/ETO renders leukaemic cell proliferation by deregulating microRNAs. 
RUNX1/ETO promotes overexpression of miR-23-27-24 cluster by replacing RUNX1 
binding sites on miR-23-27-24 locus. It was found that miR-24 downregulates MAPK 
phosphatase-7 (MKP-7) leading to phosphorylation of p38 and JNK kinases, which 
stimulate leukaemic cell proliferation (Tanoue, Yamamoto et al. 2001, Zaidi, Dowdy 
et al. 2009). The regulation of MAP kinases by leukaemic fusion proteins is not 
exclusive to RUNX1/ETO, for example, BCR/ABL also regulates MKP-7 leading to 
enhanced proliferation (Hoornaert, Marynen et al. 2003).   
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Cytokines signalling pathways are dysregulated in leukaemia due to mutations and 
genomic alterations as an early event required to promote leukaemic stem cell 
survival and proliferation (Scholl, Gilliland et al. 2008). RUNX1/ETO drives 
proliferation independent of IL-3 by maintaining high expression level of its dominant 
negative regulator miR-24 (Zaidi, Dowdy et al. 2009). RUNX1/ETO also cooperate 
with several cytokines to induce proliferation. For instance, RUNX1/ETO has a 
synergetic effect with the thrombopoietin receptor (MPL), which is highly expressed 
in HSCs, progenitors and t(8;21) AML cells. Consequently, the addition of 
thrombopoietin (THPO) induces high proliferative properties to t(8;21) cells by 
activating the JAK/STAT and PI3K/AKT pathways (Kaushansky 2009, Pulikkan, 
Madera et al. 2012). Given that RUNX1/ETO activates and synergises with several 
cytokine-mediated signalling pathways, the repression of RUNX1/ETO may have a 
therapeutic benefit.  
 
6.4.2 RUNX1/ETO depletion induces G1 cell cycle arrest  
The depletion of RUNX1/ETO led to G1 cell cycle arrest (Fig 3-10, 3-23). We have 
found that RUNX1/ETO knockdown leads to downregulation of the cell cycle gene 
CCND2 at mRNA and protein levels (3-8, 3-18 & 3-22B). Latest findings in our lab 
identified CCND2 as a downstream target of RUNX1/ETO where the fusion protein 
corporates with AP-1 to drive high expression level of CCND2 in AML. RUNX1/ETO 
activates CCND2 directly by binding to the transcription start site (TSS) and the -30 
kb region. Moreover, RUNX1/ETO upregulates CCND2 indirectly by reducing AP-1 
occupancy on CCND2 promotor resulting in histone deacetylation and increased 
RNA POL II binding (Mathas, Hinz et al. 2002). We have also assessed the effect of 
the pharmacological inhibition of CDK4/6 and found that palbociclib significantly 
impairs leukaemic cell expansion in vivo and t(8;21) primary cells. Thereby, we 
proposed RUNX1/ETO as a central regulator of the cell cycle via the CCND2-
CDK4/6 complex (Martinez-Soria 2018). 
The modified siRUNX1/ETO showed robust inhibition of RB1 phosphorylation at T-
821 (Fig 3-8). Phosphorylation of RB1 is crucial to drive the cell cycle progression. 
The cyclin kinases CDK4 and CDK6 phosphorylate RB1 at different sites including T-
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821 (Harbour, Luo et al. 1999). In our work, we showed that depletion of 
RUNX1/ETO or CCND2 reduced RB1 phosphorylation (Martinez-Soria 2018). 
We observed that modified siRUNX1/ETO induced stronger cell cycle arrest in 
Kasumi-1 cells, where SKNO-1 required continuous RUNX1/ETO depletion to 
effectively inhibit the cell cycle at G1 phase (Fig 3-10). Early studies suggested that 
the cell cycle of AML blasts is independent of GM-CSF, G-CSF, and IL-3 (Liesveld, 
Keng et al. 1994). However, it is now widely agreed that cytokines accelerate G1 to 
S transition and enhance proliferation (Herrmann, Oster et al. 1990, Matsuura, Yan 
et al. 2012). The prompt response of Kasumi-1 cells to RUNX1/ETO knockdown and 
repressing the cell cycle could be due to a KIT mutation in Asn(822)-Lys (Beghini, 
Magnani et al. 2002) combined with high expression of G-CSF (Gordon, Dias et al. 
2014). The KIT activation mutation promotes legend-independent proliferation, and 
G-CSF coordinates with the mutant KIT signalling to enhance AML expansion. 
RUNX1/ETO was found to activate G-CSF expression, and depletion of G-CSF 
results in cell cycle arrest (Elsasser, Franzen et al. 2003). On the other hand, SKNO-
1 cell line has fourfold less expression of G-CSF in comparison with Kasumi-1, which 
may explain the modest effect of RUNX1/ETO knockdown on the cell cycle. 
Furthermore, the dependency of SKNO-1 cells on GM-CSF for proliferation might 
alleviate the effect of RUNX1/ETO on the CCND-CDK4/6 complex. We were able to 
enhance the G1 cell cycle arrest by simultaneously reducing the concentration of 
GM-CSF in SKNO-1 media and depleting RUNX1/ETO. Previous research in 
endothelial progenitors has shown that GM-CSF upregulates CCND1 leading to RB1 
phosphorylation, which drives higher expression of CCNE1 and consequently 
promotes the cell cycle progression (Qiu, Xie et al. 2014). The mechanism behind 
GM-CSF-induced cell cycle progression and activation of CCND1 was proposed to 
be through the phosphorylation of GSK3β which activates PI3K/AKT and ERK 
pathways (Ono, Yanagawa et al. 2007, Giambelluca, Cloutier et al. 2013). 
The leukaemic stem cell is characterised by high proliferative capacity where it 
undergoes up to 200 doublings (Cheng, Rodrigues et al. 2000). The presence of 
oncogenic regulatory element to activate the cell cycle and enhance the DNA repair 
pathways is crucial to correct the DNA damage and prevent leukaemic stem cell 
exhaustion (Cheng 2004). Fusion proteins such as PML/RARA were found to 
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activate the cell cycle inhibitor p21 independently of TP53 status (Viale, De Franco et 
al. 2009). The high expression of p21 accelerates cell cycle propagation by CDK2-
CCNE1 complex and restricts the hyperproliferative phenotype, which accumulates a 
high level of DNA damage. It was suggested that RUNX1/ETO mimics PML/RARA 
by activating p21 and driving the cell cycle (Zhou, Li et al. 2006). Taking into account 
that the role of p21 in t(8;21) leukaemogenesis was obtained in TP53 negative cells, 
we thus speculate that the delayed leukaemia initiation in the absence of p21 could 
be due to the DNA damage agents which exhausted the leukaemic stem cells. 
Moreover, the expression of p21 in t(8;21) AML cell lines is lower than other AML cell 
lines due to mutated TP53 (Quintas-Cardama, Hu et al. 2017). Taken together, 
oncogenic mutations such as KIT and TP53 may contribute to cell cycle progression 
in t(8;21) leukaemia, and the CDK2-CCNE1 complex may not play a significant role 
in cell cycle modulation. 
 
6.4.3 RUNX1/ETO depletion induces cellular senescence   
Beta-galactosidase is an essential enzyme for cellular function in which it hydrolyses 
the β-glycosidic linkages between galactose and its partners. Senescent cells 
specifically overexpress β-galactosidase in the lysosome, which can be detected by 
X-Gal staining at pH = 6 (Dimri, Lee et al. 1995). We showed that RUNX1/ETO 
knockdown in Kasumi-1 and SKNO-1 cell lines leads to substantial increase in 
senescence (Fig 3-11, 3-24). Furthermore, we have showen that induction of 
senescence was specifically due to the gene knockdown, and not stress-mediated 
given that the mismatch transfected cells as well as the mock control had the same 
basal level of senescent cells (Ben-Porath and Weinberg 2005).  
Maintenance of genome integrity is essential for leukaemic stem cell survival. Stable 
telomerase (TERT) expression is required for stem cell self-renewal, but TERT 
expression does not lead to cancer. The enhanced proliferation and self-renewal 
capacity of leukaemic cells are prominently dependent on high TERT expression 
(Deng, Chan et al. 2008). Former work in our group showed that RUNX1/ETO 
directly binds TERT promotor and drives high expression of telomerase. The 
depletion of the RUNX1/ETO in Kasumi-1 cell line and t(8;21) primary cells was 
found to increase RUNX1 binding to TSS of TERT and reduce histone acetylation 
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(H3K9Ac) after prolonged knockdown (Ptasinska, Assi et al. 2012). Our data 
supported the previously reported findings that TERT has a delayed response to 
RUNX1/ETO knockdown (Fig 3-18, 3-20 & 3-21) where senescence was detected 
one week after RUNX1/ETO repression. 
In a broader perspective, telomere shortening leads to a state of replicative 
senescence when the cells are metabolically inactive and under cell cycle arrest 
(Allsopp and Harley 1995, Deng, Chan et al. 2008). Former work in our lab has 
showen that the knockdown of RUNX1/ETO in t(8;21) cell lines leads to telomere 
shortening and induction of senescence (Martinez, Drescher et al. 2004, Gessner, 
Thomas et al. 2010).  
Oncogenic stimuli control senescence (Campisi 2001), such as the p16/RB1 tumour 
suppressor pathway which supresses senescence (Collins and Sedivy 2003). On the 
other hand, t(8;21) AML cell lines harbour mutated TP53 which cannot 
phosphorylate RB1 at T-821, suggesting that the induction of cellular senescence in 
Kasumi-1 and SKNO-1 cells is independent of TP53 (Hangaishi, Ogawa et al. 1996, 
Gil and Peters 2006). Furthermore, we showed that the depletion of RUNX1/ETO 
leads to G1 cell cycle arrest via the CCND2-CDK4/6 complex upon RB1 
dephosphorylation at T-821 (Fig 3-8). The pharmacological inhibition of the CDK4/6 
complex in Kasumi-1 and SKNO-1 cell lines also reduces RB1 phosphorylation and 
induces senescence (Martinez-Soria 2018).  Additionally, the knockdown of the 
fusion protein also results in upregulation of the cell cycle inhibitor p27, which leads 
to the G1 cell cycle arrest (Martinez, Drescher et al. 2004). For these reasons, we 
propose that the induction of cellular senescence following the cell cycle arrest in 
t(8;21) cells could be due to loss of RB1 phosphorylation at T-821.   
 
6.4.4 RUNX1/ETO depletion impairs self-renewal  
Clonogenicity is the anchorage-independent expansion of cells, which maintains the 
stem cell properties (Hamburger and Salmon 1977). The in vitro assays of colony 
formation replating, using methylcellulose or sloppy agar are considered the most 
stringent methods to assess the oncogenic transformation of haematopoietic stem 
cells (Lieber and Kovach 1982, Bizzari and Mackillop 1985, Coulombel 2004, 
Borowicz, Van Scoyk et al. 2014).  
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Several chromosomal translocations result in the expression of fusion proteins which 
drive leukaemia propagation and promote survival by upregulating the self-renewal 
genes and downregulating the differentiation pathways. The RNAi-mediated 
depletion of some fusion genes, such as BCR/ABL in t(9;22) and MLL/AF4 in t(4;11) 
reduces the clonogenic  potential of leukaemic cells (Scherr, Battmer et al. 2003, 
Thomas, Gessner et al. 2005). While previous work in our group showed that 
transient depletion of RUNX1/ETO by siRNA reduces clonogenicity of Kasumi-1 and 
SKNO-1 (Soria, Tussiwand et al. 2009), in this study we have shown that 
RUNX1/ETO depletion, using the modified siRUNX1/ETO delivered by 
electroporation or nanoparticles treatment, provides a stronger reduction in 
clonogenicity (Fig 3-13 & 3-25). The knockdown of RUNX1/ETO had a prolonged 
effect on clonogenicity until five sequential replatings (Fig 3-14). This confirms that 
RUNX1/ETO repression maintains the self-renewal ability of leukemic stem cells.  
Conceptually, in order for a cell to form a colony, it should have an active cell cycle, 
enhanced proliferative capacity and high expression of self-renewal genes 
(Katayama, Takenaka et al. 1998). Former work from our group, as well as this 
study, has shown that RUNX1/ETO regulates the cell cycle, proliferation and self-
renewal (Martinez, Drescher et al. 2004, Soria, Tussiwand et al. 2009, Ptasinska, 
Assi et al. 2012, Martinez-Soria 2018). We looked at the transcriptional level of 
RUNX1/ETO and its downstream targets after performing the colony formation. 
Surprisingly, we found that RUNX1/ETO and its direct target genes were significantly 
deregulated (Fig 3-26 & 3-27). There could be several reasons that may contribute to 
this finding, such as efficient recycling of the antisense-RISC complex. The chemical 
modification of the siRNA does not only provide stable gene knockdown, but it also 
guarantees that a sufficient amount of the RNAi machinery is maintained after cell 
division and therewith-associated dilution. The robust repression of RUNX1/ETO 
also might have led to irreversible changes in RUNX1/ETO transcriptional network. 
One might argue that this is a matter of concern, as the knockdown cells are adapted 
to the new transformations and rescued the leukaemic phenotype. However, the new 
transformation of cells, with a new transcriptional network might also open new 




6.5 Pharmacokinetics and biodistribution of LNP/siRNA  
6.5.1 The rationale behind siRNAs delivery system  
Naked and unmodified oligonucleotides have unfavourable biodistribution and 
pharmacokinetics due to the fast clearance upon administration. Pharmacokinetic 
studies in rodent and non-human primates have shown that naked siRNA displays 
fast initial accumulation in the liver and kidneys after intravenous injection. It was 
also found that intact or partially metabolised siRNA in the liver excretes and 
accumulates in the hepatobiliary system before being delivered to the intestines with 
no evidence of relevant enterohepatic recirculation. Moreover, siRNA can also be 
filtered by the kidney, and accumulate in the bladder before being eliminated in the 
urine where fully intact siRNA duplexes can be detected. The endothelial properties 
of the organs’ vasculature, especially the presence of fenestrated or sinusoidal 
capillaries, facilitate siRNA transport out of the circulation. Thus, siRNA effectively 
accumulates in several organs, such as the submandibular and bulbourethral glands 
and the pancreas, here the siRNA remains for long periods suggesting that these 
glands may function as a second natural drug reservoir, with potential bioavailability 
implications. (Huang, Hong et al. 2011, Huang, Cheng et al. 2016).  
Furthermore, leukaemic stem cells are hidden within a complex protective niche in 
the bone marrow sanctuary (Asada 2018). In this manner, it is most unlikely for any 
naked siRNA to be able to reach these malignant cells in therapeutic doses capable 
of causing gene knockdown. Furthermore, leukaemia is known to invade the central 
nervous system (CNS) (Suzuki, Ino et al. 2008). To date, there is no evidence of 
detecting siRNA in the CNS, suggesting that naked siRNA cannot cross the brain-
blood barrier.  
Taken together, our strategy for siRNA delivery was to use a lipid nanoparticle with 
relevant clinical settings. Of notice, such a delivery system would also eliminate the 
activation of the innate immune response to the siRNA, which would be clinically 
advantageous (Yoneyama, Kikuchi et al. 2004, Karpala, Doran et al. 2005). That is 
because the activation of TLRs pathways by siRNA disrupt the immune homeostasis 
leading to the development of autoimmune diseases (Gao, Xiong et al. 2017). 
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siRNA chemical modifications and introducing conjugates alter the biodistribution 
and affect the elimination routes. For instance, 2'-O-methylation modifications 
enhance siRNA uptake by the submandibular and bulbourethral glands and 
subsequent secretion of the siRNA with exosomes (Lendvai, Velikyan et al. 2005). 
Cholesterol conjugate prolongs retention of siRNA in the liver, lungs and heart 
(Huang, Hong et al. 2011). The retention of siRNA in the liver may be advantageous, 
considering its involvement in a plethora of human diseases. Indeed, specific 
conjugates, such as trivalent N-acetylgalactosamine (GalNAc), enhances 
hepatocytes uptake of siRNA (Geary, Norris et al. 2015, Janas, Schlegel et al. 2018). 
Our lipid nanoparticle consisted of 38.5% cholesterol, which may lead to retention of 
the siRNA in the liver. Therefore, it is possible that the siRNA was secreted inside 
exosomes, which aided in vivo knockdown. We suggest investigating the potential of 
detecting exosome encapsulating siRNA in circulation. We recommend isolating the 
extracellular vesicles and exosomes by ultracentrifugation. If the modified siRNA 
were detected, then examine their integrity and ability to cause gene knockdown.    
 
6.5.2 Developing protocol for LNP/siRNA labelling  
In order to study the biodistribution of the nanoparticles, we developed a method to 
label the surface of the nanoparticles with a NIR fluorescent dye. We have chosen 
SulfoCyanine7.5 to label the nanoparticles because the dye excitation and emission 
spectra do not overlap with the mice auto-fluorescence, and we were able to detect 
the NIR fluorescence by IVIS (Fig 4-9 & 4-10). To that end, we did not find a suitable 
protocol for coupling a ligand to the surface of the nanoparticles in the literature. 
Thus, we generated a protocol that relies on a click reaction, a copper-catalysed 
reaction between alkyne and azide. The protocol is versatile, where the dye can be 
substituted by other ligands, such as aptamers, peptides or antibodies. However, the 
position and orientation of the ligands on the surface and stability of the new-labelled 
nanoparticles will require an extensive investigation. 
We found that our in-house labelling protocol did not affect the nanoparticles 
physical parameters, and both the diameter and the polydispersity index (PDI) did 
not change significantly after the addition of the NIR dye to the nanoparticles ( Fig 4-
7). However, as we have anticipated the surface charge became slightly negative, 
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given the fact that SulfoCyanine7.5 carries a negative charge (Fig 4-7C). The 
change in the surface charge was also in accordance with equivalent studies, where 
the addition of negatively charged ligands increased the negative charge of 
liposomes (Leung, Tam et al. 2014, Weinstein, Toker et al. 2016). Nevertheless, our 
technique might be superior to other approaches. That is because the click reaction 
did not change the nanoparticles diameter more than ±5 nm, while a previously 
published technique relied on thiol-maleimide crosslinking protocol led to a twofold 
increase in the size of the lipid nanoparticles (Weinstein, Toker et al. 2016). For this 
reason, we speculate that the structure of the nanoparticles remained unchanged, 
which is crucial to keep the cellular uptake efficiency (Viger-Gravel, Schantz et al. 
2018). 
The use of SulfoCyanine7.5 was strategic in which it allowed the in vivo imaging. 
However, we were not able to quantify the amount of coupled molecules on the 
surface of the nanoparticles because the dye spectra were beyond the detection limit 
of the microplate reader. It was also not feasible to measure the in vitro or in vivo 
uptake of the labelled nanoparticles for the same reason. Hence, we recommend 
replacing SulfoCyanine7.5 with other dye that is suitable for in vivo imaging, but also 
compatible with the in vitro assays such as flow cytometry and optical density 
measurements. 
Although we were not able to quantify the NIR dye molecules after labelling, we 
included several control conditions to assure successful incorporation of the dye onto 
the lipid nanoparticle. For instance, elimination of the ascorbic acid or copper from 
the reaction mixture led to less association of the SulfoCyanine7.5 with the 
nanoparticles. This finding was based on observing the changes in the LNP/siRNA 
colour from pink (due to the presence of the Dil dye) into dark green (the colour of 
SulfoCyanine7.5) after performing the click reaction and purification. Furthermore, 
the labelled nanoparticles were dialysed overnight using a membrane with 3.5 kDa 
cut-off that is three times larger than the molecular weight of SulfoCyanine7.5 
(MWCO~ 1.1 kDa). Thus, it is fair to claim that the labelled nanoparticles contained 
insignificant traces of the free dye. However, due to the hydrophobic properties of 
SulfoCyanine7.5, some molecules might have been intercalated into the lipid layers 
rather than being chemically clicked to the surface. We suggest further physical and 
chemical characterisation to quantify the amount of chemically-bound 
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6.5.3 Pharmacokinetics and biodistribution of LNP/siRNA  
We studied the biodistribution of the nanoparticles after systemic administration (Fig 
4-8). It was not surprising to detect the nanoparticles in the liver two hours after 
intravenous injection, given that the liver is a highly perfused organ with fenestrated 
endothelium making it the first reservoir to any particle larger than 50 nm in diameter 
(Zimmermann, Lee et al. 2006). It was reported that lipid nanoparticles acquire 
positive charge after interaction with apolipoproteins, which enhances the uptake by 
hepatocytes (Bogorad, Yin et al. 2014). Gene knockdown by siRNA encapsulated 
into nanoparticles is successfully achieved in several animal models including non-
human primates (Akinc, Goldberg et al. 2009, Love, Mahon et al. 2010, Maier, 
Jayaraman et al. 2013). Furthermore, we detected the NIR dye fluorescence signal 
in the liver five days post-administration (Fig 4-8). Several PK studies in rodent have 
shown that the liver can retain siRNA encapsulated into cholesterol-enriched 
liposomes up to ten days after intravenous injection (Semple, Akinc et al. 2010, 
Novobrantseva, Borodovsky et al. 2012). Additionally, the liver could entrap 
hydrophobic fluorescence dyes up to one month after uptake (Akinc, Goldberg et al. 
2009). For these reasons, our IVIS imaging cannot assure that the detected 
fluorescence signal is coming from intact nanoparticles or from the SulfoCyanine7.5 
molecules that might have been released from the labelled nanoparticles. 
To increase the circulation of the nanoparticles we aimed in the second PK study to 
saturate the liver by pre-treatment with unlabelled nanoparticles, but we did not see 
any change in labelled nanoparticles biodistribution (Fig 4-7 & 4-8). There might be 
several explanations why the liver did not absorb less labelled nanoparticles in that 
experiment, such as high liver cells turnover, and uncompleted saturation of the liver 
with the unlabelled lipid nanoparticles. 
The nanoparticles were detected in the tumours, and we showed the overlap 
between the bioluminescence of leukaemic cells and the NIR fluorescence of the 
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nanoparticles. Moreover, our PK and biodistribution studies showed that the lipid 
nanoparticles were widely distributed throughout the body, and enriched in the 
haematological tissues and relevant leukaemic compartments such as the liver, 
spleen, vertebral column, bones, and brain (Fig 4-9 & 4-10). However, the IVIS 
imaging alone cannot confirm the exact localisation of the nanoparticles in the 
tumour. That is because the tumours are vascular with complex extracellular matrix 
assuring the blood supply (Kalluri 2016, De Palma, Biziato et al. 2017). Moreover, 
we cannot claim that the nanoparticles were accumulated within the bone tissue, as 
both the bone marrow and periosteum membrane are profusely vascularised 
(Saulacic, Schaller et al. 2012, Saulacic, Schaller et al. 2013). Even so, in contrast 
with the periosteal capillary system, the bone marrow is supplied by extensively 
specialised sinusoidal and fenestrated capillaries which are essential for its 
haematopoietic functions. Therefore, it is fair to assume that at least a significant part 
of the signal detected in the bones might have come from accumulation of the 
nanoparticles in the bone marrow. 
Novel lipid nanoparticles have prolonged first phase elimination up to 3 days, and the 
lipid metabolites are detectable up to 28 days in the plasma (Christensen, Litherland 
et al. 2014). This favourable pharmacokinetic profile ensure that the nanoparticle can 
reach the leukaemic malignant niche. On the other hand, the enhanced permeation 
and retention of the nanoparticles in the reticuloendothelial system for a prolonged 
period of time might cause in vivo toxicity (Juliano, Bauman et al. 2009). For these 
reasons, we recommend performing dose-escalation experiments to study the 
stability and toxicity of the nanoparticles. Moreover, the pharmacokinetic and 
biodistribution of the nanoparticles alone do not confirm the efficacy of the delivery 
system. That is because the localisation of the nanoparticles in a specific site might 
not correlate with the efficient release of the siRNA (Wei, Jones et al. 2011). We 
advise performing pharmacokinetic experiments to establish the relationship 
between the gene knockdown and the dose regimen in the relevant leukaemic 






6.6 LNP/siRNA has on-target effect on leukaemic cells in vivo  
Having confirmed the pharmacokinetics and biodistribution of the nanoparticles, the 
next question for our in vivo experiments was: can the nanoparticles achieve 
RUNX1/ETO silencing in vivo, and what are the consequences? We showed a 
specific slicing of RUNX1/ETO by siRNA in t(8;21) in vivo model. The concept of 
using nanoparticles to target fusion genes in vivo was experimented previously by 
silencing TCF3/PBX1 in a murine model of t(1;19) childhood acute lymphoblastic 
leukaemia. However, about 17-fold higher dose of the nanoparticles was used to 
achieve a comparable knockdown to RUNX/ETO (Jyotsana, Sharma et al. 2018). 
This may suggest that RUNX1/ETO is more prone to siRNA silencing than previously 
investigated fusion genes with potential clinical implications.  
The relationship between pharmacokinetics and pharmacodynamics determines the 
clinical suitability of the drug. Ideally, the nanoparticles are expected to achieve a 
maximal therapeutic effect with minimal dosage. We rationalised that the therapeutic 
profile of the siRNA is assessed by the measured RUNX1/TEO knockdown and the 
half-life of the pharmacological effect. We found that despite the difference in the 
dosing schedules, one additional dose of the nanoparticles provided a more 
significant reduction in RUNX1/ETO mRNA (Fig 4-11), suggesting that the effect is 
dose-dependent. However, the enhanced knockdown, we have observed, could also 
be due to the discrepancy in the leukaemic burden between the two experiments.  
The reduction in RUNX1/ETO protein level was comparable between the mice, 
which suggests that the pharmacological effect was similar regardless of the dosing 
schedule, or the time of the analysis (endpoint by culling the mice) (Fig 3-12). The 
consistent reduction in RUNX1/ETO between the mice also suggests that the half-life 
of the RISC-siRNA complex was similar. Arguably, given that RUNX1/ETO 
knockdown impairs proliferation, the RISC-siRNA complex should not be diluted over 
time, as cells do not proliferate. However, in our experiments, the nanoparticle 
treatment did not reduce the leukaemic burden (Fig 4-13 & 4-14). Therefore, mice 
culled 10 days after treatment should have more leukaemic cells, and consequently, 
the intracellular content of the siRNA is diluted with cell doubling. This implies that 
continues dosing in these experiments was unlikely to cause more gene knockdown, 
otherwise it would have been expected to find less RUNX1/ETO knockdown in the 
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mice culled after 10 days of treatment, but this was not the case. We explain the 
comparable knockdown in vivo by the enhanced stability and efficient recycling of the 
RISC-siRNA complex. The 2’-sugar modifications of the siRNA were supposed to 
prolong the siRNA duplex stability. The 3’-end antisense modifications also meant to 
enhance the selectivity and reduce the off-target effect (Morrissey, Blanchard et al. 
2005).  Therefore, we surmise that the modified siRNA intrinsic properties enhanced 
RUNX1/ETO knockdown in vivo. 
Pharmacodynamics studies in rat have shown that 500 siRNA molecules per cells 
are adequate to achieve 50% gene knockdown in the hepatocytes, 10 days after 
systemic application of the nanoparticles (Landesman, Svrzikapa et al. 2010). Due to 
the time constraints and viability of the nanoparticles, it was not possible to perform 
pharmacodynamics studies. We recommend utilising the nanoparticles platform to 
determine, in a clinically relevant setting in vivo, the optimal dose regimen needed to 
achieve potent RUNX1/ETO knockdown. We suggest collecting plasma samples and 
relevant leukaemic tissues at several time points after applying the nanoparticles 
treatment. We also advise performing dose-escalation treatment in vivo followed by 
isolation of cells from the bone marrow and RISC pulldown assays to quantify the 
antisense of siRUNX1/ETO by qRT-PCR. The simultaneous quantification of 
RUNX1/ETO expressing and the siRNA in the leukaemic cells will determine the 
therapeutic profiles of our siRNA and nanoparticles.  
 
6.7 RUNX1/ETO repression in vivo enhances the survival 
Previous work in our lab has shown that transient depletion of RUNX1/ETO in vitro 
by electroporation significantly prolongs the survival of transplanted mice from 64 to 
90 days (p<0.02) (Soria, Tussiwand et al. 2009). That study provided the concept 
that interfering with RUNX1/ETO expression might, be therapeutically beneficial, but 
the delivery method was unsuitable for clinical implementation. In this study, we 
implemented a clinically relevant approach to exploit the therapeutic potential of 
repressing RUINX1/ETO. Indeed, the siRNA-mediated knockdown in vivo 
significantly increased the median survival of mice from 44 to 80 days (p<0.0001) 
(Fig 4-18). Our result highlights the therapeutic potential of targeting RUNX1/ETO in 
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t(8;21) AML and presents a versatile siRNA delivery system that has a clinical 
relevance. 
siRNA-mediated knockdown of leukaemic fusion genes in vivo, such as TCF3/PBX1 
in t(1;19) or BCR/ABL in t(9;22) increase the survival of leukaemic mice (Jyotsana, 
Sharma et al. 2015, Jyotsana, Sharma et al. 2018). Moreover, knockdown of proto-
oncogenes that control proliferation, such as CCND1 in t(11;14) B-ALL reduces cell 
proliferation in vivo and enhance the survival (Weinstein, Toker et al. 2016). We 
have shown for the first time that direct repression of RUNX1ETO in vivo suppressed 
leukaemia expansion in a xenotransplantation model of t(8;21) AML, but it did not 
eliminate the leukaemic cells as all mice developed leukaemia at the end. 
 
 
6.8 The consequences of RUNX1/ETO knockdown in vivo 
In vitro studies showed that RUNX1/ETO knockdown inhibits proliferation, induces 
cells cycle arrest and triggers senescence. The knockdown also dysregulates the 
leukaemic-specific transcriptional network by reducing the expression of self-renewal 
genes and activating the C/EBPα myeloid differentiation programme (Ptasinska, Assi 
et al. 2012, Ptasinska, Assi et al. 2014, Loke, Assi et al. 2017, Martinez-Soria 2018). 
However, due to the difficulty in achieving transient depletion of RUNX1/ETO in vivo, 
it has never been investigated that whether knocking down the fusion in vivo would 
recapitulate the in vitro effects. Our nanoparticle delivery system did not only prove 
that RUNX1/ETO depletion in vivo enhances the survival of leukaemic mice, but it 
also provided the opportunity to study the effect of modulating RUNX1/ETO 
expression under a complex microenvironment in vivo. 
 
6.8.1 RUNX1/ETO knockdown dysregulates t(8;21) transcriptional network 
The N-terminus of RUNX1/ETO shares with RUNX1 the RHD domain that controls 
binding to DNA. Former studies in our group have demonstrated that RUNX1 and 
RUNX1/ETO could activate gene expression by binding to the promotor or TSS of 
target genes. On the other hand, RUNX1/ETO can also repress transcription by the 
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ETO component of the fusion, which recruits histone deacetylases (Ptasinska, Assi 
et al. 2012, Ptasinska, Assi et al. 2014). Our in vivo knockdown experiments showed 
that repressing RUNX1/ETO alters the expression of its target genes such as 
CCND2, TERT, CD34, ANGPT1 and LAPTM5 in a similar manner to the in vitro 
knockdown (Fig 4-11, 4-12 & 4-23). Thus, the in vivo targeting of RUNX1/ETO might 
cause similar transcriptomic changes to those observed in vitro.  
Principal component (PC) analysis of the RNA-seq data showed that the control 
mice cluster next to each other while the RUXN1/ETO targeted mice are separate 
apart from each other and from the control (Fig 4-24). This affirms that RUNX1/ETO 
knockdown has an impact on t(8;21) transcriptome in vivo. The RUNX1/ETO 
targeted mice were culled at different time points, which might explain why they 
scored differently in the PC analysis. Despite having only two mice in each group, 
making the statistical analysis inadequate, the RNA-seq data revealed some parts of 
the changes in RUNX1/ETO transcriptional network. A closer look into the RNA-seq 
most dysregulated genes we can propose that the repression of RUNX1/ETO in vivo 
downregulates the self-renewal genes and impairs stemness, and triggers a myeloid 
differentiation programme assisted by a pro-inflammatory response and senescence. 
RUNX1/ETO knockdown in vivo recapitulated the in vitro knockdown in initiating the 
myeloid differentiation and repression of self-renewal programmes. However, there 
was some discrepancy in the expression of some genes in comparison with the in 
vitro knockdown. For instance, the in vivo knockdown did not upregulate CEBPA, but 
we found substantial changes in C/EBPα direct target genes. Hence, the transit 
repression of RUNX1/ETO might have modulated CEBPA expression temporarily but 
sufficiently to disturb C/EBPα transcriptional network. Further studies are needed to 
confirm this hypothesis, such as ChIP-Seq. Moreover, cell growth in vivo is affected 
by the microenvironment in which leukaemic niche promotes survival (Schmidt and 
Carmeliet 2011). The complex signalling pathways in vivo might have contributed to 
the differences between the in vitro and in vivo dysregulated genes, justifying our 
observation in the RNA-seq. 
Furthermore, several microRNAs are also involved in t(8;21) leukaemogenesis 
(Jongen-Lavrencic, Sun et al. 2008, Li, Lu et al. 2008). In RUNX1/ETO-driven 
leukaemia, the tumour repressors microRNAs, such as miR-9, miR-193a, and miR-
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223 are downregulated, and the proliferation inducer miR-126 is upregulated (Fazi, 
Racanicchi et al. 2007, Li, Lu et al. 2008, Li, Gao et al. 2013, Emmrich, Katsman-
Kuipers et al. 2014). We observed changes in the expression of several microRNAs 
that are known to be regulated by RUNX1/ETO. For instance, RUNX1/ETO 
knockdown in vivo reproduced the previously described downregulation of miR-23a 
and miR-27a expression. The repression of RUNX1/ETO also upregulated miR-142 
which has restricted expression in the haematopoietic system and regulates RUNX1 
expression in HSCs (Sun, Varambally et al. 2011). The transcription factor PU.1 
stringently controls miR-142 expression by coordinating RUNX1, C/EBPβ and CBFβ 
binding to its promotor (Sun, Sun et al. 2013). Therefore, the upregulation of miR-
142 can provide compelling evidence for retrieving RUNX1 and PU.1 transcriptional 
activity upon RUNX1/ETO knockdown.   
Taken together, these findings confirm the specific-silencing of RUNX1/ETO after the 
nanoparticles treatment and present examples of the complex regulatory network of 
RUNX1/ETO in t(8;12) AML. 
 
6.8.2. RUNX1/ETO knockdown induces senescent and cytostatic phenotype      
We have previously proposed that the in vitro knockdown of RUNX1/ETO induces 
cellular senescence by RB1 dephosphorylation. In line with the in vitro experiments, 
we observed induction of senescence after depleting RUNX1/ETO in vivo. Moreover, 
we also found a significant decrease in CCND2 and TERT protein level (Fig 4-12), 
which were shown to predispose cellular senescence following in vitro knockdown 
(Fig 4-16). Therefore, we surmise that senescence induction in vitro and in vivo after 
RUNX1/ETO knockdown follows a similar mechanism. Nevertheless, further 
experiments are required to support this hypothesis, such as cell cycle profiling and 
assessment of RB1 phosphorylation status by Western blotting or flow cytometry. 
Senescent cells are characterised by a unique secretory signature, known as the 
senescence-associated secretory phenotype (SASP), which is regulated by the 
transcription factors nuclear factor (NF-κB) (Coppe, Desprez et al. 2010, Chien, 
Scuoppo et al. 2011). The SASP factors include interleukins (IL-6, IL-7, IL-1α/β, IL-
13 and IL-15), chemokines (IL-8, HCC-4, MIP-1a and MCP-2/4), growth factors 
(HGF, VEGF; SCF and SDF-1), proteases (NMP-1/3/10/14, TIMP-2 and PAI-1), and 
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soluble or shed receptors or ligands (ICAM-1/3, OPG and EGF-R). The RNA-seq 
showed upregulation of the genes coding these inflammatory cytokines and growth 
factors. Moreover, analysis of RNA-seq revealed a strong pro-inflammatory response 
by NF-κB pathway (Fig 4-25). Specifically, we found upregulation in the expression 
of NFKB1 and a set of genes known to activate NF-κB pathway, including TNF and 
several members of the TNF receptor superfamily (Hayden and Ghosh 2014, 
Munoz-Espin and Serrano 2014). We propose that RUNX1/ETO knockdown in vivo 
provides the SASP-associated pro-inflammatory signature that supports the 
cytostatic phenotype. This finding has a significant clinical relevance since it was 
shown recently that the senescence inflammatory microenvironment could be 
effectively targeted for the eradication of senescent cells and subsequently avoiding 
the tissue damage and dysfunction following chemotherapies (Xu, Pirtskhalava et al. 
2018). 
The translocation of the High Mobility Group Box-1 (HMGB1) protein from the 
nucleus to the cytoplasm is a senescence marker (Yamada and Maruyama 2007, 
Kumar, Singal et al. 2008). HMGB1 is an inflammatory mediator that controls the 
release of SASP cytokines (Davalos, Kawahara et al. 2013). Therefore, we suggest 
performing immunofluorescence staining to investigate the changes in HMGB1 
expression in the nucleus, which supports our findings. 
Senescent cells are characterised by a decrease in LMNB1 expression and changes 
in the nuclear lamina (Shimi, Butin-Israeli et al. 2011, Freund, Laberge et al. 2012). 
In our in vivo experiments, RUNX1/ETO knockdown downregulated LMNB2 while 
LMNB1 remained unchanged. One explanation of this observation could be 
attributed to the mutated P53 in Kasumi-1 cells, as the activation of P53 is required 
for deregulating LMNB1 (Sablina, Budanov et al. 2005, Shimi, Butin-Israeli et al. 
2011). Moreover, the induction of senescence by LMNB1 downregulation is 
independent of telomere dysfunction, but telomere shortening in t(8;21) cell lines 
leads to senescence (Martinez, Drescher et al. 2004, Shimi, Butin-Israeli et al. 2011). 
It is possible that the knockdown of RUNX1/ETO in vivo caused nuclear lamina 
aberrations by reducing LMNB2 expression. Further measurements are required to 
support this hypothesis, such as quantification of the nuclear Laminin B1 and B2 
after RUNX1/ETO knockdown. 
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Furthermore, overexpression of the tumour-suppressor protein p16INK4a, coded by 
CDKN2A gene (cyclin-dependent kinase inhibitor 2A), is a senescence marker in 
cells do develop SASP (Michaloglou, Vredeveld et al. 2005). Our RNA-seq data did 
not show any changes in CDKN2A expression, which complements the literature in 
which only the cells that harbour dysfunctional P53 secrete SASP (Coppe, Patil et al. 
2008, Rodier, Coppe et al. 2009). We performed the in vivo known experiments on 
Kasumi-1 cells, which carries mutated P53 and resembles the SASP-induced 
senescence. However, the vast majority of t(8;21) AML patients have wild type P53. 
Therefore, the knockdown of RUNX1/ETO in vivo on PDXs with functional P53 may 
upregulate p16INK4a and induce senescence. Thus, we suggest investigating p16INK4a 
expression when performing RUNX1/ETO knockdown on PDXs in future 
experiments. 
Overall, the induction of cellular senescence in vivo upon RUNX1/ETO depletion 
may provide a possible therapeutic avenue that prevents relapse and tissue 
dysfunction. Recent studies support the concept of ‘’Achilles’ heel of senescent 
cells’’ or senolytics which are potent drug combinations such as (dasatinib and 
quercetin) or potent siRNAs against proto-oncogenes such as CDKN1A or 
SERPINB2. These senolytics, under specific conditions, can eliminate the senescent 
cells and alleviate the physical dysfunction (Zhu, Tchkonia et al. 2015, Xu, 
Pirtskhalava et al. 2018).  
 
6.8.3. RUNX1/ETO knockdown affects angiogenesis 
RUNX1/ETO knockdown in vitro reduced ANGPT1 mRNA in Kasumi-1, primary 
patient cells and PDXs (Fig 3-20F, 3-27C, 3-28 & 3-29). Our in vivo experiments 
have shown that the expression level of ANGPT1 and ANGPT2 were downregulated 
after RUNX1/ETO knockdown (Fig 4-11A). Pathway analysis of the RNA-seq data 
has also revealed a signature of dysregulated angiogenesis (Fig 4-26). Furthermore, 
we have observed the formation of leaky vessels in tumours collected from the 
RUNX1/ETO targeted mice (Fig 4-13D). We hypothesise that this could be due to 
dysregulated vascular angiogenesis (Fukuhara, Sako et al. 2009, Wu, Lee et al. 
2015). The human ANGPT1 effectively binds murine Tie2 (endothelium-specific 
receptor tyrosine kinase 2) surface receptor, which mediates vascular maintenance 
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and remodelling (Davis, Aldrich et al. 1996). Therefore, reduction in ANGPT1 
expression might reduce the amount of secreted ANGPT1 and consequently impair 
the ANGPT1-Tie2 interaction.    
Angiogenesis via ANGPT1-TIE2 crosstalk has been shown to be critical for 
haematopoietic lineage specification as well as HSCs activity and differentiation 
(Mendelson and Frenette 2014). On the other hand, leukaemic stem cells control 
neoangiogenesis by modulating the levels of secreted ANGPT1/2 and VEGF ligands 
and consequently affect the sinusoidal endothelium integrity and perivascular niche 
(de Bont, Rosati et al. 2001, Zhou, Ding et al. 2015, Itkin, Gur-Cohen et al. 2016, 
Asada 2018). The clinical implication of neoangiogenesis is that leukaemic stem 
cells can escape the toxic bone marrow environment caused by different 
chemotherapies. Thus, it is not surprising to find increasing evidences about the 
effectiveness of antiangiogenic therapeutics against leukaemia (Schmidt and 
Carmeliet 2011, Ikushima, Arai et al. 2013, Harney, Karagiannis et al. 2017). The 
infiltration of the bone marrow with leukaemic cells and induction of angiogenesis 
have been shown in several haematological malignancies including AML, ALL, CML, 
and myelodysplastic syndromes (Perez-Atayde, Sallan et al. 1997, Lundberg, Lerner 
et al. 1998, Aguayo, Kantarjian et al. 2000, Hussong, Rodgers et al. 2000). It has 
also been shown that blocking the ANGPT1-Tie2 interaction between the primary 
human AML cells and murine fibroblasts or osteoblasts effectively reduces AML cell 
expansion (Reikvam, Hatfield et al. 2010). In CML, BCR/ABL upregulates VEGF 
expression, and it has been proposed that pharmacological inhibition of the fusion 
protein reduces VEGF secretion, impairs angiogenesis and inhibits proliferation 
(Dias, Shmelkov et al. 2002, Mayerhofer, Valent et al. 2002). It can be speculated 
that similar to BCR/ABL, the depletion of RUNX1/ETO might dysregulate 
angiogenesis with potential therapeutic benefits.  
Furthermore, Leupaxin (LPXN) is a member of the paxillin protein family was found 
upregulated after RUNX1/ETO knockdown. It was shown in bladder cancer that the 
overexpression of LPXN is associated with dysregulated angiogenesis and 
enhanced proliferation (Regha, Assi et al. 2015). Several studies have demonstrated 
that overexpression of LPXN induces high expression of S100P and S100A4 
(members of the S100 calcium-binding protein family), and secretion of S100P and 
S100A4 dysregulates angiogenesis (Semov, Moreno et al. 2005, Hernandez, Padilla 
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et al. 2013). The knockdown of RUNX1/ETO in vivo also upregulated both S100P 
and S00A4 expressions. Therefore, we propose that overexpression of LPXN, 
S100P, and S100A4 may affect angiogenesis in t(8;21) AML following RUNX1/ETO 
knockdown. 
 
6.8.4 RUNX1/ETO knockdown impairs proliferation  
We have shown in this thesis that RUNX1/ETO knockdown in vitro inhibits 
proliferation, but this effect was less dominant in vivo. Despite having on-target 
effects in three independent in vivo experiments, RUNX1/ETO knockdown did not 
reduce proliferation (Fig 4-13A-C & 4-14). We anticipated that the repression of 
RUNX1/ETO in a well-established leukaemic mass might not reduce proliferation 
due to the complex leukaemic niche which supports proliferation by cell to cell 
contact and secretion of stimulatory growth factors and cytokines (Schmidt and 
Carmeliet 2011). Indeed, upon removal from the niche support into a simple 
intercellular communication context, the in vivo knockdown showed a significant 
effect on proliferation ex vivo (Fig 4-15). 
RUNX1/ETO knockdown in vitro and in vivo was associated with a marked reduction 
in the stem cell gene CD34 at the transcript and protein levels (Fig 4-15). 
Downregulation of CD34 in haematopoietic stem cells precedes differentiation in 
which the cells make less interaction with the haematopoietic niche and gain 
enhanced migration potential (Salati, Zini et al. 2008). It is possible that the 
aforementioned dysregulated neoangiogenesis and improved migration capability of 
Kasumi-1 cells have promoted the proliferation, which can justify our observation that 
the RUNX1/ETO knockdown in vivo did not inhibit leukaemia expansion. 
One aspect of tumorigenesis is the interplay between microRNAs and oncogenes to 
promote cell growth (Iorio and Croce 2012, Iorio and Croce 2017). Several 
microRNAs regulate leukaemic cell proliferation by modulating kinases or 
epigenetically interfering with the expression of key onto-oncogenes. For instance, it 
has been shown that RUNX1/ETO represses miR-193a by displacing RUNX1 on its 
promotor, while increased expression of miR-193a leads to repression RUNX1/ETO, 
KIT, CCND1, DNMT3A, and HDAC3 and activation of PTEN (Li, Gao et al. 2013). 
Although our RNA-seq did not show a substantial increase in miR-193a expression, 
236 
 
several microRNAs were modulated, including miR-4534 and miR-570. It was shown 
that miR-4534 targets PTEN and represses PTEN/PI3K pathway, while its 
knockdown impairs proliferation and induces G1 cell cycle (Nip, Dar et al. 2016). 
Moreover, overexpression of miR-570 inhibits leukaemic cells proliferation and 
impairs glycolysis in CML cell lines (Zhao, Liu et al. 2017). Therefore, changes in 
miR-4534 and miR-570 might have affected proliferation after RUNX1/ETO 
repression. Nevertheless, microRNAs have lineage-specific expressions, and they 
can act in cis- and trans-regulatory mechanisms. The role of miR-4534 and miR-570 
in t(8;21) AML and their effect on proliferation require further validation.   
 
6.8.5 RUNX1/ETO knockdown impairs leukaemic self-renewal   
We have shown in several independent experiments that RUNX1/ETO knockdown in 
vivo downregulates several genes that play essential roles in self-renewal (Fig 4-11 
& 4-23). We have also confirmed that the disruption of RUNX1/ETO transcriptional 
network in vivo severely impairs clonogenicity (Fig 4-20 & 4-21).  These findings 
were consistent with the replating experiments in vitro as RUNX1/ETO knockdown 
showed a prolonged impact on the colony formation ability (Fig 3-14 & 3-25). 
Therefore, we followed a compelling approach to assess the impact of RUNX1/ETO 
on self-renewal by investigating the re-engraftment capacity of leukaemic cells upon 
the nanoparticles treatment. Our in vivo stringent retransplantation assay showed 
that RUNX1/ETO knockdown resulted in strikingly extended survival of transplanted 
mice (Fig 4-22B).  
Furthermore, although half of the secondary transplanted mice had delayed 
engraftment spans over 7 months, the remaining 50% of the secondary recipients 
did not develop leukaemia or any sign of illness. The therapeutic effect of the 
nanoparticles depends on their pharmacodynamics and spatial location in the 
leukaemic tumours (Christensen, Litherland et al. 2014), this may lead to 
discrepancy in the level of RUNX1/ETO knockdown. For instance, cells located near 
the surface of the tumour might have had stronger RUNX1/ETO knockdown from 




In order for AML to engraft, a minimal population of leukaemic stem cells is needed, 
known as the leukaemia-initiating cells or the LICs (Bonnet and Dick 1997, Blair, 
Hogge et al. 1998). These cells are characteristically resistant to chemotherapy and 
result in relapse. The LIC number inversely correlates with leukaemia propagation 
and is conventionally determined by transplanting a limiting dilution of leukaemic 
cells followed by assessing the mice survival. Importantly, the LIC cells are 
exclusively capable of propagating leukaemia in secondary receipts (Taussig, 
Vargaftig et al. 2010). Therefore, we suggest that RUNX1/ETO knockdown 
significantly reduced the LICs number of Kasumi-1 cells. Based on our finding in the 
re-engraftment assay, ex vivo colony formation, and the in vitro replating 
experiments, we propose that RUNX1/ETO is critical for LICs maintenance and 
consequently targeting t(8;12) cells with nanoparticles as a second-line treatment 
might be potentially an effective therapy to prevent relapse.    
Over 70% of AML patients have overexpression of CITED2, which is critically 
involved in HSCs maintenance and affects pluripotency by controlling the octamer-
binding transcription factor (OCT4) (Li, Ramirez-Bergeron et al. 2012, Schepers, 
Korthuis et al. 2013, Kranc, Oliveira et al. 2015). It has been shown that leukaemic 
stem cells transformation depends on the interplay between overexpression of 
CITED2 and low level of the myeloid transcription factor PU.1. The ectopic 
expression of CITED2 in normal CD34+ progenitors enhances clonogenicity and 
accelerates engraftment in immunodeficient hosts (Schepers, Korthuis et al. 2015). 
Our RNA-seq have revealed downregulation of CITED2 expression upon 
RUNX1/ETO knockdown in vivo. Moreover, RUNX1 mutations require a high 
expression of CITED2 to impair myeloid differentiation and enhance self-renewal 
(Gerritsen, Tijchon et al. 2016). Hence, it can be assumed that downregulation of 
CITED2 gene contributed to the prolonged survival of the secondary transplant mice 
and the severe reduction in clonogenicity. We propose that RUNX1/ETO 
leukaemogenesis requires a consecutive expression of CITED2 to enhance the 






6.8.6 RUNX1/ETO knockdown in vivo triggers myeloid differentiation   
Previous work in our group have revealed the molecular mechanism in which 
RUNX1/ETO competes with RUNX1 binding to DNA and causes a differentiation 
block on the myeloid lineage by repressing CEBPA (Ptasinska, Assi et al. 2014). The 
knockdown of RUNX1/ETO in vivo led to changes in genes that are known to induce 
myeloid differentiation as revealed by the RNA-seq, such as SMAD3, Src kinases, 
S100 family, GPRIN3 and others. Most of these upregulated genes are known to 
control signal transduction, extracellular matrix remodelling and inhibition of 
proliferation by cytokine binding. Although we did not observe an apparent myeloid 
phenotype upon the lipid nanoparticles treatment, cells retrieved from the re-
engraftment experiments manifested a mature phenotype (Fig 4-23).  
Previous work has shown showed that in vitro knockdown of RUNX1/ETO followed 
by TGF-β1 and vitamin D3 treatment leads to growth inhibition and myeloid 
differentiation (Heidenreich, Krauter et al. 2003). KEGG pathway analysis of RNA-
seq data revealed fourfold enrichment in TGF-β signalling upon RUNX1/ETO 
knockdown in vivo and 16% of the canonical pathways were downstream of TGF-β 
(Fig 4-25 & 4-26). Furthermore, we have observed in the RNA-seq upregulation of 
SMAD3 expression, which is known to be the activator of TGF-β1 signalling. On the 
other hand, it was shown that RUNX1/ETO represses SMAD3 and hence 
deactivates TGF-β1-mediated differentiation (Jakubowiak, Pouponnot et al. 2000). In 
our in vivo experiments, we did not apply TGF-β1 treatment after using the 
nanoparticles, but we found that 15% of the activated cytokine-receptor signalling 
were related to the TGF-β family (Fig 4-26). Therefore, it is possible that the murine 
Tgf-β1 provided the substrate for inducing differentiation following the priming of 
TGF-β1 signalling pathway by SMAD3 overexpression. 
The S100 calcium-binding protein family are expressed on the surface of mature 
myocytes. Members of the S100 family control proliferation, differentiation, 
angiogenesis, metastasis, and immune stimulation. The bone marrow CD11b+ cells 
express high levels of S100A8/9, which induce the serum amyloid A3 (SAA3) 
expression and secretion followed by TLR-6 activation. We found upregulation of 
S100A8, S100A9 and TLR-6 expression following RUNX1/ETO knockdown. Several 
studies suggested that overexpression of SAA3 and TLR-6 promotes a pro-
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inflammatory response by NF-κB signalling (Hiratsuka, Watanabe et al. 2008, 
Shimizu, Kida et al. 2008, Liu, Kosaka et al. 2013). Furthermore, we also found 
upregulation of S100A16 expression, which was shown to promote differentiation of 
oral squamous cell carcinoma (Sapkota, Bruland et al. 2015). However, the role of 
S100A16 is not fully understood as its overexpression in cancers has been shown to 
be associated with enhanced metastasis and poor prognoses in breast cancer and 
non-small cell lung adenocarcinoma (Tanaka, Ichikawa-Tomikawa et al. 2015, Chen, 
Luo et al. 2018). On the other hand, S100A16 repression has been found to reduce 
the level of the pluripotent markers Oct4 and Nanog (Tomiyama, Ikeda et al. 2018). 
Further validation of the S100 family members is required to elucidate the possible 
mechanisms of myeloid differentiation upon RUNX1/ETO repression. 
Furthermore, several genes from the Src family kinases such as HCK, FYN, and 
FGR were upregulated in the RNA-seq. These kinases are involved in serval cell 
signalling and signal transduction pathways, including cell migration and adhesion 
(Corey, Dombrosky-Ferlan et al. 1998, Harder, Parsons et al. 2001). Some Src 
family members have a lineage-restricted expression such as HCK which is 
overexpressed in monocytes and granulocytes. Both HCK and FGR are potent 
inducers of G-CSF-dependent proliferation (Santini, Scappini et al. 2003, Mermel, 
McLemore et al. 2006). Moreover, Src kinases are negative regulators of myeloid 
differentiation (Miranda and Johnson 2007, Miranda, Redner et al. 2007, Jones, 
Wang et al. 2009). Taken together, the overexpression of Src family members upon 
the in vivo RUNX1/ETO depletion might have contributed to mature myeloid 
phenotype that were observed in our experiments.  
The repression of RUNX1/ETO in vivo led to overexpression of 9 genes belonging to 
the C/EBPα-activation signature upon granulocytic differentiation (Liss, Ooi et al. 
2014). RNA-seq showed upregulation of IL18RAP, EPAS1, SAT1, ACSL1, 
FAM129A, TRIB3, CCL3, TNFRSF10B, and TNFRSF10D. Some of the 
aforementioned genes are involved in signal transduction, immunostimulation and 
metastasises. For instance, activation of IL-18 was found to increase CD11b 
expression and enhance differentiation (Wyman, Dinarello et al. 2002). Although the 
RNA-seq did not show any changes in CEBPA expression upon RUNX1/ETO 
knockdown, the CEBPA mRNA level was significantly upregulated in the secondary 
transplant, as shown by qRT-PCR (Fig 4-19). This finding might indicate that a 
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modest upregulation of CEBPA expression could be sufficient to trigger the 
differentiation programme.  
Interestingly, we found several interleukins modulated upon RUNX1/ETO repression 
in vivo, such as IL1, IL4, and IL18. The activation of these interleukins indicates self-
renewal repression and enhanced differentiation, which might provide a window for 
therapeutic interventions. It has been reported that HSCs undergo a rapid 
transcriptional remodelling upon PU.1 induction of IL-1β signalling in which the 
stemness is severely impaired, and HSCs are forced to differentiate. Arguably, 
myeloid differentiation requires a low expression of PU.1 (Dahl, Walsh et al. 2003, 
Laslo, Spooner et al. 2006, Dakic, Wu et al. 2007). However, IL-1β signalling has 
been shown to be reversible and exclusive to chronic stress or induction of pro-
inflammatory signalling by NF-κB or TLRs signals, where PU.1 activation proceeded 
the kinases induction (Sullivan, Porter et al. 2014, Pietras, Mirantes-Barbeito et al. 
2016). Furthermore, IL4R expression was found upregulated in the RNA-seq. The 
signalling pathway of  IL-4 predisposes myeloid differentiation (Feldman, Ruhl et al. 
1991), and inhibits G-CSF-dependant proliferation of myeloid progenitors 
(Woytschak, Keller et al. 2016). Recent studies suggested that selective antibodies 
and cytokines, which can inhibit IL-4 signalling might have efficacy in several 
haematological cancers (Woytschak, Keller et al. 2016). Our data suggest the 
induction of immune-specific antigens upon RUNX1/ETO knockdown, which may be 
beneficial for AML patients.   
Given that RUNX1/ETO regulates several microRNA clusters in AML, it was not 
surprising to find modulation of miR-23-24-27a cluster upon treatment with 
nanoparticles in vivo. Each microRNA form this cluster has a distinct function. For 
instance, miR-23a enhances proliferation and blocks myeloid differentiation (Zaidi, 
Dowdy et al. 2009, Chhabra, Dubey et al. 2010, Ptasinska, Assi et al. 2012). 
Moreover, miR-23a is one of the most potent regulators of haematopoiesis and its 
downregulation primes progenitors to myeloid lineage commitment (Kurkewich, 
Hansen et al. 2017). Our RNA-seq showed that the knockdown of RUNX1/ETO in 
vivo downregulated miR-23a expression, which further affirms our observations of 
the mature phenotype. 
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Collectively, the induction of myeloid differentiation upon RUNX1/ETO repression 
might increase the susceptibility of t(8;21) leukaemia to differentiation therapy or 
selective cytokines, providing potential therapeutic benefits for t(8;21) AML patients.  
 
6.9 Possible combinational therapies with RUNX1/ETO repression  
Several lines of evidence obtained during our comprehensive in vitro and in vivo 
experiments indicated that RUNX1/ETO knockdown might open a therapeutic 
window for patients with t(8;21) positive leukaemia. We have showed that inhibition 
of RUNX1/ETO conveys a cytostatic phenotype to leukaemic cells, which is 
characterised by G1 cell cycle arrest followed by senescence. We have also 
demonstrated that the knockdown severely impairs self-renewal and triggers myeloid 
differentiation. Although senescence is recognised as degenerative and irreversible 
cell fate, marked by permanent proliferative arrest (Futreal and Barrett 1991), current 
studies emphasise the adverse effect of senescence-associated secretory cytokines 
that cause local tissue dysfunction (Xu, Pirtskhalava et al. 2018). Searching for a 
therapeutic approach that assures a certain cell death and leukaemia eradication, we 
have investigated combinational treatments with RUNX1/ETO knockdown.  
 
6.9.1 RUNX1/ETO repression in vitro desensitise AML to DNA damage agents  
As a result of silencing RUNX1/ETO, Kasumi-1 cells lost their sensitivity to AraC (Fig 
5-5). Kasumi-1 sensitivity to AraC was in concordance with the literature and 
clinically achievable (Xie, Edwards et al. 2010). The activity of AraC is driven by the 
incorporation of AraC-triphosphate into the elongating DNA strands, resulting in 
chain termination and consequently, inhibition of DNA synthesis (Grant 1998). The 
decreased sensitivity following RUNX1/ETO knockdown can be explained by the 
reduction in the S phase caused by the G1 cell cycle arrest (Kohn, Ruth et al. 2002). 
Recent work in our lab has shown that the pharmacological inhibition of CDK4/6 by 
palbociclib induces cell cycle arrest and senescence implying an effective 
therapeutic option for t(8;21) AML patients (Martinez-Soria 2018). Nucleoside 
analogues, including AraC, are recognised as potent inhibitors and standard 
chemotherapeutics for AML. Moreover, recent clinical studies suggested improving 
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the cytotoxicity by consecutive treatments of AraC followed by differentiation agents, 
such as Vitamin D analogues (Wang, Harrison et al. 2016). Based on these findings, 
we speculate that the inhibition of the cell cycle is not recommended to precede 
AraC treatment in t(8;21) leukaemia. However, repression of RUNX1/ETO following 
the treatment with DNA damage agents might be beneficial to reduce the leukaemic 
burden.  
Although mutations in the DNA damage response genes (DDR) in AML are not as 
common as in other malignancies, such as ovarian or breast cancers, the 
pharmacological inhibition of poly (ADP-ribose) polymerase (PARP) using PARP 
potent inhibitors (such as olaparib or rucaparib) have shown to be effective in t(8;12) 
and t(15;17) AML (Alcalay, Meani et al. 2003, Esposito and So 2014). In parallel, 
RNAi knockdown or pharmacological inhibition of PARP by olaparib causes 
senescence and induces differentiation of Kasumi-1 cells (Esposito, Zhao et al. 
2015). Although we have achieved PARP inhibition, in Kasumi-1 by rucaparib, with 
tenfold lower IC50 in comparison with olaparib (Wang, Cai et al. 2015), the effect 
appeared to be more cytostatic than cytotoxic. The repression of RUNX1/ETO also 
desensitised the cells to PARP inhibition (Fig-6). This could be due to the cytostatic 
phenotype and G1 cell cycle arrest upon RUNX1/ETO repression.  
 
6.9.2 RUNX1/ETO repression enhances BCL2 inhibition in vitro  
Inhibition of the B-cell lymphoma 2 (BCL2) has been implicated as an attractive 
approach to combat chemoresistance in AML. To date, the most selective single 
agent for BCL2 inhibition is ABT-199 (venetoclax). In line with the literature, we 
have observed a consistent activity of venetoclax in t(8;21) cell lines (Fig 5-7) 
(Pan, Hogdal et al. 2014). The combination of RUNX1/ETO knockdown and 
venetoclax treatment in vitro enhanced cytotoxicity to venetoclax by further 
reducing the protein level of MCL1 and BCLXL (Fig 5-11). While depleting 
RUNX1/ETO did not markedly change BCL2 level, we have noticed a slight 
increase in MCL1, suggesting that the increased cell death was possibly due to 
stabilisation of MCL1 level (Raje, Kumar et al. 2005). In vitro and in vivo RNA-seq 
data, as well as Chip-seq, (unpublished data and not included in this thesis) did 
not show any effect of RUNX1/ETO knockdown on MCL1 expression. However, 
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RUNX1/ETO-downstream targets may regulate MCL1 post-translationally. We 
suggest performing immunoprecipitation to reveal the interaction between 
RUNX1/ETO and its targets with BCL2 and MCL1. 
Furthermore, BCL2 inhibitors reduce BIM binding to BCL2, causing cell death (Del 
Gaizo Moore, Brown et al. 2007, Huang and Sinicrope 2008). The repression of 
RUNX1/ETO in vitro resulted in increased BIM protein level, which might have 
contributed to the cytotoxicity of venetoclax. Moreover, HDACs inhibitors which 
activate BIM, enhance BCL2 inhibition lethality (Zhao, Tan et al. 2005). The 
molecular mechanism of HDACs inhibitors and BIM activation was suggested to 
be dependent on acetylation of the forkhead box protein O1 (FOXO1) (Chen, Dai 
et al. 2009, Yang, Zhao et al. 2009). We hypothesise that RUNX1/ETO depletion 
mimics the HDACs inhibitor mechanism in overexpressing BIM. Indeed, RUNX1, 
RUNX1/ETO, and FOXO1 share many loci (Lin, Ptasinska et al. 2017, Loke, Assi 
et al. 2017). Thus, we speculate that the knockdown of RUNX1/ETO possibly 
changes the acetylation of FOXO1 or other direct genes regulated by RUNX1 and 
FOXO1 transcription factors.  
Since we did not further explore the mechanism of BCL2 inhibition in t(8;21) cell 
lines in downstream experiments, we cannot draw a definite conclusion or provide 
substantial evidence of our hypothesis that RUNX1/ETO regulates MCL1 and 
BCL2 indirectly. Further investigation is needed to confirm the changes in BIM 
isoforms and BCLXS protein levels. We suggest quantifying the level of apoptotic 
cells following venetoclax treatment by annexin V staining or caspase assays. 
Induction of apoptosis by caspase-3 and activation and PARP cleavage and 
translocation from the cytoplasm into the nucleus could also be a method to 
confirm the apoptosis using Western blotting.     
 
 
6.9.3 BCL2 inhibition in SKNO-1 in vitro is independent from the cell cycle  
Previous work in our lab has shown that RUNX1/ETO transcriptionally activates 
the cell cycle in t(8;21) leukaemic cells by causing overexpression of CCND2. 
Repression of either genes leads to G1 cell cycle arrest. In SKNO-1 cell line, we 
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showed that the depletion of CCND2 by siRNA did not enhance the cytotoxicity of 
ABT-199. Inversely, RUNX1/ETO knockdown had a prolonged impact on the 
sensitivity to ABT-199 (Fig 5-9 & 5-10). These findings contradict previous studies 
which suggest that BCL2 affects the cell cycle by modulating p27 expression 
(Vairo, Innes et al. 1996, Vairo, Soos et al. 2000). Other studies have shown that 
BCL2 is more effective under a quiescent phenotype that is guarded by p27 
overexpression (Brady, Gil-Gomez et al. 1996, Mazel, Burtrum et al. 1996). 
Arguably, the cell cycle machinery in t(8;21) is controlled by RUNX1/ETO, and the 
depletion of the fusion gene alone can upregulate p27 expression and induce 
senescence (Martinez, Drescher et al. 2004, Gu, Hu et al. 2014). Since we did not 
see any major increase in the G0 fraction after RUNX1/ETO knockdown in other 
work not reported in this thesis, we could reasonably propose that RUNX1/ETO 
depletion in vitro does not lead to increased G0 and quiescence. Thereby our 
observation of the increased sensitivity towards ABT-199 after RUNX1/ETO 
knockdown independently from the G1 cell cycle justifies the need to further 
experiments to unveil the relationship between the cell cycle and BCL2 inhibition 
in t(8;21) leukaemia. 
 
 
6.9.4 RUNX1/ETO knockdown in vivo desensitises Kasumi-1 to BCL2 inhibition   
Clinical and preclinical studies indicate that venetoclax has great therapeutic 
benefits in ALL, CLL and AML due to its selectivity and manageable toxicity 
(Roberts, Seymour et al. 2012, Souers, Leverson et al. 2013, Kipps, Eradat et al. 
2015). The combinational treatment of venetoclax with AraC or hypomethylating 
agents has been shown to be synergistic in newly diagnosed, relapsed, or 
refractory adult AML patients (Mihalyova, Jelinek et al. 2018). While we observed 
potent toxicity of venetoclax in AML cell lines in vitro, the in vivo treatment showed 
minimal prolonged median survival by only 10 days (p=0.057) (Fig 5-12). For the 
in vivo experiments, we followed a recommended dose regimen from our 
collaborators to achieve the therapeutic plasma level (Scherr, Kirchhoff et al. 
2019). However, we could not confirm that the maximal BCL2 inhibition was 
achieved. For future in vivo studies involving BCL2 inhibitors, we recommend 
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confirming the induction of apoptosis by quantifying changes in the mitochondrial 
membrane potential using tetramethylrhodamine ethyl ester (TMRE) staining. 
Unexpectedly, venetoclax treatment antagonised RUNX1/ETO knockdown in vivo 
and reduced the median survival by two weeks (Fig 5-12). We noticed an increase 
in BCLXL protein level following RUNX1/ETO knockdown in vitro, but the 
enhanced BCLXL expression did not affect venetoclax toxicity (Fig 5-11). On the 
contrary, it is possible that RUNX1/ETO depletion in vivo led to a more significant 
increase in BLCXL which hijacked BCL2 inhibition and rescued the mitochondrial 
apoptosis. Clinical studies on AML patients have shown that BCLXL is immune to 
venetoclax (Souers, Leverson et al. 2013, Pan, Hogdal et al. 2014). In order to 
prevent BCLXL upregulation and effectively trigger the mitochondria apoptosis, 
ABT-263 (navitoclax) has been developed as a potent inhibitor for both BCL2 and 
BCLXL, which is considered as a senolytic agent as well (Tse, Shoemaker et al. 
2008, Shafer and Grant 2016). Further experiments are required to evaluate the 
protein level of BCL family members, BIM isoforms and MCL1 after RUNX1/ETO 
depletion in vivo. We also propose to investigate the synergy between 
RUNX1/ETO knockdown and navitoclax in vitro and in vivo.  
Although RUXN1/ETO knockdown in vitro did not change BCL2 protein level (Fig 
5-11), RNA-seq obtained from the in vivo knockdown showed downregulation of 
BCL2 expression. Typically, reduction in BCL2 protein level leads to adverse 
effect of venetoclax in which BCLXL can be upregulated and enhance the anti-
apoptotic phenotype. Our RNA-seq did not show any changes in BCLXL 
expression, however this finding needs to be further investigated at protein level in 
future work. The depletion of RUNX1/ETO in vivo modulated the expression of 
genes involved in the mitochondria apoptosis pathways such as BBC3, LPNX, and 
BMF.   
We found in our RNA-seq that RUNX1/ETO knockdown in vivo upregulated the 
BCL2 modifying factor (BMF). It has been shown that co-expression of the pro-
apoptotic factors BMF and BIM enhances apoptosis in mutated TP53 cells 
(Grespi, Soratroi et al. 2010, Hornsveld, Tenhagen et al. 2016). However, in our 
experiment, the increased expression of BMF did not enhance BCL2 inhibition. 
Additionally, upregulation of BBC3 in wild-type TP53 malignant cells leads to a 
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robust pro-apoptotic phenotype as a response to various stimuli (Han, Flemington 
et al. 2001, Omori, Mitsuhashi et al. 2011). Although TP53 is mutated in Kasumi-1, 
we found that RUNX1/ETO knockdown in vivo caused BBC3 upregulation. The 
expression of BBC3 in t(8;21) AML is higher than premature progenitors and 
HSCs, and it increases upon myeloid differentiation (Folkerts, Hilgendorf et al. 
2017). It could be speculated that RUNX1/ETO knockdown may activate these 
pro-apoptotic regulators, which can compensate BCL2 inhibition. Further 
experiments are required to confirm the regulation of BMF and BBC3 by 
RUNX1/ETO, and whether overexpression of either genes desensitise t(8;21) 
leukaemia to BCL2 inhibition. 
Furthermore, we found that the in vivo depletion of RUNX1/ETO upregulated 
leupaxin (LPXN) expression, which is a member of the paxillin focal adhesion 
proteins family. Overexpression of LPXN is characteristic for aggressive tumours 
metastasise and migration (Kaulfuss, Grzmil et al. 2008, Chen and Kroog 2010). 
Moreover, BCL2 and LPXN share several complementary binning motifs, which 
their interaction leads to stabilisation of both proteins (Sheibani, Tang et al. 2008). 
It has been suggested that LPXN enhances AML invasion by upregulating BCL2 
and downregulation of BAX (Dai, Zhu et al. 2016). Therefore, perhaps 
RUNX1/ETO knockdown in vivo led to upregulation of LPNX followed by 
stabilisation of BCL2 protein, hence reducing venetoclax activity. To prove our 
hypothesis, we recommend performing co-immunoprecipitation to evaluate the 
effect of RUNX1/ETO knockdown on the interaction of LPNX and BCL2 proteins in 
























7.1. General summary 
RUNX1/ETO, the oncogenic transcription factor produced by the translocation 
t(8;21), represent an excellent example of the leukaemic-specific genes. Former 
work revealed that RUNX1/ETO dysregulates RUNX1 transcriptome to drive and 
maintain leukaemia by modulating genes involved in self-renewal, differentiation, cell 
cycle and genome stability. We showed that depleting RUNX1/ETO could provide a 
therapeutic window for t(8;21) AML patients, which may stratify for intervention and 
dose reduction in the current toxic chemotherapies. 
To date, RNAi-mediated repression of several leukaemic fusion genes, such as 
BCR/ABL, MLL/AF9, MLL/AF6, and PML/RARA have been achieved by constitutive 
or conditional expression of shRNAs targeting these genes (Ward, Sternsdorf et al. 
2011, Deshpande, Chen et al. 2013, Goyama, Schibler et al. 2013, Barabe, Gil et al. 
2017). For clinical implementation, it is not feasible to use shRNA to treat men. 
However, we have established transient gene knockdown using lipid nanoparticles 
encapsulating siRNA. Our approach has demonstrated the possibility to alter 
RUNX1/ETO leukaemogenesis in vivo, which could have the potential to be used in 
clinical setting. This thesis emphasises the functional importance of disrupting 
RUNX1/ETO transcriptional network, thereby confirming the therapeutic potential of 
targeting RUNX1/ETO to impair relapse. 
Our findings provide a comprehensive picture on the consequences of RUNX1/ETO 
repression, despite the limitations of our xenotransplantation model, which partially 
recapitulates the niche-leukaemic stem cell interactions, and possible deceptively of 
cell lines. We have extensively proven the robustness of our siRNA delivery system 
in patient primary and patient-derived xenograft cells in a co-culture system that 
mimics the complex signalling pathways required to maintain leukaemic stem cells in 
a quiescent state. The intersection of our in vitro, in vivo and ex vivo findings with the 
results obtained from patient primary and PDXs cells that represent the patients 
clonal complexity, we provide valuable insight into understanding the underlying 
mechanism of RUNX1/ETO leukaemogenesis. The in vivo knockdown of 
RUNX1/ETO indicated a robust disruption of multipotent stem cells genes, thereby 
confirming the therapeutic potential of targeting RUNX1/ETO to impair relapse.   
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Patients with t(8;21) AML have a favourable prognosis, but recurrence of AML 
remains a major clinical obstacle. Development of novel drugs and improvement in 
diagnoses have improved the management of toxicity in standard AML 
chemotherapies. However, the vast majority of survivors still experience long-term 
side effects, such as cardiotoxicity and bone marrow failure (Siddiqui, Hogge et al. 
2016). Relapse is driven by dormant cells, and it has been recently revealed that 
these cells remain susceptible to chemotherapies across a spectrum of genetically 
diverse AML (Boyd, Aslostovar et al. 2018).  
Intriguingly, having proved the effectiveness of depleting RUNX1/ETO to inhibit 
leukaemia propagation, we tested the combinational effect of gene knockdown with 
current AML chemotherapies. Our observation of the reduced sensitivity of AML cell 
lines in vitro to the DNA damage agents after RUNX1/ETO inhibition complements 
the principle of ‘‘timed sequential therapy’’ in which the induction of chemotherapy 
must match the proliferative states of leukaemic cells in order to increase the 
effectiveness of treatments and improve the outcome for AML patients. 
Evading apoptosis is an intrinsic feature of dormant leukaemic stem cells in which 
the anti- and pro-apoptotic machineries are modulated transcriptionally, 
translationally, and post-translationally to circumvent cell death. The mitochondrial 
apoptosis regulator BLC2 has been implicated as a critical pro-survival regulator in 
AML with great potential of venetoclax treatment. From another perspective, the 
elimination of senescent cells is an emerging topic in degenerative diseases (Xu, 
Pirtskhalava et al. 2018). Given that RUNX1/ETO repression is a potent 
senescence inducer, it is likely that treatment targeting the fusion protein alone 
would induce tissue damage. Thereby, we interrogated the possibility if 
RUNX1/ETO overrides the apoptotic resistance machinery of leukaemic cells, and 
aimed to eradicate leukaemia by testing the combinational therapy of RUNX1/ETO 
knockdown and venetoclax treatment. Although leukaemic cells were amenable to 
a combination of venetoclax and RUNX1/ETO knockdown in vitro, we could not 
conclusively prove that t(8;21) leukaemia is vulnerable to such combination. Due 
to time constraints, no further investigation into the combinational therapies could 




7.2 Considerations for future directions of siRNA therapeutics  
The promise of siRNA targeted therapy is evolving rapidly with advances in 
oligonucleotides chemistry and siRNA delivery systems. RNAi-based therapeutics 
might be efficacious drugs to target leukaemic specific genes, such as RUNX1/ETO. 
Although some siRNA therapeutics are already approved for use in men, and dozens 
are now in clinical trials for several diseases, yet many challenges remain to be 
addressed. These include the low on-target activity, off-target effect by unintended 
silencing, immunogenic reaction to the siRNA duplex and toxicity of the excipient 
chemicals.    
 
7.2.1 Sequence selection and the structural motif design      
The antisense of siRNA is the putative strand for specific silencing of the targeted 
transcript. Hence, upon incorporation of the antisense in the RISC complex, the 
sequence of antisense is the exclusive determinant of gene knockdown. Additionally, 
sequence selection affects the on-target potency and off-target silencing. Nowadays, 
several software packages and databases are available to design selective siRNAs 
and predict their activity, such as Dharmacon’s siDESIGN Center and IDT DNA 
custom DsiRNA design centre. These platforms screen the genomic and 
transcriptomic sequences to identify regions with extensive complementarity to the 
putative antisense. The algorithms in these platforms, such as blastn algorithms, can 
reliably predict the siRNA duplex thermodynamic stability and off-target matches. 
Generally, the ideal siRNA triggers are AU rich at the 5’-end of the antisense 
(Agrawal and Kandimalla 2001, Hu and Hu 2014, Hagedorn, Hansen et al. 2017).     
The RNAi machinery has restrictive structural requirements in which RNA duplexes 
smaller than 15 bp do not incorporate into RISC, and those larger than 30 bp 
activate the PKR pathway and hereby the associated toxicity. The duplex structure 
affects siRNA processing and loading into RISC. Asymmetric siRNA, with two 
nucleotides at the 3’-overhangs at one side and a blunt end at the other, biases the 
selection of the antisense strand to the favour the strand carrying the 3’-overhangs. 
Moreover, the avoidance of immune stimulatory repeats, such as GU-rich motifs, is 
required to improve the safety profile of the siRNA (Zhang, Ohto et al. 2017, Seok, 
Lee et al. 2018).  
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7.2.2 siRNA chemical modifications  
Oligonucleotides chemical modifications serve two vital functions. First, they improve 
the stability of the siRNA. Second, they attenuate the immunogenicity of the siRNA. 
In particular, introducing 2’-ribose and phosphorothioate modifications improve the 
siRNA pharmacokinetics and pharmacodynamics. Besides increasing the nuclease 
resistance, these modifications enhance the selective binding to RISC and reduce 
the off-target silencing (Lee, Seok et al. 2015, Kobayashi and Tomari 2016, Jiang, 
Zhu et al. 2017). 
siRNAs stimulate and activate the TLR-dependent innate and adaptive immune 
responses primarily by TLR-7/8 in the endosome. Base modifications and 
introducing 2’-sugar modifications improve the safety of siRNA, especially 2’-O-Me 
modification by alleviating the TLR-mediated immune effects.  
 
7.2.3 Delivery systems 
Regardless of the sequence, duplex structure and chemical modifications, 
hydrophilicity, size and charge of the siRNA remain major obstetricals for stability in 
the systemic circulation, organs and tissue penetration, cellular uptake and 
endosomal escape. Therefore, biocompatible excipients are mandatory to overcome 
the siRNAs inherited poor pharmacokinetics. 
Owing to the current vibrant research on delivery vehicles, siRNA therapeutics are 
moving through more mature clinical relevant development and pipelines. In 
particular, novel lipid nanoparticles formulations have proven to be efficacious in 
delivering several payloads, including siRNA. These nanoparticles allow the 
systemic administration of siRNA by intravenous infusion as well as site-specific 
injection. To treat leukaemia, the diameter of nanoparticles should be below 100 nm 
to ensure the delivery to the leukaemic niche through the endosteum membrane. 
Given that leukaemia may invade the CNS, the ability of the nanoparticles to pass 
the blood-brain barrier is also desirable.  
In addition to the improved pharmacokinetics, the potency of siRNA could also 
benefit from enhanced targeted delivery. For instance, lipid nanoparticles allow for 
tissue-specific targeting by decorating the surface with ligands, such as antibodies, 
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scFv, aptamers or peptides, which ultimately increases the retention of the particles 
in the relevant tissues. 
 
 

















Cell lines authentication certificates.  
 










Plating efficiency of t(8;21) AML cell line.  
 
Kasumi-1      
seeded cells 500 1000 2000 5000 10000 
counted 
colonies 
148 312 601 1409 3178 
140 289 593 1523 2268 
137 305 583 1331 2970 
141 308 600 1316   
Avg CFA 141.5 303.5 594.25 1394.75 2805.333 
CFA%  28.3 30.35 29.7125 27.895 28.05333 
stdv  4.031129 8.732125 7.189402 82.03162 389.3253 
stdv%  2.848854 2.877142 1.209828 5.881457 13.87804 
 
      
SKNO-1      
seeded cells 500 1000 2000 5000 10000 
counted 
colonies 
113 235 516 1003 2132 
125 215 487 973 2094 
99 261 525 1231 2346 
103 236 499 1167   
Avg CFA 110 236.75 506.75 1093.5 2190.667 
CFA%  22 23.675 25.3375 21.87 21.90667 
stdv  10.04988 16.31525 14.73728 108.4193 110.9274 
stdv%  9.136251 6.891343 2.908196 9.91489 5.063637 
 
s-Table 3: The plating efficiency of Kasumi-1 and SKNO-1 cell line. The exact 







P.SLIEW vector map.  
 
 
s-Fig 1: Vector map of the lentiviral expression vector p.SLIEW-shRNA. 
Kasumi-1 p.SLIEW and SKNO-1 p.SLIEW cells were generated by Dr. Simon 

























s-Fig 5: KEGG pathway analysis. Cell Cycle.  
 













s-Fig 9: KEGG pathway analysis. Toll-like receptor signalling.  
 
 
s-Fig 10: KEGG pathway analysis. Signalling pathways regulating pluripotency 






















Abu Lila, A. S. and T. Ishida (2017). "Liposomal Delivery Systems: Design Optimization and Current 
Applications." Biol Pharm Bull 40(1): 1-10. 
Adams, D., A. Gonzalez-Duarte, W. D. O'Riordan, C. C. Yang, M. Ueda, A. V. Kristen, I. Tournev, H. H. 
Schmidt, T. Coelho, J. L. Berk, K. P. Lin, G. Vita, S. Attarian, V. Plante-Bordeneuve, M. M. Mezei, J. M. 
Campistol, J. Buades, T. H. Brannagan, 3rd, B. J. Kim, J. Oh, Y. Parman, Y. Sekijima, P. N. Hawkins, S. 
D. Solomon, M. Polydefkis, P. J. Dyck, P. J. Gandhi, S. Goyal, J. Chen, A. L. Strahs, S. V. Nochur, M. T. 
Sweetser, P. P. Garg, A. K. Vaishnaw, J. A. Gollob and O. B. Suhr (2018). "Patisiran, an RNAi 
Therapeutic, for Hereditary Transthyretin Amyloidosis." N Engl J Med 379(1): 11-21. 
Agrawal, S. and E. R. Kandimalla (2001). "Antisense and/or immunostimulatory oligonucleotide 
therapeutics." Curr Cancer Drug Targets 1(3): 197-209. 
Aguayo, A., H. Kantarjian, T. Manshouri, C. Gidel, E. Estey, D. Thomas, C. Koller, Z. Estrov, S. O'Brien, 
M. Keating, E. Freireich and M. Albitar (2000). "Angiogenesis in acute and chronic leukemias and 
myelodysplastic syndromes." Blood 96(6): 2240-2245. 
Akinc, A., M. Goldberg, J. Qin, J. R. Dorkin, C. Gamba-Vitalo, M. Maier, K. N. Jayaprakash, M. 
Jayaraman, K. G. Rajeev, M. Manoharan, V. Koteliansky, I. Rohl, E. S. Leshchiner, R. Langer and D. G. 
Anderson (2009). "Development of lipidoid-siRNA formulations for systemic delivery to the liver." 
Mol Ther 17(5): 872-879. 
Al-Jamal, W. T. and K. Kostarelos (2011). "Liposomes: from a clinically established drug delivery 
system to a nanoparticle platform for theranostic nanomedicine." Acc Chem Res 44(10): 1094-1104. 
Alcalay, M., N. Meani, V. Gelmetti, A. Fantozzi, M. Fagioli, A. Orleth, D. Riganelli, C. Sebastiani, E. 
Cappelli, C. Casciari, M. T. Sciurpi, A. R. Mariano, S. P. Minardi, L. Luzi, H. Muller, P. P. Di Fiore, G. 
Frosina and P. G. Pelicci (2003). "Acute myeloid leukemia fusion proteins deregulate genes involved 
in stem cell maintenance and DNA repair." J Clin Invest 112(11): 1751-1761. 
Allsopp, R. C. and C. B. Harley (1995). "Evidence for a critical telomere length in senescent human 
fibroblasts." Exp Cell Res 219(1): 130-136. 
Amabile, G., R. S. Welner, C. Nombela-Arrieta, A. M. D'Alise, A. Di Ruscio, A. K. Ebralidze, Y. 
Kraytsberg, M. Ye, O. Kocher, D. S. Neuberg, K. Khrapko, L. E. Silberstein and D. G. Tenen (2013). "In 
vivo generation of transplantable human hematopoietic cells from induced pluripotent stem cells." 
Blood 121(8): 1255-1264. 
Amann, J. M., J. Nip, D. K. Strom, B. Lutterbach, H. Harada, N. Lenny, J. R. Downing, S. Meyers and S. 
W. Hiebert (2001). "ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple 
histone deacetylases and binds mSin3A through its oligomerization domain." Mol Cell Biol 21(19): 
6470-6483. 
Ameres, S. L., J. Martinez and R. Schroeder (2007). "Molecular basis for target RNA recognition and 
cleavage by human RISC." Cell 130(1): 101-112. 
Andre, M. C., A. Erbacher, C. Gille, V. Schmauke, B. Goecke, A. Hohberger, P. Mang, A. Wilhelm, I. 
Mueller, W. Herr, P. Lang, R. Handgretinger and U. F. Hartwig (2010). "Long-term human CD34+ stem 
cell-engrafted nonobese diabetic/SCID/IL-2R gamma(null) mice show impaired CD8+ T cell 
maintenance and a functional arrest of immature NK cells." J Immunol 185(5): 2710-2720. 
Anzahaee, M. Y., J. K. Watts, N. R. Alla, A. W. Nicholson and M. J. Damha (2011). "Energetically 
important C-H...F-C pseudohydrogen bonding in water: evidence and application to rational design 
of oligonucleotides with high binding affinity." J Am Chem Soc 133(4): 728-731. 
Asada, N. (2018). "Regulation of Malignant Hematopoiesis by Bone Marrow Microenvironment." 
Front Oncol 8: 119. 
Bailey, J. K., W. Shen, X. H. Liang and S. T. Crooke (2017). "Nucleic acid binding proteins affect the 
subcellular distribution of phosphorothioate antisense oligonucleotides." Nucleic Acids Res 45(18): 
10649-10671. 
Bali, P., M. Pranpat, J. Bradner, M. Balasis, W. Fiskus, F. Guo, K. Rocha, S. Kumaraswamy, S. 
Boyapalle, P. Atadja, E. Seto and K. Bhalla (2005). "Inhibition of histone deacetylase 6 acetylates and 
disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of 
histone deacetylase inhibitors." J Biol Chem 280(29): 26729-26734. 
269 
 
Bangham, A. D., M. M. Standish and J. C. Watkins (1965). "Diffusion of univalent ions across the 
lamellae of swollen phospholipids." Journal of Molecular Biology 13(1): 238-IN227. 
Bao, Y., Y. Jin, P. Chivukula, J. Zhang, Y. Liu, J. Liu, J. P. Clamme, R. I. Mahato, D. Ng, W. Ying, Y. Wang 
and L. Yu (2013). "Effect of PEGylation on biodistribution and gene silencing of siRNA/lipid 
nanoparticle complexes." Pharm Res 30(2): 342-351. 
Barabe, F., L. Gil, M. Celton, A. Bergeron, V. Lamontagne, E. Roques, K. Lagace, A. Forest, R. Johnson, 
L. Pecheux, J. Simard, J. Pelloux, A. Bellemare-Pelletier, E. Gagnon, J. Hebert, S. Cellot and B. T. 
Wilhelm (2017). "Modeling human MLL-AF9 translocated acute myeloid leukemia from single donors 
reveals RET as a potential therapeutic target." Leukemia 31(5): 1166-1176. 
Barata, P., A. K. Sood and D. S. Hong (2016). "RNA-targeted therapeutics in cancer clinical trials: 
Current status and future directions." Cancer Treat Rev 50: 35-47. 
Barseguian, K., B. Lutterbach, S. W. Hiebert, J. Nickerson, J. B. Lian, J. L. Stein, A. J. van Wijnen and G. 
S. Stein (2002). "Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO 
repressor proteins." Proc Natl Acad Sci U S A 99(24): 15434-15439. 
Bartsch, M., A. H. Weeke-Klimp, E. P. Hoenselaar, M. C. Stuart, D. K. Meijer, G. L. Scherphof and J. A. 
Kamps (2004). "Stabilized lipid coated lipoplexes for the delivery of antisense oligonucleotides to 
liver endothelial cells in vitro and in vivo." J Drug Target 12(9-10): 613-621. 
Beaudin, A. E., S. W. Boyer, J. Perez-Cunningham, G. E. Hernandez, S. C. Derderian, C. Jujjavarapu, E. 
Aaserude, T. MacKenzie and E. C. Forsberg (2016). "A Transient Developmental Hematopoietic Stem 
Cell Gives Rise to Innate-like B and T Cells." Cell Stem Cell 19(6): 768-783. 
Beghini, A., I. Magnani, C. B. Ripamonti and L. Larizza (2002). "Amplification of a novel c-Kit 
activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute 
myeloid leukemia." Hematol J 3(3): 157-163. 
Beigelman, L., A. Karpeisky, J. Matulicadamic, P. Haeberli, D. Sweedler and N. Usman (1995). 
"Synthesis of 2'-Modified Nucleotides and Their Incorporation into Hammerhead Ribozymes." 
Nucleic Acids Research 23(21): 4434-4442. 
Belair, C., S. Sim and S. L. Wolin (2018). "Noncoding RNA Surveillance: The Ends Justify the Means."  
118(8): 4422-4447. 
Belliveau, N. M., J. Huft, P. J. Lin, S. Chen, A. K. Leung, T. J. Leaver, A. W. Wild, J. B. Lee, R. J. Taylor, Y. 
K. Tam, C. L. Hansen and P. R. Cullis (2012). "Microfluidic Synthesis of Highly Potent Limit-size Lipid 
Nanoparticles for In Vivo Delivery of siRNA." Mol Ther Nucleic Acids 1: e37. 
Ben-Porath, I. and R. A. Weinberg (2005). "The signals and pathways activating cellular senescence." 
Int J Biochem Cell Biol 37(5): 961-976. 
Benjaminsen, R. V., M. A. Mattebjerg, J. R. Henriksen, S. M. Moghimi and T. L. Andresen (2013). "The 
possible "proton sponge " effect of polyethylenimine (PEI) does not include change in lysosomal pH." 
Mol Ther 21(1): 149-157. 
Benjaminsen, R. V., M. A. Mattebjerg, J. R. Henriksen, S. M. Moghimi and T. L. Andresen (2013). "The 
Possible "Proton Sponge" Effect of Polyethylenimine (PEI) Does Not Include Change in Lysosomal 
pH." Molecular Therapy 21(1): 149-157. 
Bennett, J. M., D. Catovsky, M. T. Daniel, G. Flandrin, D. A. Galton, H. R. Gralnick and C. Sultan (1976). 
"Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative 
group." Br J Haematol 33(4): 451-458. 
Bertoli, C., J. M. Skotheim and R. A. de Bruin (2013). "Control of cell cycle transcription during G1 and 
S phases." Nat Rev Mol Cell Biol 14(8): 518-528. 
Bertrand, J. Y., S. Giroux, R. Golub, M. Klaine, A. Jalil, L. Boucontet, I. Godin and A. Cumano (2005). 
"Characterization of purified intraembryonic hematopoietic stem cells as a tool to define their site of 
origin." Proceedings of the National Academy of Sciences of the United States of America 102(1): 
134-139. 
Bizzari, J. P. and W. J. Mackillop (1985). "The estimation of self-renewal in the clonogenic cells of 




Blair, A., D. E. Hogge and H. J. Sutherland (1998). "Most acute myeloid leukemia progenitor cells with 
long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR-." 
Blood 92(11): 4325-4335. 
Bloom, W. and G. W. Bartelmez (1940). "Hematopoiesis in young human embryos." American 
Journal of Anatomy 67(1): 21-53. 
Blumenthal, E., S. Greenblatt, G. Huang, K. Ando, Y. Xu and S. D. Nimer (2017). Covalent 
Modifications of RUNX Proteins: Structure Affects Function. RUNX Proteins in Development and 
Cancer. Y. Groner, Y. Ito, P. Liu et al. Singapore, Springer Singapore: 33-44. 
Bobo, D., K. J. Robinson, J. Islam, K. J. Thurecht and S. R. Corrie (2016). "Nanoparticle-Based 
Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date." Pharm Res 33(10): 
2373-2387. 
Bogorad, R. L., H. Yin, A. Zeigerer, H. Nonaka, V. M. Ruda, M. Zerial, D. G. Anderson and V. 
Koteliansky (2014). "Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular 
carcinoma progression in mice." Nat Commun 5: 3869. 
Bolu, B. S., R. Sanyal and A. Sanyal (2018). "Drug Delivery Systems from Self-Assembly of Dendron-
Polymer Conjugates (dagger)." Molecules 23(7). 
Bomken, S., L. Buechler, K. Rehe, F. Ponthan, A. Elder, H. Blair, C. M. Bacon, J. Vormoor and O. 
Heidenreich (2013). "Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells 
allows in vivo tracking of disease progression." Leukemia 27(3): 718-721. 
Bonnet, D. and J. E. Dick (1997). "Human acute myeloid leukemia is organized as a hierarchy that 
originates from a primitive hematopoietic cell." Nature Medicine 3(7): 730-737. 
Borowicz, S., M. Van Scoyk, S. Avasarala, M. K. Karuppusamy Rathinam, J. Tauler, R. K. Bikkavilli and 
R. A. Winn (2014). "The soft agar colony formation assay." J Vis Exp(92): e51998. 
Boyd, A. L., L. Aslostovar, J. Reid, W. Ye, B. Tanasijevic, D. P. Porras, Z. Shapovalova, M. Almakadi, R. 
Foley, B. Leber, A. Xenocostas and M. Bhatia (2018). "Identification of Chemotherapy-Induced 
Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML Recurrence." Cancer 
Cell 34(3): 483-498 e485. 
Bracht, J. R., X. Wang, K. Shetty, X. Chen, G. J. Uttarotai, E. C. Callihan, S. S. McCloud, D. M. Clay, J. 
Wang, M. Nowacki and L. F. Landweber (2017). "Chromosome fusions triggered by noncoding RNA." 
RNA Biol 14(5): 620-631. 
Brady, H. J., G. Gil-Gomez, J. Kirberg and A. J. Berns (1996). "Bax alpha perturbs T cell development 
and affects cell cycle entry of T cells." EMBO J 15(24): 6991-7001. 
Braunova, A., L. Kostka, L. Sivak, L. Cuchalova, Z. Hvezdova, R. Laga, S. Filippov, P. Cernoch, M. 
Pechar, O. Janouskova, M. Sirova and T. Etrych (2017). "Tumor-targeted micelle-forming block 
copolymers for overcoming of multidrug resistance." J Control Release 245: 41-51. 
Buess, H. (1959). "Albrecht von Haller and his Elementa Physiologiae as the beginning of pathological 
physiology." Med Hist 3(2): 123-131. 
Burel, S. A., N. Harakawa, L. Zhou, T. Pabst, D. G. Tenen and D. E. Zhang (2001). "Dichotomy of AML1-
ETO functions: growth arrest versus block of differentiation." Mol Cell Biol 21(16): 5577-5590. 
Burnett, A. K., R. K. Hills, D. W. Milligan, A. H. Goldstone, A. G. Prentice, M. F. McMullin, A. 
Duncombe, B. Gibson and K. Wheatley (2010). "Attempts to optimize induction and consolidation 
treatment in acute myeloid leukemia: results of the MRC AML12 trial." J Clin Oncol 28(4): 586-595. 
Buschges, R., R. G. Weber, B. Actor, P. Lichter, V. P. Collins and G. Reifenberger (1999). 
"Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant 
gliomas." Brain Pathol 9(3): 435-442; discussion 432-433. 
Cairoli, R., A. Beghini, G. Grillo, G. Nadali, F. Elice, C. B. Ripamonti, P. Colapietro, M. Nichelatti, L. 
Pezzetti, M. Lunghi, A. Cuneo, A. Viola, F. Ferrara, M. Lazzarino, F. Rodeghiero, G. Pizzolo, L. Larizza 
and E. Morra (2006). "Prognostic impact of c-KIT mutations in core binding factor leukemias: an 
Italian retrospective study." Blood 107(9): 3463-3468. 




Cao, J., M. Spielmann, X. Qiu, X. Huang, D. M. Ibrahim, A. J. Hill, F. Zhang, S. Mundlos, L. Christiansen, 
F. J. Steemers, C. Trapnell and J. Shendure (2019). "The single-cell transcriptional landscape of 
mammalian organogenesis." Nature 566(7745): 496-502. 
Carthew, R. W. and E. J. Sontheimer (2009). "Origins and Mechanisms of miRNAs and siRNAs." Cell 
136(4): 642-655. 
Cech, T. R. and J. A. Steitz (2014). "The noncoding RNA revolution-trashing old rules to forge new 
ones." Cell 157(1): 77-94. 
Cerutti, L., N. Mian and A. Bateman (2000). "Domains in gene silencing and cell differentiation 
proteins: the novel PAZ domain and redefinition of the Piwi domain." Trends Biochem Sci 25(10): 
481-482. 
Chaikovsky, A. C. and J. Sage (2018). "Beyond the Cell Cycle: Enhancing the Immune Surveillance of 
Tumors Via CDK4/6 Inhibition." Mol Cancer Res 16(10): 1454-1457. 
Charan, J. and N. Kantharia (2013). "How to calculate sample size in animal studies?" Journal of 
Pharmacology and Pharmacotherapeutics 4(4): 303-306. 
Charan, J. and N. D. Kantharia (2013). "How to calculate sample size in animal studies?" J Pharmacol 
Pharmacother 4(4): 303-306. 
Chen, D., L. J. Luo and C. Liang (2018). "Aberrant S100A16 expression might be an independent 
prognostic indicator of unfavorable survival in non-small cell lung adenocarcinoma." Plos One 13(5). 
Chen, L., G. Wang, Y. Luo, Y. Wang, C. Xie, W. Jiang, Y. Xiao, G. Qian and X. Wang (2017). 
"Downregulation of LAPTM5 suppresses cell proliferation and viability inducing cell cycle arrest at 
G0/G1 phase of bladder cancer cells." Int J Oncol 50(1): 263-271. 
Chen, P. W. and G. S. Kroog (2010). "Leupaxin is similar to paxillin in focal adhesion targeting and 
tyrosine phosphorylation but has distinct roles in cell adhesion and spreading." Cell Adhesion & 
Migration 4(4): 527-540. 
Chen, S., Y. Dai, X. Y. Pei and S. Grant (2009). "Bim upregulation by histone deacetylase inhibitors 
mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, 
and Mcl-1." Mol Cell Biol 29(23): 6149-6169. 
Chen, S., Y. Y. Tam, P. J. Lin, A. K. Leung, Y. K. Tam and P. R. Cullis (2014). "Development of lipid 
nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous 
administration." J Control Release 196: 106-112. 
Chen, S., Y. Y. C. Tam, P. J. C. Lin, M. M. H. Sung, Y. K. Tam and P. R. Cullis (2016). "Influence of 
particle size on the in vivo potency of lipid nanoparticle formulations of siRNA." J Control Release 
235: 236-244. 
Cheng, T. (2004). "Cell cycle inhibitors in normal and tumor stem cells." Oncogene 23(43): 7256-
7266. 
Cheng, T., N. Rodrigues, H. Shen, Y. Yang, D. Dombkowski, M. Sykes and D. T. Scadden (2000). 
"Hematopoietic stem cell quiescence maintained by p21cip1/waf1." Science 287(5459): 1804-1808. 
Cheng, X. and R. J. Lee (2016). "The role of helper lipids in lipid nanoparticles (LNPs) designed for 
oligonucleotide delivery." Adv Drug Deliv Rev 99(Pt A): 129-137. 
Cheung, A. M., T. K. Fung, A. K. Fan, T. S. Wan, H. C. Chow, J. C. Leung, L. Y. Chan, Y. L. Kwong, R. 
Liang and A. Y. Leung (2010). "Successful engraftment by leukemia initiating cells in adult acute 
lymphoblastic leukemia after direct intrahepatic injection into unconditioned newborn NOD/SCID 
mice." Exp Hematol 38(1): 3-10. 
Chhabra, R., R. Dubey and N. Saini (2010). "Cooperative and individualistic functions of the 
microRNAs in the miR-23a~27a~24-2 cluster and its implication in human diseases." Mol Cancer 9: 
232. 
Chiang, H. R., L. W. Schoenfeld, J. G. Ruby, V. C. Auyeung, N. Spies, D. Baek, W. K. Johnston, C. Russ, 
S. Luo, J. E. Babiarz, R. Blelloch, G. P. Schroth, C. Nusbaum and D. P. Bartel (2010). "Mammalian 




Chien, Y. C., C. Scuoppo, X. W. Wang, X. P. Fang, B. Balgley, J. E. Bolden, P. Premsrirut, W. J. Luo, A. 
Chicas, C. S. Lee, S. C. Kogan and S. W. Lowe (2011). "Control of the senescence-associated secretory 
phenotype by NF-kappa B promotes senescence and enhances chemosensitivity." Genes & 
Development 25(20): 2125-2136. 
Childs, B. G., D. J. Baker, J. L. Kirkland, J. Campisi and J. M. van Deursen (2014). "Senescence and 
apoptosis: dueling or complementary cell fates?" EMBO reports 15(11): 1139-1153. 
Christensen, J., K. Litherland, T. Faller, E. van de Kerkhof, F. Natt, J. Hunziker, J. Boos, I. Beuvink, K. 
Bowman, J. Baryza, M. Beverly, C. Vargeese, O. Heudi, M. Stoeckli, J. Krauser and P. Swart (2014). 
"Biodistribution and metabolism studies of lipid nanoparticle-formulated internally [3H]-labeled 
siRNA in mice." Drug Metab Dispos 42(3): 431-440. 
Clemens, M. J. and A. Elia (1997). "The double-stranded RNA-dependent protein kinase PKR: 
Structure and function." Journal of Interferon and Cytokine Research 17(9): 503-524. 
Collins, C. J. and J. M. Sedivy (2003). "Involvement of the INK4a/Arf gene locus in senescence." Aging 
Cell 2(3): 145-150. 
Cook, A. F., M. J. Holman and A. L. Nussbaum (1969). "Nucleoside S-alkyl phosphorothioates. II. 
Preparation and chemical and enzymatic properties." J Am Chem Soc 91(6): 1522-1527. 
Coppe, J. P., P. Y. Desprez, A. Krtolica and J. Campisi (2010). "The senescence-associated secretory 
phenotype: the dark side of tumor suppression." Annu Rev Pathol 5: 99-118. 
Coppe, J. P., C. K. Patil, F. Rodier, Y. Sun, D. P. Munoz, J. Goldstein, P. S. Nelson, P. Y. Desprez and J. 
Campisi (2008). "Senescence-associated secretory phenotypes reveal cell-nonautonomous functions 
of oncogenic RAS and the p53 tumor suppressor." PLoS Biol 6(12): 2853-2868. 
Cordeiro Gomes, A., T. Hara, V. Y. Lim, D. Herndler-Brandstetter, E. Nevius, T. Sugiyama, S. Tani-Ichi, 
S. Schlenner, E. Richie, H. R. Rodewald, R. A. Flavell, T. Nagasawa, K. Ikuta and J. P. Pereira (2016). 
"Hematopoietic Stem Cell Niches Produce Lineage-Instructive Signals to Control Multipotent 
Progenitor Differentiation." Immunity 45(6): 1219-1231. 
Corey, S. J., P. M. Dombrosky-Ferlan, S. Zuo, E. Krohn, A. D. Donnenberg, P. Zorich, G. Romero, M. 
Takata and T. Kurosaki (1998). "Requirement of Src kinase Lyn for induction of DNA synthesis by 
granulocyte colony-stimulating factor." J Biol Chem 273(6): 3230-3235. 
Coulombel, L. (2004). "Identification of hematopoietic stem/progenitor cells: strength and 
drawbacks of functional assays." Oncogene 23(43): 7210-7222. 
Creusat, G., A. S. Rinaldi, E. Weiss, R. Elbaghdadi, J. S. Remy, R. Mulherkar and G. Zuber (2010). 
"Proton sponge trick for pH-sensitive disassembly of polyethylenimine-based siRNA delivery 
systems." Bioconjug Chem 21(5): 994-1002. 
Cullen, P. (1811). "Case of splenitis acutus in which the serum of the blood drawn from the arm had 
the appearance of milk." Edinburgh Medical Journal 7: 169-171. 
Cullis, P. R. and M. J. Hope (2017). "Lipid Nanoparticle Systems for Enabling Gene Therapies." Mol 
Ther 25(7): 1467-1475. 
Dagle, J. M., D. L. Weeks and J. A. Walder (1991). "Pathways of degradation and mechanism of action 
of antisense oligonucleotides in Xenopus laevis embryos." Antisense Res Dev 1(1): 11-20. 
Dahl, R., J. C. Walsh, D. Lancki, P. Laslo, S. R. Iyer, H. Singh and M. C. Simon (2003). "Regulation of 
macrophage and neutrophil cell fates by the PU.1:C/EBPalpha ratio and granulocyte colony-
stimulating factor." Nat Immunol 4(10): 1029-1036. 
Dai, H. P., G. H. Zhu, Q. Shen, L. L. Wu, Q. Wang, Q. R. Wang, L. J. Wen, H. Yao, H. Y. Qiu, S. N. Chen 
and D. P. Wu (2016). "Lpxn Regulates Proliferation, Adhesion and Invasion of Acute Myeloid 
Leukemic Cells." Blood 128(22). 
Dakic, A., L. Wu and S. L. Nutt (2007). "Is PU.1 a dosage-sensitive regulator of haemopoietic lineage 
commitment and leukaemogenesis?" Trends in Immunology 28(3): 108-114. 
Dalpke, A. and M. Helm (2012). "RNA mediated Toll-like receptor stimulation in health and disease." 
RNA Biol 9(6): 828-842. 
273 
 
Davalos, A. R., M. Kawahara, G. K. Malhotra, N. Schaum, J. Huang, U. Ved, C. M. Beausejour, J. P. 
Coppe, F. Rodier and J. Campisi (2013). "p53-dependent release of Alarmin HMGB1 is a central 
mediator of senescent phenotypes." J Cell Biol 201(4): 613-629. 
Davis, M. E., J. E. Zuckerman, C. H. Choi, D. Seligson, A. Tolcher, C. A. Alabi, Y. Yen, J. D. Heidel and A. 
Ribas (2010). "Evidence of RNAi in humans from systemically administered siRNA via targeted 
nanoparticles." Nature 464(7291): 1067-1070. 
Davis, S., T. H. Aldrich, P. F. Jones, A. Acheson, D. L. Compton, V. Jain, T. E. Ryan, J. Bruno, C. 
Radziejewski, P. C. Maisonpierre and G. D. Yancopoulos (1996). "Isolation of angiopoietin-1, a ligand 
for the TIE2 receptor, by secretion-trap expression cloning." Cell 87(7): 1161-1169. 
de Bont, E. S., S. Rosati, S. Jacobs, W. A. Kamps and E. Vellenga (2001). "Increased bone marrow 
vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial 
growth factor." Br J Haematol 113(2): 296-304. 
De Palma, M., D. Biziato and T. V. Petrova (2017). "Microenvironmental regulation of tumour 
angiogenesis." Nat Rev Cancer 17(8): 457-474. 
DeKelver, R. C., B. Lewin, K. Lam, Y. Komeno, M. Yan, C. Rundle, M. C. Lo and D. E. Zhang (2013). 
"Cooperation between RUNX1-ETO9a and novel transcriptional partner KLF6 in upregulation of 
Alox5 in acute myeloid leukemia." PLoS Genet 9(10): e1003765. 
Del Gaizo Moore, V., J. R. Brown, M. Certo, T. M. Love, C. D. Novina and A. Letai (2007). "Chronic 
lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 
antagonist ABT-737." J Clin Invest 117(1): 112-121. 
Deleavey, G. F. and M. J. Damha (2012). "Designing chemically modified oligonucleotides for 
targeted gene silencing." Chem Biol 19(8): 937-954. 
Delgado, A. V., F. Gonzalez-Caballero, R. J. Hunter, L. K. Koopal, J. Lyklema, P. International Union of, 
P. Applied Chemistry and I. T. R. Biophysical Chemistry Division (2007). "Measurement and 
interpretation of electrokinetic phenomena." J Colloid Interface Sci 309(2): 194-224. 
Deng, Y., S. S. Chan and S. Chang (2008). "Telomere dysfunction and tumour suppression: the 
senescence connection." Nat Rev Cancer 8(6): 450-458. 
Deniz, E. and B. Erman (2017). "Long noncoding RNA (lincRNA), a new paradigm in gene expression 
control." Funct Integr Genomics 17(2-3): 135-143. 
Deshpande, A. J., L. Chen, M. Fazio, A. U. Sinha, K. M. Bernt, D. Banka, S. Dias, J. Chang, E. J. Olhava, 
S. R. Daigle, V. M. Richon, R. M. Pollock and S. A. Armstrong (2013). "Leukemic transformation by the 
MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l." Blood 121(13): 2533-2541. 
Dias, S., S. V. Shmelkov, G. Lam and S. Rafii (2002). "VEGF(165) promotes survival of leukemic cells by 
Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition." Blood 99(7): 2532-2540. 
Diederichs, S. (2014). "The four dimensions of noncoding RNA conservation." Trends Genet 30(4): 
121-123. 
Dimri, G. P., X. H. Lee, G. Basile, M. Acosta, C. Scott, C. Roskelley, E. E. Medrano, M. Linskens, I. 
Rubelj, O. Pereirasmith, M. Peacocke and J. Campisi (1995). "A Biomarker That Identifies Senescent 
Human-Cells in Culture and in Aging Skin in-Vivo." Proceedings of the National Academy of Sciences 
of the United States of America 92(20): 9363-9367. 
Dohner, H., E. H. Estey, S. Amadori, F. R. Appelbaum, T. Buchner, A. K. Burnett, H. Dombret, P. 
Fenaux, D. Grimwade, R. A. Larson, F. Lo-Coco, T. Naoe, D. Niederwieser, G. J. Ossenkoppele, M. A. 
Sanz, J. Sierra, M. S. Tallman, B. Lowenberg, C. D. Bloomfield and L. European (2010). "Diagnosis and 
management of acute myeloid leukemia in adults: recommendations from an international expert 
panel, on behalf of the European LeukemiaNet." Blood 115(3): 453-474. 
Eder, P. S., R. J. DeVine, J. M. Dagle and J. A. Walder (1991). "Substrate specificity and kinetics of 
degradation of antisense oligonucleotides by a 3' exonuclease in plasma." Antisense Res Dev 1(2): 
141-151. 
Elsasser, A., M. Franzen, A. Kohlmann, M. Weisser, S. Schnittger, C. Schoch, V. A. Reddy, S. Burel, D. 
E. Zhang, M. Ueffing, D. G. Tenen, W. Hiddemann and G. Behre (2003). "The fusion protein AML1-
ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the 
274 
 
proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner." Oncogene 22(36): 
5646-5657. 
Emmrich, S., J. E. Katsman-Kuipers, K. Henke, M. E. Khatib, R. Jammal, F. Engeland, F. Dasci, C. M. 
Zwaan, M. L. den Boer, L. Verboon, J. Stary, A. Baruchel, V. de Haas, A. A. Danen-van Oorschot, M. 
Fornerod, R. Pieters, D. Reinhardt, J. H. Klusmann and M. M. van den Heuvel-Eibrink (2014). "miR-9 
is a tumor suppressor in pediatric AML with t(8;21)." Leukemia 28(5): 1022-1032. 
Esposito, M. T. and C. W. So (2014). "DNA damage accumulation and repair defects in acute myeloid 
leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance." 
Chromosoma 123(6): 545-561. 
Falini, B., E. Tiacci, M. P. Martelli, S. Ascani and S. A. Pileri (2010). "New classification of acute 
myeloid leukemia and precursor-related neoplasms: changes and unsolved issues." Discov Med 
10(53): 281-292. 
Fazi, F., S. Racanicchi, G. Zardo, L. M. Starnes, M. Mancini, L. Travaglini, D. Diverio, E. Ammatuna, G. 
Cimino, F. Lo-Coco, F. Grignani and C. Nervi (2007). "Epigenetic silencing of the myelopoiesis 
regulator microRNA-223 by the AML1/ETO oncoprotein." Cancer Cell 12(5): 457-466. 
Fazi, F., G. Zardo, V. Gelmetti, L. Travaglini, A. Ciolfi, L. Di Croce, A. Rosa, I. Bozzoni, F. Grignani, F. Lo-
Coco, P. G. Pelicci and C. Nervi (2007). "Heterochromatic gene repression of the retinoic acid 
pathway in acute myeloid leukemia." Blood 109(10): 4432-4440. 
Fekri, F., R. C. Delos Santos, R. Karshafian and C. N. Antonescu (2016). "Ultrasound Microbubble 
Treatment Enhances Clathrin-Mediated Endocytosis and Fluid-Phase Uptake through Distinct 
Mechanisms." PLoS One 11(6): e0156754. 
Feldman, G. M., S. Ruhl, M. Bickel, D. S. Finbloom and D. H. Pluznik (1991). "Regulation of 
interleukin-4 receptors on murine myeloid progenitor cells by interleukin-6." Blood 78(7): 1678-
1684. 
Ferrara, F. F., F. Fazi, A. Bianchini, F. Padula, V. Gelmetti, S. Minucci, M. Mancini, P. G. Pelicci, F. Lo 
Coco and C. Nervi (2001). "Histone deacetylase-targeted treatment restores retinoic acid signaling 
and differentiation in acute myeloid leukemia." Cancer Res 61(1): 2-7. 
Festing, M. F. and D. G. Altman (2002). "Guidelines for the design and statistical analysis of 
experiments using laboratory animals." Ilar j 43(4): 244-258. 
Filipowicz, W. (2005). "RNAi: the nuts and bolts of the RISC machine." Cell 122(1): 17-20. 
Fisher, R. K., S. I. Mattern-Schain, M. D. Best, S. S. Kirkpatrick, M. B. Freeman, O. H. Grandas and D. J. 
H. Mountain (2017). "Improving the efficacy of liposome-mediated vascular gene therapy via lipid 
surface modifications." J Surg Res 219: 136-144. 
Folkerts, H., S. Hilgendorf, A. T. J. Wierenga, J. Jaques, A. B. Mulder, P. J. Coffer and J. J. Schuringa 
(2017). "Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia."  
8(7): e2927. 
Fontana, F., D. Liu, J. Hirvonen and H. A. Santos (2017). "Delivery of therapeutics with nanoparticles: 
what's new in cancer immunotherapy?" Wiley Interdiscip Rev Nanomed Nanobiotechnol 9(1). 
Forsbach, A., J. G. Nemorin, C. Montino, C. Muller, U. Samulowitz, A. P. Vicari, M. Jurk, G. K. Mutwiri, 
A. M. Krieg, G. B. Lipford and J. Vollmer (2008). "Identification of RNA sequence motifs stimulating 
sequence-specific TLR8-dependent immune responses." J Immunol 180(6): 3729-3738. 
Frank, F. and B. Nagar (2017). "Structural and Functional Characterization of Plant ARGONAUTE MID 
Domains." Methods Mol Biol 1640: 227-239. 
Freund, A., R. M. Laberge, M. Demaria and J. Campisi (2012). "Lamin B1 loss is a senescence-
associated biomarker." Molecular Biology of the Cell 23(11): 2066-2075. 
Fukuhara, S., K. Sako, K. Noda, K. Nagao, K. Miura and N. Mochizuki (2009). "Tie2 is tied at the cell-
cell contacts and to extracellular matrix by Angiopoietin-1." Experimental and Molecular Medicine 
41(3): 133-139. 
Futreal, P. A. and J. C. Barrett (1991). "Failure of senescent cells to phosphorylate the RB protein." 
Oncogene 6(7): 1109-1113. 
275 
 
Gao, W., Y. Xiong, Q. Li and H. Yang (2017). "Inhibition of Toll-Like Receptor Signaling as a Promising 
Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics." Frontiers in 
Physiology 8. 
Garg, M., Y. Nagata, D. Kanojia, A. Mayakonda, K. Yoshida, S. H. Keloth, Z. J. Zang, Y. Okuno, Y. 
Shiraishi, K. Chiba, H. Tanaka, S. Miyano, L. W. Ding, T. Alpermann, Q. Y. Sun, D. C. Lin, W. W. Chien, 
V. Madan, L. Z. Liu, K. T. Tan, A. Sampath, S. Venkatesan, K. Inokuchi, S. Wakita, H. Yamaguchi, W. J. 
Chng, S. K. Y. Kham, A. E. J. Yeoh, M. Sanada, J. Schiller, K. A. Kreuzer, S. M. Kornblau, H. M. 
Kantarjian, T. Haferlach, M. Lill, M. C. Kuo, L. Y. Shih, I. W. Blau, O. Blau, H. Yang, S. Ogawa and H. P. 
Koeffler (2015). "Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis 
and relapse." Blood 126(22): 2491-2501. 
Geary, R. S., D. Norris, R. Yu and C. F. Bennett (2015). "Pharmacokinetics, biodistribution and cell 
uptake of antisense oligonucleotides." Adv Drug Deliv Rev 87: 46-51. 
Gerritsen, M., E. Tijchon, A. Mandoli, J. H. A. Martens, J. J. Schuringa and E. Vellenga (2016). "RUNX1 
Mutations Cause a Myeloid Differentiation Block Leading to the Formation of a Long Term Expanding 
CD34(+) / CD33(+) / CD45RA(+) / CD123(+) Cell Population." Blood 128(22). 
Gessner, A., M. Thomas, P. G. Castro, L. Buchler, A. Scholz, T. H. Brummendorf, N. M. Soria, J. 
Vormoor, J. Greil and O. Heidenreich (2010). "Leukemic fusion genes MLL/AF4 and AML1/MTG8 
support leukemic self-renewal by controlling expression of the telomerase subunit TERT." Leukemia 
24(10): 1751-1759. 
Gialesaki, S., A. K. Mahnken, L. Schmid, M. Labuhn, R. Bhayadia, D. Heckl and J. H. Klusmann (2018). 
"GATA1s exerts developmental stage-specific effects in human hematopoiesis." Haematologica 
103(8): e336-e340. 
Giambelluca, M. S., N. Cloutier, E. Rollet-Labelle, E. Boilard and M. Pouliot (2013). "Expression and 
regulation of glycogen synthase kinase 3 in human neutrophils." Int J Biochem Cell Biol 45(11): 2660-
2665. 
Gil, J. and G. Peters (2006). "Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one 
or one for all." Nature Reviews Molecular Cell Biology 7(9): 667-677. 
Gilleron, J., W. Querbes, A. Zeigerer, A. Borodovsky, G. Marsico, U. Schubert, K. Manygoats, S. 
Seifert, C. Andree, M. Stoter, H. Epstein-Barash, L. Zhang, V. Koteliansky, K. Fitzgerald, E. Fava, M. 
Bickle, Y. Kalaidzidis, A. Akinc, M. Maier and M. Zerial (2013). "Image-based analysis of lipid 
nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape." Nat 
Biotechnol 31(7): 638-646. 
Goel, S., M. J. DeCristo, S. S. McAllister and J. J. Zhao (2018). "CDK4/6 Inhibition in Cancer: Beyond 
Cell Cycle Arrest." Trends Cell Biol 28(11): 911-925. 
Gordon, P. M., S. Dias and D. A. Williams (2014). "Cytokines secreted by bone marrow stromal cells 
protect c-KIT mutant AML cells from c-KIT inhibitor-induced apoptosis." Leukemia 28(11): 2257-
2260. 
Goyama, S., J. Schibler, L. Cunningham, Y. Zhang, Y. Rao, N. Nishimoto, M. Nakagawa, A. Olsson, M. 
Wunderlich, K. A. Link, B. Mizukawa, H. L. Grimes, M. Kurokawa, P. P. Liu, G. Huang and J. C. Mulloy 
(2013). "Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells." J Clin Invest 
123(9): 3876-3888. 
Graf, T. (2002). "Differentiation plasticity of hematopoietic cells." Blood 99(9): 3089-3101. 
Grant, S. (1998). "Ara-C: cellular and molecular pharmacology." Adv Cancer Res 72: 197-233. 
Grespi, F., C. Soratroi, G. Krumschnabel, B. Sohm, C. Ploner, S. Geley, L. Hengst, G. Hacker and A. 
Villunger (2010). "BH3-only protein Bmf mediates apoptosis upon inhibition of CAP-dependent 
protein synthesis." Cell Death Differ 17(11): 1672-1683. 
Grimwade, D., R. K. Hills, A. V. Moorman, H. Walker, S. Chatters, A. H. Goldstone, K. Wheatley, C. J. 
Harrison, A. K. Burnett and G. National Cancer Research Institute Adult Leukaemia Working (2010). 
"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic 
significance of rare recurring chromosomal abnormalities among 5876 younger adult patients 
treated in the United Kingdom Medical Research Council trials." Blood 116(3): 354-365. 
276 
 
Gu, S., L. Jin, Y. Huang, F. Zhang and M. A. Kay (2012). "Slicing-independent RISC activation requires 
the argonaute PAZ domain." Curr Biol 22(16): 1536-1542. 
Gu, X., Z. Hu, Q. Ebrahem, J. S. Crabb, R. Z. Mahfouz, T. Radivoyevitch, J. W. Crabb and Y. 
Saunthararajah (2014). "Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies 
specific molecular targets for leukemia differentiation therapy." J Biol Chem 289(21): 14881-14895. 
Guan, X., Z. Guo, T. Wang, L. Lin, J. Chen, H. Tian and X. Chen (2017). "A pH-Responsive Detachable 
PEG Shielding Strategy for Gene Delivery System in Cancer Therapy." Biomacromolecules 18(4): 
1342-1349. 
Haas, S., A. Trumpp and M. D. Milsom (2018). "Causes and Consequences of Hematopoietic Stem 
Cell Heterogeneity." Cell Stem Cell 22(5): 627-638. 
Hafez, I. M., N. Maurer and P. R. Cullis (2001). "On the mechanism whereby cationic lipids promote 
intracellular delivery of polynucleic acids." Gene Ther 8(15): 1188-1196. 
Hagedorn, P. H., B. R. Hansen, T. Koch and M. Lindow (2017). "Managing the sequence-specificity of 
antisense oligonucleotides in drug discovery." Nucleic Acids Res 45(5): 2262-2282. 
Haley, B. and P. D. Zamore (2004). "Kinetic analysis of the RNAi enzyme complex." Nat Struct Mol 
Biol 11(7): 599-606. 
Hamburger, A. W. and S. E. Salmon (1977). "Primary bioassay of human tumor stem cells." Science 
197(4302): 461-463. 
Han, J. W., C. Flemington, A. B. Houghton, Z. M. Gu, G. P. Zambetti, R. J. Lutz, L. Zhu and T. 
Chittenden (2001). "Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell 
death and survival signals." Proceedings of the National Academy of Sciences of the United States of 
America 98(20): 11318-11323. 
Hangaishi, A., S. Ogawa, N. Imamura, S. Miyawaki, Y. Miura, N. Uike, C. Shimazaki, N. Emi, K. 
Takeyama, S. Hirosawa, N. Kamada, Y. Kobayashi, Y. Takemoto, T. Kitani, K. Toyama, S. Ohtake, Y. 
Yazaki, R. Ueda and H. Hirai (1996). "Inactivation of multiple tumor-suppressor genes involved in 
negative regulation of the cell cycle, MTS1/p16(INK4A)/CDKN2, MTS2/p15(INK4B), p53, and Rb 
genes in primary lymphoid malignancies." Blood 87(12): 4949-4958. 
Harada, Y., D. Inoue, Y. Ding, J. Imagawa, N. Doki, H. Matsui, T. Yahata, H. Matsushita, K. Ando, G. 
Sashida, A. Iwama, T. Kitamura and H. Harada (2013). "RUNX1/AML1 mutant collaborates with BMI1 
overexpression in the development of human and murine myelodysplastic syndromes." Blood 
121(17): 3434-3446. 
Harbour, J. W., R. X. Luo, A. D. Santi, A. A. Postigo and D. C. Dean (1999). "Cdk phosphorylation 
triggers sequential intramolecular interactions that progressively block Rb functions as cells move 
through G1." Cell 98(6): 859-869. 
Harder, K. W., L. M. Parsons, J. Armes, N. Evans, N. Kountouri, R. Clark, C. Quilici, D. Grail, G. S. 
Hodgson, A. R. Dunn and M. L. Hibbs (2001). "Gain- and loss-of-function Lyn mutant mice define a 
critical inhibitory role for Lyn in the myeloid lineage." Immunity 15(4): 603-615. 
Harney, A. S., G. S. Karagiannis, J. Pignatelli, B. D. Smith, E. Kadioglu, S. C. Wise, M. M. Hood, M. D. 
Kaufman, C. B. Leary, W. P. Lu, G. Al-Ani, X. Chen, D. Entenberg, M. H. Oktay, Y. Wang, L. Chun, M. De 
Palma, J. G. Jones, D. L. Flynn and J. S. Condeelis (2017). "The Selective Tie2 Inhibitor Rebastinib 
Blocks Recruitment and Function of Tie2(Hi) Macrophages in Breast Cancer and Pancreatic 
Neuroendocrine Tumors." Mol Cancer Ther 16(11): 2486-2501. 
Hashiba, K., Y. Sato and H. Harashima (2017). "pH-labile PEGylation of siRNA-loaded lipid 
nanoparticle improves active targeting and gene silencing activity in hepatocytes." J Control Release 
262: 239-246. 
Hassett, K. J., K. E. Benenato, E. Jacquinet, A. Lee, A. Woods, O. Yuzhakov, S. Himansu, J. Deterling, B. 
M. Geilich, T. Ketova, C. Mihai, A. Lynn, I. McFadyen, M. J. Moore, J. J. Senn, M. G. Stanton, Ö. 
Almarsson, G. Ciaramella and L. A. Brito (2019). "Optimization of Lipid Nanoparticles for 
Intramuscular Administration of mRNA Vaccines." Molecular therapy. Nucleic acids 15: 1-11. 
Hayden, M. S. and S. Ghosh (2014). "Regulation of NF-kappaB by TNF family cytokines." Semin 
Immunol 26(3): 253-266. 
277 
 
He, W., M. J. Bennett, L. Luistro, D. Carvajal, T. Nevins, M. Smith, G. Tyagi, J. Cai, X. Wei, T. A. Lin, D. 
C. Heimbrook, K. Packman and J. F. Boylan (2014). "Discovery of siRNA lipid nanoparticles to 
transfect suspension leukemia cells and provide in vivo delivery capability." Mol Ther 22(2): 359-370. 
Heemskerk, H. A., C. L. de Winter, S. J. de Kimpe, P. van Kuik-Romeijn, N. Heuvelmans, G. J. 
Platenburg, G. J. van Ommen, J. C. van Deutekom and A. Aartsma-Rus (2009). "In vivo comparison of 
2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular 
dystrophy exon skipping." J Gene Med 11(3): 257-266. 
Heidenreich, O., J. Krauter, H. Riehle, P. Hadwiger, M. John, G. Heil, H. P. Vornlocher and A. 
Nordheim (2003). "AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid 
differentiation of t(8;21)-positive leukemic cells." Blood 101(8): 3157-3163. 
Helsten, T., S. Kato, M. Schwaederle, B. N. Tomson, T. P. Buys, S. K. Elkin, J. L. Carter and R. Kurzrock 
(2016). "Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: 
Implications for Targeted Therapeutics." Mol Cancer Ther 15(7): 1682-1690. 
Hernandez, F. J., K. R. Stockdale, L. Huang, A. R. Horswill, M. A. Behlke and J. O. McNamara, 2nd 
(2012). "Degradation of nuclease-stabilized RNA oligonucleotides in Mycoplasma-contaminated cell 
culture media." Nucleic Acid Ther 22(1): 58-68. 
Hernandez, J. L., L. Padilla, S. Dakhel, T. Coll, R. Hervas, J. Adan, M. Masa, F. Mitjans, J. M. Martinez, 
S. Coma, L. Rodriguez, V. Noe, C. J. Ciudad, F. Blasco and R. Messeguer (2013). "Therapeutic targeting 
of tumor growth and angiogenesis with a novel anti-S100A4 monoclonal antibody." PLoS One 8(9): 
e72480. 
Herrmann, F., W. Oster and R. Mertelsmann (1990). "Control of blast cell proliferation and 
differentiation in acute myelogenous leukemia by soluble polypeptide growth factors." Klin Padiatr 
202(4): 212-217. 
Hiratsuka, S., A. Watanabe, Y. Sakurai, S. Akashi-Takamura, S. Ishibashi, K. Miyake, M. Shibuya, S. 
Akira, H. Aburatani and Y. Maru (2008). "The S100A8-serum amyloid A3-TLR4 paracrine cascade 
establishes a pre-metastatic phase." Nat Cell Biol 10(11): 1349-1355. 
Hirschi, K. K. (2012). "Hemogenic endothelium during development and beyond." Blood 119(21): 
4823-4827. 
Hoarau, D., P. Delmas, S. David, E. Roux and J. C. Leroux (2004). "Novel long-circulating lipid 
nanocapsules." Pharm Res 21(10): 1783-1789. 
Hoornaert, I., P. Marynen, J. Goris, R. Sciot and M. Baens (2003). "MAPK phosphatase DUSP16/MKP-
7, a candidate tumor suppressor for chromosome region 12p12-13, reduces BCR-ABL-induced 
transformation." Oncogene 22(49): 7728-7736. 
Hope, K. J., L. Jin and J. E. Dick (2004). "Acute myeloid leukemia originates from a hierarchy of 
leukemic stem cell classes that differ in self-renewal capacity." Nat Immunol 5(7): 738-743. 
Hornsveld, M., M. Tenhagen, R. A. van de Ven, A. M. Smits, M. H. van Triest, M. van Amersfoort, D. E. 
Kloet, T. B. Dansen, B. M. Burgering and P. W. Derksen (2016). "Restraining FOXO3-dependent 
transcriptional BMF activation underpins tumour growth and metastasis of E-cadherin-negative 
breast cancer." Cell Death Differ 23(9): 1483-1492. 
Hoy, S. M. (2018). "Patisiran: First Global Approval." Drugs 78(15): 1625-1631. 
Hu, W. and J. Hu (2014). "Prediction of siRNA potency using sparse logistic regression." J Comput Biol 
21(6): 420-427. 
Huang, S. and F. A. Sinicrope (2008). "BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic 
signaling by unsequestering Bim and Bak in human pancreatic cancer cells." Cancer Res 68(8): 2944-
2951. 
Huang, Y., Q. Cheng, J. L. Ji, S. Zheng, L. Du, L. Meng, Y. Wu, D. Zhao, X. Wang, L. Lai, H. Cao, K. Xiao, 
S. Gao and Z. Liang (2016). "Pharmacokinetic Behaviors of Intravenously Administered siRNA in 
Glandular Tissues." Theranostics 6(10): 1528-1541. 
Huang, Y., J. Hong, S. Zheng, Y. Ding, S. Guo, H. Zhang, X. Zhang, Q. Du and Z. Liang (2011). 
"Elimination pathways of systemically delivered siRNA." Mol Ther 19(2): 381-385. 
278 
 
Hussong, J. W., G. M. Rodgers and P. J. Shami (2000). "Evidence of increased angiogenesis in patients 
with acute myeloid leukemia." Blood 95(1): 309-313. 
Hyde, R. K., L. Zhao, L. Alemu and P. P. Liu (2015). "Runx1 is required for hematopoietic defects and 
leukemogenesis in Cbfb-MYH11 knock-in mice." Leukemia 29(8): 1771-1778. 
Iannitti, T., J. C. Morales-Medina and B. Palmieri (2014). "Phosphorothioate oligonucleotides: 
effectiveness and toxicity." Curr Drug Targets 15(7): 663-673. 
Ichikawa, M., A. Yoshimi, M. Nakagawa, N. Nishimoto, N. Watanabe-Okochi and M. Kurokawa 
(2013). "A role for RUNX1 in hematopoiesis and myeloid leukemia." Int J Hematol 97(6): 726-734. 
Ikushima, Y. M., F. Arai, Y. Nakamura, K. Hosokawa, Y. Kubota, M. Hirashima, H. Toyama and T. Suda 
(2013). "Enhanced Angpt1/Tie2 signaling affects the differentiation and long-term repopulation 
ability of hematopoietic stem cells." Biochem Biophys Res Commun 430(1): 20-25. 
Incarnato, D., F. Anselmi, E. Morandi, F. Neri, M. Maldotti, S. Rapelli, C. Parlato, G. Basile and S. 
Oliviero (2017). "High-throughput single-base resolution mapping of RNA 2-O-methylated residues." 
Nucleic Acids Res 45(3): 1433-1441. 
Indovina, P., F. Pentimalli, N. Casini, I. Vocca and A. Giordano (2015). "RB1 dual role in proliferation 
and apoptosis: cell fate control and implications for cancer therapy." Oncotarget 6(20): 17873-
17890. 
Inoue, J., A. Misawa, Y. Tanaka, S. Ichinose, Y. Sugino, H. Hosoi, T. Sugimoto, I. Imoto and J. Inazawa 
(2009). "Lysosomal-associated protein multispanning transmembrane 5 gene (LAPTM5) is associated 
with spontaneous regression of neuroblastomas." PLoS One 4(9): e7099. 
Iorio, M. V. and C. M. Croce (2012). "MicroRNA dysregulation in cancer: diagnostics, monitoring and 
therapeutics. A comprehensive review." EMBO Mol Med 4(3): 143-159. 
Iorio, M. V. and C. M. Croce (2017). "MicroRNA dysregulation in cancer: diagnostics, monitoring and 
therapeutics. A comprehensive review." EMBO Mol Med 9(6): 852. 
Ishihara, T., M. Goto, K. Kodera, H. Kanazawa, Y. Murakami, Y. Mizushima and M. Higaki (2009). 
"Intracellular delivery of siRNA by cell-penetrating peptides modified with cationic oligopeptides." 
Drug Deliv 16(3): 153-159. 
Itkin, T., S. Gur-Cohen, J. A. Spencer, A. Schajnovitz, S. K. Ramasamy, A. P. Kusumbe, G. Ledergor, Y. 
Jung, I. Milo, M. G. Poulos, A. Kalinkovich, A. Ludin, O. Kollet, G. Shakhar, J. M. Butler, S. Rafii, R. H. 
Adams, D. T. Scadden, C. P. Lin and T. Lapidot (2016). "Distinct bone marrow blood vessels 
differentially regulate haematopoiesis." Nature 532(7599): 323-328. 
Ito, M., H. Hiramatsu, K. Kobayashi, K. Suzue, M. Kawahata, K. Hioki, Y. Ueyama, Y. Koyanagi, K. 
Sugamura, K. Tsuji, T. Heike and T. Nakahata (2002). "NOD/SCID/gamma(c)(null) mouse: an excellent 
recipient mouse model for engraftment of human cells." Blood 100(9): 3175-3182. 
Itzykson, R., C. Gardin, C. Pautas, X. Thomas, P. Turlure, E. Raffoux, C. Terre, P. Fenaux, S. Castaigne, 
H. Dombret, N. Boissel and A. Acute Leukemia French (2011). "Impact of post-remission therapy in 
patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant 
randomized ALFA trials with overlapping age inclusion criteria." Haematologica 96(6): 837-844. 
Ivanovs, A., S. Rybtsov, E. S. Ng, E. G. Stanley, A. G. Elefanty and A. Medvinsky (2017). "Human 
haematopoietic stem cell development: from the embryo to the dish." Development 144(13): 2323-
2337. 
Jakubowiak, A., C. Pouponnot, F. Berguido, R. Frank, S. F. Mao, J. Massague and S. D. Nimer (2000). 
"Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-
associated fusion protein." Journal of Biological Chemistry 275(51): 40282-40287. 
Janas, M. M., M. K. Schlegel, C. E. Harbison, V. O. Yilmaz, Y. Jiang, R. Parmar, I. Zlatev, A. Castoreno, 
H. Xu, S. Shulga-Morskaya, K. G. Rajeev, M. Manoharan, N. D. Keirstead, M. A. Maier and V. Jadhav 
(2018). "Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity." 
Nat Commun 9(1): 723. 
Jaroszewski, J. W., V. Clausen, J. S. Cohen and O. Dahl (1996). "NMR investigations of duplex stability 
of phosphorothioate and phosphorodithioate DNA analogues modified in both strands." Nucleic 
Acids Res 24(5): 829-834. 
279 
 
Jayaraman, M., S. M. Ansell, B. L. Mui, Y. K. Tam, J. Chen, X. Du, D. Butler, L. Eltepu, S. Matsuda, J. K. 
Narayanannair, K. G. Rajeev, I. M. Hafez, A. Akinc, M. A. Maier, M. A. Tracy, P. R. Cullis, T. D. Madden, 
M. Manoharan and M. J. Hope (2012). "Maximizing the potency of siRNA lipid nanoparticles for 
hepatic gene silencing in vivo." Angew Chem Int Ed Engl 51(34): 8529-8533. 
Jhaveri, A. M. and V. P. Torchilin (2014). "Multifunctional polymeric micelles for delivery of drugs and 
siRNA." Front Pharmacol 5: 77. 
Jiang, H., L. Zhu, A. Heliou, X. Gao, J. Bernauer and X. Huang (2017). "Elucidating Mechanisms of 
Molecular Recognition Between Human Argonaute and miRNA Using Computational Approaches." 
Methods Mol Biol 1517: 251-275. 
Jin, Y. H., E. J. Jeon, Q. L. Li, Y. H. Lee, J. K. Choi, W. J. Kim, K. Y. Lee and S. C. Bae (2004). 
"Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits 
ubiquitination-mediated degradation." Journal of Biological Chemistry 279(28): 29409-29417. 
Jones, J. E., L. Wang, P. L. Kropf, R. Duan and D. E. Johnson (2009). "Src family kinase gene targets 
during myeloid differentiation: identification of the EGR-1 gene as a direct target." Leukemia 23(10): 
1933-1935. 
Jones, M. and J. Leroux (1999). "Polymeric micelles - a new generation of colloidal drug carriers." Eur 
J Pharm Biopharm 48(2): 101-111. 
Jongen-Lavrencic, M., S. M. Sun, M. K. Dijkstra, P. J. Valk and B. Lowenberg (2008). "MicroRNA 
expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia." Blood 
111(10): 5078-5085. 
Juliano, R., J. Bauman, H. Kang and X. Ming (2009). "Biological Barriers to Therapy with Antisense and 
siRNA Oligonucleotides." Molecular Pharmaceutics 6(3): 686-695. 
Juliano, R. L. (2016). "The delivery of therapeutic oligonucleotides." Nucleic Acids Res 44(14): 6518-
6548. 
Jun, D. Y., H. Kim, W. Y. Jang, J. Y. Lee, K. Fukui and Y. H. Kim (2017). "Ectopic overexpression of 
LAPTM5 results in lysosomal targeting and induces Mcl-1 down-regulation, Bak activation, and 
mitochondria-dependent apoptosis in human HeLa cells." PLoS One 12(5): e0176544. 
Jyotsana, N., A. Sharma, A. Chaturvedi, R. Budida, M. Scherr, F. Kuchenbauer, R. Lindner, F. Noyan, 
K.-W. Sühs, M. Stangel, D. Grote-Koska, K. Brand, H.-P. Vornlocher, M. Eder, F. Thol, A. Ganser, R. K. 
Humphries, E. Ramsay, P. Cullis and M. Heuser (2019). "Lipid nanoparticle-mediated siRNA delivery 
for safe targeting of human CML in vivo." Annals of Hematology 98(8): 1905-1918. 
Jyotsana, N., A. Sharma, A. Chaturvedi, M. Scherr, F. Kuchenbauer, L. Sajti, A. Barchanski, R. Lindner, 
F. Noyan, K. W. Suhs, D. Grote-Koska, K. Brand, H. P. Vornlocher, M. Stanulla, B. Bornhauser, J. P. 
Bourquin, M. Eder, F. Thol, A. Ganser, R. K. Humphries, E. Ramsay, P. Cullis and M. Heuser (2018). 
"RNA interference efficiently targets human leukemia driven by a fusion oncogene in vivo." 
Leukemia 32(1): 224-226. 
Jyotsana, N., A. Sharma, A. Chaturvedi, C. Walsh, A. Thomas, M. Scherr, M. Eder, K. Battmer, F. 
Kuchenbauer, S. Laszlo, A. Barchanski, K. Goerlich, R. Lindner, F. Noyan, S. K. Wolfram, D. Grote-
Koska, K. Brand, H. P. Vornlocher, A. Ganser, E. Ramsay, P. Cullis and M. Heuser (2015). "Effective 
Treatment of Human CML By RNAi In Vivo in a Xenotransplantation Mouse Model." Blood 126(23). 
Kaczmarek, J. C., P. S. Kowalski and D. G. Anderson (2017). "Advances in the delivery of RNA 
therapeutics: from concept to clinical reality." Genome Med 9(1): 60. 
Kaksonen, M. and A. Roux (2018). "Mechanisms of clathrin-mediated endocytosis." Nat Rev Mol Cell 
Biol 19(5): 313-326. 
Kalluri, R. (2016). "The biology and function of fibroblasts in cancer." Nat Rev Cancer 16(9): 582-598. 
Kanasty, R., J. R. Dorkin, A. Vegas and D. Anderson (2013). "Delivery materials for siRNA 
therapeutics." Nat Mater 12(11): 967-977. 
Karpala, A. J., T. J. Doran and A. G. Bean (2005). "Immune responses to dsRNA: implications for gene 
silencing technologies." Immunol Cell Biol 83(3): 211-216. 
Katayama, Y., K. Takenaka, N. Mahmut, T. Teshima, K. Shinagawa, E. Omoto and M. Harada (1998). 
"Replating potential of colony-forming units of granulocytes/macrophages (CFU-GM) expanded ex 
280 
 
vivo by stem cell factor, interleukin (IL)-3, IL-6, granulocyte colony-stimulating factor, erythropoietin 
with or without thrombopoietin." Int J Hematol 68(2): 157-168. 
Kaulfuss, S., M. Grzmil, B. Hemmerlein, P. Thelen, S. Schweyer, J. Neesen, L. Bubendorf, A. G. Glass, 
H. Jarry, B. Auber and P. Burfeind (2008). "Leupaxin, a novel coactivator of the androgen receptor, is 
expressed in prostate cancer and plays a role in adhesion and invasion of prostate carcinoma cells." 
Molecular Endocrinology 22(7): 1606-1621. 
Kaushansky, K. (2009). "Molecular mechanisms of thrombopoietin signaling." J Thromb Haemost 7 
Suppl 1: 235-238. 
Kawamata, T. and Y. Tomari (2011). "Native gel analysis for RISC assembly." Methods Mol Biol 725: 
91-105. 
Keskin, D. and A. Tezcaner (2017). "Micelles As Delivery System for Cancer Treatment." Curr Pharm 
Des 23(35): 5230-5241. 
Khvorova, A. and J. K. Watts (2017). "The chemical evolution of oligonucleotide therapies of clinical 
utility." Nat Biotechnol 35(3): 238-248. 
Kipps, T. J., H. Eradat, S. Grosicki, J. Catalano, W. Cosolo, I. S. Dyagil, S. Yalamanchili, A. Chai, S. 
Sahasranaman, E. Punnoose, D. Hurst and H. Pylypenko (2015). "A phase 2 study of the BH3 mimetic 
BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic 
lymphocytic leukemia." Leukemia & Lymphoma 56(10): 2826-2833. 
Klusmann, J. H., F. J. Godinho, K. Heitmann, A. Maroz, M. L. Koch, D. Reinhardt, S. H. Orkin and Z. Li 
(2010). "Developmental stage-specific interplay of GATA1 and IGF signaling in fetal 
megakaryopoiesis and leukemogenesis." Genes Dev 24(15): 1659-1672. 
Kobayashi, H. and Y. Tomari (2016). "RISC assembly: Coordination between small RNAs and 
Argonaute proteins." Biochim Biophys Acta 1859(1): 71-81. 
Kohn, E. A., N. D. Ruth, M. K. Brown, M. Livingstone and A. Eastman (2002). "Abrogation of the S 
phase DNA damage checkpoint results in S phase progression or premature mitosis depending on 
the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation." Journal of 
Biological Chemistry 277(29): 26553-26564. 
Koltover, I., T. Salditt, J. O. Radler and C. R. Safinya (1998). "An inverted hexagonal phase of cationic 
liposome-DNA complexes related to DNA release and delivery." Science 281(5373): 78-81. 
Kozu, T., T. Fukuyama, T. Yamami, K. Akagi and Y. Kaneko (2005). "MYND-less splice variants of 
AML1-MTG8 (RUNX1-CBFA2T1) are expressed in leukemia with t(8;21)." Genes Chromosomes 
Cancer 43(1): 45-53. 
Kranc, K. R., D. V. Oliveira, A. Armesilla-Diaz, I. Pacheco-Leyva, A. C. Matias, A. L. Escapa, C. 
Subramani, H. Wheadon, M. Trindade, J. Nichols, K. Kaji, T. Enver and J. Braganca (2015). "Acute Loss 
of Cited2 Impairs Nanog Expression and Decreases Self-Renewal of Mouse Embryonic Stem Cells." 
Stem Cells 33(3): 699-712. 
Kuang, H., S. H. Ku and E. Kokkoli (2017). "The design of peptide-amphiphiles as functional ligands 
for liposomal anticancer drug and gene delivery." Adv Drug Deliv Rev 110-111: 80-101. 
Kumar, K., A. Singal, M. M. Rizvi and V. S. Chauhan (2008). "High mobility group box (HMGB) proteins 
of Plasmodium falciparum: DNA binding proteins with pro-inflammatory activity." Parasitol Int 57(2): 
150-157. 
Kurkewich, J. L., J. Hansen, N. Klopfenstein, H. Zhang, C. Wood, A. Boucher, J. Hickman, D. E. 
Muench, H. L. Grimes and R. Dahl (2017). "The miR-23a~27a~24-2 microRNA cluster buffers 
transcription and signaling pathways during hematopoiesis." PLoS Genet 13(7): e1006887. 
Kwak, P. B. and Y. Tomari (2012). "The N domain of Argonaute drives duplex unwinding during RISC 
assembly." Nat Struct Mol Biol 19(2): 145-151. 
Lam, K. and D. E. Zhang (2012). "RUNX1 and RUNX1-ETO: roles in hematopoiesis and 
leukemogenesis." Front Biosci (Landmark Ed) 17: 1120-1139. 
Landesman, Y., N. Svrzikapa, A. Cognetta, 3rd, X. Zhang, B. R. Bettencourt, S. Kuchimanchi, K. 
Dufault, S. Shaikh, M. Gioia, A. Akinc, R. Hutabarat and R. Meyers (2010). "In vivo quantification of 
281 
 
formulated and chemically modified small interfering RNA by heating-in-Triton quantitative reverse 
transcription polymerase chain reaction (HIT qRT-PCR)." Silence 1(1): 16. 
Lapidot, T., C. Sirard, J. Vormoor, B. Murdoch, T. Hoang, J. Cacerescortes, M. Minden, B. Paterson, M. 
A. Caligiuri and J. E. Dick (1994). "A Cell Initiating Human Acute Myeloid-Leukemia after 
Transplantation into Scid Mice." Nature 367(6464): 645-648. 
Laslo, P., C. J. Spooner, A. Warmflash, D. W. Lancki, H. J. Lee, R. Sciammas, B. N. Gantner, A. R. 
Dinner and H. Singh (2006). "Multilineage transcriptional priming and determination of alternate 
hematopoietic cell fates." Cell 126(4): 755-766. 
Lee, H. S., H. Seok, D. H. Lee, J. Ham, W. Lee, E. M. Youm, J. S. Yoo, Y. S. Lee, E. S. Jang and S. W. Chi 
(2015). "Abasic pivot substitution harnesses target specificity of RNA interference." Nat Commun 6: 
10154. 
Lendvai, G., I. Velikyan, M. Bergstrom, S. Estrada, D. Laryea, M. Valila, S. Salomaki, B. Langstrom and 
A. Roivainen (2005). "Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2'-O-
methyl phosphodiester oligonucleotides in normal rats." Eur J Pharm Sci 26(1): 26-38. 
Leung, A. K., I. M. Hafez, S. Baoukina, N. M. Belliveau, I. V. Zhigaltsev, E. Afshinmanesh, D. P. 
Tieleman, C. L. Hansen, M. J. Hope and P. R. Cullis (2012). "Lipid Nanoparticles Containing siRNA 
Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core." J Phys Chem C 
Nanomater Interfaces 116(34): 18440-18450. 
Leung, A. K., Y. Y. Tam, S. Chen, I. M. Hafez and P. R. Cullis (2015). "Microfluidic Mixing: A General 
Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems." J Phys Chem B 119(28): 
8698-8706. 
Leung, A. K., Y. Y. Tam and P. R. Cullis (2014). "Lipid nanoparticles for short interfering RNA delivery." 
Adv Genet 88: 71-110. 
Li, K., X. X. Lv, F. Hua, H. Lin, W. Sun, W. B. Cao, X. M. Fu, J. Xie, J. J. Yu, Z. Li, H. Liu, M. Z. Han and Z. 
W. Hu (2014). "Targeting acute myeloid leukemia with a proapoptotic peptide conjugated to a Toll-
like receptor 2-mediated cell-penetrating peptide." Int J Cancer 134(3): 692-702. 
Li, L. M., Z. X. Chen, J. N. Cen, H. J. Shen, L. Yao, Y. Y. Wang and X. F. Qi (2012). "[Monitoring the 
expression ratio of AML1-ETO9a isoform in t(8;21) acute myeloid leukemia and its significance]." 
Zhonghua Xue Ye Xue Za Zhi 33(1): 1-5. 
Li, Q., D. L. Ramirez-Bergeron, S. L. Dunwoodie and Y. C. Yang (2012). "Cited2 gene controls 
pluripotency and cardiomyocyte differentiation of murine embryonic stem cells through Oct4 gene." 
J Biol Chem 287(34): 29088-29100. 
Li, Y., L. Gao, X. Luo, L. Wang, X. Gao, W. Wang, J. Sun, L. Dou, J. Li, C. Xu, L. Wang, M. Zhou, M. Jiang, 
J. Zhou, M. A. Caligiuri, C. Nervi, C. D. Bloomfield, G. Marcucci and L. Yu (2013). "Epigenetic silencing 
of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the 
PTEN/PI3K signal pathway." Blood 121(3): 499-509. 
Li, Z., J. Lu, M. Sun, S. Mi, H. Zhang, R. T. Luo, P. Chen, Y. Wang, M. Yan, Z. Qian, M. B. Neilly, J. Jin, Y. 
Zhang, S. K. Bohlander, D. E. Zhang, R. A. Larson, M. M. Le Beau, M. J. Thirman, T. R. Golub, J. D. 
Rowley and J. Chen (2008). "Distinct microRNA expression profiles in acute myeloid leukemia with 
common translocations." Proc Natl Acad Sci U S A 105(40): 15535-15540. 
Lie, A. L. M., E. Marinopoulou, A. J. Lilly, M. Challinor, R. Patel, C. Lancrin and V. Kouskoff (2018). 
"Regulation of RUNX1 dosage is crucial for efficient blood formation from hemogenic endothelium."  
145(5). 
Lieber, M. M. and J. S. Kovach (1982). "Soft agar colony formation assay for chemotherapy sensitivity 
testing of human solid tumors." Mayo Clin Proc 57(8): 527-528. 
Liesveld, J. L., P. C. Keng, J. M. Rowe, J. F. DiPersio and C. N. Abboud (1994). "Effects of GM-CSF on 
Ki67 expression and cell cycle traverse in acute myelogenous leukemia specimens and cell lines." 
Leuk Res 18(8): 609-616. 




Lin, S., A. Ptasinska, X. Chen, M. Shrestha, S. A. Assi, P. S. Chin, M. R. Imperato, B. J. Aronow, J. Zhang, 
M. T. Weirauch, C. Bonifer and J. C. Mulloy (2017). "A FOXO1-induced oncogenic network defines the 
AML1-ETO preleukemic program." Blood 130(10): 1213-1222. 
Lingel, A., B. Simon, E. Izaurralde and M. Sattler (2003). "Structure and nucleic-acid binding of the 
Drosophila Argonaute 2 PAZ domain." Nature 426(6965): 465-469. 
Liss, A., C. H. Ooi, P. Zjablovskaja, T. Benoukraf, H. S. Radomska, C. Ju, M. Wu, M. Balastik, R. Delwel, 
T. Brdicka, P. Tan, D. G. Tenen and M. Alberich-Jorda (2014). "The gene signature in CCAAT-
enhancer-binding protein alpha dysfunctional acute myeloid leukemia predicts responsiveness to 
histone deacetylase inhibitors." Haematologica 99(4): 697-705. 
Liu, J., T. Liu, X. Wang and A. He (2017). "Circles reshaping the RNA world: from waste to treasure." 
Mol Cancer 16(1): 58. 
Liu, Y., A. Kosaka, M. Ikeura, G. Kohanbash, W. Fellows-Mayle, L. A. Snyder and H. Okada (2013). 
"Premetastatic soil and prevention of breast cancer brain metastasis." Neuro Oncol 15(7): 891-903. 
Loke, J., S. A. Assi, M. R. Imperato, A. Ptasinska, P. Cauchy, Y. Grabovska, N. M. Soria, M. Raghavan, 
H. R. Delwel, P. N. Cockerill, O. Heidenreich and C. Bonifer (2017). "RUNX1-ETO and RUNX1-EVI1 
Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML." Cell Rep 19(8): 1654-
1668. 
Lorsbach, R. B., J. Moore, S. O. Ang, W. Sun, N. Lenny and J. R. Downing (2004). "Role of RUNX1 in 
adult hematopoiesis: analysis of RUNX1-IRES-GFP knock-in mice reveals differential lineage 
expression." Blood 103(7): 2522-2529. 
Love, K. T., K. P. Mahon, C. G. Levins, K. A. Whitehead, W. Querbes, J. R. Dorkin, J. Qin, W. Cantley, L. 
L. Qin, T. Racie, M. Frank-Kamenetsky, K. N. Yip, R. Alvarez, D. W. Y. Sah, A. de Fougerolles, K. 
Fitzgerald, V. Koteliansky, A. Akinc, R. Langer and D. G. Anderson (2010). "Lipid-like materials for 
low-dose, in vivo gene silencing (vol 107, pg 1864, 2010)." Proceedings of the National Academy of 
Sciences of the United States of America 107(21): 9915-9915. 
Lundberg, F. N. M. L. G., R. Lerner, P. Sundelin, R. Rogers, J. Folkman and J. Palmblad (1998). "Bone 
marrow in polycythemia vera, chronic myelocytic leukemia and myelofibrosis has an increased 
vascular density." Blood 92(10): 425a-425a. 
Maciel-Baron, L. A., S. L. Morales-Rosales, A. A. Aquino-Cruz, F. Triana-Martinez, S. Galvan-Arzate, A. 
Luna-Lopez, V. Y. Gonzalez-Puertos, N. E. Lopez-Diazguerrero, C. Torres and M. Konigsberg (2016). 
"Senescence associated secretory phenotype profile from primary lung mice fibroblasts depends on 
the senescence induction stimuli." Age (Dordr) 38(1): 26. 
Maier, M. A., M. Jayaraman, S. Matsuda, J. Liu, S. Barros, W. Querbes, Y. K. Tam, S. M. Ansell, V. 
Kumar, J. Qin, X. Zhang, Q. Wang, S. Panesar, R. Hutabarat, M. Carioto, J. Hettinger, P. Kandasamy, D. 
Butler, K. G. Rajeev, B. Pang, K. Charisse, K. Fitzgerald, B. L. Mui, X. Du, P. Cullis, T. D. Madden, M. J. 
Hope, M. Manoharan and A. Akinc (2013). "Biodegradable lipids enabling rapidly eliminated lipid 
nanoparticles for systemic delivery of RNAi therapeutics." Mol Ther 21(8): 1570-1578. 
Maiti, M., K. Nauwelaerts, E. Lescrinier and P. Herdewijn (2011). "Structural and binding study of 
modified siRNAs with the Argonaute 2 PAZ domain by NMR spectroscopy." Chemistry 17(5): 1519-
1528. 
Martinez-Soria , L. M., Julia Draper, Anetta Ptasinska, Hasan Issa, Sandeep Potluri, Helen J. Blair, 
Anna Pickin, Asmida Isa, Paulynn Suyin Chin, Ricky Tirtakusuma, Daniel Coleman, Sirintra Nakjang, 
Salam Assi, Victoria Forster, Mojgan Reza, Ed Law, Philip Berry, Dorothee Mueller, Alex Elder, Simon 
N. Bomken, Deepali Pal, James M. Allan, Gareth J. Veal, Peter N. Cockerill, Christian Wichmann, Josef 
Vormoor, Georges Lacaud, Constanze Bonifer, Olaf Heidenreich (2018). "The Oncogenic 
Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation " 
Cancer Cell. 
Martinez, J. and T. Tuschl (2004). "RISC is a 5 ' phosphomonoester-producing RNA endonuclease." 
Genes & Development 18(9): 975-980. 
283 
 
Martinez, M., M. Hinojosa, D. Trombly, V. Morin, J. Stein, G. Stein, A. Javed and S. E. Gutierrez 
(2016). "Transcriptional Auto-Regulation of RUNX1 P1 Promoter." PloS one 11(2): e0149119-
e0149119. 
Martinez, N., B. Drescher, H. Riehle, C. Cullmann, H. P. Vornlocher, A. Ganser, G. Heil, A. Nordheim, J. 
Krauter and O. Heidenreich (2004). "The oncogenic fusion protein RUNX1-CBFA2T1 supports 
proliferation and inhibits senescence in t(8;21)-positive leukaemic cells." BMC Cancer 4: 44. 
Mathas, S., M. Hinz, I. Anagnostopoulos, D. Krappmann, A. Lietz, F. Jundt, K. Bommert, F. Mechta-
Grigoriou, H. Stein, B. Dorken and C. Scheidereit (2002). "Aberrantly expressed c-Jun and JunB are a 
hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B." EMBO 
J 21(15): 4104-4113. 
Matsuura, S., M. Yan, M. C. Lo, E. Y. Ahn, S. Weng, D. Dangoor, M. Matin, T. Higashi, G. S. Feng and 
D. E. Zhang (2012). "Negative effects of GM-CSF signaling in a murine model of t(8;21)-induced 
leukemia." Blood 119(13): 3155-3163. 
Matzke, M. A. and J. A. Birchler (2005). "RNAi-mediated pathways in the nucleus." Nat Rev Genet 
6(1): 24-35. 
Mayerhofer, M., P. Valent, W. R. Sperr, J. D. Griffin and C. Sillaber (2002). "BCR/ABL induces 
expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible 
factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of 
rapamycin." Blood 100(10): 3767-3775. 
Mazel, S., D. Burtrum and H. T. Petrie (1996). "Regulation of cell division cycle progression by bcl-2 
expression: a potential mechanism for inhibition of programmed cell death." J Exp Med 183(5): 
2219-2226. 
Mazurier, F., A. Fontanellas, S. Salesse, L. Taine, S. Landriau, F. Moreau-Gaudry, J. Reiffers, B. Peault, 
J. P. D. Santo and H. D. Verneuil (1999). "A Novel Immunodeficient Mouse Model-RAG2 gamma 
Cytokine Receptor Chain Double Mutants-Requiring Exogenous Cytokine Administration for Human 
Hematopoietic Stem Cell Engraftment Common." Journal of Interferon & Cytokine Research 19(5): 
533-541. 
Mendelson, A. and P. S. Frenette (2014). "Hematopoietic stem cell niche maintenance during 
homeostasis and regeneration." Nat Med 20(8): 833-846. 
Meng, Z. and M. Lu (2017). "RNA Interference-Induced Innate Immunity, Off-Target Effect, or 
Immune Adjuvant?" Front Immunol 8: 331. 
Mermel, C. H., M. L. McLemore, F. Liu, S. Pereira, J. Woloszynek, C. A. Lowell and D. C. Link (2006). 
"Src family kinases are important negative regulators of G-CSF-dependent granulopoiesis." Blood 
108(8): 2562-2568. 
Mettlen, M., D. Loerke, D. Yarar, G. Danuser and S. L. Schmid (2010). "Cargo- and adaptor-specific 
mechanisms regulate clathrin-mediated endocytosis." J Cell Biol 188(6): 919-933. 
Metzeler, K. H. and C. D. Bloomfield (2017). Clinical Relevance of RUNX1 and CBFB Alterations in 
Acute Myeloid Leukemia and Other Hematological Disorders. RUNX Proteins in Development and 
Cancer. Y. Groner, Y. Ito, P. Liu et al. Singapore, Springer Singapore: 175-199. 
Michaloglou, C., L. C. Vredeveld, M. S. Soengas, C. Denoyelle, T. Kuilman, C. M. van der Horst, D. M. 
Majoor, J. W. Shay, W. J. Mooi and D. S. Peeper (2005). "BRAFE600-associated senescence-like cell 
cycle arrest of human naevi." Nature 436(7051): 720-724. 
Mihalyova, J., T. Jelinek, K. Growkova, M. Hrdinka, M. Simicek and R. Hajek (2018). "Venetoclax: A 
new wave in hematooncology." Exp Hematol 61: 10-25. 
Miranda, M. B. and D. E. Johnson (2007). "Signal transduction pathways that contribute to myeloid 
differentiation." Leukemia 21(7): 1363-1377. 
Miranda, M. B., R. L. Redner and D. E. Johnson (2007). "Inhibition of Src family kinases enhances 




Morrissey, D. V., K. Blanchard, L. Shaw, K. Jensen, J. A. Lockridge, B. Dickinson, J. A. McSwiggen, C. 
Vargeese, K. Bowman, C. S. Shaffer, B. A. Polisky and S. Zinnen (2005). "Activity of stabilized short 
interfering RNA in a mouse model of hepatitis B virus replication." Hepatology 41(6): 1349-1356. 
Mu, Q., T. Hu and J. Yu (2013). "Molecular insight into the steric shielding effect of PEG on the 
conjugated staphylokinase: biochemical characterization and molecular dynamics simulation." PLoS 
One 8(7): e68559. 
Mui, B. L., Y. K. Tam, M. Jayaraman, S. M. Ansell, X. Du, Y. Y. Tam, P. J. Lin, S. Chen, J. K. 
Narayanannair, K. G. Rajeev, M. Manoharan, A. Akinc, M. A. Maier, P. Cullis, T. D. Madden and M. J. 
Hope (2013). "Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and 
Pharmacodynamics of siRNA Lipid Nanoparticles." Mol Ther Nucleic Acids 2: e139. 
Mund, M., J. A. van der Beek, J. Deschamps, S. Dmitrieff, P. Hoess, J. L. Monster, A. Picco, F. Nedelec, 
M. Kaksonen and J. Ries (2018). "Systematic Nanoscale Analysis of Endocytosis Links Efficient Vesicle 
Formation to Patterned Actin Nucleation." Cell 174(4): 884-896 e817. 
Munoz-Espin, D. and M. Serrano (2014). "Cellular senescence: from physiology to pathology." Nat 
Rev Mol Cell Biol 15(7): 482-496. 
Nakanishi, K. (2016). "Anatomy of RISC: how do small RNAs and chaperones activate Argonaute 
proteins?" Wiley Interdiscip Rev RNA 7(5): 637-660. 
Naruse, K., E. Matsuura-Suzuki, M. Watanabe, S. Iwasaki and Y. Tomari (2018). "In vitro 
reconstitution of chaperone-mediated human RISC assembly." Rna 24(1): 6-11. 
Navarro, G., J. Y. Pan and V. P. Torchilin (2015). "Micelle-like Nanoparticles as Carriers for DNA and 
siRNA." Molecular Pharmaceutics 12(2): 301-313. 
Nelson, G., O. Kucheryavenko, J. Wordsworth and T. von Zglinicki (2018). "The senescent bystander 
effect is caused by ROS-activated NF-kappaB signalling." Mech Ageing Dev 170: 30-36. 
Nick, H. J., H. G. Kim, C. W. Chang, K. W. Harris, V. Reddy and C. A. Klug (2012). "Distinct classes of c-
Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid 
leukemia." Blood 119(6): 1522-1531. 
Nip, H., A. A. Dar, S. Saini, M. Colden, S. Varahram, H. Chowdhary, S. Yamamura, Y. Mitsui, Y. Tanaka, 
T. Kato, Y. Hashimoto, M. Shiina, P. Kulkarni, P. Dasgupta, M. Imai-Sumida, Z. L. Tabatabai, K. Greene, 
G. Deng, R. Dahiya and S. Majid (2016). "Oncogenic microRNA-4534 regulates PTEN pathway in 
prostate cancer." Oncotarget 7(42): 68371-68384. 
Novobrantseva, T. I., A. Borodovsky, J. Wong, B. Klebanov, M. Zafari, K. Yucius, W. Querbes, P. Ge, V. 
M. Ruda, S. Milstein, L. Speciner, R. Duncan, S. Barros, G. Basha, P. Cullis, A. Akinc, J. S. Donahoe, K. 
Narayanannair Jayaprakash, M. Jayaraman, R. L. Bogorad, K. Love, K. Whitehead, C. Levins, M. 
Manoharan, F. K. Swirski, R. Weissleder, R. Langer, D. G. Anderson, A. de Fougerolles, M. Nahrendorf 
and V. Koteliansky (2012). "Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and 
Rodent Myeloid Cells." Mol Ther Nucleic Acids 1: e4. 
Nuylan, M., T. Kawano, J. Inazawa and J. Inoue (2016). "Down-regulation of LAPTM5 in human 
cancer cells." Oncotarget 7(19): 28320-28328. 
O'Brien, S. G., M. A. Kirkland, J. V. Melo, M. H. Rao, R. J. Davidson, C. McDonald and J. M. Goldman 
(1994). "Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell 
lines." Leukemia 8(12): 2156-2162. 
Obenauer, J. C., P. M. H. van Strien, R. M. Hoogenboezem, M. M. van den Heuvel-Eibrink and I. P. 
Touw (2015). "RUNX1 TAD and RHD Mutations Found in SCN/AML Differentially Affect HSPC 
Expansion in Conjunction with Truncated CSF3 Receptors." Blood 126(23). 
Oh, N. and J. H. Park (2014). "Endocytosis and exocytosis of nanoparticles in mammalian cells." Int J 
Nanomedicine 9 Suppl 1: 51-63. 
Ohbo, K., T. Suda, M. Hashiyama, A. Mantani, M. Ikebe, K. Miyakawa, M. Moriyama, M. Nakamura, 
M. Katsuki, K. Takahashi, K. Yamamura and K. Sugamura (1996). "Modulation of hematopoiesis in 
mice with a truncated mutant of the interleukin-2 receptor gamma chain." Blood 87(3): 956-967. 
285 
 
Omori, K., M. Mitsuhashi, K. Ishiyama, I. Nair, J. Rawson, I. Todorov, F. Kandeel and Y. Mullen (2011). 
"mRNA of the pro-apoptotic gene BBC3 serves as a molecular marker for TNF-alpha-induced islet 
damage in humans." Diabetologia 54(8): 2056-2066. 
Ono, T., Y. Yanagawa, K. Iwabuchi, K. Nonomura and K. Onoe (2007). "Glycogen synthase kinase 3 
activity during development of bone marrow-derived dendritic cells (DCs) essential for the DC 
function to induce T helper 2 polarization." Immunology 122(2): 189-198. 
Opferman, J. T., H. Iwasaki, C. C. Ong, H. Suh, S. Mizuno, K. Akashi and S. J. Korsmeyer (2005). 
"Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells." Science 
307(5712): 1101-1104. 
Pal, D., H. J. Blair, A. Elder, K. Dormon, K. J. Rennie, D. J. Coleman, J. Weiland, K. S. Rankin, A. Filby, O. 
Heidenreich and J. Vormoor (2016). "Long-term in vitro maintenance of clonal abundance and 
leukaemia-initiating potential in acute lymphoblastic leukaemia." Leukemia 30(8): 1691-1700. 
Pal, D., H. J. Blair, A. Elder, K. Dormon, K. J. Rennie, D. J. L. Coleman, J. Weiland, K. S. Rankin, A. Filby, 
O. Heidenreich and J. Vormoor (2016). "Long-term in vitro maintenance of clonal abundance and 
leukaemia-initiating potential in acute lymphoblastic leukaemia." Leukemia 30: 1691. 
Pan, R., L. J. Hogdal, J. M. Benito, D. Bucci, L. Han, G. Borthakur, J. Cortes, D. J. DeAngelo, L. Debose, 
H. Mu, H. Dohner, V. I. Gaidzik, I. Galinsky, L. S. Golfman, T. Haferlach, K. G. Harutyunyan, J. Hu, J. D. 
Leverson, G. Marcucci, M. Muschen, R. Newman, E. Park, P. P. Ruvolo, V. Ruvolo, J. Ryan, S. 
Schindela, P. Zweidler-McKay, R. M. Stone, H. Kantarjian, M. Andreeff, M. Konopleva and A. G. Letai 
(2014). "Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid 
leukemia." Cancer Discov 4(3): 362-375. 
Pang, Q. S., W. Keeble, T. A. Christianson, J. Diaz, M. O'Dwyer, S. Fagerlie, K. Rathbun, G. R. Faulkner 
and G. C. Bagby (2000). "Interferon gamma (IFN-gamma) hypersensitivity of Fanconi anemia (FA) 
cells: The role of double-stranded RNA dependent protein kinase (PKR)." Blood 96(11): 569a-+. 
Papisov, M. I. (1998). "Theoretical considerations of RES-avoiding liposomes: Molecular mechanics 
and chemistry of liposome interactions." Adv Drug Deliv Rev 32(1-2): 119-138. 
Parikh, S. M. (2017). "Angiopoietins and Tie2 in vascular inflammation." Curr Opin Hematol 24(5): 
432-438. 
Park, J., J. Park, Y. Pei, J. Xu and Y. Yeo (2016). "Pharmacokinetics and biodistribution of recently-
developed siRNA nanomedicines." Adv Drug Deliv Rev 104: 93-109. 
Patan, S. (1998). "TIE1 and TIE2 receptor tyrosine kinases inversely regulate embryonic angiogenesis 
by the mechanism of intussusceptive microvascular growth." Microvasc Res 56(1): 1-21. 
Perez-Atayde, A. R., S. E. Sallan, U. Tedrow, S. Connors, E. Allred and J. Folkman (1997). "Spectrum of 
tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia." Am J Pathol 
150(3): 815-821. 
Peterson, L. F. and D. E. Zhang (2004). "The 8;21 translocation in leukemogenesis." Oncogene 23(24): 
4255-4262. 
Pham, J. W. and E. J. Sontheimer (2005). "Molecular requirements for RNA-induced silencing 
complex assembly in the Drosophila RNA interference pathway." J Biol Chem 280(47): 39278-39283. 
Pieken, W. A., D. B. Olsen, F. Benseler, H. Aurup and F. Eckstein (1991). "Kinetic characterization of 
ribonuclease-resistant 2'-modified hammerhead ribozymes." Science 253(5017): 314-317. 
Pietras, E. M., C. Mirantes-Barbeito, S. Fong, D. Loeffler, L. V. Kovtonyuk, S. Zhang, R. 
Lakshminarasimhan, C. P. Chin, J. M. Techner, B. Will, C. Nerlov, U. Steidl, M. G. Manz, T. Schroeder 
and E. Passegue (2016). "Chronic interleukin-1 exposure drives haematopoietic stem cells towards 
precocious myeloid differentiation at the expense of self-renewal." Nat Cell Biol 18(6): 607-618. 
Piller, G. (2001). "Leukaemia - a brief historical review from ancient times to 1950." Br J Haematol 
112(2): 282-292. 
Ptasinska, A., S. A. Assi, D. Mannari, S. R. James, D. Williamson, J. Dunne, M. Hoogenkamp, M. Wu, 
M. Care, H. McNeill, P. Cauchy, M. Cullen, R. M. Tooze, D. G. Tenen, B. D. Young, P. N. Cockerill, D. R. 
Westhead, O. Heidenreich and C. Bonifer (2012). "Depletion of RUNX1/ETO in t(8;21) AML cells leads 
286 
 
to genome-wide changes in chromatin structure and transcription factor binding." Leukemia 26(8): 
1829-1841. 
Ptasinska, A., S. A. Assi, N. Martinez-Soria, M. R. Imperato, J. Piper, P. Cauchy, A. Pickin, S. R. James, 
M. Hoogenkamp, D. Williamson, M. Wu, D. G. Tenen, S. Ott, D. R. Westhead, P. N. Cockerill, O. 
Heidenreich and C. Bonifer (2014). "Identification of a dynamic core transcriptional network in 
t(8;21) AML that regulates differentiation block and self-renewal." Cell Rep 8(6): 1974-1988. 
Pulikkan, J. A., D. Madera, L. Xue, P. Bradley, S. F. Landrette, Y. H. Kuo, S. Abbas, L. J. Zhu, P. Valk and 
L. H. Castilla (2012). "Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO 
acute myeloid leukemia via PI3K/AKT signaling." Blood 120(4): 868-879. 
Qiu, C., Q. Xie, D. Zhang, Q. Chen, J. Hu and L. Xu (2014). "GM-CSF induces cyclin D1 expression and 
proliferation of endothelial progenitor cells via PI3K and MAPK signaling." Cell Physiol Biochem 
33(3): 784-795. 
Quintas-Cardama, A., C. Hu, A. Qutub, Y. H. Qiu, X. Zhang, S. M. Post, N. Zhang, K. Coombes and S. M. 
Kornblau (2017). "p53 pathway dysfunction is highly prevalent in acute myeloid leukemia 
independent of TP53 mutational status." Leukemia 31(6): 1296-1305. 
Raje, N., S. Kumar, T. Hideshima, A. Roccaro, K. Ishitsuka, H. Yasui, N. Shiraishi, D. Chauhan, N. C. 
Munshi, S. R. Green and K. C. Anderson (2005). "Seliciclib (CYC202 or R-roscovitine), a small-molecule 
cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple 
myeloma." Blood 106(3): 1042-1047. 
Regha, K., S. A. Assi, O. Tsoulaki, J. Gilmour, G. Lacaud and C. Bonifer (2015). "Developmental-stage-
dependent transcriptional response to leukaemic oncogene expression." Nat Commun 6: 7203. 
Reikvam, H., K. J. Hatfield, P. Lassalle, A. O. Kittang, E. Ersvaer and O. Bruserud (2010). "Targeting the 
angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial 
cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic 
Ang-1 release." Expert Opinion on Investigational Drugs 19(2): 169-183. 
Reinhardt, D., K. Reinhardt, C. Neuhoff, A. Sander, J. H. Klusmann, A. Pekrun, A. Sauerbrey, A. von 
Stackelberg, C. Rossig, U. Creutzig and A. Kolenova (2012). "[GATA1-mutation associated leukemia in 
children with trisomy 21 mosaic]." Klin Padiatr 224(3): 153-155. 
Rejman, J., A. Bragonzi and M. Conese (2005). "Role of clathrin- and caveolae-mediated endocytosis 
in gene transfer mediated by lipo- and polyplexes." Mol Ther 12(3): 468-474. 
Rejman, J., M. Conese and D. Hoekstra (2006). "Gene transfer by means of lipo- and polyplexes: role 
of clathrin and caveolae-mediated endocytosis." J Liposome Res 16(3): 237-247. 
Ritschka, B., M. Storer, A. Mas, F. Heinzmann, M. C. Ortells, J. P. Morton, O. J. Sansom, L. Zender and 
W. M. Keyes (2017). "The senescence-associated secretory phenotype induces cellular plasticity and 
tissue regeneration." Genes Dev 31(2): 172-183. 
Rizk, M. and S. Tuzmen (2017). "Update on the clinical utility of an RNA interference-based 
treatment: focus on Patisiran." Pharmgenomics Pers Med 10: 267-278. 
Roberts, A. W., J. F. Seymour, J. R. Brown, W. G. Wierda, T. J. Kipps, S. L. Khaw, D. A. Carney, S. Z. He, 
D. C. Huang, H. Xiong, Y. Cui, T. A. Busman, E. M. McKeegan, A. P. Krivoshik, S. H. Enschede and R. 
Humerickhouse (2012). "Substantial susceptibility of chronic lymphocytic leukemia to BCL2 
inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease." J 
Clin Oncol 30(5): 488-496. 
Rodier, F., J. P. Coppe, C. K. Patil, W. A. Hoeijmakers, D. P. Munoz, S. R. Raza, A. Freund, E. Campeau, 
A. R. Davalos and J. Campisi (2009). "Persistent DNA damage signalling triggers senescence-
associated inflammatory cytokine secretion." Nat Cell Biol 11(8): 973-979. 
Rongvaux, A., T. Willinger, J. Martinek, T. Strowig, S. V. Gearty, L. L. Teichmann, Y. Saito, F. Marches, 
S. Halene, A. K. Palucka, M. G. Manz and R. A. Flavell (2014). "Development and function of human 
innate immune cells in a humanized mouse model." Nat Biotechnol 32(4): 364-372. 
Rulina, A. V., P. V. Spirin and V. S. Prassolov (2010). "Activated leukemic oncogenes AML1-ETO and c-
kit: role in development of acute myeloid leukemia and current approaches for their inhibition." 
Biochemistry (Mosc) 75(13): 1650-1666. 
287 
 
Ryotokuji, T., H. Yamaguchi, T. Ueki, K. Usuki, S. Kurosawa, Y. Kobayashi, E. Kawata, K. Tajika, S. 
Gomi, J. Kanda, A. Kobayashi, I. Omori, A. Marumo, Y. Fujiwara, S. Yui, K. Terada, K. Fukunaga, T. 
Hirakawa, K. Arai, T. Kitano, F. Kosaka, H. Tamai, K. Nakayama, S. Wakita, T. Fukuda and K. Inokuchi 
(2016). "Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-
methylation regulatory gene mutations." Haematologica 101(9): 1074-1081. 
Sabbath, K. D., E. D. Ball, P. Larcom, R. B. Davis and J. D. Griffin (1985). "Heterogeneity of clonogenic 
cells in acute myeloblastic leukemia." J Clin Invest 75(2): 746-753. 
Sablina, A. A., A. V. Budanov, G. V. Ilyinskaya, L. S. Agapova, J. E. Kravchenko and P. M. Chumakov 
(2005). "The antioxidant function of the p53 tumor suppressor." Nat Med 11(12): 1306-1313. 
Saito, Y., J. M. Ellegast, A. Rafiei, Y. Song, D. Kull, M. Heikenwalder, A. Rongvaux, S. Halene, R. A. 
Flavell and M. G. Manz (2016). "Peripheral blood CD34(+) cells efficiently engraft human cytokine 
knock-in mice." Blood 128(14): 1829-1833. 
Salati, S., R. Zini, E. Bianchi, A. Testa, F. Mavilio, R. Manfredini and S. Ferrari (2008). "Role of CD34 
antigen in myeloid differentiation of human hematopoietic progenitor cells." Stem Cells 26(4): 950-
959. 
Salminen, A., A. Kauppinen and K. Kaarniranta (2012). "Emerging role of NF-kappaB signaling in the 
induction of senescence-associated secretory phenotype (SASP)." Cell Signal 24(4): 835-845. 
Santini, V., B. Scappini, Z. K. Indik, A. Gozzini, P. R. Ferrini and A. D. Schreiber (2003). "The carboxy-
terminal region of the granulocyte colony-stimulating factor receptor transduces a phagocytic 
signal." Blood 101(11): 4615-4622. 
Sapkota, D., O. Bruland, H. Parajuli, T. A. Osman, M. T. Teh, A. C. Johannessen and D. E. Costea 
(2015). "S100A16 promotes differentiation and contributes to a less aggressive tumor phenotype in 
oral squamous cell carcinoma." BMC Cancer 15: 631. 
Sasaki, H. M., H. Tadakuma and Y. Tomari (2018). "Single-Molecule Analysis for RISC Assembly and 
Target Cleavage." Methods Mol Biol 1680: 145-164. 
Saulacic, N., B. Schaller, D. D. Bosshardt, D. Buser, P. Jaun, H. Haeniwa and T. Iizuka (2012). 
"Periosteal distraction osteogenesis and barrier membrane application: an experimental study in the 
rat calvaria." J Periodontol 83(6): 757-765. 
Saulacic, N., B. Schaller, T. Iizuka, D. Buser, C. Hug and D. D. Bosshardt (2013). "Analysis of new bone 
formation induced by periosteal distraction in a rat calvarium model." Clin Implant Dent Relat Res 
15(2): 283-291. 
Scheer, C., C. Kratz, O. Witt, U. Creutzig, D. Reinhardt and J. H. Klusmann (2016). "Hematologic 
Response to Vorinostat Treatment in Relapsed Myeloid Leukemia of Down Syndrome." Pediatr Blood 
Cancer 63(9): 1677-1679. 
Schepers, H., P. Korthuis, M. Geugien, J. Jaques, T. I. Todorova, U. Steidl, J. J. Schuringa and E. 
Vellenga (2015). "CITED2 Cooperates with Low PU.1 and DNMT3A to Maintain Self-Renewal in 
Hematopoietic Stem Cells." Blood 126(23). 
Schepers, H., P. M. Korthuis, J. J. Schuringa and E. Vellenga (2013). "Decreased PU.1 and Enhanced 
CITED2 Cooperate To Maintain Self-Renewal In Hematopoietic Stem/Progenitors." Blood 122(21). 
Scherr, M., K. Battmer, T. Winkler, O. Heidenreich, A. Ganser and M. Eder (2003). "Specific inhibition 
of bcr-abl gene expression by small interfering RNA." Blood 101(4): 1566-1569. 
Scherr, M., H. Kirchhoff, K. Battmer, K. Wohlan, C. W. Lee, M. Ricke-Hoch, S. Erschow, E. Law, A. 
Kloos, M. Heuser, A. Ganser, D. Hilfiker-Kleiner and O. Heidenreich (2019). "Optimized induction of 
mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic 
leukemia."  33(6): 1313-1323. 
Schirle, N. T., J. Sheu-Gruttadauria and I. J. MacRae (2014). "Structural basis for microRNA targeting." 
Science 346(6209): 608-613. 
Schlenk, R. F., K. Dohner, J. Krauter, S. Frohling, A. Corbacioglu, L. Bullinger, M. Habdank, D. Spath, 
M. Morgan, A. Benner, B. Schlegelberger, G. Heil, A. Ganser, H. Dohner and G. German-Austrian 
Acute Myeloid Leukemia Study (2008). "Mutations and treatment outcome in cytogenetically normal 
acute myeloid leukemia." N Engl J Med 358(18): 1909-1918. 
288 
 
Schlossman, D. M., S. L. Schmid, W. A. Braell and J. E. Rothman (1984). "An Enzyme That Removes 
Clathrin Coats - Purification of an Uncoating Atpase." Journal of Cell Biology 99(2): 723-733. 
Schlundt, A., J. N. Tants and M. Sattler (2017). "Integrated structural biology to unravel molecular 
mechanisms of protein-RNA recognition." Methods 118-119: 119-136. 
Schmidt, T. and P. Carmeliet (2011). "Angiogenesis: A Target in Solid Tumors, Also in Leukemia?" 
Hematology-American Society of Hematology Education Program: 1-8. 
Scholl, C., D. G. Gilliland and S. Frohling (2008). "Deregulation of signaling pathways in acute myeloid 
leukemia." Semin Oncol 35(4): 336-345. 
Schuck, J., T. Gursinsky, V. Pantaleo, J. Burgyan and S. E. Behrens (2013). "AGO/RISC-mediated 
antiviral RNA silencing in a plant in vitro system." Nucleic Acids Res 41(9): 5090-5103. 
Schwarz, D. S., Y. Tomari and P. D. Zamore (2004). "The RNA-induced silencing complex is a Mg2+-
dependent endonuclease." Current Biology 14(9): 787-791. 
Semov, A., M. J. Moreno, A. Onichtchenko, A. Abulrob, M. Ball, I. Ekiel, G. Pietrzynski, D. Stanimirovic 
and V. Alakhov (2005). "Metastasis-associated protein S100A4 induces angiogenesis through 
interaction with annexin II and accelerated plasmin formation." Journal of Biological Chemistry 
280(21): 20833-20841. 
Semple, S. C., A. Akinc, J. Chen, A. P. Sandhu, B. L. Mui, C. K. Cho, D. W. Sah, D. Stebbing, E. J. Crosley, 
E. Yaworski, I. M. Hafez, J. R. Dorkin, J. Qin, K. Lam, K. G. Rajeev, K. F. Wong, L. B. Jeffs, L. Nechev, M. 
L. Eisenhardt, M. Jayaraman, M. Kazem, M. A. Maier, M. Srinivasulu, M. J. Weinstein, Q. Chen, R. 
Alvarez, S. A. Barros, S. De, S. K. Klimuk, T. Borland, V. Kosovrasti, W. L. Cantley, Y. K. Tam, M. 
Manoharan, M. A. Ciufolini, M. A. Tracy, A. de Fougerolles, I. MacLachlan, P. R. Cullis, T. D. Madden 
and M. J. Hope (2010). "Rational design of cationic lipids for siRNA delivery." Nat Biotechnol 28(2): 
172-176. 
Senac, J. B. (1926). "Traite de la structure du coeur, de son action, et de ses maladies, Vol 2, p 366. 
Paris, Breasson, 1749. As quoted by Beck CS: Wounds of the heart. The technic of suture." Arch Surg 
13: 205-227. 
Seok, H., H. Lee, E. S. Jang and S. W. Chi (2018). "Evaluation and control of miRNA-like off-target 
repression for RNA interference."  75(5): 797-814. 
Setten, R. L., J. J. Rossi and S. P. Han (2019). "The current state and future directions of RNAi-based 
therapeutics."  18(6): 421-446. 
Shafer, D. and S. Grant (2016). "Update on rational targeted therapy in AML." Blood Rev 30(4): 275-
283. 
Shajari, N., B. Mansoori, S. Davudian, A. Mohammadi and B. Baradaran (2017). "Overcoming the 
Challenges of siRNA Delivery: Nanoparticle Strategies." Curr Drug Deliv 14(1): 36-46. 
Sheibani, N., Y. Tang and C. M. Sorenson (2008). "Paxillin's LD4 motif interacts with bcl-2." J Cell 
Physiol 214(3): 655-661. 
Shen, X. and D. R. Corey (2018). "Chemistry, mechanism and clinical status of antisense 
oligonucleotides and duplex RNAs." Nucleic Acids Res 46(4): 1584-1600. 
Shen, Y., Y. M. Zhu, X. Fan, J. Y. Shi, Q. R. Wang, X. J. Yan, Z. H. Gu, Y. Y. Wang, B. Chen, C. L. Jiang, H. 
Yan, F. F. Chen, H. M. Chen, Z. Chen, J. Jin and S. J. Chen (2011). "Gene mutation patterns and their 
prognostic impact in a cohort of 1185 patients with acute myeloid leukemia." Blood 118(20): 5593-
5603. 
Shi, J., B. Chou, J. L. Choi, A. L. Ta and S. H. Pun (2013). "Investigation of Polyethylenimine/DNA 
Polyplex Transfection to Cultured Cells Using Radiolabeling and Subcellular Fractionation Methods." 
Mol Pharm 10(6): 2145-2156. 
Shimi, T., V. Butin-Israeli, S. A. Adam, R. B. Hamanaka, A. E. Goldman, C. A. Lucas, D. K. Shumaker, S. 
T. Kosak, N. S. Chandel and R. D. Goldman (2011). "The role of nuclear lamin B1 in cell proliferation 
and senescence." Genes Dev 25(24): 2579-2593. 
Shimizu, T., Y. Kida and K. Kuwano (2008). "Ureaplasma parvum lipoproteins, including MB antigen, 
activate NF-{kappa}B through TLR1, TLR2 and TLR6." Microbiology 154(Pt 5): 1318-1325. 
289 
 
Siddiqui, A., D. E. Hogge, T. J. Nevill, S. H. Nantel, M. J. Barnett, R. Broady, D. L. Forrest, S. Narayanan, 
M. M. Power, K. W. Song, C. L. Toze, Y. Abou Mourad, H. J. Sutherland, A. S. Gerrie and D. Sanford 
(2016). "Long-Term Outcomes of Patients with Acute Myeloid Leukemia Treated with Salvage High-
Dose Etoposide and Cyclophosphamide." Blood 128(22). 
Singh, A. A., A. Mandoli, K. H. Prange, M. Laakso and J. H. Martens (2017). "AML associated 
oncofusion proteins PML-RARA, AML1-ETO and CBFB-MYH11 target RUNX/ETS-factor binding sites 
to modulate H3ac levels and drive leukemogenesis." Oncotarget 8(8): 12855-12865. 
Sipa, K., E. Sochacka, J. Kazmierczak-Baranska, M. Maszewska, M. Janicka, G. Nowak and B. Nawrot 
(2007). "Effect of base modifications on structure, thermodynamic stability, and gene silencing 
activity of short interfering RNA." RNA 13(8): 1301-1316. 
Skorski, T., C. Szczylik, L. Malaguarnera and B. Calabretta (1991). "Gene-targeted specific inhibition 
of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides." Folia 
Histochem Cytobiol 29(3): 85-89. 
Somoza, A., M. Terrazas and R. Eritja (2010). "Modified siRNAs for the study of the PAZ domain." 
Chem Commun (Camb) 46(24): 4270-4272. 
Sontheimer, E. J. (2005). "Assembly and function of RNA silencing complexes." Nat Rev Mol Cell Biol 
6(2): 127-138. 
Soria, N. M., R. Tussiwand, P. Ziegler, M. G. Manz and O. Heidenreich (2008). "Transient depletion of 
RUNX1/RUNX1T1 by RNA interference delays tumour formation in vivo." Leukemia 23: 188. 
Soria, N. M., R. Tussiwand, P. Ziegler, M. G. Manz and O. Heidenreich (2009). "Transient depletion of 
RUNX1/RUNX1T1 by RNA interference delays tumour formation in vivo." Leukemia 23(1): 188-190. 
Souers, A. J., J. D. Leverson, E. R. Boghaert, S. L. Ackler, N. D. Catron, J. Chen, B. D. Dayton, H. Ding, S. 
H. Enschede, W. J. Fairbrother, D. C. S. Huang, S. G. Hymowitz, S. Jin, S. L. Khaw, P. J. Kovar, L. T. Lam, 
J. Lee, H. L. Maecker, K. C. Marsh, K. D. Mason, M. J. Mitten, P. M. Nimmer, A. Oleksijew, C. H. Park, 
C. M. Park, D. C. Phillips, A. W. Roberts, D. Sampath, J. F. Seymour, M. L. Smith, G. M. Sullivan, S. K. 
Tahir, C. Tse, M. D. Wendt, Y. Xiao, J. C. Xue, H. C. Zhang, R. A. Humerickhouse, S. H. Rosenberg and 
S. W. Elmore (2013). "ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity 
while sparing platelets." Nature Medicine 19(2): 202-208. 
Sroczynska, P., C. Lancrin, V. Kouskoff and G. Lacaud (2009). "The differential activities of Runx1 
promoters define milestones during embryonic hematopoiesis." Blood 114(26): 5279-5289. 
Stewart, J. C. (1980). "Colorimetric determination of phospholipids with ammonium 
ferrothiocyanate." Anal Biochem 104(1): 10-14. 
Stochaj, W. R., T. Berkelman and N. Laird (2006). "Staining membrane-bound proteins with ponceau 
s." CSH Protoc 2006(5). 
Strobel, S. L. and J. T. Brandt (1986). "The value of the Wright-Giemsa stain for diagnosing hairy cell 
leukemia in body cavity fluids." J Surg Oncol 33(3): 182-185. 
Stuart, D. D. and T. M. Allen (2000). "A new liposomal formulation for antisense 
oligodeoxynucleotides with small size, high incorporation efficiency and good stability." Biochim 
Biophys Acta 1463(2): 219-229. 
Sugamura, K., H. Asao, M. Kondo, N. Tanaka, N. Ishii, K. Ohbo, M. Nakamura and T. Takeshita (1996). 
"The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T 
cell development in XSCID." Annu Rev Immunol 14: 179-205. 
Sullivan, C. B., R. M. Porter, C. H. Evans, T. Ritter, G. Shaw, F. Barry and J. M. Murphy (2014). 
"TNFalpha and IL-1beta influence the differentiation and migration of murine MSCs independently of 
the NF-kappaB pathway." Stem Cell Res Ther 5(4): 104. 
Sun, Y., J. Sun, T. Tomomi, E. Nieves, N. Mathewson, H. Tamaki, R. Evers and P. Reddy (2013). "PU.1-
dependent transcriptional regulation of miR-142 contributes to its hematopoietic cell-specific 
expression and modulation of IL-6." J Immunol 190(8): 4005-4013. 
Sun, Y., S. Varambally, C. A. Maher, Q. Cao, P. Chockley, T. Toubai, C. Malter, E. Nieves, I. Tawara, Y. 
Wang, P. A. Ward, A. Chinnaiyan and P. Reddy (2011). "Targeting of microRNA-142-3p in dendritic 
cells regulates endotoxin-induced mortality." Blood 117(23): 6172-6183. 
290 
 
Sune-Pou, M., M. J. Limeres, I. Nofrerias, A. Nardi-Ricart, S. Prieto-Sanchez, Y. El-Yousfi, P. Perez-
Lozano, E. Garcia-Montoya, M. Minarro-Carmona, J. R. Tico, C. Hernandez-Munain, C. Sune and J. M. 
Sune-Negre (2019). "Improved synthesis and characterization of cholesteryl oleate-loaded cationic 
solid lipid nanoparticles with high transfection efficiency for gene therapy applications." Colloids Surf 
B Biointerfaces 180: 159-167. 
Suzuki, K., K. Ino, Y. Sugawara, M. Mizutani, T. Sekine and N. Katayama (2008). "[Acute myeloid 
leukemia invasion of the central nervous system, detected only along the Virchow Robin space]." 
Rinsho Ketsueki 49(5): 340-343. 
Tabe, Y., M. Konopleva, Y. Kondo, R. Contractor, L. Jin, V. Ruvolo, Y. Tsutsumi-Ishii, K. Miyake, N. 
Miyake, A. Ohsaka, I. Nagaoka, J. P. Issa and M. Andreeff (2006). "PML-RARalpha and AML1-ETO 
translocations are rarely associated with methylation of the RARbeta2 promoter." Ann Hematol 
85(10): 689-704. 
Tadin-Strapps, M., L. B. Peterson, A. M. Cumiskey, R. L. Rosa, V. H. Mendoza, J. Castro-Perez, O. Puig, 
L. Zhang, W. R. Strapps, S. Yendluri, L. Andrews, V. Pickering, J. Rice, L. Luo, Z. Chen, S. Tep, B. Ason, 
E. P. Somers, A. B. Sachs, S. R. Bartz, J. Tian, J. Chin, B. K. Hubbard, K. K. Wong and L. J. Mitnaul 
(2011). "siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with 
human-like serum lipids." J Lipid Res 52(6): 1084-1097. 
Takakura, N., T. Watanabe, S. Suenobu, Y. Yamada, T. Noda, Y. Ito, M. Satake and T. Suda (2000). "A 
role for hematopoietic stem cells in promoting angiogenesis." Cell 102(2): 199-209. 
Tanaka, M., N. Ichikawa-Tomikawa, N. Shishito, K. Nishiura, T. Miura, A. Hozumi, H. Chiba, S. Yoshida, 
T. Ohtake and T. Sugino (2015). "Co-expression of S100A14 and S100A16 correlates with a poor 
prognosis in human breast cancer and promotes cancer cell invasion." Bmc Cancer 15. 
Tanoue, T., T. Yamamoto, R. Maeda and E. Nishida (2001). "A Novel MAPK phosphatase MKP-7 acts 
preferentially on JNK/SAPK and p38 alpha and beta MAPKs." J Biol Chem 276(28): 26629-26639. 
Taussig, D. C., J. Vargaftig, F. Miraki-Moud, E. Griessinger, K. Sharrock, T. Luke, D. Lillington, H. 
Oakervee, J. Cavenagh, S. G. Agrawal, T. A. Lister, J. G. Gribben and D. Bonnet (2010). "Leukemia-
initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in 
the CD34(-) fraction." Blood 115(10): 1976-1984. 
Teh, T. C., N. Y. Nguyen, D. M. Moujalled, D. Segal, G. Pomilio, S. Rijal, A. Jabbour, K. Cummins, K. 
Lackovic, P. Blombery, E. Thompson, P. G. Ekert, G. Lessene, S. P. Glaser, D. C. S. Huang, A. W. 
Roberts, M. A. Guthridge and A. H. Wei (2018). "Enhancing venetoclax activity in acute myeloid 
leukemia by co-targeting MCL1." Leukemia 32(2): 303-312. 
Teichert-Kuliszewska, K., P. C. Maisonpierre, N. Jones, A. I. Campbell, Z. Master, M. P. Bendeck, K. 
Alitalo, D. J. Dumont, G. D. Yancopoulos and D. J. Stewart (2001). "Biological action of angiopoietin-2 
in a fibrin matrix model of angiogenesis is associated with activation of Tie2." Cardiovasc Res 49(3): 
659-670. 
Thol, F., B. Kolking, F. Damm, K. Reinhardt, J. H. Klusmann, D. Reinhardt, N. von Neuhoff, M. H. 
Brugman, B. Schlegelberger, S. Suerbaum, J. Krauter, A. Ganser and M. Heuser (2012). "Next-
generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients 
with FLT3-ITD or NPM1 mutations." Genes Chromosomes Cancer 51(7): 689-695. 
Thomas, M., A. Gessner, H. P. Vornlocher, P. Hadwiger, J. Greil and O. Heidenreich (2005). "Targeting 
MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive 
human leukemic cells." Blood 106(10): 3559-3566. 
Thomson, S. P. and F. L. Meyskens, Jr. (1982). "Method for measurement of self-renewal capacity of 
clonogenic cells from biopsies of metastatic human malignant melanoma." Cancer Res 42(11): 4606-
4613. 
Thwaites, M. J., M. J. Cecchini and D. T. Passos (2017). "Interchangeable Roles for E2F Transcriptional 
Repression by the Retinoblastoma Protein and p27KIP1-Cyclin-Dependent Kinase Regulation in Cell 
Cycle Control and Tumor Suppression."  37(2). 
291 
 
Tian, Y., D. K. Simanshu, J. B. Ma, J. E. Park, I. Heo, V. N. Kim and D. J. Patel (2014). "A Phosphate-
Binding Pocket within the Platform-PAZ-Connector Helix Cassette of Human Dicer." Molecular Cell 
53(4): 606-616. 
Tomari, Y. and P. D. Zamore (2005). "Perspective: machines for RNAi." Genes Dev 19(5): 517-529. 
Tomiyama, N., R. Ikeda, Y. Nishizawa, S. Masuda, Y. Tajitsu and Y. Takeda (2018). "S100A16 up-
regulates Oct4 and Nanog expression in cancer stem-like cells of Yumoto human cervical carcinoma 
cells." Oncol Lett 15(6): 9929-9933. 
Trombly, D. J., T. W. Whitfield, S. Padmanabhan, J. A. Gordon, J. B. Lian, A. J. van Wijnen, S. K. Zaidi, 
J. L. Stein and G. S. Stein (2015). "Genome-wide co-occupancy of AML1-ETO and N-CoR defines the 
t(8;21) AML signature in leukemic cells." BMC Genomics 16: 309. 
Tse, C., A. R. Shoemaker, J. Adickes, M. G. Anderson, J. Chen, S. Jin, E. F. Johnson, K. C. Marsh, M. J. 
Mitten, P. Nimmer, L. Roberts, S. K. Tahir, Y. Xiao, X. Yang, H. Zhang, S. Fesik, S. H. Rosenberg and S. 
W. Elmore (2008). "ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor." Cancer Res 
68(9): 3421-3428. 
Uffmann, M., M. Rasche, M. Zimmermann, C. von Neuhoff, U. Creutzig, M. Dworzak, L. Scheffers, H. 
Hasle, C. M. Zwaan, D. Reinhardt and J. H. Klusmann (2017). "Therapy reduction in patients with 
Down syndrome and myeloid leukemia: the international ML-DS 2006 trial."  129(25): 3314-3321. 
Vairo, G., K. M. Innes and J. M. Adams (1996). "Bcl-2 has a cell cycle inhibitory function separable 
from its enhancement of cell survival." Oncogene 13(7): 1511-1519. 
Vairo, G., T. J. Soos, T. M. Upton, J. Zalvide, J. A. DeCaprio, M. E. Ewen, A. Koff and J. M. Adams 
(2000). "Bcl-2 retards cell cycle entry through p27(Kip1), pRB relative p130, and altered E2F 
regulation." Molecular and Cellular Biology 20(13): 4745-4753. 
Valenzuela, R. A., K. Onizuka, A. A. Ball-Jones, T. Hu, S. R. Suter and P. A. Beal (2016). "Guide Strand 
3'-End Modifications Regulate siRNA Specificity." Chembiochem 17(24): 2340-2345. 
Vaskova, J., K. Dubayova, G. Cakanova, I. Luckova, I. Bochova, G. Novotna, J. Sabo, S. Palasthy, E. 
Tothova, N. Stecova and A. Karabinos (2015). "Incidence and Prognostic Value of Known Genetic 
Aberrations in Patients with Acute Myeloid Leukemia--a Two Year Study." Klin Onkol 28(4): 278-283. 
Vasselon, T., M. Bouttier, A. Saumet and C. H. Lecellier (2013). "RNAi and retroviruses: are they in 
RISC?" Biomol Concepts 4(1): 43-52. 
Viale, A., F. De Franco, A. Orleth, V. Cambiaghi, V. Giuliani, D. Bossi, C. Ronchini, S. Ronzoni, I. 
Muradore, S. Monestiroli, A. Gobbi, M. Alcalay, S. Minucci and P. G. Pelicci (2009). "Cell-cycle 
restriction limits DNA damage and maintains self-renewal of leukaemia stem cells." Nature 
457(7225): 51-56. 
Viale, A. and P. G. Pelicci (2009). "Awaking stem cells from dormancy: growing old and fighting 
cancer." EMBO Mol Med 1(2): 88-91. 
Viger-Gravel, J., A. Schantz, A. C. Pinon, A. J. Rossini, S. Schantz and L. Emsley (2018). "Structure of 
Lipid Nanoparticles Containing siRNA or mRNA by Dynamic Nuclear Polarization-Enhanced NMR 
Spectroscopy." J Phys Chem B 122(7): 2073-2081. 
Virchow, R. (1855). "Cellular-pathologie." Archiv für pathologische Anatomie und Physiologie und für 
klinische Medicin 8(1): 3-39. 
Vonarbourg, A., C. Passirani, P. Saulnier, P. Simard, J. C. Leroux and J. P. Benoit (2006). "Evaluation of 
pegylated lipid nanocapsules versus complement system activation and macrophage uptake." J 
Biomed Mater Res A 78(3): 620-628. 
Vu, L. P. and M. G. Kharas (2018). "Targeting the Residual Leukemia Cells after Chemotherapy." 
Cancer Cell 34(3): 353-355. 
Walker, D. K., R. M. Jones, A. N. R. Nedderman and P. A. Wright (2010). Chapter 4 Primary, 
Secondary and Tertiary Amines and their Isosteres. Metabolism, Pharmacokinetics and Toxicity of 




Wang, H., W. Li, R. Guo, J. Sun, J. Cui, G. Wang, A. R. Hoffman and J. F. Hu (2014). "An intragenic long 
noncoding RNA interacts epigenetically with the RUNX1 promoter and enhancer chromatin DNA in 
hematopoietic malignancies." Int J Cancer 135(12): 2783-2794. 
Wang, L., W. Cai, W. Zhang, X. Chen, W. Dong, D. Tang, Y. Zhang, C. Ji and M. Zhang (2015). 
"Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by 
suppressing the myeloproliferative leukemia virus oncogene." Oncotarget 6(29): 27490-27504. 
Wang, L., G. Huang, X. Zhao, M. A. Hatlen, L. Vu, F. Liu and S. D. Nimer (2009). "Post-translational 
modifications of Runx1 regulate its activity in the cell." Blood Cells Mol Dis 43(1): 30-34. 
Wang, X., J. S. Harrison and G. P. Studzinski (2016). "Enhancement of arabinocytosine (AraC) toxicity 
to AML cells by a differentiation agent combination." J Steroid Biochem Mol Biol 164: 72-78. 
Wang, Y. L., S. Juranek, H. T. Li, G. Sheng, G. S. Wardle, T. Tuschl and D. J. Patel (2009). "Nucleation, 
propagation and cleavage of target RNAs in Ago silencing complexes." Nature 461(7265): 754-U753. 
Ward, S. V., T. Sternsdorf and N. B. Woods (2011). "Targeting expression of the leukemogenic PML-
RARalpha fusion protein by lentiviral vector-mediated small interfering RNA results in leukemic cell 
differentiation and apoptosis." Hum Gene Ther 22(12): 1593-1598. 
Watts, J. K., N. Martin-Pintado, I. Gomez-Pinto, J. Schwartzentruber, G. Portella, M. Orozco, C. 
Gonzalez and M. J. Damha (2010). "Differential stability of 2'F-ANA*RNA and ANA*RNA hybrid 
duplexes: roles of structure, pseudohydrogen bonding, hydration, ion uptake and flexibility." Nucleic 
Acids Res 38(7): 2498-2511. 
Wei, J., J. Jones, J. Kang, A. Card, M. Krimm, P. Hancock, Y. Pei, B. Ason, E. Payson, N. Dubinina, M. 
Cancilla, M. Stroh, J. Burchard, A. B. Sachs, J. H. Hochman, W. M. Flanagan and N. A. Kuklin (2011). 
"RNA-induced silencing complex-bound small interfering RNA is a determinant of RNA interference-
mediated gene silencing in mice." Mol Pharmacol 79(6): 953-963. 
Weinstein, S., I. A. Toker, R. Emmanuel, S. Ramishetti, I. Hazan-Halevy, D. Rosenblum, M. Goldsmith, 
A. Abraham, O. Benjamini, O. Bairey, P. Raanani, A. Nagler, J. Lieberman and D. Peer (2016). 
"Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies." Proc 
Natl Acad Sci U S A 113(1): E16-22. 
Werfel, T. A., M. A. Jackson, T. E. Kavanaugh, K. C. Kirkbride, M. Miteva, T. D. Giorgio and C. Duvall 
(2017). "Combinatorial optimization of PEG architecture and hydrophobic content improves ternary 
siRNA polyplex stability, pharmacokinetics, and potency in vivo." Journal of Controlled Release 255: 
12-26. 
Whitehead, K. A., J. E. Dahlman, R. S. Langer and D. G. Anderson (2011). "Silencing or stimulation? 
siRNA delivery and the immune system." Annu Rev Chem Biomol Eng 2: 77-96. 
Wichmann, C., L. Chen, M. Heinrich, D. Baus, E. Pfitzner, M. Zornig, O. G. Ottmann and M. Grez 
(2007). "Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity 
in t(8;21)-positive leukemic cells." Cancer Res 67(5): 2280-2289. 
Woronzoff-Dashkoff, K. K. (2002). "The wright-giemsa stain. Secrets revealed." Clin Lab Med 22(1): 
15-23. 
Woytschak, J., N. Keller, C. Krieg, D. Impellizzieri, R. W. Thompson, T. A. Wynn, A. S. Zinkernagel and 
O. Boyman (2016). "Type 2 Interleukin-4 Receptor Signaling in Neutrophils Antagonizes Their 
Expansion and Migration during Infection and Inflammation." Immunity 45(1): 172-184. 
Wu, F. T., C. R. Lee, E. Bogdanovic, A. Prodeus, J. Gariepy and R. S. Kerbel (2015). "Vasculotide 
reduces endothelial permeability and tumor cell extravasation in the absence of binding to or 
agonistic activation of Tie2." EMBO Mol Med 7(6): 770-787. 
Wunderlich, M. and J. C. Mulloy (2016). "MISTRG extends PDX modeling to favorable AMLs." Blood 
128(17): 2111-2112. 
Wyman, T. H., C. A. Dinarello, A. Banerjee, F. Gamboni-Robertson, A. A. Hiester, K. M. England, M. 
Kelher and C. C. Silliman (2002). "Physiological levels of interleukin-18 stimulate multiple neutrophil 
functions through p38 MAP kinase activation." J Leukoc Biol 72(2): 401-409. 
Xie, C. Z., H. Edwards, X. L. Xu, H. Zhou, S. A. Buck, M. L. Stout, Q. Yu, J. E. Rubnitz, L. H. Matherly, J. 
W. Taub and Y. B. Ge (2010). "Mechanisms of Synergistic Antileukemic Interactions between Valproic 
293 
 
Acid and Cytarabine in Pediatric Acute Myeloid Leukemia." Clinical Cancer Research 16(22): 5499-
5510. 
Xu, L., X. Wang, H. He, J. Zhou, X. Li, H. Ma, Z. Li, Y. Zeng, R. Shao, S. Cen and Y. Wang (2015). 
"Structure-based design of novel chemical modification of the 3'-overhang for optimization of short 
interfering RNA performance." Biochemistry 54(5): 1268-1277. 
Xu, M., T. Pirtskhalava, J. N. Farr, B. M. Weigand, A. K. Palmer, M. M. Weivoda, C. L. Inman, M. B. 
Ogrodnik, C. M. Hachfeld, D. G. Fraser, J. L. Onken, K. O. Johnson, G. C. Verzosa, L. G. P. Langhi, M. 
Weigl, N. Giorgadze, N. K. LeBrasseur, J. D. Miller, D. Jurk, R. J. Singh, D. B. Allison, K. Ejima, G. B. 
Hubbard, Y. Ikeno, H. Cubro, V. D. Garovic, X. Hou, S. J. Weroha, P. D. Robbins, L. J. Niedernhofer, S. 
Khosla, T. Tchkonia and J. L. Kirkland (2018). "Senolytics improve physical function and increase 
lifespan in old age." Nat Med 24(8): 1246-1256. 
Yamada, S. and I. Maruyama (2007). "HMGB1, a novel inflammatory cytokine." Clin Chim Acta 375(1-
2): 36-42. 
Yan, M., E. Kanbe, L. F. Peterson, A. Boyapati, Y. Miao, Y. Wang, I. M. Chen, Z. Chen, J. D. Rowley, C. 
L. Willman and D. E. Zhang (2006). "A previously unidentified alternatively spliced isoform of t(8;21) 
transcript promotes leukemogenesis." Nat Med 12(8): 945-949. 
Yan, M., E. Kanbe, L. F. Peterson, A. Boyapati, Y. Miao, Y. Wang, I. M. Chen, Z. X. Chen, J. D. Rowley, 
C. L. Willman and D. E. Zhang (2006). "A previously unidentified alternatively spliced isoform of 
t(8;21) transcript promotes leukemogenesis." Nature Medicine 12(8): 945-949. 
Yang, G., M. A. Thompson, S. J. Brandt and S. W. Hiebert (2007). "Histone deacetylase inhibitors 
induce the degradation of the t(8;21) fusion oncoprotein." Oncogene 26(1): 91-101. 
Yang, Y., Y. Zhao, W. Liao, J. Yang, L. Wu, Z. Zheng, Y. Yu, W. Zhou, L. Li, J. Feng, H. Wang and W. G. 
Zhu (2009). "Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to 
histone deacetylase inhibitor depsipeptide treatment." Neoplasia 11(4): 313-324. 
Yi, T. (2018). "Identifying RISC Components Using Ago2 Immunoprecipitation and Mass 
Spectrometry." Methods Mol Biol 1720: 149-159. 
Yoneyama, M., M. Kikuchi, T. Natsukawa, N. Shinobu, T. Imaizumi, M. Miyagishi, K. Taira, S. Akira and 
T. Fujita (2004). "The RNA helicase RIG-I has an essential function in double-stranded RNA-induced 
innate antiviral responses." Nature Immunology 5(7): 730-737. 
Yuan, Y. Z., L. M. Zhou, T. Miyamoto, H. Iwasaki, N. Harakawa, C. J. Hetherington, S. A. Burel, E. 
Lagasse, I. L. Weissman, K. Akashi and D. E. Zhang (2001). "AML1-ETO expression is directly involved 
in the development of acute myeloid leukemia in the presence of additional mutations." Blood 
98(11): 565a-566a. 
Yue, X. and Z. Dai (2018). "Liposomal Nanotechnology for Cancer Theranostics." Curr Med Chem 
25(12): 1397-1408. 
Zaidi, S. K., C. R. Dowdy, A. J. van Wijnen, J. B. Lian, A. Raza, J. L. Stein, C. M. Croce and G. S. Stein 
(2009). "Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks 
differentiation by activating a miR-24/MKP-7/MAPK network." Cancer Res 69(21): 8249-8255. 
Zhang, D. E., K. I. Fujioka, C. J. Hetherington, L. H. Shapiro, H. M. Chen, A. T. Look and D. G. Tenen 
(1994). "Identification of a Region Which Directs the Monocytic Activity of the Colony-Stimulating 
Factor-1 (Macrophage-Colony-Stimulating Factor) Receptor Promoter and Binds Pebp2/Cbf (Aml1)." 
Molecular and Cellular Biology 14(12): 8085-8095. 
Zhang, D. E., C. J. Hetherington, S. Meyers, K. L. Rhoades, C. J. Larson, H. M. Chen, S. W. Hiebert and 
D. G. Tenen (1996). "CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically 
activate the macrophage colony-stimulating factor receptor promoter." Mol Cell Biol 16(3): 1231-
1240. 
Zhang, Y., Y. Huang and S. Li (2014). "Polymeric micelles: nanocarriers for cancer-targeted drug 
delivery." AAPS PharmSciTech 15(4): 862-871. 
Zhang, Z., U. Ohto and T. Shimizu (2017). "Toward a structural understanding of nucleic acid-sensing 
Toll-like receptors in the innate immune system." FEBS Lett 591(20): 3167-3181. 
294 
 
Zhao, H., F. Liu, R. Jia, H. Chang, H. Li, M. Miao, H. Wang and Z. Yang (2017). "MiR-570 inhibits cell 
proliferation and glucose metabolism by targeting IRS1 and IRS2 in human chronic myelogenous 
leukemia." Iran J Basic Med Sci 20(5): 481-488. 
Zhao, Y., J. Tan, L. Zhuang, X. Jiang, E. T. Liu and Q. Yu (2005). "Inhibitors of histone deacetylases 
target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim." 
Proceedings of the National Academy of Sciences of the United States of America 102(44): 16090-
16095. 
Zhigaltsev, I. V., N. Maurer, K. F. Wong and P. R. Cullis (2002). "Triggered release of doxorubicin 
following mixing of cationic and anionic liposomes." Biochim Biophys Acta 1565(1): 129-135. 
Zhou, B. O., L. Ding and S. J. Morrison (2015). "Hematopoietic stem and progenitor cells regulate the 
regeneration of their niche by secreting Angiopoietin-1." Elife 4. 
Zhou, C., Z. Li, H. Diao, Y. Yu, W. Zhu, Y. Dai, F. F. Chen and J. Yang (2006). "DNA damage evaluated 
by gammaH2AX foci formation by a selective group of chemical/physical stressors." Mutat Res 
604(1-2): 8-18. 
Zhu, Y., T. Tchkonia, T. Pirtskhalava, A. C. Gower, H. S. Ding, N. Giorgadze, A. K. Palmer, Y. Ikeno, G. B. 
Hubbard, M. Lenburg, S. P. O'Hara, N. F. LaRusso, J. D. Miller, C. M. Roos, G. C. Verzosa, N. K. 
LeBrasseur, J. D. Wren, J. N. Farr, S. Khosla, M. B. Stout, S. J. McGowan, H. Fuhrmann-Stroissnigg, A. 
U. Gurkar, J. Zhao, D. Colangelo, A. Dorronsoro, Y. Y. Ling, A. S. Barghouthy, D. C. Navarro, T. Sano, P. 
D. Robbins, L. J. Niedernhofer and J. L. Kirkland (2015). "The Achilles' heel of senescent cells: from 
transcriptome to senolytic drugs." Aging Cell 14(4): 644-658. 
Ziello, J. E., Y. Huang and I. S. Jovin (2010). "Cellular endocytosis and gene delivery." Mol Med 16(5-
6): 222-229. 
Zimmermann, T. S., A. C. Lee, A. Akinc, B. Bramlage, D. Bumcrot, M. N. Fedoruk, J. Harborth, J. A. 
Heyes, L. B. Jeffs, M. John, A. D. Judge, K. Lam, K. McClintock, L. V. Nechev, L. R. Palmer, T. Racie, I. 
Rohl, S. Seiffert, S. Shanmugam, V. Sood, J. Soutschek, I. Toudjarska, A. J. Wheat, E. Yaworski, W. 
Zedalis, V. Koteliansky, M. Manoharan, H. P. Vornlocher and I. MacLachlan (2006). "RNAi-mediated 
gene silencing in non-human primates." Nature 441(7089): 111-114. 
Zon, G. and T. G. Geiser (1991). "Phosphorothioate oligonucleotides: chemistry, purification, 
analysis, scale-up and future directions." Anticancer Drug Des 6(6): 539-568. 
 
